T RK-INHIBIT ING COMPOUND
ABSTRACT
      The present invention provides a drug containing a compound
having Trk-inhibiting activity as an active ingredient in
prophylaxis and/or therapy for Trk-related diseases such as
pain, pruritus,       lower urinary tract dysfunction, asthma,
allergic rhinitis, inflammatory bowel disease or Chagas disease.
A  compound represented by the general                   formula (I):
            A3
           Aj       0    A,         0            ip
(R2)q                              N      N
              6 5Y                  N'JN
         CY   6         (143)r      HH
wherein all symbols represent the same meanings as                     described in
the specification, a salt thereof, an N-oxide thereof, a solvate
thereof or a prodrug thereof is useful as a drug component
having Trk-inhibiting            activity      in    prophylaxis and/or therapy  of
diseases   such as pain,           pruritus,       lower urinary tract
dysfunction,      asthma,      allergic      rhinitis,     inflammatory bowel
disease or Chagas disease.

                              DESCRIPTION
                       Trk-INHIBITING COMPOUND
                            TECHNICAL FIELD
       The present invention relates to a Trk-inhibiting
compound or a salt thereof and a medicament containing the
same as an active ingredient.      More specifically, the present
invention relates to a Trk-inhibiting compound represented by
the general formula    (I):
(R2)q       A3  0   A   1i  0
      Cy2    A6     (R3)r H   H
       wherein all symbols represent the same meanings as
described hereinbelow, and a salt thereof, an N-oxide thereof,
a solvate thereof or a prodrug thereof      (hereinafter referred
to as "the present compound")     and a medicament containing the
same as an active ingredient.
                            BACKGROUND ART
       The tropomyosin receptor kinase    (hereinafter abbreviated
as   "Trk") family is classified as receptor tyrosine kinases
and comprises TrkA which is a high-affinity receptor of nerve
growth factor   (hereinafter abbreviated as NGF),    TrkB which is
a high-affinity receptor of brain-derived neutrophic factor
 (BDNF) and neurotrophin    (hereinafter abbreviated as NT)-4/5
and TrkC which is a high-affinity receptor of NT-3.       All Trk
                                   1

 receptors are highly expressed in nerve tissues and are
 involved in differentiation and maintenance of functions of
nerve cells   (see Non-Patent Document 1).   Meanwhile it has been
 known that activation of TrkA in peripheral nerves by NGF
initiates hyperalgesia    (see Non-Patent Document 2) and based
on clinical and non-clinical test results using anti-NGF
antibodies and non-clinical test results using low-molecular
weight Trk inhibitors, involvement of TrkA has been reported
in nociceptive pain of osteoarthritis, chronic low back pain,
rheumatoid arthritis, bone fracture, interstitial cystitis and
chronic pancreatitis, neuropathic pain as well as cancer pain
combining both types of pain described above (see Non-Patent
Document 3 to 10).   Moreover, Trk receptors are expressed on
cancer cells such as neuroblastoma, prostate cancer and
pancreatic cancer, inflammatory cells such as mast cells and
eosinophils, immunocompetent cells such as T cells and B cells
and keratinocytes and are reported to be potentially involved
in proliferation, migration and metastasis of cancer cells,
inflammatory diseases such as ulcerative colitis and Crohn's
disease, allergic diseases such as asthma, rhinitis and atopic
dermatitis and other diseases such as psoriasis     (see Non
Patent Document 11 to 15).    Therefore compounds having Trk
inhibiting activity may be applied to therapy of nociceptive
pain, neuropathic pain and pain combining both types of pain,
cancer, inflammatory diseases, allergic diseases and
psoriasis.

      Accordingly it is expected that development of Trk
inhibiting agents may provide novel types of prophylactic
and/or therapeutic agents for pain and the like.
      Meanwhile Patent Document 1 discloses a method for
treating or preventing a disease in a human or other mammal
regulated by tyrosine kinase, comprising administering, to a
human or other mammal in need thereof, a compound of the
following formula      (Ia), a salt thereof, an isomer thereof or a
prodrug.
      The general formula      (Ia) is as follows:
      0
AasN    N'Ba   ([a)
    H   H
      wherein Aa is selected from the group consisting of the
following   (i) to   (iii) and the like;
      (i) phenyl, optionally substituted with 1 to 3
substituents independently selected from the group consisting
of Ra',  ORal,  a halogen and the like;
      (ii) naphthyl, optionally substituted with 1 to 3
substituents independently selected from the group consisting
of Ral,  ORal, a   halogen and the like;
      (iii) a 5-    to 6-membered monocyclic heteroaryl group,
optionally substituted with 1 to 3 substituents independently
selected from the group consisting of Ra',       ORal, a halogen and
the like and having 1 to 3 heteroatoms independently selected
from the group consisting of 0,       N and S;

         Ba is selected from the group consisting of the following
  (i) to      (iii) and the like;
          (i) phenyl, optionally substituted with 1 to 3
substituents independently selected from the group consisting
of -La-Ma,          Ci-C 5 linear or branched alkyl,      halogen and the
like;
          (ii) naphthyl, optionally substituted with 1 to 3
substituents independently selected from the group consisting
of -La-Ma,          a Ci-C 5 linear or branched alkyl,      a halogen and the
like;
          (iii) a 5- to 6-membered monocyclic heteroaryl group,
optionally substituted with 1 to 3 substituents independently
selected from the group consisting of -La-Ma,                 a Ci-C 5  linear or
branched alkyl, a halogen and the like and having 1 to 3
heteroatoms independently selected from the group consisting
of 0, N and S;
         La is selected from the group consisting of -(CH              2 )ma-O
 (CH 2 )ia-,     -(CH 2 )ma-C(O)-(CH 2 )ia- and the like,   wherein   the
variables ma and la are integers independently selected from 0
to 4;
         Ma is      selected from the group consisting of the following
 (i)   to    (iii)    and the like;
         (i) phenyl, optionally substituted with 1 to 3
substituents independently selected from the group consisting
of Ral,      ORal,     a halogen and the like;
         (ii) naphthyl, optionally substituted with 1 to 3
                                             A

substituents independently selected from the group consisting
of Ral,  ORa',  a halogen and the like;
       (iii) a 5- to 6-membered monocyclic heteroaryl group,
optionally substituted with 1 to 3 substituents independently
selected from the group consisting of Ra',            ORa,    a halogen and
the like and having 1 to 3 heteroatoms independently selected
from the group consisting of 0, N and S;
      wherein Ral is    independently selected from the group
consisting of    (a) a hydrogen,       (b) a Ci-C 6 alkyl,     (c)  phenyl,
 (d) a 5- to 6-membered monocyclic heteroaryl or a 8- to 10
membered bicyclic heteroaryl both having 1 to 4 heteroatoms
selected from the group consisting of 0, N and S, (e) a Ci-C                3
alkyl-phenyl and     (f) an alkyl-heteroaryl having 1 to 4
heteroatoms selected from the group consisting of 0, N and S;
Ral is, when it is not a hydrogen, optionally substituted with
1 to 3 substituents independently selected from the group
consisting   of a  Ci-C5 linear,     branched or cyclic       alkyl,   a Ci-C3
alkoxy,  hydroxy,   amino,    a Ci-C 3  alkylamino,    a C2 -C6   dialkylamino,
a halogen, cyano and nitro; and the definitions of the groups
are partially abstracted.
      Patent Document 1 discloses that the compound therein
inhibits KDR and thereby is used for a method of treatment of
diseases mediated by VEGF induced signal transduction pathways
in a human or other mammal, particularly retinopathy or
retinopathy of prematurity.        However, it is not disclosed or
suggested that the compound disclosed therein has Trk-

inhibiting activity and Patent Document 1 does not
specifically disclose the present compound.
      Patent Document 2 discloses that a compound represented
by the general formula            (Ib):
     LbI N
Rb      I      -Lb2-Rb2
               Rb3
      wherein:
      Yb is N or CH;
      Lb1   is   a bond,    -0-,     -S-,  -SO-,     -SO 2- or the like;
      Lb2 is a bond, -NHC(O)NH-, -NHC(O)-                    or the like;
      Rb1   is    (i) Rb 5 or   (ii)    a C1 -C 6 alkyl optionally
substituted with one or more halogen, Rb5 or the like;
      Rb2 is      (i) a Ci-C  6  alkyl or      (ii)    an aryl    or heteroaryl,
each of which is optionally substituted with one or more
halogen,    Rb 9 , ORb,    SRb 9 , N(Rb)    2,   C(O)Rb 9 or the like;
          3
      Rb    is   a hydrogen,      a halogen,        a C 1 -C 6 alkyl or the like;
      Rb    is a cycloalkyl, a heterocycle, an aryl or a
heteroaryl, each of which is optionally substituted with one
or more halogen,        ORb,    N(Rb6 )2 , Rb',      ORb 7 or the like;
      Rb    is a cycloalkyl, a heterocycle, an aryl or a
heteroaryl, each of which is optionally substituted with one
or more halogen, hydroxy, N(Rb6 )2 or the like; and
      each Rb 6 is     independently        a hydrogen or a C 1 -C     4 alkyl    (the
definitions of the groups are partially abstracted),                      a
tautomer, enantiomer, pharmaceutically acceptable salt,

hydrate, solvate, complex or a prodrug thereof acts as an
endogenous utrophin upregulator.              However, it is not disclosed
or suggested that the compounds have Trk-inhibiting activity.
In addition, Patent Document 2 does not specifically disclose
the present compound.
        Further, Patent Document 3 discloses that a compound
represented by the general formula              (Ic):
      Bc Cc
       Ac
    Xc5
Xc 3'Xc   4      (IC)
   Xci      Rci
        wherein:
        Ac and Cc are each independently selected from the group
consisting of an aryl and heteroaryl, both of which may be
optionally substituted;
        Bc is selected from the group consisting of
N(H)C(0)N(H)-       and -N(H)C(O)N(H)CH 2-;
                   4
        Xc 1 to Xc    are each selected from the group consisting of
C(Rc2 ) and N and at least one of Xc 1 to Xc          4
                                                        is N;
        Xc 5 is C(Rc 3 ) (Rc 4 ), N(Rc3 ), 0 or S(0)mc;  and
        Rcl is selected from the group consisting of a heteroaryl
and heterocycloalkyl, both of which may be optionally
substituted (the definitions of the groups are partially
abstracted),      a salt or ester thereof or a prodrug thereof has
B-Raf-inhibiting activity.            However, it is not disclosed or
                                          '-7

suggested that the compounds have Trk-inhibiting activity.   In
addition, Patent Document 3 does not disclose the present
compound.
     None of the Trk-inhibiting compounds which have been
known by now has a chemical structure characterized by "urea
group-ring-O-ring-ring" as the compounds of the present
invention.
     Patent Document 1: WO 2003/068228
     Patent Document 2: WO 2010/057833
     Patent Document 3: WO 2007/076473
     Non-Patent Document 1: Annual Review of Biochemistry, 72,
609-642, 2003
     Non-Patent Document 2:  Trends in Pharmacological Sciences,
27, 85-91, 2006
     Non-Patent Document 3: New England Journal of Medicine,
363, 1521-1531, 2010
     Non-Patent Document 4: Pain, 152, 2248-2258, 2011
     Non-Patent Document 5:  Journal of Urology, 185, 1716-1721,
2011
     Non-Patent Document 6: Pain, 116, 8-16, 2005
     Non-Patent Document 7: Bone, 48, 389-398, 2011
     Non-Patent Document 8: Molecular Pain, 6, 87, 2010
     Non-Patent Document 9: Journal of Pharmacological and
Experimental Therapeutics, 322, 282-287, 2007
     Non-Patent Document 10: Gastroenterology, 141, 370-377,
2011
                                0

      Non-Patent Document 11:  Expert Opinion Therapeutic
Patents, 19,  305-319, 2009
      Non-Patent Document 12: Gut, 46,  670-679, 2000
      Non-Patent Document 13: Current Opinion in Allergy and
Clinical Immunology, 10, 8-13, 2010
      Non-Patent Document 14:  Inflammation and Allergy Drug
Targets, 9, 173-180, 2010
     Non-Patent Document 15:  Journal of Investigative
Dermatology, 126, 1719-1727, 2006
                   DISCLOSURE OF THE INVENTION
     An object of the present invention is to create a
compound having selective Trk-inhibiting activity and find a
compound useful as a prophylactic and/or therapeutic agent for
various diseases typically including pain.
     The present inventors have carried out exhaustive studies
in order to find compounds which have selective Trk-inhibiting
activity and can be prophylactic and/or therapeutic agents for
various diseases typically including pain, and as a result
have found that the compounds represented by the following
general formula  (I) have Trk-inhibiting action, have excellent
kinase selectivity and can persistently inhibit NGF vascular
hyper permeability, thereby completing the present invention.
     Thus the present invention relates to the followings:
[1]  A compound represented by the general formula    (I):

                            A3 0    A,     0R~
          (R2)q         AH     O    A1     O
                   Y2      6A5   A2      N   N
                                    (RA) H    H
a compound represented by the general formula (I):
wherein:
a ring Cy1 represents a C3-10 monocyclic carbocycle           or bicyclic
carbocycle or a 4- to 10-membered monocyclic heterocycle or
bicyclic heterocycle;
a ring CY2 represents a 4-          to 10-membered monocyclic
heterocycle or bicyclic heterocycle excluding a heterocycle
1,3-thiazol-5-yl group;
R, represents:
 (1) a halogen;
 (2) a Cl-6 alkyl group, C2-6 alkenyl group or C2-6 alkynyl
group optionally substituted with a substituent selected from
the group consisting of          (i) a halogen and  (ii) a hydroxy
group;
 (3) a C5-6 monocyclic carbocycle optionally substituted with
one or two R5 groups;
 (4) a 5- to 6-membered monocyclic heterocycle optionally
substituted         with one or two R5 groups;
 (5)   -S (0)  mi-R6;
(6)    -SO 2 NR7 R8 ;
(7) -C (O)OR 9 ;
(8) -NRoC (0) R1 1 ;
                                       1r

  (9)  -C (O) NR12 R13 ;
  (10)   -OR 1 4 ;
  (11)   -NRi    5 R1 6 ;
  (12) a cyano group;                or
 (13)    a nitro group;
R5    represents:
 (1) a halogen;
 (2) -S (0) m 2 -Ri 7
 (3) -S0    2 NRiBR1 9      ;
 (4) -C(0)OR 2 0 ;
 (5) -NR    21C    (O)R 2 2 ;
 (6) -C (0) NR        2 3R 2 4 ;
 (7) -OR    25  ;
 (8) -NR    2 6 R 27 ;
 (9) a cyano group;
 (10)   a nitro group;              or
 (11) a C1-3 alkyl group optionally substituted with a
substituent selected from the group consisting of                         (i) a
halogen,          (ii) a hydroxy group and           (iii) an oxo group;
when two R5 groups are present,                   the R5 groups may be
independently the same or different;
when,     further,             two R5 groups are respectively        and independently
a C1-3 alkyl group or a hydroxy group and the R5 groups are
attached to carbon atoms adjacent to each other on the C5-6
monocyclic carbocycle or the 5- to                    6-membered monocyclic
heterocycle,              the R5 groups may together          form a  ring;
                                               11

 R 6 to R 2 7 respectively         and independently    represent   (1)     a
 hydrogen atom or             (2) a C1-6 alkyl group optionally substituted
 with     (i) a halogen or          (ii) a hydroxy group;
 when R18 and R19 are respectively              and independently a C1-6 alkyl
 group,     R18 and R 1 9 groups may together        form a  ring;
 R2 represents:
 (1) a halogen;
 (2) a C1-6 alkyl group optionally substituted with                   (i) a
halogen or             (ii) a hydroxy group;
 (3) a C3-6 cycloalkyl group optionally substituted with                        (i) a
halogen or             (ii) a hydroxy group;
 (4) a C1-6 alkoxy group optionally substituted with a halogen;
 (5)   -NR  2 8 R2 9 ;
 (6) a 3- to 7-membered monocyclic heterocycle;                 or
 (7) -O-(3- to 7-membered monocyclic heterocycle);
R 2 8 and R 2 9 respectively         and independently    represent     (1)   a
hydrogen atom or             (2) a C1-6 alkyl group optionally substituted
with     (i) a halogen or          (ii) a hydroxy group;
Ai and A 2 respectively            and independently    represent   =CR 3 -   or =N
A3 ,  A4,   A 5 and A 6 respectively       and independently     represent        =CR 4
or =N-;
R 3 and R 4 respectively           and independently    represent   a hydrogen
atom or a halogen;
ml represents an integer of 0 to 2;
m2 represents an integer of 0 to 2;
                                            1')

p represents an integer of 0 to 7;
q represents an integer of 0 to 7;
r represents an integer of 0 to 2;
provided that when p, q and r respectively represent an
integer of 2 or more,               R1 , R2 and R3 groups may be respectively
and independently the same or different, a salt thereof, an N
oxide thereof, a solvate thereof or a prodrug thereof;
 [2]    the compound according to the above [1],                         wherein the ring
Cy 2 is a 5- to 10-membered monocyclic aromatic heterocycle or
bicyclic aromatic heterocycle excluding a heterocycle 1,3
thiazol-5-yl group;
[3]    the compound according to the above                     [1]      or  [2],   wherein
the ring Cy 2 is           a pyridine ring,      a pyrimidine ring,                a
pyrazolopyrimidine ring, an imidazopyridazine ring, an
imidazopyridine ring, a pyrrolopyridine ring, an
imidazopyrazine ring or a pyrazolopyridine ring;
[4]    the compound according to any one of the above [1]                               to [3],
wherein one of A 1 and A2 is               =N- and the other is               =CH-   or both
are =N-          and A3 , A 4 , A 5 and A6 are =CH-;
[5]   the compound according to the above [1],                           wherein the
general formula             (I) is represented by the general formula                      (I
i) or the general formula                (I-ii):
     (R4)t         (R )r                             (R4)t       (R3 )r
                           2
N            ,N   ON\N N            RN                          0 \ N      NN        1 )
      -     a            H     H                      (    .H                  H
       (R2-a)q-a                                  K ,(R2.a)q-a

         wherein R2-a represents          the same meaning as R 2 ;              q-a
represents         an integer of 0 to 3;           t represents an integer of 0
to 4;      and other symbols represent the same meanings as those
described in the above              [1],  provided that when q-a and t
represent         an integer     of 2 or more,        R2-a and R 4 groups may be
respectively and independently the same or different;
 [6]  the compound according to the above                        [5], wherein R2-a is a
3- to 7-membered monocyclic heterocycle;
 [7]  the compound according to the above                        [1], wherein the
general formula            (I) is represented by the general formula                        (I
iii) or the general formula               (I-iv):
     (R4)t        RA       NR         j)N            (R4)t        (R  N        N    R   j    V)
     NN
  N                                              N
        (R2-b)q-b                                      (R2-b)q-b
         wherein     R2-b    represents   the same meaning            as R 2 ;   q-b
represents an integer of 0 to 4;                   and other symbols represent
the same meanings as those described in the above                              [1]   and    [5],
provided that when q-b represents an integer of 2 or more,                                   R2-b
groups may be respectively and independently the same or
different;
[8]   the compound according to the above                        [7], wherein      R2-b   is a
3- to 7-membered monocyclic heterocycle;
[9]   the compound according to any one of the above                            [1]   to    [8],
wherein the ring Cyi             is a benzene ring or a 5- to 6-membered
                                             I A

monocyclic aromatic heterocycle;
 [10] the compound according to the above  [9],   wherein the ring
Cyi is a benzene ring, a pyridine ring or a pyrazole ring;
 [11] a pharmaceutical composition including the compound
represented by the general formula   (I) according to the above
 [1], a salt thereof, an N-oxide thereof, a solvate thereof or
a prodrug thereof as an active ingredient;
 [12] the composition according to the above [11],    which is a
Trk inhibitor;
 [13] the composition according to the above    [11], which is a
prophylactic and/or therapeutic agent for Trk-related disease;
 [14] the composition according to the above    [13], wherein the
Trk-related disease is pain, pruritus, lower urinary tract
dysfunction, asthma, allergic rhinitis, inflammatory bowel
disease or Chagas disease;
[15]  the composition according to the above    [14], wherein the
pain is pain of osteoarthritis, cancer pain, chronic low back
pain, low back pain of osteoporosis, pain of bone fracture,
pain of rheumatoid arthritis, neuropathic pain, postherpetic
pain, pain of diabetic neuropathy, fibromyalgia, pain of
pancreatitis, pain of interstitial cystitis, pain of
endometriosis, pain of irritable bowel syndrome, migraine,
postoperative pain or pain of pulpitis;
[16]  a medicament which is a combination of the compound
represented by the general formula (I) according to the above
[1],  a salt thereof, an N-oxide thereof, a solvate thereof or
                                1I

a prodrug thereof and at least one selected from
acetaminophen, a nonsteroid antiinflammatory drug, an opioid,
an antidepressant, an antiepileptic agent, an N-methyl-D
aspartate antagonist, a muscle relaxant, an antiarrhythmic
agent, a steroid and a bisphosphonate;
 [17] a method for prophylaxis and/or therapy of Trk-related
disease, including administering, to a patient, an effective
amount of the compound represented by the general formula      (I)
according to the above [1],    a salt thereof, an N-oxide
thereof, a solvate thereof or a prodrug thereof;
[18]  the compound represented by the general formula    (I)
according to the above   [1],  a salt thereof, an N-oxide
thereof, a solvate thereof or a prodrug thereof for
prophylaxis and/or therapy of Trk-related disease;
[19]  a method for inhibiting Trk, including administering, to
a patient, an effective amount of the compound represented by
the general formula (I) according to the above    [1], a salt
thereof, an N-oxide thereof, a solvate thereof or a prodrug
thereof;
[20]  use of the compound represented by the general formula
(I) according to the above    [1], a salt thereof, an N-oxide
thereof, a solvate thereof or a prodrug thereof for
manufacturing a prophylactic and/or therapeutic agent for Trk
related disease;
[21]  the compound according to any one of the above    [1] to
[5],  which is:

 (1) 1-(2-(1H-pyrazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(2-(4
 (2-amino-5-chloropyridin-3-yl)phenoxy)pyrimidin-5-yl)urea,
 (2) 1-(2-(4-(2-amino-5-chloropyridin-3-yl)phenoxy)pyrimidin-5
yl)-3-(2-(4-methyl-1H-1,2,3-triazol-1-yl)-5
 (trifluoromethyl)phenyl)urea,
 (3) 1-(2-(4-(2-amino-5-chloropyridin-3-yl)phenoxy)pyrimidin-5
yl)-3-(5-(trifluoromethyl)-2-(3-(trifluoromethyl)-1H-pyrazol
1-yl)phenyl)urea,
 (4) 1-(2-(4-(2-amino-5-chloropyridin-3-yl)phenoxy)pyrimidin-5
yl)-3-(2-chloro-5-(trifluoromethyl)phenyl)urea,
(5) 1-(2-(1H-pyrazol-1-yl)-5-(trifluoromethyl)phenyl-3-(6-(4
(2-amino-5-chloropyridin-3-yl)phenoxy)pyridin-3-yl)urea,
(6) 1-(2-(1H-1,2,3-triazol-1-yl)-5-(trifluoromethyl)phenyl-3
(6-(4-(2-amino-5-chloropyridin-3-yl)phenoxy)pyridin-3-yl)urea,
(7) 1-(6-(4-(2-amino-5-chloropyridin-3-yl)phenoxy)pyridin-3
yl)-3-(2-(pyridin-3-yl)-5-(trifluoromethyl)phenyl)urea,
(8) 1-(2-(4-(2-amino-5-chloropyridin-3-yl)phenoxy)pyrimidin-5
yl)-3-(2-(1-methyl-1H-pyrazol-5-yl)-5
(trifluoromethyl)phenyl)urea,
(9) 1-(2-(lH-1,2,3-triazol-1-yl)-5-(trifluoromethyl)phenyl)-3
(2-(4-(2-amino-5-fluoropyridin-3-yl)phenoxy)pyrimidin-5
yl)urea,
(10) 1-(2-(4-(2-amino-5-fluoropyridin-3-yl)phenoxy)pyrimidin
5-yl)-3-(2-(pyridin-3-yl)-5-(trifluoromethyl)phenyl)urea,
(11) 1-(2-(lH-pyrazol-1-yl)-4-(trifluoromethyl)phenyl)-3-(2
(4-(2-amino-5-chloropyridin-3-yl)phenoxy)pyrimidin-5-yl)urea,
                               1-7

 (12) 1-(2-(4-(2-amino-5-chloropyridin-3-yl)phenoxy)pyrimidin
5-yl)-3-(2-fluoro-4-(trifluoromethyl)phenyl)urea,
 (13) 1-(2-(4-(2-amino-5-chloropyridin-3-yl)phenoxy)pyrimidin
5-yl)-3-(2-chloro-4-(trifluoromethyl)phenyl)urea,
 (14) 1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyllphenoxy}-5-pyrimidinyl)-3-{5-(trifluoromethyl)-2-[3
 (trifluoromethyl)-1H-pyrazol-1-yl]phenyl}urea,
 (15) 1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]-5
pyrimidinyl}-3-[4-(trifluoromethyl)-2-biphenylyllurea,
 (16) 1-{2-[4-(2-amino-5-fluoro-3-pyridinyl)phenoxy]-5
pyrimidinyl}-3-[4-(trifluoromethyl)-2-biphenylyl]urea,
 (17) 1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]-5
pyrimidinyll-3-[2-(4-chloro-1H-pyrazol-1-yl)-5
 (trifluoromethyl)phenyl]urea,
(18) 1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]-5
pyrimidinyl}-3-{5-chloro-2-[3-(trifluoromethyl)-1H-pyrazol-1
yl]phenyl}urea,
(19) 1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]-5
pyrimidinyl}-3-[2,4-bis(trifluoromethyl)phenyl]urea,
(20) 1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-[2-(4-chloro-1H-pyrazol-1
yl)-5-(trifluoromethyl)phenyl]urea,
(21) 1-{2-[4-(2-amino-5-fluoro-3-pyridinyl)phenoxy]-5
pyrimidinyl}-3-[2-(methylsulfonyl)-5
(trifluoromethyl)phenyl]urea,
(22) 1-(2-{4-[2-amino-5-(trifluoromethyl)-3
                                11 r

pyridinyl]phenoxy}-5-pyrimidinyl)-3-[2-(methylsulfonyl)-5
 (trifluoromethyl)phenyl]urea,
 (23) 1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]-5
pyrimidinyl}-3-[2-(methylsulfonyl)-5
 (trifluoromethyl)phenyl]urea or
 (24) 2-{[(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyllphenoxy}-5-pyrimidinyl)carbamoyl]amino}-N,N
dimethyl-4-(trifluoromethyl)benzenesulfonamide;
[22] the compound according to any one of the above [1] to  [4]
and the above  [7], which is:
(1) 1-(2-(4-(5-(azetidin-1-yl)pyrazolo[1,5-a]pyrimidin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-(pyridin-3-yl)-5
(trifluoromethyl)phenyl)urea,
(2) 1-(2-(4-(5-(azetidin-1-yl)pyrazolo[1,5-alpyrimidin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-(1-methyl-1H-pyrazol-5-yl)-5
(trifluoromethyl)phenyl)urea,
(3) 1-(2-(4-(5-methoxypyrazolo[1,5-a]pyrimidin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-(pyridin-3-yl)-5
(trifluoromethyl)phenyl)urea,
(4) 1-(2-(4-(pyrazolo[1,5-a]pyrimidin-3-yl)phenoxy)pyrimidin
5-yl)-3-(2-(pyridin-3-yl)-5-(trifluoromethyl)phenyl)urea,
(5) 1-(2-{4-[5-(dimethylamino)pyrazolo[1,5-a]pyrimidin-3
yl]phenoxy}-5-pyrimidinyl)-3-[2-(3-pyridinyl)-5
(trifluoromethyl)phenyl]urea,
(6) 1-(2-{4-[5-(dimethylamino)pyrazolo[1,5-a]pyrimidin-3
yl]phenoxy}-5-pyrimidinyl)-3-[2-(1-methyl-1H-pyrazol-5-yl)-5
                                I1Q

 (trifluoromethyl)phenyl]urea,
 (7) 1-{2-[4-(5-methylpyrazolo[1,5-a]pyrimidin-3-yl)phenoxy]-5
pyrimidinyl}-3-[2-(3-pyridinyl)-5
 (trifluoromethyl)phenyl]urea,
 (8) 1-(2-{4-[5-(ethylamino)pyrazolo[1,5-a]pyrimidin-3
yl]phenoxy}-5-pyrimidinyl)-3-[3'-methyl-4-(trifluoromethyl)-2
biphenylyllurea,
(9) 1-(2-{4-[5-(dimethylamino)pyrazolo[1,5-apyrimidin-3
yljphenoxy}-5-pyrimidinyl)-3-[4-(trifluoromethyl)-2
biphenylyl]urea,
(10) 1-(2-{4-[5-(dimethylamino)pyrazolo[1,5-alpyrimidin-3
yl]phenoxy}-5-pyrimidinyl)-3-[3'-methyl-4-(trifluoromethyl)-2
biphenylyllurea or
(11)  1-(2-{4-[5-(dimethylamino)pyrazolo[1,5-a]pyrimidin-3
yl]phenoxy}-5-pyrimidinyl)-3-[2'-methyl-4-(trifluoromethyl)-2
biphenylyl]urea;
[23] an article of manufacture including (1) a pharmaceutical
composition including the compound represented by the general
formula   (I) according to the above [1], a salt thereof, an N
oxide thereof, a solvate thereof or a prodrug thereof, (2) a
container and (3) an instruction, a description, a package
insert or a product label indicating that the composition can
be used for prophylaxis and/or therapy of Trk-related disease;
[24]  the article of manufacture according to the above  [23],
wherein the Trk-related disease is pain;
[25]  an article of manufacture including  (1) a pharmaceutical

composition including the compound represented by the general
formula (I) according to the above   [1], a salt thereof, an N
oxide thereof, a solvate thereof or a prodrug thereof,    (2) a
container and (3) an instruction, a description, a package
insert or a product label indicating that the composition can
be used for prophylaxis and/or therapy of Trk-related disease
in combination with acetaminophen, a nonsteroid
antiinflammatory drug, an opioid, an antidepressant, an
antiepileptic agent, an N-methyl-D-aspartate antagonist, a
muscle relaxant, an antiarrhythmic agent, a steroid and/or a
bisphosphonate;
 [26] the article of manufacture according to the above [25],
wherein the Trk-related disease is pain;
 [27] an article of manufacture including (1) a pharmaceutical
composition in the form of a combination drug including the
compound represented by the general formula   (I) according to
the above [1],  a salt thereof, an N-oxide thereof, a solvate
thereof or a prodrug thereof and acetaminophen, a nonsteroid
antiinflammatory drug, an opioid, an antidepressant, an
antiepileptic agent, an N-methyl-D-aspartate antagonist, a
muscle relaxant, an antiarrhythmic agent, a steroid and/or a
bisphosphonate,  (2) a container and (3) an instruction, a
description, a package insert or a product label indicating
that the composition can be used for prophylaxis and/or
therapy of Trk-related disease; and
[28]  the article of manufacture according to the above   [27],

wherein the Trk-related disease is pain;
Effect of the Invention
      The present compound has Trk-inhibiting activity and
excellent kinase selectivity.    Further, the present compound
persistently inhibits NGF vascular hyper permeability.
Therefore the present compound can be a prophylactic and/or
therapeutic agent for Trk-related diseases such as pain,
pruritus, lower urinary tract dysfunction, asthma, allergic
rhinitis, inflammatory bowel disease or Chagas disease.
             BEST MODE FOR CARRYING OUT THE INVENTION
      The present invention is hereinafter specifically
described.
      In the present invention, "a C3-10 monocyclic carbocycle
or bicyclic carbocycle" may include, for example,
cyclopropane, cyclobutane, cyclopentane, cyclohexane,
cycloheptane, cyclooctane, cyclononane, cyclodecane,
cyclopentene, cyclohexene, cycloheptene, cyclooctene,
cyclopentadiene, cyclohexadiene, cycloheptadiene,
cyclooctadiene, benzene, pentalene, perhydropentalene,
azulene, perhydroazulene, indene, perhydroindene, indane,
naphthalene, dihydronaphthalene, tetrahydronaphthalene and
perhydronaphthalene rings.
      In the present invention, "a 4- to 10-membered monocyclic
heterocycle or bicyclic heterocycle"    in the ring Cy1 may
include, for example, oxetane, azetidine, pyrrolidine,
                                1) '

pyrrole, imidazole, triazole, tetrazole, pyrazole, pyridine,
piperidine, piperazine, pyrazine, pyrimidine, pyridazine,
azepine, diazepine, furan, pyran, oxepin, thiophene,
thiopyran, thiepine, oxazole, isoxazole, thiazole,
isothiazole, furazan, oxadiazole, oxazine, oxadiazine,
oxazepine, oxadiazepine, thiadiazole, thiazine, thiadiazine,
thiazepine, thiadiazepine, indole, isoindole, indolizine,
benzofuran, isobenzofuran, benzothiophene, isobenzothiophene,
indazole, quinoline, isoquinoline, quinolidine, purine,
phthalazine, pteridine, naphthyridine, quinoxaline,
quinazoline, cinnoline, benzoxazole, benzothiazole,
benzimidazole, benzodioxole, benzoxathiole, chromene,
benzofurazan, benzothiadiazole, benzotriazole, pyrroline,
pyrrolidine, imidazoline, imidazolidine, triazoline,
triazolidine, tetrazoline, tetrazolidine, pyrazoline,
pyrazolidine, dihydropyridine, tetrahydropyridine,
dihydropyrazine, tetrahydropyrazine, dihydropyrimidine,
tetrahydropyrimidine, perhydropyrimidine, dihydropyridazine,
tetrahydropyridazine, perhydropyridazine, dihydroazepine,
tetrahydroazepine, perhydroazepine, dihydrodiazepine,
tetrahydrodiazepine, perhydrodiazepine, dihydrofuran,
tetrahydrofuran, dihydropyran, tetrahydropyran, dihydrooxepin,
tetrahydrooxepin, perhydrooxepin, dihydrothiophene,
tetrahydrothiophene, dihydrothiopyran, tetrahydrothiopyran,
dihydrothiepine, tetrahydrothiepine, perhydrothiepine,
dihydrooxazole, tetrahydrooxazole (oxazolidine),

dihydroisoxazole, tetrahydroisoxazole (isoxazolidine),
dihydrothiazole, tetrahydrothiazole   (thiazolidine),
dihydroisothiazole, tetrahydroisothiazole   (isothiazolidine),
dihydrofurazan, tetrahydrofurazan, dihydrooxadiazole,
tetrahydrooxadiazole  (oxadiazolidine), dihydrooxazine,
tetrahydrooxazine, dihydrooxadiazine, tetrahydrooxadiazine,
dihydrooxazepine, tetrahydrooxazepine, perhydrooxazepine,
dihydrooxadiazepine, tetrahydrooxadiazepine,
perhydrooxadiazepine, dihydrothiadiazole,
tetrahydrothiadiazole  (thiadiazolidine), dihydrothiazine,
tetrahydrothiazine, dihydrothiadiazine, tetrahydrothiadiazine,
dihydrothiazepine, tetrahydrothiazepine, perhydrothiazepine,
dihydrothiadiazepine, tetrahydrothiadiazepine,
perhydrothiadiazepine, morpholine, thiomorpholine, oxathiane,
indoline, isoindoline, dihydrobenzofuran, perhydrobenzofuran,
dihydroisobenzofuran, perhydroisobenzofuran,
dihydrobenzothiophene, perhydrobenzothiophene,
dihydroisobenzothiophene, perhydroisobenzothiophene,
dihydroindazole, perhydroindazole, dihydroquinoline,
tetrahydroquinoline, perhydroquinoline, dihydroisoquinoline,
tetrahydroisoquinoline, perhydroisoquinoline,
dihydrophthalazine, tetrahydrophthalazine,
perhydrophthalazine, dihydronaphthyridine,
tetrahydronaphthyridine, perhydronaphthyridine,
dihydroquinoxaline, tetrahydroquinoxaline,
perhydroquinoxaline, dihydroquinazoline,
                               n~ A

tetrahydroquinazoline, perhydroquinazoline, dihydrocinnoline,
tetrahydrocinnoline, perhydrocinnoline, benzoxathiane,
dihydrobenzoxazine, dihydrobenzothiazine, pyrazinomorpholine,
dihydrobenzoxazole, perhydrobenzoxazole, dihydrobenzothiazole,
perhydrobenzothiazole, dihydrobenzimidazole,
perhydrobenzimidazole, dioxolane, dioxane, dioxaindane,
benzodioxane, thiochromane, dihydrobenzodioxine,
dihydrobenzoxathiine, chromane, pyrazolopyrimidine,
imidazopyridazine, imidazopyridine, pyrrolopyridine,
imidazopyrazine, pyrazolopyridine, pyrazolopyrimidine,
imidazopyridine and triazolopyridine rings.
       In the present invention, "a 4- to 10-membered monocyclic
heterocycle or bicyclic heterocycle excluding a heterocycle
1,3-thiazol-5-yl      group" in  the ring Cy 2 has the same meaning as
"a 4- to 10-membered monocyclic heterocycle or bicyclic
heterocycle"      in the ring Cy1 as described above,   excluding the
heterocycle 1,3-thiazol-5-yl group.
       In the present invention, the compound wherein the ring
Cy 2 is "a 4- to 10-membered monocyclic heterocycle or bicyclic
heterocycle excluding a heterocycle 1,3-thiazol-5-yl group"
corresponds to the compound of the general formula (I)
excluding the compound of the following general formula         (I'):
                     A 3
       (R2 )                O        N    NH1
                         A5   A2         N8
               S   5
             N- 4                   H    H
             3

      wherein q' represents an integer of 0 to 2 and other
symbols represent the same meanings as those described in the
above   [1], provided that when q' represents 2, R2 groups may be
respectively and independently the same or different.
      In the present invention, "a halogen" may include
fluorine, chlorine, bromine and iodine.
      In the present invention, "a C1-6 alkyl group" may
include, for example, methyl, ethyl, n-propyl, isopropyl, n
butyl, sec-butyl, tert-butyl, isobutyl, pentyl, 1-methylbutyl,
2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2
dimethylpropyl, 2,2-dimethylpropyl, hexyl, 1-methylpentyl, 2
methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1
dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2
dimethylbutyl, 2,3-dimethylbutyl, 1-methyl-1-ethylpropyl, 2
methyl-2-ethylpropyl, 1-ethylbutyl, 2-ethylbutyl and 1,1
dimethylpentyl groups.
      In the present invention, "a C2-6 alkenyl group" may
include, for example, vinyl, 1-propenyl, 2-propenyl, 1
butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3
pentenyl, 4-pentenyl, 3-methyl-1-butenyl, 3-methyl-2-butenyl,
3-methyl-3-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl
and 5-hexenyl groups.
      In the present invention, "a C2-6 alkynyl group" may
include, for example, ethynyl, 1-propynyl, 2-propynyl, 1
butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3
pentynyl, 4-pentynyl, 3-methyl-1-butynyl, 1-hexynyl, 2-

hexynyl, 3-hexynyl, 4-hexynyl and 5-hexynyl groups.
      In the present invention, "a C5-6 monocyclic carbocycle"
may include, for example, cyclopentane, cyclohexane,
cyclopentene, cyclohexene, cyclopentadiene, cyclohexadiene and
benzene rings.
     In the present invention, "a 5- to 6-membered monocyclic
heterocycle" may include, for example, pyrrole, imidazole,
triazole, tetrazole, pyrazole, pyridine, piperidine,
piperazine, pyrazine, pyrimidine, pyridazine, furan, pyran,
thiophene, thiopyran, oxazole, isoxazole, thiazole,
isothiazole, furazan, oxadiazole, oxazine, oxadiazine,
thiadiazole, thiazine, thiadiazine, pyrroline, pyrrolidine,
imidazoline, imidazolidine, triazoline, triazolidine,
tetrazoline, tetrazolidine, pyrazoline, pyrazolidine,
dihydropyridine, tetrahydropyridine, dihydropyrazine,
tetrahydropyrazine, dihydropyrimidine, tetrahydropyrimidine,
perhydropyrimidine, dihydropyridazine, tetrahydropyridazine,
perhydropyridazine, dihydrofuran, tetrahydrofuran,
dihydropyran, tetrahydropyran, dihydrothiophene,
tetrahydrothiophene, dihydrothiopyran, tetrahydrothiopyran,
dihydrooxazole, tetrahydrooxazole  (oxazolidine),
dihydroisoxazole, tetrahydroisoxazole   (isoxazolidine),
dihydrothiazole, tetrahydrothiazole   (thiazolidine),
dihydroisothiazole, tetrahydroisothiazole   (isothiazolidine),
dihydrofurazan, tetrahydrofurazan, dihydrooxadiazole,
tetrahydrooxadiazole  (oxadiazolidine), dihydrooxazine,

tetrahydrooxazine, dihydrooxadiazine, tetrahydrooxadiazine,
dihydrothiadiazole, tetrahydrothiadiazole   (thiadiazolidine),
dihydrothiazine, tetrahydrothiazine, dihydrothiadiazine,
tetrahydrothiadiazine, morpholine, thiomorpholine and
oxathiane rings.
      In the present invention, "a Cl-3 alkyl group" includes
methyl, ethyl, n-propyl and isopropyl groups.
      In the present invention, "a C3-6 cycloalkyl group"
includes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl
groups.
     In the present invention, "a Cl-6 alkoxy group" may
include, for example, methoxy, ethoxy, propoxy, isopropoxy,
butoxy, 1-methylpropoxy, tert-butoxy, isobutoxy, pentyloxy, 1
methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 1,1
dimethylpropoxy, 1,2-dimethylpropoxy, 2,2-dimethylpropoxy,
hexyloxy, 1-methylpentyloxy, 2-methylpentyloxy, 3
methylpentyloxy, 4-methylpentyloxy, 1,1-dimethylbutoxy, 1,2
dimethylbutoxy, 1,3-dimethylbutoxy, 1-methyl-l-ethylpropoxy,
1-methyl-2-ethylpropoxy, 1,2-dimethylbutoxy, 2,2
dimethylbutoxy, 1-ethyl-2-methylpropoxy, 2-ethyl-2
methylpropoxy and 1-ethylbutoxy groups.
     In the present invention, "a 3- to 7-membered monocyclic
heterocycle" may include, for example, aziridine, oxetane,
azetidine, pyrrole, imidazole, triazole, tetrazole, pyrazole,
pyridine, piperidine, piperazine, pyrazine, pyrimidine,
pyridazine, azepine, diazepine, furan, pyran, oxepin,

thiophene, thiopyran, thiepine, oxazole, isoxazole, thiazole,
isothiazole, furazan, oxadiazole, oxazine, oxadiazine,
oxazepine, oxadiazepine, thiadiazole, thiazine, thiadiazine,
thiazepine, thiadiazepine, pyrroline, pyrrolidine,
imidazoline, imidazolidine, triazoline, triazolidine,
tetrazoline, tetrazolidine, pyrazoline, pyrazolidine,
dihydropyridine, tetrahydropyridine, dihydropyrazine,
tetrahydropyrazine, dihydropyrimidine, tetrahydropyrimidine,
perhydropyrimidine, dihydropyridazine, tetrahydropyridazine,
perhydropyridazine, dihydroazepine, tetrahydroazepine,
perhydroazepine, dihydrodiazepine, tetrahydrodiazepine,
perhydrodiazepine, dihydrofuran, tetrahydrofuran,
dihydropyran, tetrahydropyran, dihydrooxepin,
tetrahydrooxepin, perhydrooxepin, dihydrothiophene,
tetrahydrothiophene, dihydrothiopyran, tetrahydrothiopyran,
dihydrothiepine, tetrahydrothiepine, perhydrothiepine,
dihydrooxazole, tetrahydrooxazole   (oxazolidine),
dihydroisoxazole, tetrahydroisoxazole   (isoxazolidine),
dihydrothiazole, tetrahydrothiazole   (thiazolidine),
dihydroisothiazole, tetrahydroisothiazole   (isothiazolidine),
dihydrofurazan, tetrahydrofurazan, dihydrooxadiazole,
tetrahydrooxadiazole  (oxadiazolidine), dihydrooxazine,
tetrahydrooxazine, dihydrooxadiazine, tetrahydrooxadiazine,
dihydrooxazepine, tetrahydrooxazepine, perhydrooxazepine,
dihydrooxadiazepine, tetrahydrooxadiazepine,
perhydrooxadiazepine, dihydrothiadiazole,

tetrahydrothiadiazole  (thiadiazolidine), dihydrothiazine,
tetrahydrothiazine, dihydrothiadiazine, tetrahydrothiadiazine,
dihydrothiazepine, tetrahydrothiazepine, perhydrothiazepine,
dihydrothiadiazepine, tetrahydrothiadiazepine,
perhydrothiadiazepine, morpholine, thiomorpholine and
oxathiane rings.
      In the present invention, "a 5- to 10-membered monocyclic
aromatic heterocycle or bicyclic aromatic heterocycle
excluding a heterocycle 1,3-thiazol-5-yl group" may include,
for example, pyrrole, imidazole, triazole, tetrazole,
pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, azepine,
diazepine, furan, oxepin, thiophene, thiepine, oxazole,
isoxazole, isothiazole, furazan, oxadiazole, oxazepine,
oxadiazepine, thiadiazole, indole, isoindole, indolizine,
benzofuran, isobenzofuran, benzothiophene, isobenzothiophene,
indazole, quinoline, isoquinoline, quinolidine, purine,
phthalazine, pteridine, naphthyridine, quinoxaline,
quinazoline, cinnoline, benzoxazole, benzothiazole,
benzimidazole, benzofurazan, benzothiadiazole, benzotriazole,
pyrazolopyrimidine, imidazopyridazine, imidazopyridine,
pyrrolopyridine, imidazopyrazine, pyrazolopyridine,
pyrazolopyrimidine, imidazopyridine and triazolopyridine
rings.
     In the present invention, "a 5- to 6-membered monocyclic
aromatic heterocycle" may include, for example, pyrrole,
imidazole, triazole, tetrazole, pyrazole, pyridine, pyrazine,
                                1)

pyrimidine, pyridazine, furan, thiophene, oxazole, isoxazole,
thiazole, isothiazole, furazan, oxadiazole and thiadiazole
rings.
       In the present invention, the phrase "when, further, two
R5 groups are respectively and independently a Cl-3 alkyl group
or a hydroxy group and the R5 groups are attached to carbon
atoms adjacent to each other on the C5-6 monocyclic carbocycle
or the 5-       to 6-membered monocyclic heterocycle,          the R5 groups
may together form a ring" may indicate, for example, the
following groups:
         Cy3              Cy3             Cy3         Cy3
         Cy3                     Cy3
             0       ,  and        o
      wherein a ring Cy3 represents a C5-6 monocyclic
carbocycle or a 5- to 6-membered monocyclic heterocycle and an
arrow means binding to the ring Cyi.
      In   the present        invention,   the phrase  "R 5 is  -S0 2NR1 8 R1 9 and
when R18 and R19 are respectively and independently a Cl-6 alkyl
group,   Ri8 and R19 may together form a ring" may indicate,                  for
example, the following groups:
                            0            0                  0
             O         /S//S
                         N           N/N               //S\
           //,O            N        O N               O'/N
       O    N
                                                 and

      In the present invention, the ring Cyi is  preferably a
C5-6 monocyclic carbocycle or a 5- to 6-membered monocyclic
heterocycle.
      In the present invention, the ring Cy1 is  more preferably
cyclopentane, cyclohexane, benzene, pyran, thiopyran,
pyrrolidine, piperidine, piperazine, imidazoline,
imidazolidine, morpholine, thiomorpholine or a 5- to 6
membered monocyclic aromatic heterocycle.
      In the present invention, the ring Cy1 is  further
preferably benzene or a 5- to 6-membered monocyclic aromatic
heterocycle.
     In  the present invention, the ring Cy1 is  still   more
preferably a benzene, pyrrole, imidazole, pyrazole, pyridine,
pyrazine, pyrimidine, pyridazine, furan, thiophene, oxazole,
isoxazole, thiazole or isothiazole ring.
     In  the present invention, the ring Cyi is  yet more
preferably a benzene, imidazole, pyrazole, pyridine, pyrazine,
pyrimidine or pyridazine ring.
     In  the present invention, the ring Cyi is  yet still    more
preferably a benzene, pyrazole or pyridine ring.
     In  the present invention, the ring Cyi is  the most
preferably a benzene or pyridine ring.
     In  the present invention, the ring Cy 2 is preferably a 5
to 10-membered monocyclic aromatic heterocycle or bicyclic
aromatic heterocycle excluding a heterocycle 1,3-thiazol-5-yl
group.

      In the present invention, the ring Cy2 is  more preferably
a pyridine, pyrazine, pyrimidine, pyridazine, indole,
isoindole, indolizine, benzofuran, isobenzofuran,
benzothiophene, isobenzothiophene, indazole, quinoline,
isoquinoline, quinolidine, purine, phthalazine, pteridine,
naphthyridine, quinoxaline, quinazoline, cinnoline,
benzoxazole, benzothiazole, benzimidazole, benzofurazan,
benzothiadiazole, benzotriazole, pyrazolopyrimidine,
imidazopyridazine, imidazopyridine, pyrrolopyridine,
imidazopyrazine, pyrazolopyridine, pyrazolopyrimidine,
imidazopyridine or triazolopyridine ring.
     In  the present invention, the ring Cy 2 is still more
preferably a pyridine, pyrazine, pyrimidine, pyridazine,
indole, isoindole, indolizine, indazole, quinoline,
isoquinoline, quinolidine, purine, phthalazine, pteridine,
naphthyridine, quinoxaline, quinazoline, cinnoline,
benzoxazole, benzothiazole, benzimidazole, benzofurazan,
benzothiadiazole, benzotriazole, pyrazolopyrimidine,
imidazopyridazine, imidazopyridine, pyrrolopyridine,
imidazopyrazine, pyrazolopyridine, pyrazolopyrimidine,
imidazopyridine or triazolopyridine ring.
     In  the present invention, the ring Cy2 is  yet more
preferably a pyridine, pyrazine, pyrimidine, pyridazine,
pyrazolopyrimidine, imidazopyridazine, imidazopyridine,
pyrrolopyridine, imidazopyrazine, pyrazolopyridine,
pyrazolopyrimidine, imidazopyridine or triazolopyridine ring.

          In the present invention,       the ring Cy2 is      yet still        more
preferably a pyridine, pyrimidine, pyrazolopyrimidine,
imidazopyridazine, imidazopyridine, pyrrolopyridine,
imidazopyrazine or pyrazolopyridine ring.
          In the present invention,       the ring Cy 2 is     the most
preferably a pyridine or pyrazolopyrimidine ring.
          In the present invention,       R1 is preferably       (1)     a halogen,
 (2) a Cl-3 alkyl group optionally substituted with a halogen,
 (3) a benzene ring optionally substituted with one or two R5
groups,       (4) a 5- to    6-membered monocyclic aromatic heterocycle
optionally       substituted    with one or two R5 groups,           (5)   a
methylsulfonyl group or          (6) N,N-dimethylsulfonamide.
          In the present     invention,   R1 is more preferably           (1)   a
halogen,       (2) a methyl group,      (3) a trifluoromethyl group,              (4)
a difluoromethyl group,          (5) a monofluoromethyl group,               (6) a
trichloromethyl group,          (7) a dichloromethyl group, (8) a
monochloromethyl group,          (9) a benzene ring optionally
substituted        with one or two R5 groups,         (10)  a pyrrole,
imidazole, triazole, tetrazole, pyrazole, pyridine, pyrazine,
pyrimidine, pyridazine, furan, thiophene, oxazole, isoxazole,
thiazole,       isothiazole, furazan, oxadiazole or thiadiazole ring
optionally       substituted    with one or two R 5 groups,          (11)     a
methylsulfonyl group or          (12) N,N-dimethylsulfonamide.
         In  the present     invention,   Ri is still      more preferably         (1)
a halogen,        (2) a methyl group,     (3) a trifluoromethyl group,
(4) a difluoromethyl group,           (5) a monofluoromethyl group,               (6)

a benzene ring,   (7) an indane ring,     (8) a tolyl group,   (9) a
dimethylbenzene ring,    (10) an imidazole, triazole, pyrazole or
pyridine ring optionally substituted with one or two R5 groups
or  (11) a methylsulfonyl group.
      In the present invention,   R1 is    yet more preferably   (1)  a
halogen,   (2) a trifluoromethyl group,      (3) a difluoromethyl
group, (4) a benzene ring,    (5) an indane ring,     (6) a tolyl
group, (7) a dimethylbenzene ring,       (8) an imidazole, triazole,
pyrazole or pyridine ring optionally substituted with one or
two methyl, difluoromethyl or trifluoromethyl groups or         (9) a
methylsulfonyl group.
      In the present invention,   Ri is    yet still  more preferably
(1) a trifluoromethyl group,    (2) a difluoromethyl group,       (3) a
benzene ring,   (4) a triazole, pyrazole or pyridine ring
optionally substituted with one or two methyl, difluoromethyl
or trifluoromethyl groups or    (5) a methylsulfonyl group.
      In the present invention,   R 1 is   the most preferably   (1)  a
trifluoromethyl group or    (2) a triazole, pyrazole or pyridine
ring optionally substituted with one or two methyl,
difluoromethyl or trifluoromethyl groups.
      In the present  invention,  R5 is    preferably  (1) a halogen,
(2) a methyl group optionally substituted with a halogen or
(3) a Cl-3 alkyl group optionally substituted with a hydroxy
group or an oxo group.
      In the present invention,   R5 is   more preferably a methyl
group, a trifluoromethyl group, a difluoromethyl group, an

acetyl group or a hydroxyethyl group.
      In the present invention,   R5 is  the most preferably a
methyl group, a trifluoromethyl group or a difluoromethyl
group.
      In the present invention,   R2 is  preferably  (1)  a halogen,
 (2) a Cl-3 alkyl group optionally substituted with a halogen
or a hydroxy group,    (3) a C3-6 cycloalkyl group,    (4) a C1-3
alkoxy group,   (5) an amino group,   (6) a methylamino,
ethylamino, n-propylamino, isopropylamino, n-butylamino, sec
butylamino, tert-butylamino, isobutylamino or dimethylamino
group optionally substituted with a hydroxy group,       (7) a 3- to
7-membered monocyclic heterocycle or      (8) -0-(3- to 7-membered
monocyclic heterocycle).
      In the present invention, R 2 is more preferably a
halogen, a methyl group, a trifluoromethyl group, a
difluoromethyl group, a monofluoromethyl group, a
hydroxymethyl group, a hydroxyethyl group, a 2-methyl
hydroxyethyl group, a cyclopropyl group, a methoxy group, an
ethoxy group, an amino group, a methylamino group, an
ethylamino group, a dimethylamino group, a 2-methyl-2
hydroxypropylamino group, an oxetanyloxy group, an azetidine
ring, a pyrrolidine ring or a piperidine ring.
      In the present invention, R 2 is still more preferably a
halogen, a methyl group, a cyclopropyl group, a methoxy group,
an amino group, a dimethylamino group, an oxetanyloxy group,
an azetidine ring, a pyrrolidine ring or a piperidine ring.

      In  the present  invention, R 2 is yet more preferably a
halogen, a methyl group, an amino group, an azetidine ring or
a pyrrolidine ring.
      In  the present invention,  R 2 is the most preferably
fluorine, chlorine, a methyl group, an amino group or an
azetidine ring.
      In the present  invention,  R 3 is preferably   hydrogen or
fluorine and the most preferably hydrogen.
      In the present  invention,  R 4 is preferably hydrogen or
fluorine and the most preferably hydrogen.
      In the present invention,   R6 is  preferably a    C1-3 alkyl
group optionally substituted with a halogen.
      In the present invention,   R6 is  more preferably a methyl
group, an ethyl group or a n-propyl group.
     In  the present  invention,  preferably R7 and R8 are
respectively and independently a hydrogen atom or a C1-3 alkyl
group optionally substituted with a hydroxy group.
     In  the present  invention,  more preferably R7 and R8 are
respectively and independently a hydrogen atom, a methyl
group, an ethyl group, a n-propyl group, an isopropyl group or
a 2-hydroxypropyl group.
     In  the present invention,   still  more preferably R7 and R8
are respectively and independently a hydrogen atom, a methyl
group, an ethyl group or a n-propyl group.
     In  the present  invention,  R 9 is preferably  a hydrogen
atom, a methyl group or an ethyl group.

       In  the present  invention, preferably R10 to R1 6 are
respectively and independently a hydrogen atom, a methyl
group, an ethyl group or a n-propyl group.
      In   the present  invention, R 1 7 is   preferably a Cl-3    alkyl
group optionally substituted with a halogen.
      In   the present invention,  R1 7 is    more preferably a methyl
group,    an ethyl group or a n-propyl      group.
      In   the present invention,  preferably      R1 8 and R19 are
respectively and independently a hydrogen atom or a C1-3 alkyl
group optionally substituted with a hydroxy group.
      In   the present invention,  more preferably R18 and R19 are
respectively and independently a hydrogen atom, a methyl
group, an ethyl group, a n-propyl group, an isopropyl group or
a 2-hydroxypropyl group.
      In   the present invention,  still     more preferably R1 8 and
R19 are respectively and independently a hydrogen atom, a
methyl group, an ethyl group or a n-propyl group.
      In   the present invention,  R 2 0 is   preferably a hydrogen
atom, a methyl group or an ethyl group.
      In   the present invention,  preferably R 2 1 to R 2 9 are
respectively and independently a hydrogen atom, a methyl
group, an ethyl group or a n-propyl group.
      In the present invention, ml is preferably an integer of
2.
      In the present invention, m2 is preferably an integer of
2.

       In the present invention, p is preferably an integer of 0
to 3.
       In the present invention, q is preferably an integer of 0
to 3.
       In the present invention, r is preferably an integer of 0
to 1.
      In the present invention, R2-a and R2-b respectively and
independently have the same meaning as R2 and preferable                    groups
thereof are also the same as R 2.
      In the present invention, q-a is preferably an integer of
0 to 1.
      In the present invention, q-b is preferably an integer of
0 to 1.
      In the present invention, the general formula (I) is
preferably those having the combinations of preferable
definitions for the ring Cyi,           the ring Cy 2 , R1 , R2 , R 3 , R4 , R5 ,
R2-a, R2-b,   ml,     m2, p,   q, r, t, q-a and q-b.
      In the present invention, the general formula                (I) is more
preferably the general formula            (I-a) or the general formula
(I-b):
                   (R4)t     (R3)r              R)p
      (R2)q        (NR
                  y2-a               H    H          (I-a)
            CY2-b                     H   H

      wherein a ring CY2-a and a ring Cy2-b represent a 5- to 10
membered monocyclic aromatic heterocycle or bicyclic aromatic
heterocycle excluding a heterocycle 1,3-thiazol-5-yl group,
and other symbols represent the same meanings as those
described in           [1] and [5]  above, a salt thereof, an N-oxide
thereof, a solvate thereof or a prodrug thereof.
      In the present invention, the general formula              (I) is
still more preferably the general formula              (I-c) or the general
formula      (I-d):
                    (R4 )t    (RA)r    ~
      (R2)q            4     OR                        -C)
             Cy 2-c                    N
                                       H    Nk
                                            H
                    (R4)t     (R3)r               R p
      (R 2)q         (                 N    N      R 1
              0
               Y2-d                    N    N
                      CY raH                H
      wherein a ring Cy2-c and a ring Cy2-d represent a pyridine
ring,  a pyrimidine ring,           a pyrazolopyrimidine   ring, an
imidazopyridazine ring, an imidazopyridine ring, a
pyrrolopyridine ring, an imidazopyrazine ring or a
pyrazolopyridine ring, and other symbols represent the same
meanings as those described in             [1] and [5] above, a salt
thereof, an N-oxide thereof, a solvate thereof or a prodrug
thereof.
      In the present invention, the general formula              (I) is yet
more preferably the general formula (I-e) or the general

formula (I-f):
      (R2)q        (
                                                           (I-e)
             y2                           H       H
                   (R4)t      (R                  NR1)p
      (R2)q           \   I      \-aN-f
                                N ,,      N 'E    N"8(
            CY2                           H       H
      wherein a ring Cyi-e and a ring Cylf represent a benzene
ring or a 5- to          6-membered monocyclic aromatic heterocycle,
and other symbols represent the same meanings as those
described in         [1]  and   [5]   above, a salt thereof, an N-oxide
thereof, a solvate thereof or a prodrug thereof.
      In the present invention, the general formula                    (I) is yet
still more preferably the general formula                    (I-g) or the general
formula     (I-h):
                   (R4)t       (RA)r)
      (R2)q   C                  \      NN
                                              NCW'8          (I-g)
              Y2                           H       H
                  (R4)t     0(RA )r)
     (R2)q C0(RN
                                                  N     R)  (1-h)
                 Cy 2
                                          N '     Nk
              Y2r                         H       H
     wherein a ring Cyig and a ring Cyi-h represent a benzene
ring, a pyridine ring or a pyrazole ring, and other symbols
represent the same meanings as those described in                    [1]  and [5]
above, a salt thereof, an N-oxide thereof, a solvate thereof
                                               AI

or a prodrug thereof.
      In the present invention, the general formula (I) is yet
still more preferably the general formula (I-j) or the general
formula (I-k):
      (R2)q        (
                        Y(I-j
             y2-a                 H   H
                  (R4)t     (R        NR1)p
      (R2)q                    <N   0
                                  N   N"8CY~ (1-k)
             Y2-k                 H
     wherein a ring Cy 2-j and a ring Cy2-k represent a 5- to 10
membered monocyclic aromatic heterocycle or bicyclic aromatic
heterocycle excluding a heterocycle 1,3-thiazol-5-yl group;     a
ring Cyi-j and a ring Cy-ak represent a benzene ring or a 5- to
6-membered monocyclic aromatic heterocycle; and other symbols
represent the same meanings as those described in [1]     and [5]
above, a salt thereof, an N-oxide thereof, a solvate thereof
or a prodrug thereof.
     In the present invention, the general formula (I) is yet
still more preferably the general formula     (I-m) or the general
formula     (I-n):

                   (R4)t     (R3)r                (R)
      (R2)q                   O          N     N
              Y2-m                     H     H
                   (R4)t     (R                      j)
       (R2)q0
                                N      N-)   N8         (I-n)
             Cy
              2 rn                     H     H
      wherein a ring CY2-m and a ring Cy2-n represent a pyridine
ring, a pyrimidine ring, a pyrazolopyrimidine ring, an
imidazopyridazine ring, an imidazopyridine ring, a
pyrrolopyridine ring, an imidazopyrazine ring or a
pyrazolopyridine ring;            a ring Cyi-m and a ring Cyi-,, represent a
benzene ring, a pyridine ring or a pyrazole ring; and other
symbols represent the same meanings as those described in                  [1]
and  [5]    above, a salt thereof, an N-oxide thereof, a solvate
thereof or a prodrug thereof.
      In the present invention, the compound represented by the
general formula          (I-n) wherein Cy2-n is a pyrimidine ring is
preferably the present compound of any of Example 16-1 to
Example 16-8        as described hereinbelow, a salt thereof, an N
oxide thereof, a solvate thereof or a prodrug thereof.
      In the present invention, the compound represented by the
general formula          (I-m) or the general formula         (I-n) wherein the
ring Cy 2 -m or Cy2-l is an imidazopyridazine ring is preferably
the present compound of any of Example 22-1 to Example 22-67
as described hereinbelow, a salt thereof, an N-oxide thereof,
                                           A

a solvate thereof or a prodrug thereof.
      In the present invention, the general formula (I-m) or
the general formula          (I-n) is preferably the present compound
of any of Example 23-1 to Example 23-12 as described
hereinbelow, a salt thereof, an N-oxide thereof, a solvate
thereof or a prodrug thereof.
     In the present invention, the general formula                (I) is
still more preferably the general formula                (I-i) or the general
formula   (I-ii):
              (R4 )t       (R )r
         NH2       -0O
      N                     N        N         Cy 1    (-i)
               (R2-a)q-a
             (R 4 )t      (R 3)r
         NH2                           O
                                       0ON
      N                             N     N    Cy 1
       I                            H      H
              (R2-a)q-a
     wherein all symbols represent the same meanings as those
described in        [1] and    [5] above, a salt thereof, an N-oxide
thereof, a solvate thereof or a prodrug thereof.
     In the present invention, the general formula                (I-i) or
the general formula          (I-ii) is preferably the general formula
(I-i-a) or the general formula               (I-ii-b):
                                           A A

              (R4 )t         (R3)r
         NH 2                      N               (R1
      N  N2                           N    NG           (-i-a)
                                      H    H
                (R2-a)q-a
              (R4)t         (R )r
        NH2               0\-N          O
      N           NNN                         Cy1il-   (Ijib)
                I                    H     H
                (R2-a)q-a
     wherein a ring Cyi-i-a and a ring CY-ii-b represent             a
benzene ring or a 5-             to 6-membered monocyclic aromatic
heterocycle and other symbols represent the same meanings as
those described in            [1] and   [5]  above, a salt thereof, an N
oxide thereof, a solvate thereof or a prodrug thereof.
     In the present invention, the general formula                (I-i) or
the general formula             (I-ii) is more preferably the general
formula   (I-i-c) or the general formula                (I-ii-d):
             (R4)t          (R3 )r
        NH 2      -                     O
      N                       N           NN Cy18       (j-i-C)
               I    -~H                   H
               (R2-a)q-a
              (R4)t         (R )r
        NH2               0 \N(
      N           'NN                         Cy1-i-d  (-ii-d)
                (qH                        H
                (R2-a)q-a

      wherein a ring Cy1 -i-c and a ring Cyii-d represent a
benzene ring, a pyridine ring or a pyrazole ring and other
symbols represent the same meanings as those described in      [1]
and  [5] above, a salt thereof, an N-oxide thereof, a solvate
thereof or a prodrug thereof.
      In the present invention, the general formula    (I-i) or
the general formula (I-ii) is the most preferably the present
compound of any of Example 7, Example 8-1 to Example 8-22,
Example 9-1 to Example 9-3, Example 11, Example 12, Example
13-1 to Example 13-4, Example 14-1 to Example 14-20 and
Example 15-1 to Example 15-251, a salt thereof, an N-oxide
thereof, a solvate thereof or a prodrug thereof.
      In the present invention, the general formula    (I) is
still more preferably the general formula (I-iii) or the
general formula       (I-iv):
           (R4)t         (R3 )r
      N                   N     N   H      (1-ii)
                                H   H
        N
              (R2-b)q-b
           (R4 )t        (R3 )r
       NN                         JN8(-v
           N
              (R2-b)q-b

      wherein all symbols represent the same meanings as those
described in        [1],   [5]    and [7] above, a salt thereof, an N
oxide thereof, a solvate thereof or a prodrug thereof.
      In the present invention, the general formula (I-iii) or
the general formula            (I-iv) is preferably the general formula
 (I-iii-a) or the general formula               (I-iv-b):
            (R 4 )t       (R3)r
                    '\.                    Cy1
      N           IH       N        N   N
                                        H             (-jjj-a)
        N
           N
               (R2-b)q-b
           (R4)t         (R 3)r
      N                             N           R1-
                                    H   H             (-iv-b)
       N
           N
              (R2-b)q-b
      wherein a ring Cyi-iii-a and a ring Cyi-iv-b represent a
benzene ring or a 5-            to 6-membered monocyclic aromatic
heterocycle and other symbols represent the same meanings as
those described in           [1],   [5] and [7] above, a salt thereof, an
N-oxide thereof, a solvate thereof or a prodrug thereof.
      In the present invention, the general formula             (I-iii) or
the general formula            (I-iv) is more preferably the general
formula   (I-iii-c) or the general formula (I-iv-d):
                                           A '7

            (R4)t          (R3)r
       N    N                I   N H N(iC
                                        H
        N
               (R2-b)q-b
            (R4)t        0(R )rj~
                            O N               (R)
       N                                              (N-V-d
        N
               (R2-b)q-b
      wherein      a ring Cy1-iii-c and a ring Cy1-iv-d represent         a
benzene ring or a pyridine ring and other symbols represent
the same meanings as those described in                 [1], [5] and  [7]
above, a salt thereof, an N-oxide thereof, a solvate thereof
or a prodrug thereof.
      In the present invention, the general formula                 (I-iii) or
the general formula            (I-iv) is the most preferably the present
compound of any of Example 20 and Example 21-1 to Example 21
134 as described hereinbelow, a salt thereof, an N-oxide
thereof, a solvate thereof or a prodrug thereof.
      All isomers are encompassed by the present invention
unless specifically stated.              For example, an alkyl group, an
alkenyl group, an alkynyl group and an alkoxy group comprise
linear and branched groups.              Further, rings, isomers in fused
rings   (E, Z, cis and trans forms),              isomers due to asymmetric
carbons   (R and S forms, cc and           p forms,   enantiomers,

diastereomers),    optically active substances with optical
rotatory    (D, L, d and 1 forms),     polar substances by
chromatographic separation      (high-polarity substances, low
polarity substances),     equilibrated compounds, rotational
isomers, mixtures thereof with any proportions and racemic
mixtures are all encompassed by the present invention.        Isomers
due to tautomeric properties are also encompassed by the
present invention.
      In the present invention, as is apparent to the one
skilled in the art, unless otherwise stated the symbol:
      indicates that the bond projects below the plane of the
paper (i.e. a-configuration),      the symbol:
      indicates that the bond projects above the plane of the
paper   (i.e.  p-configuration),  the symbol:
      indicates that the bond is the a-configuration or the      p
configuration, and the symbol:
      indicates that the bond is a mixture of the a
configuration and the p-configuration with any proportions.
[Salts]
      The compound represented by the general formula      (I) may
                                   A n

be converted to a salt according to well known methods.
      The salt is preferably a pharmaceutically acceptable
salt.
      The salt is preferably water soluble.
      The salt may include, for example, acid addition salts,
alkali metal salts, alkaline-earth metal salts, ammonium salts
and amine salts.
      The acid addition salt may include, for example,
inorganic acid salts such as hydrochlorides, hydrobromides,
hydroiodides, sulfates, phosphates and nitrates and organic
acid salts such as acetates, lactates, tartrates, benzoates,
citrates, methanesulfonates, ethanesulfonates,
trifluoroacetates, benzenesulfonates, toluenesulfonates,
isethionates, glucuronates and gluconates.
      The alkali metal salt may include, for example, potassium
and sodium.
      The alkaline-earth metal salt may include, for example,
calcium and magnesium.
      The ammonium salt may include, for example,
tetramethylammonium.
      The amine salt may include, for example, triethylamine,
methylamine, dimethylamine, cyclopentylamine, benzylamine,
phenethylamine, piperidine, monoethanolamine, diethanolamine,
tris(hydroxymethyl)aminomethane, lysine, arginine and N
methyl-D-glucamine.
      The present compound may be converted to an N-oxide

according to any methods.           The N-oxide represents the compound
of the general formula          (I) in which a nitrogen atom thereof is
oxidized and specifically may be the compound represented by
the general formula (I) wherein the nitrogen atom in A,, A 2 ,
A3 , A 4 , A 5 or A 6 , which is  =N-,  is  oxidized.    Alternatively,        the
N-oxide may be the compound represented by the general formula
 (I) wherein the nitrogen atom in          Cyi and Cy 2 , which are a
nitrogen-containing heterocycle, is oxidized.                Further, the N
oxide may be the compound represented by the general formula
 (I) wherein an amino group is oxidized.
        The compound represented by the general formula                 (I) and a
salt thereof may be converted to a solvate.
        The solvate is preferably non-toxic and water soluble.
Appropriate solvates may include, for example, solvates with
water or an alcoholic solvent (e.g., ethanol).
[Prodrugs]
       A prodrug of the compound represented by the general
formula      (I) refers to a compound that is converted to the
compound represented by the general formula              (I) by in vivo
reaction with an enzyme or gastric acid.            The prodrug of the
compound represented by the general formula              (I) may include,
for example, compounds wherein an amino group in the compound
represented by the general formula (I) is acylated, alkylated
or phosphated (e.g., compounds wherein an amino group in the
compound represented by the general formula              (I) is derivatized
to eicosanoyl, alanyl, pentylaminocarbonyl,              (5-methyl-2-oxo-

1,3-dioxolen-4-yl)methoxycarbonyl, tetrahydrofuranyl,
pyrrolidylmethyl, pivaloyloxymethyl, acetoxymethyl or tert
butyl); compounds wherein a hydroxy group in the compound
represented by the general formula   (I) is acylated, alkylated,
phosphated or borated  (e.g., compounds wherein a hydroxy group
in the compound represented by the general formula    (I) is
derivatized to acetyl, palmitoyl, propanoyl, pivaloyl,
succinyl, fumaryl, alanyl or dimethylaminomethylcarbonyl);
compounds wherein a carboxy group in the compound represented
by the general formula  (I) is esterified or amidated (e.g.,
compounds wherein a carboxy group in the compound represented
by the general formula (I) is derivatized to ethyl ester,
phenyl ester, carboxymethyl ester, dimethylaminomethyl ester,
pivaloyloxymethyl ester, 1-{(ethoxycarbonyl)oxy}ethyl ester,
phthalidyl ester,  (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl
ester, 1-{[(cyclohexyloxy)carbonyl]oxy}ethyl ester or
methylamide) and the like.   These compounds may be prepared
according to the methods well known per se.    The prodrug of the
compound represented by the general formula    (I) may be a
hydrate or non-hydrate.  The prodrug of the compound
represented by the general formula (I) may be the one which is
converted to the compound represented by the general formula
(I) under physiological conditions described in "Iyakuhin no
Kaihatsu (Development of Medicines)", vol. 7, "Bunshi Sekkei
(Molecular Designs)", Hirokawa Shoten Co.,   1990, pp. 163-198.
     The atoms constituting the compound represented by the
                                R' )

general formula (I) may respectively be substituted with
isotopes thereof                       (e.g., 2H,              3H,       13C,      1C,     15N,    1N,       o,        o,     3S,
3Cl,        77Br,       1I        and the like).
 [Production method of the present compound]
           The present compound represented by the general formula
 (I) can be produced according to well known methods, for
example the methods described hereinbelow, equivalent methods
thereof or methods described in Examples.                                                        In the production
methods described hereinbelow, starting compounds may be
salts.            The salts may include those described as
pharmaceutically acceptable salts of the general formula                                                                      (I).
          The present compound of the general formula (I) can be
prepared, for example, according to the following reaction
scheme:
                                                          Reaction scheme
                    (R1)p                                                            (R1)p
      HN     1                  1
                                3     oC13ci     b               0C         N'
       2                    Carbamate   reaction                            H
             (II)                                                      (Ill)
                                                                                                             (R2)q
         AA 3      OH          X2
                                    I
                                      A1             1) Ether reaction               A3    O ~iA1     (R )X               3
                         +               >(R    3 )r  _    _____                   A                                       VI
          X1 A                     A2         NO2    2) Reduction reaction X1           A5    A2      NH
    X       A6                                N02X                                    6               NH2    Arylation reaction
                                                                                 1
           (iv)                       (V)                                                   (VI)
                                                                         (R1)p
(R2)q              A3     Oio)    A1    R3)r          U      Ct                (R2)q        AO      0     A1                  c
                        (vq                                      (IX)
        cy2          6A    ill A2        NH2          Urea reaction                  c(RA        6      2A~      H      H

      wherein Xi represents a boronic acid group       (-B(OH) 2) or a
boronate ester group (-B(ORi) (ORii), wherein Ri and Rii
represent a Cl-3 alkyl group and Ri and Rii may together form
a ring, such as 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl);
X2 represents  a halogen;   X 3 represents  a halogen;   and other
symbols represent the same meanings as those described in the
above   [1].
      The present compound having an amino group, an ester
group and a hydroxy group can be produced by carrying out the
reactions up to urea derivatization reaction as indicated in
the above reaction scheme with a compound which may be
optionally protected with a protecting group conventionally
used for the above-mentioned groups as described in, for
example, "Comprehensive Organic Transformations: A Guide to
Functional Group Preparations 2nd Edition (Richard C. Larock,
John Wiley & Sons Inc, 1999)"      followed by a well known
deprotection reaction or the deprotection reaction described
in, for example, "Comprehensive Organic Transformations: A
Guide to Functional Group Preparations 2nd Edition (Richard C.
Larock, John Wiley & Sons Inc, 1999)".
      In the reaction scheme, the reaction step       (carbamate
derivatization reaction) of producing the compound represented
by the general formula    (III) from the compound represented by
the general formula   (II) is well known.     The compound
represented by the general formula      (III) obtained thereby can
be produced by, for example, allowing reaction of the compound

represented by the general formula     (II) with 2,2,2
trichloroethoxycarbonyl chloride in an organic solvent       (e.g.,
pyridine, ethyl acetate, methylene chloride, dioxane, diethyl
ether or an appropriately mixed solvent thereof) or in a mixed
solvent of the organic solvent with water in the presence or
absence of a base     (e.g., 4-dimethylaminopyridine, pyridine,
triethylamine, sodium hydrogen carbonate) at a temperature of
about -200C  to 800C.
      In the reaction scheme, the reaction step     (etherification
reaction, reduction reaction) of producing the compound
represented by the general formula     (VI) from the compound
represented by the general formula     (IV) is well known.   The
compound represented by the general formula      (VI) obtained
thereby can be produced by, for example, allowing reaction of
the compound represented by the general formula (IV) and the
compound represented by the general formula      (V) in an organic
solvent  (e.g., dimethylsulfoxide, dimethylformamide, methanol,
acetonitrile, tetrahydrofuran or an appropriately mixed
solvent thereof) or in a mixed solvent of the organic solvent
with water in the presence of a base     (e.g., potassium
fluoride, potassium carbonate, tripotassium phosphate, sodium
hydroxide, sodium hydride, triethylamine) at a temperature of
about 0OC to 1200C and subjecting the obtained compound to
reaction under a hydrogen atmosphere in an organic solvent
(e.g., methanol, ethanol, ethyl acetate, tetrahydrofuran,
acetic acid, 1,2-dimethoxyethane or an appropriately mixed

solvent thereof) or in a mixed solvent of the organic solvent
with water in the presence of a catalyst (e.g., a silver
catalyst   (e.g., silver acetate),  a platinum catalyst (e.g.,
platinum-carbon, platinum oxide),    a rhodium catalyst     (e.g.,
rhodium-carbon),   an iron catalyst   (e.g., iron acetate),    a
ruthenium catalyst    (e.g., ruthenium-carbon),   a palladium
catalyst   (e.g., palladium-carbon, palladium hydroxide),      a zinc
catalyst   (zinc bromide, zinc iodide, zinc acetate),      Raney
nickel or an appropriately mixed catalyst thereof) at a
temperature of from room temperature to about 800C or
subjecting to reaction in an organic solvent       (e.g., acetic
acid, hydrochloric acid, ethanol, methanol, dimethylformamide,
toluene or an appropriately mixed solvent thereof) or in a
mixed solvent of the organic solvent with water in the
presence of a catalyst    (e.g., an iron catalyst    (e.g., iron,
iron chloride, iron-ammonium chloride),     a zinc catalyst     (e.g.,
zinc),  a nickel catalyst   (e.g., nickel chloride),     an indium
catalyst  (e.g., indium),   a tin catalyst   (e.g., tin, tin
chloride) or an appropriately mixed catalyst thereof) at a
temperature of from room temperature to about 800C.
      In the reaction scheme, the reaction step       (aryl
derivatization reaction) of producing the compound represented
by the general formula    (VIII) from the compound represented by
the general formula    (VI) is well known.   The compound
represented by the general formula     (VIII) obtained thereby can
be produced by, for example, allowing reaction of the compound

represented by the general formula    (VI) and the compound
represented by the general formula    (VII) in an organic solvent
 (e.g., dimethylacetamide, dimethylformamide, an alcohol     (e.g.,
methanol, ethanol, isopropyl alcohol),    diethyl carbonate,
dioxane, 1,2-dimethoxyethane, toluene or an appropriately
mixed solvent thereof) or in a mixed solvent of the organic
solvent with water, in the presence or absence of a base
(e.g., caesium carbonate, potassium acetate, potassium
carbonate, sodium carbonate, lithium-t-butoxide, silver
carbonate, tripotassium phosphate, triethylamine or an
appropriately mixed base thereof) in a catalyst     (e.g., a
palladium catalyst   (e.g., palladium hydroxide, palladium
acetate, bis(tri-t-butylphosphine)palladium, palladium(O)
tetrakis(triphenylphosphine),
bis(triphenylphosphine)dichloropalladium (II) or an
appropriately mixed catalyst thereof))    at a temperature of
from room temperature to about 1200C.
      In the reaction scheme, the reaction step    (urea
derivatization reaction) of producing the present compound
represented by the general formula    (I) from the compound
represented by the general formula    (VIII) is the reaction
carried out with the compound represented by the general
formula  (VIII) and the compound represented by the general
formula  (III) or general formula   (IX) under the conditions
described in Examples herein or under well known conditions.
      In the reaction scheme, compounds used as starting
                                 -7

materials and represented by the general formulae    (II), (IV),
 (V),  (VI) and (IX) are well known or can be easily produced
according to well known methods, for example, the method
described in "Comprehensive Organic Transformations: A Guide
to Functional Group Preparations 2nd Edition (Richard C.
Larock, John Wiley & Sons Inc, 1999)".
      The present compound of the general formula  (I) can be
alternatively produced by subjecting to urea derivatization
reaction the compound represented by the general formula (II)
and a 2,2,2-trichloroethyl carbamate derivative produced from
the compound represented by the general formula   (VIII) in the
above reaction scheme and 2,2,2-trichloroethoxycarbonyl
chloride.
      The present compounds represented by the general formula
 (I) other than those indicated above can be produced according
to the methods described in Examples herein or to the
combinations of well known methods, for example, the method
described in "Comprehensive Organic Transformations: A Guide
to Functional Group Preparations 2nd Edition   (Richard C.
Larock, John Wiley & Sons Inc, 1999)".
      The respective reactions involving heating as described
herein can be carried out, as apparent to a person skilled in
the art, in a water bath, an oil bath, a sand bath or with
microwave.
      In the respective reactions as described herein, a
reagent supported on a solid phase of a high-molecular weight

polymer   (e.g., polystyrene, polyacrylamide, polypropylene,
polyethylene glycol) may be appropriately used.
      In the respective reactions as described herein, reaction
products can be purified by conventional purification means,
e.g.,  by methods including distillation under normal or
reduced pressure, high speed liquid chromatography using
silica gel or magnesium silicate, thin layer chromatography,
ion exchange resins, scavenger resins or column chromatography
or washing and recrystallization.    Purification may be carried
out after each reaction step or may be carried out after more
than one reaction steps.
 [Toxicity]
      The present compound has sufficiently low toxicity.   The
present compound does not cause, for example, hepatotoxicity
or gastrointestinal dysfunction and has low brain transition.
Thus the present compound can be used safely as a medicament.
[Application to medicaments]
      The present compound exhibits Trk-inhibiting activity and
thus is useful as a prophylactic and/or therapeutic agent for
Trk-related diseases e.g., pain, pruritus, lower urinary tract
dysfunction, asthma, allergic rhinitis, inflammatory bowel
disease and Chagas disease.
      More specifically, pain may include, for example, pain of
osteoarthritis, cancer pain, chronic low back pain, low back
pain of osteoporosis, pain of bone fracture, pain of
rheumatoid arthritis, neuropathic pain, postherpetic pain,

pain of diabetic neuropathy, fibromyalgia, pain of
pancreatitis, pain of interstitial cystitis, pain of
endometriosis, pain of irritable bowel syndrome, migraine,
postoperative pain,   pain of pulpitis and the like.  Pruritus
may include systemic cutaneous pruritus, localized cutaneous
pruritus, senile cutaneous pruritus, gestational pruritus,
pruritus ani,  vulvar pruritus and the like.  Inflammatory bowel
disease may include, for example, ulcerative colitis, Crohn's
disease and the like.
      The present compound is particularly useful as a
prophylactic and/or therapeutic agent for pain.
      The present compound may be administered as a combination
drug with another drug in order to:
1) complement and/or enhance the prophylactic and/or
therapeutic effect of the compound;
2) improve the kinetics and absorption and reduce the dosage
of the compound; and/or
3) alleviate the side effect of the compound.
      The combination drug of the present compound and another
drug may be administered in the form of one formulation
containing both components or may be administered as separate
formulations.   Administration of separate formulations may
include simultaneous administration and sequential
administration.   In the sequential administration, the present
compound may be first administered followed by another drug or
another drug may be first administered followed by the present

compound.   The respective manners of administration may be the
same or different.
      The disease for which the combination drug exhibits the
prophylactic and/or therapeutic effect is not particularly
limited and may be the disease which may complement and/or
enhance the prophylactic and/or therapeutic effect of the
present compound.
     Another drug for complementing and/or enhancing the
prophylactic and/or therapeutic effect of the present compound
for pain may include, for example, acetaminophen, a nonsteroid
antiinflammatory drug, an opioid, an antidepressant, an
antiepileptic agent, an N-methyl-D-aspartate antagonist, a
muscle relaxant, an antiarrhythmic agent, a steroid and a
bisphosphonate.
     The nonsteroid antiinflammatory drug may include, for
example, sasapyrine, sodium salicylate, aspirin, aspirin
formulations such as those containing aspirin-dialuminate,
diflunisal, indomethacin, suprofen, ufenamate,
dimethylisopropylazulene, bufexamac, felbinac, diclofenac,
tolmetin sodium, Clinoril, fenbufen, nabumetone,
proglumetacin, indomethacin farnesil, acemetacin,
proglumetacin maleate, amfenac sodium, mofezolac, etodolac,
ibuprofen, ibuprofen piconol, naproxen, flurbiprofen,
flurbiprofen axetil, ketoprofen, fenoprofen calcium,
Tiaprofen, oxaprozin, pranoprofen, loxoprofen sodium,
alminoprofen, zaltoprofen, mefenamic acid, aluminium

mefenamate, tolfenamic acid, floctafenine, ketophenylbutazone,
oxyphenbutazone, piroxicam, tenoxicam, ampiroxicam, Napageln
ointment, epirizole, tiaramide hydrochloride, tinoridine
hydrochloride, emorfazone, sulpyrine, Migrenin, Saridon, Sedes
G, Amipylo-N, Sorbon, pilin cold remedies, acetaminophen,
phenacetin, dimetotiazine mesilate, meloxicam, celecoxib,
rofecoxib, valdecoxib, simetride-containing formulations and
non-pilin cold remedies and the like.
      The opioid may include, for example, codeine, fentanyl,
hydromorphone, levorphanol, meperidine, methadone, morphine,
oxycodone, oxymorphone, propoxyphene and the like.
      The antidepressant may include, for example, tricyclic
antidepressants  (e.g., amitriptyline hydrochloride, imipramine
hydrochloride, clomipramine hydrochloride, dosulepin
hydrochloride, nortriptyline hydrochloride, lofepramine
hydrochloride, trimipramine maleate, amoxapine),    tetracyclic
antidepressants  (e.g., maprotiline hydrochloride, mianserin
hydrochloride, setiptiline maleate), monoamine oxidase     (MAO)
inhibitors  (safrazine hydrochloride),  serotonin and
noradrenaline reuptake inhibitors   (SNRIs) (e.g., milnacipran
hydrochloride, venlafaxine hydrochloride),   selective serotonin
reuptake inhibitors (SSRIs) (e.g., fluvoxamine maleate,
paroxetine hydrochloride, fluoxetine hydrochloride, citalopram
hydrochloride),  serotonin reuptake inhibitors   (e.g., trazodone
hydrochloride) and the like.
     The antiepileptic agent may include, for example,

phenobarbital, Puridomin, phenytoin, ethosuximide, zonisamide,
nitrazepam, clonazepam, carbamazepine, sodium valproate,
acetazolamide, sulthiame and the like.
      The N-methyl-D-aspartate antagonist may include, for
example, ketamine hydrochloride, amantadine hydrochloride,
memantine hydrochloride, dextromethorphan, methadone and the
like.
      The muscle relaxant may include, for example,
succinylcholine, suxamethonium, vecuronium bromide, pancronium
bromide, dantrolene sodium and the like.
      The antiarrhythmic agent may include, for example,
procainamide, disopyramide, cibenzoline, pirmenol, lidocaine,
mexiletine, aprindine, pilsicainide, flecainide, propafenone,
propranolol, atenolol, bisoprolol, amiodarone, sotalol,
verapamil, diltiazem, bepridil and the like.
      The steroid may include, for example, as external
medicines, clobetasol propionate, diflorasone diacetate,
fluocinonide, mometasone furoate, betamethasone dipropionate,
betamethasone butyrate propionate, betamethasone valerate,
difluprednate, pudesonide, diflucortolone valerate,
amcinonide, halcinonide, dexamethasone, dexamethasone
propionate, dexamethasone valerate, dexamethasone acetate,
hydrocortisone acetate, hydrocortisone butyrate,
hydrocortisone butyrate propionate, deprodone propionate,
prednisolone valerate acetate, fluocinolone acetonide,
peclometasone propionate, triamcinolone acetonide,

flumethasone pivalate, alclometasone dipropionate, clobetasone
butyrate, prednisolone, beclomethasone propionate,
fludroxycortide and the like.
     As medicines for internal use or for injection, cortisone
acetate, hydrocortisone, hydrocortisone sodium phosphate,
hydrocortisone sodium succinate, fludrocortisone acetate,
prednisolone, prednisolone acetate, prednisolone sodium
succinate, prednisolone butylacetate, prednisolone sodium
phosphate, halopredone acetate, methylprednisolone,
methylprednisolone acetate, methylprednisolone sodium
succinate, triamcinolone, triamcinolone acetate, triamcinolone
acetonide, dexamethasone, dexamethasone acetate, dexamethasone
sodium phosphate, dexamethasone palmitate, paramethasone
acetate, betamethasone and the like may be included.
     As inhalants, beclomethasone propionate, fluticasone
propionate, budesonide, flunisolide, triamcinolone, ST-126P,
ciclesonide, dexamethasone palmitate, mometasone furoate,
prasterone sulfonate, deflazacort, methylprednisolone
suleptanate, methylprednisolone sodium succinate and the like
may be included.
     The bisphosphonate may include, for example, etidronate,
pamidronate, alendronate, risedronate, zoledronate,
minodronate and the like.
     The mass ratio of the present compound and another drugs
is not particularly limited.
     Any combination of two or more kinds of another drugs may

be administered.
     Another drugs for complementing and/or enhancing the
prophylactic and/or therapeutic effect of the present compound
may encompass not only those have been identified to date but
also those will be identified in future based on the above
mechanism.
     The present compound or the combination drug of the
present compound and another drugs which is used for the
purpose described above is generally formulated as an
appropriate pharmaceutical composition with a pharmaceutically
acceptable carrier, and then administered systemically or
topically by oral or parenteral administration.
     The dosage may vary according to age, weight, symptoms,
therapeutic effect, mode of administration, treatment period
and the like and may be one to several oral administrations a
day within the range of 1 mg to 1000 mg per dose per adult or
one to several parenteral administrations a day within the
range of 0.1 mg to 100 mg per dose or intravenous continuous
administration for 1 hour to 24 hours a day per adult.
     As described above, the dosage may vary according to
various conditions, thus the sufficient dosage may be of
course lower than the amount described above or the amount
higher than the above may be required.
     The present compound or the combination drug of the
present compound and another drugs may be administered as an
oral solid dosage form for internal use, an internal liquid

medicine or an injection, an external medicine, a suppository,
an ophthalmic solution or an inhalation for parenteral
administration.
      The oral solid dosage form for internal use may include
tablets, pills, capsules, powders, granules and the like.
Capsules may include hard capsules and soft capsules.     Tablets
may include sublingual tablets, oral patches, orally
disintegrating tablets and the like.
      In the solid dosage form for internal use, one or more
active substances per se may be formulated or may be
formulated after mixing thereof with a excipient    (lactose,
mannitol, glucose, microcrystalline cellulose, starch and the
like),  a binder  (hydroxypropylcellulose, polyvinylpyrrolidone,
magnesium aluminate metasilicate and the like),    a disintegrant
(calcium cellulose glycolate and the like),    a lubricant
(magnesium stearate and the like),   a stabilizer, a solution
adjuvant   (glutamic acid, aspartic acid and the like) according
to conventional methods.    The solid dosage form may be
optionally coated with a coating agent    (sucrose, gelatin,
hydroxypropylcellulose, hydroxypropyl methylcellulose
phthalate and the like) and may be coated with two or more
layers.   The solid dosage form may further encompass capsules
of an absorbable substance such as gelatin.
      The internal liquid medicine may include pharmaceutically
acceptable waters, suspensions, emulsions, syrups, elixirs and
the like.   In the liquid medicine, one or more active

substances are dissolved, suspended or emulsified in a diluent
of general use (purified water, ethanol or a mixed solution
thereof).  The liquid medicine may further contain a wetting
agent, a suspending agent, an emulsifying agent, a sweetening
agent, a flavouring agent, an aroma, a preservative, a
buffering agent and the like.
     The dosage form of the external medicine for parenteral
administration may include, for example, ointments, gels,
creams, cataplasms, plasters and pressure sensitive adhesives,
liniments, atomized agents, inhalations, sprays, aerosols,
ophthalmic solutions, nasal solutions and the like.  The dosage
forms contain one or more active substances and may be
prepared according to well known methods or formulations which
are generally used.
     Atomized agents, inhalations and sprays may contain, in
addition to a diluent which is generally used, a stabilizer
such as sodium hydrogen sulfite and a buffering agent that
confers isotonicity, e.g., sodium chloride, sodium citrate or
an isotonicity agent such as citric acid.  Methods for
producing sprays are specifically described in, for example,
US 2,868,691 and US 3,095,355.
     The injection for parenteral administration may encompass
injections in the form of solution, suspension, emulsion and
solid that is dissolved or suspended in a solvent upon use.
The injection may be used by dissolving, suspending or
emulsifying one or more active substances in a solvent.   The
                               /- -7

solvent may be, for example, distilled water for injection,
saline, vegetable oil, propylene glycol, polyethylene glycol,
alcohols such as ethanol and combinations thereof.     The
injection may further contain a stabilizer, a solution
adjuvant   (glutamic acid, aspartic acid, Polysorbate 800 and
the like),   a suspending agent, an emulsifying agent, a
soothing agent, a buffering agent, a preservative and the
like.   The injection may be produced by sterilization in the
final step or through aseptic technique.    Aseptic solid agents,
e.g.,  lyophilized products may be manufactured and dissolved
in sterilized or aseptic distilled water or other solvents for
injection before use.
      Other compositions for parenteral administration may
include suppositories for rectal administration and pessaries
for vaginal administration which contain one or more active
substances and are formulated according to conventional
methods.
      In the present invention, "an article of manufacture"
comprises   (1) a pharmaceutical composition including the
present compound or a pharmaceutical composition in the form
of a combination drug including the present compound with a
concomitant drug other than the present compound, (2) a
container containing the composition and    (3) at least one of
an instruction, a description, a package insert and a product
label  (including those corresponding to a label and a labeling
in the United States),   all of which indicate that the
                                 /-C)

composition can be used for prophylaxis and/or therapy of Trk
related disease optionally in combination with an appropriate
concomitant drug   (preferably acetaminophen, a nonsteroid
antiinflammatory drug, an opioid, an antidepressant, an
antiepileptic agent, an N-methyl-D-aspartate antagonist, a
muscle relaxant, an antiarrhythmic agent, a steroid and/or a
bisphosphonate).
      The package insert as used herein means an official
document attached to a medicament which provides necessary
information for appropriate use of the medicament and
corresponds to "Tenpu Bunsho"   (also referred to as "Nou-gaki")
in accordance with the Pharmaceutical Affairs Act in Japan,
"Summary of Product Characteristics   (SPC or SmPC)"  in
accordance with Directive in EU, "US Package Insert     (USPI)" in
accordance with Federal Regulations in the United States and
equivalent documents elsewhere.
     The information provided by these documents is
specifically prescribed by Articles 52,    54 and 68 (4) and the
like in the Pharmaceutical Affairs Act    (see, if necessary,
Notification Nos. 606 and 607 of Pharmaceutical Affairs Bureau
as of 25 April 1997 and/or related notifications) for "Tenpu
Bunsho" in Japan, by Directive 2001/83/EC Article 11 and the
like  (see, if necessary, A guideline on SmPC and/or related
guidelines) for Summary of Product Characteristics in EU, and
by 21 CFR 201.100 and the like   (see, if necessary, 21 CFR
201.57 and/or related Federal Regulations) for US Package
                                 C'

Insert in the United States and generally includes information
on indications, dosage and administration, method of
administration, warnings and/or contraindications.
      In the United States, 21 CFR 201 Subpart B requires that
in addition to the US Package Insert, a label or a labeling
 (or labelling) should contain a part or all information
provided on the US Package Insert.    A label herein means the
one directly provided on a container and a labeling means the
concept encompassing the label, printing on packages and
printed matters attached to articles of manufacture.
      In the present invention, the term "container" means the
one which directly accommodates the pharmaceutical composition
comprising the present compound or the pharmaceutical
composition in the form of a combination drug including the
present compound with a concomitant drug other than the
present compound and may also be referred to as "an immediate
container", "an immediate wrapper", "an inner seal" or the
like.   The container includes, for example, cans/tins, bottles,
boxes, ampoules, vials, tubes, unit dose containers for eye
drops, paper, cloth, plastics, plastic bags, SP sheets, PTP
sheets, plastic containers and the like.
      The container containing the pharmaceutical composition
therein is combined with at least one of an instruction, a
description, a package insert and a product label    (including
the one corresponding to a label or labeling in the United
Stated) as described above, and then may be generally packaged
                                ,-7 n

in an outer container or an outer wrapper and distributed to
the market.
     The present invention also discloses a method for
advertisement of a pharmaceutical composition comprising the
present compound or a pharmaceutical composition in the form
of a combination drug including the present compound with a
concomitant drug, the method including encouraging a target
viewer to use the composition for prophylaxis and/or therapy
of Trk-related disease.
     The above method involves publicly distributing
information that describes the value, particularly a health
benefit of using, in prophylaxis and/or therapy for Trk
related diseases, the pharmaceutical composition including the
present compound or the pharmaceutical composition in the form
of the combination drug including the present compound with
another concomitant drug.   Such information is distributed
through an appropriate advertising medium in addition to
verbal communication.   The advertising medium may be any of
newspaper, magazines, television, radio, video, brochures,
leaflets, posters, social networking systems, e-mail,
electronic signboards, digital signage, internet
advertisements (homepages/websites, banner advertisements and
the like),  outdoor advertisements  (poster boards, neon signs,
large screen displays and the like),   transportation
advertisements  (advertisements suspended in trains, buses,
cabs and the like, advertisements above windows and beside
                                -71

doors of trains, buses, cabs and the like, advertisements in
stations),  movie theatre slide advertisements     (advertisements
on screens in movie theatres),     POP advertisements
 (advertisements at shop front and in shops),    direct
advertisements   (direct mails, newspaper inserts, flyers),
specialty advertisements    (novelty advertisements such as
calendars, pens and the like),     other advertisements
 (skywriting, advertisements on benches and the like) .    A person
skilled in the art can easily produce the advertising media.
      Unless otherwise defined, all technical and scientific
terms and abbreviations used herein have the same meanings as
are usually understood by a person skilled in the art to which
the present invention pertains.
      The present application claims the priority of Japanese
Patent Application Nos. 2013-029563 and 2013-141246 filed
respectively on 19 February 2013 and 5 July 2013, the entire
contents of which are incorporated herein by reference.
      The contents of all Patent Document and Non-Patent
Document or references explicitly cited herein may be entirely
incorporated herein as a part of the present specification.
EXAMPLES
      The present invention is hereinafter specifically
described by way of Examples which do not limit the present
invention.
      The solvents indicated in brackets described in
                                 -70)

chromatographic separation and TLC sections indicate elution
solvents or development solvents used and the proportions are
expressed in volume ratio.
      The solvents indicates in brackets described in NMR
sections indicate the solvents used for measurements.
      LC-MS/ELSD was carried out under the following
conditions:
{Column:   Waters ACQUITY C 1 8 (particle diameter:      1.7 x 10-6 m;
column length:    30 x 2.1 mm I.D.); flow rate:      1.0 mL/min;
column temperature:     40*C; mobile phase   (A) : 0.1%
trifluoroacetic acid aqueous solution; mobile phase           (B): 0.1%
trifluoroacetic acid-acetonitrile solution; gradient            (the
ratio of mobile phase (A) : mobile phase        (B)):   [0 min]   95:5;
 [0.1 min]  95:5;  [1.2 min]  5:95;  [1.4 min]    5:95;   [1.41 min]
95:5;   [1.5 min]  95:5; detector: UV(PDA),     ELSD, MS}
      The compounds described herein were named by using a
computer programme generally according to IUPAC nomenclature
system, ACD/Name*, or Chemdraw Ultra       (version 12.0, Cambridge
Soft),   or according to IUPAC nomenclature system.
Example 1:   1-(2-nitro-4-(trifluoromethyl)phenyl)-1H-pyrazole
      To a solution of 1H-pyrazole      (0.39 g) in
dimethylsulfoxide    (hereinafter abbreviated as DMSO)        (5.2 mL)
was added potassium tert-butoxide      (0.7  g) .   The reaction
mixture was stirred at room temperature for 40 minutes.             To the
reaction mixture was gradually added 1-fluoro-2-nitro-4-

 (trifluoromethyl)benzene (1.1 g) and the reaction mixture was
further stirred for 90 minutes.          The reaction mixture was
poured with a saturated ammonium chloride aqueous solution and
extracted with ethyl acetate.         The obtained organic layer was
washed with water and a saturated sodium chloride aqueous
solution, dried over magnesium sulfate and then concentrated
under reduced pressure.       The obtained residue was purified on
silica gel column chromatography (hexane : ethyl acetate                 =
10:1 -> 2:1) to give the titled compound having the following
physical characteristics       (0.43 g).
TLC : Rf 0.43 (Hexane : Ethyl Acetate = 3 : 1);
1H-NMR  (DMSO-d 6 )  : 5  6.61-6.64    (m,  1H),   7.82   (d,  1H),   8.07   (d,
1H),  8.20  (dd, 1H),    8.45-8.49 (m, 2H).
Example 2: 2-(lH-pyrazol-1-yl)-5-(trifluoromethyl)aniline
      To a solution of the compound produced in Example 1 (430
mg) in methanol     (16 mL) was added palladium-carbon (5% wet,
380 mg) .  The reaction mixture was placed in           a hydrogen
atmosphere and stirred at room temperature for 6 hours.                  The
reaction mixture was filtered through Celite              (trade name)
followed by concentration of the filtrate to give the titled
compound having the following physical characteristics                 (357
mg).
TLC : Rf 0.56    (Hexane : Ethyl Acetate = 3 : 1);
'H-NMR (DMSO-d6 ) : 5 6.10      (s, 2H),   6.52-6.56     (m, 1H),    6.92   (dd,
1H),  7.19  (d, 1H),   7.45   (d, 1H),   7.79    (d, 1H),   8.21   (d, 1H).
Example 3:   2,2,2-trichloroethyl(2-(lH-pyrazol-1-yl)-5-

 (trifluoromethyl)phenyl)carbamate
                           CF 3
                 O    N
          CI               N
                              N
      To a solution of the compound produced in Example 2 (356
mg) in ethyl acetate (8 mL) were added sodium hydrogen
carbonate       (400 mg) and 2,2,2-trichloroethyl carbonochloridate
 (430 mg) .      The reaction mixture was stirred          at room temperature
for 150 minutes.             The reaction mixture was added with water and
extracted with ethyl acetate.               The obtained organic layer was
dried over magnesium sulfate and then concentrated under
reduced pressure.             The obtained residue was purified on silica
gel column chromatography              (hexane : ethyl acetate = 10:1 -+
2:1) to give the titled compound having the                following physical
characteristics           (610 mg).
TLC  : Rf 0.60         (Hexane : Ethyl Acetate = 3 :       1);
1H-NMR   (DMSO-d     6 )  : 5 4.93    (s, 2H),   6.63-6.66  (m,  1H),  7.66 (dd,
1H),  7.88       (d,    1H),    7.94 (d,  1H),   8.29  (s, 1H),   8.42  (d, 1H),
10.6  (s, 1H).
Example 4:        5-nitro-2-(4-(4,4,5,5-tetramethyl-1,3,2
dioxaborolan-2-yl)phenoxy)pyrimidine
       H3C   O 'BNO              NO2
      HC      0
       H3C   CH3
      To a solution of 4-(4,4,5,5-tetramethyl-1,3,2
dioxaborolan-2-yl)phenol             (10 g)   in tetrahydrofuran

 (hereinafter abbreviated as THF)                     (91 mL) were added
triethylamine (7 mL) and 2-chloro-5-nitropyrimidine                         (7.6 g).
The reaction mixture was                 stirred      at 00C for 1 hour.    The
reaction mixture was diluted in ethyl acetate and washed with
a saturated sodium hydrogen carbonate aqueous solution, water
and a saturated sodium chloride aqueous solution.                         The obtained
organic layer was dried over sodium sulfate and then
concentrated under reduced pressure to give the titled
compound having the              following physical characteristics              (17 g).
TLC  : Rf     0.45      (Hexane : Ethyl Acetate = 4 :             1);
1H-NMR    (CDCl    3 )   :   5  1.35    (s,     12H),   7.20  (d, 2H),  7.93    (d,   2H),
9.31   (s, 2H).
Example 5: 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2
yl)phenoxy)pyrimidin-5-amine
            H0O            Y- N
            HCOB         O        NH2
      H3C     0
        H3C   CH 3
      To a solution of the compound produced in Example 4                           (17
g)  in a mixture of ethanol                   (187 mL) and ethyl acetate       (94 mL)
was added palladium hydroxide                     (20% wet,  1.56 g).   The reaction
mixture was        stirred       in   a hydrogen       atmosphere  at 350C for 4
hours.     The reaction mixture was added with methanol                      (90 mL)
and activated carbon                (0.32 g) and stirred at room temperature
for 5 minutes.             The reaction mixture was filtered through
Celite    (trade name) followed by concentration of the filtrate.
To the obtained residue was added an 1:1 mixed solvent of

 tert-butyl methyl ether/hexane and the precipitated solid was
filtered to give the titled compound having the following
physical characteristics          (12.8 g).
TLC : Rf 0.29       (Hexane : Ethyl Acetate = 1 : 1);
'H-NMR     (CDCl 3)  : 5 1.33  (s,  12H),       3.51 (br s,   2H),  7.14   (d, 2H),
7.85   (d, 2H),     8.06  (s, 2H).
Example 6: 2- (4- (2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-amine
                    ON
         NH2  I
       N NH2NH            2
         I
       To a solution of the compound produced in Example 5 (1 g)
in a mixture of 2-propanol          (6.4 mL) and 1,2-dimethoxyethane
 (1.6 mL) were added 3-bromo-5-chloropyridin-2-amine (662 mg),
potassium phosphate aqueous solution (2 M, 3.2 mL) and
bis(triphenylphosphinepalladium)               dichloride   (112 mg).    The
reaction mixture was stirred          in      an argon atmosphere at 85*C for
2 hours.      The reaction mixture was cooled to room temperature,
diluted in ethyl acetate and then washed with water.                   The
obtained organic layer was back extracted with hydrochloric
acid (0.5 M, 120 mL).         The obtained aqueous layer was
neutralized with a saturated sodium carbonate aqueous solution
and extracted with ethyl acetate.                The obtained organic layer
was washed with a saturated sodium chloride aqueous solution,
dried over sodium sulfate and then filtered.                  The obtained
organic layer was concentrated to around 100 mL.                   The
                                         -7,-7

 concentrated solution was purified on column chromatography
 (Fuji Silysia Chromatorex NH DM1020             (trade name),     ethyl
 acetate) to give the titled compound having the following
physical characteristics            (857 mg).
TLC      Rf 0.32      (Dichloromethane     : Ethyl Acetate       : Methanol    = 8
 : 4     1);
'H-NMR    (DMSO-d 6 )   : 5 5.28    (br s,  2H),    5.82  (br s,  2H),   7.14   (d,
2H),  7.39    (d, 1H),     7.45  (d, 2H),    7.94    (d, 1H),  7.99    (s, 2H).
Example 7:     1-(2-(1H-pyrazol-1-yl)-5-(trifluoromethyl)phenyl)
3-(2-(4-(2-amino-5-chloropyridin-3-yl)phenoxy)pyrimidin-5
yl)urea
                                CF3
         NH2      O         O
       N                  N   N
                          H
                              H
         CI
      To a solution of the compound produced in Example 6 (400
mg) and the compound produced in Example 3 (513 mg) in N,N
dimethylacetamide (hereinafter abbreviated as DMA)                  (2.6 mL)
was added triethylamine          (0.018 mL) .     In  an argon atmosphere,
the reaction mixture was stirred at 65'C for 21 hours.                    The
reaction mixture was cooled to room temperature and then
diluted in ethyl acetate.            The obtained organic layer was
washed three times with water and once with a saturated sodium
chloride aqueous solution.            The obtained organic layer was
dried over sodium sulfate, filtered and then concentrated.                     The
obtained residue was purified on silica gel column
chromatography (dichloromethane : ethyl acetate = 2:1) to give

 the present compound having the following physical
characteristics               (465 mg).
TLC : Rf 0.29           (Hexane : Ethyl Acetate                    =  1 : 3);
'H-NMR      (DMSO-d   6  )      : 5 5.86          (br s,     2H),    6.68      (dd,     1H),   7.27     (d,
2H),    7.42     (d,     1H),        7.46-7.56         (m,   3H),    7.75      (d,   1H),     7.92-7.99
  (m, 2H),     8.41     (d,       1H),     8.58      (d,   1H),    8.70    (s,     2H),     9.71    (br s,
1H),   9.97      (br s, 1H).
Example 8
       The similar procedure as Example 7 was carried out with a
corresponding carbamate or isocyanate compound in place of the
compound produced in Example 3 to give the present compounds
having the following physical characteristics.
Example 8-1:         1-(2-(4-(2-amino-5-chloropyridin-3
yl) phenoxy) pyrimidin-5-yl) -3- (2- (4-methyl-1H-1,2, 3-triazol-1
yl)-5-(trifluoromethyl)phenyl)urea
                                          CF3
          NH 2   "    Y    N,0
       N N           O N '       N 1, N
                                 H    H
          C1                             N
                  c                          CH 3
TLC : Rf 0.21           (Hexane            Ethyl Acetate = 1 : 3);
  H-NMR    (DMSO-d    6 )      : 5 2.38          (s,   3H),     5.85   (s,    2H),      7.26    (d,   2H),
7.41    (d,    1H),     7.50         (d,   2H),      7.58     (dd,   1H),    7.69       (d,   1H),    7.94
 (d,  1H),     8.39       (s,      1H),     8.58-8.61          (m,  1H),     8.68       (s,   2H),    8.76
 (s,  1H),     9.69     (s,      1H).
Example 8-2: 1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(5-(trifluoromethyl)-2-(3-

   (trifluoromethyl)-1H-pyrazol-1-yl)phenyl)urea
                                           CF3
            NH2      O
         N                N~N N              l
                                  H    H   N
           CI                             C    CF3
 TLC : Rf 0.80           (Ethyl Acetate               : Hexane = 2       : 1);
 IH-NMR      (DMSO-d   6  )     : 5     5.85      (s,   2H),  7.12   (d,   1H),  7.26   (s, 2H),
 7.42    (s,    1H),     7.51         (d,   2H),      7.58   (dd,  1H),    7.71  (d,  1H),  7.95
  (d,  1H),      8.47       (s,     2H),       8.59     (s,  1H),   8.67    (s, 2H),   9.48   (s,
 1H).
 Example 8-3:        1-(2-(lH-1,2,3-triazol-1-yl)-5
  (trifluoromethyl)phenyl)-3-(2-(4-(2-amino-5-chloropyridin-3
 yl)phenoxy)pyrimidin-5-yl)urea
TLC    : Rf 0.69         (Ethyl Acetate);
1
   H-NMR     (DMSO-d  6  )      : 5     5.84      (s,  2H),   7.26   (d,   2H),  7.41   (d, 1H),
7.51     (d,    2H),     7.61         (dd,     1H),    7.74   (d,  1H),    7.95  (d,  1H),  8.09
  (d,  1H),      8.57       (s,     1H),       8.67     (s,  3H),   8.71    (s, 1H),   9.65   (s,
 1H).
Example 8-4:         1-(2-(4-(2-amino-5-chloropyridin-3
yl) phenoxy) pyrimidin-5-yl) -3- (2-chloro-5
 (trifluoromethyl)phenyl)urea
                                           CF3
           NH2          yN          0
        N N              O       N ' N
                                 H     H
                                           CI
           CI
TLC    : Rf 0.52         (Hexane : Ethyl Acetate = 1                    : 2);
1
  H-NMR     (DMSO-d   6  )     :   5 5.85        (s,   2H),   7.26   (d,   2H),  7.41  (d,  1H),
                                                        Q(n

 7.51    (d,   2H),      7.68   (dd,   1H),     7.86-7.89          (m, 1H),       7.94      (d,   1H),
 8.42   (s,    1H),     8.74   (s,   2H),     8.79   (s,     1H),     9.76    (s,     1H).
 Example 8-5:        1-(2-(4-(2-amino-5-chloropyridin-3
 yl)phenoxy)pyrimidin-5-yl)-3-(5-(trifluoromethyl)-2-(4
 trifluoromethyl)-1H-pyrazol-1-yl)phenyl)urea
 TLC : Rf 0.36          (Hexane : Ethyl Acetate = 1 : 2);
 IH-NMR     (DMSO-d   6  )  : 5 5.85      (s,   2H),     7.26      (d,   2H),     7.42      (d,  1H),
 7.50   (d,    2H),     7.56    (dd,   1H),     7.76     (d,    1H),     7.95      (d,    1H),   8.38
  (s, 1H),     8.54-8.59        (m,   1H),     8.69     (s,    2H),     8.98      (d,    2H),    9.75
  (s, 1H).
Example 8-6:         1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-(3-(difluoromethyl)-1H
pyrazol-1-yl)-5-(trifluoromethyl)phenyl)urea
TLC : Rf 0.27           (Hexane : Ethyl Acetate = 1 : 2);
1H-NMR
            (DMSO-d 6 )     : 5 5.85      (s, 2H),       6.90-6.96         (m,    1H),     7.14    (t,
1H),   7.26      (d,     2H),   7.41    (d,    1H),    7.50       (d,   2H),      7.53-7.59        (m,
1H),   7.72      (d,     1H),   7.95    (d,    1H),    8.41-8.46          (m, 1H),         8.53    (s,
1H),   8.68     (s, 2H),      8.95    (s, 1H),       9.66 (s, 1H).
Example 8-7:         1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(5-(trifluoromethyl)-2-(3
 (trifluoromethyl)-1H-1,2,4-triazol-1-yl)phenyl)urea
TLC : Rf 0.62           (Hexane : Ethyl Acetate = 1 : 2);
IH-NMR     (DMSO-d   6  )  : 5 5.85       (s,   2H),    7.26       (d,   2H),     7.42     (d,   1H),
7.50   (d,    2H),     7.63    (dd,   1H),     7.81    (d,    1H),     7.95      (d,    1H),    8.47
8.50    (m,    1H),     8.65    (s,   1H),     8.66    (s,     2H),     9.24      (s,    1H),    9.33
 (s, 1H).
                                                 01

 Example 8-8:          1-(2-(3-acetyl-lH-pyrazol-1-yl)-5
  (trifluoromethyl)phenyl)-3-(2-(4-(2-amino-5-chloropyridin-3
 yl)phenoxy)pyrimidin-5-yl)urea
 TLC   : Rf     0.34      (Hexane : Ethyl Acetate = 1 : 2);
 1
   H-NMR     (DMSO-d   6   )    : 5     2.58       (s,   3H),    5.85   (s,   2H),  7.05   (d, 1H),
 7.26    (d,    2H),      7.42        (d,     1H),     7.50    (d,  2H),    7.57   (dd,  1H),  7.74
  (d,  1H),      7.95        (d,     1H),       8.39     (d,   1H),   8.63     (s, 1H),   8.68   (s,
 2H),   8.74      (s, 1H),           9.63      (s, 1H).
Example 8-9:          1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl) -3- (2- (3-methyl-1H-pyrazol-1-yl)-5
  (trifluoromethyl)phenyl)urea
TLC    : Rf 0.50          (Ethyl Acetate               : Hexane = 2 : 1);
1
   H-NMR   (DMSO-d     6  )     :   5   2.37       (s,   3H),   5.85    (s,   2H),  6.45   (d, 1H),
7.27     (d,    2H),       7.43        (d,     1H),     7.47-7.54      (m,   3H),   7.70   (d, 1H),
7.95     (d,    1H),      8.28        (d,      1H),    8.57     (s,  1H),    8.70   (s,  2H),  9.81
 (s, 1H),       9.92      (s, 1H).
Example 8-10:            1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(3-(trifluoromethyl)phenyl)urea
                                             CF3
          NH2        O        N         N
             NN                            IttN*N'
                                   H    H
          CI
TLC    : Rf 0.47         (Hexane : Ethyl Acetate =                     1 : 4);
1
  H-NMR      (DMSO-d    6   )     :   5    7.27-7.34          (m,   3H),    7.42-7.53     (m,  4H),
7.61-7.66         (m, 1H),          7.88-7.92          (m, 2H),     8.73    (s, 2H).
Example 8-11:           1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-fluoro-5
                                                         0

   (trifluoromethyl)phenyl)urea
 TLC : Rf 0.50         (Hexane : Ethyl Acetate = 1 : 2);
  1H-NMR
             (DMSO-d 6  )     : 5 5.85   (s,  2H),   7.26    (d,  2H),  7.38-7.55    (m,
  5H),  7.95      (d, 1H),        8.51-8.55    (m,  1H),   8.74    (s, 2H),   9.09   (s,
  1H),  9.30     (s,   lH).
 Example 8-12: 1-(2-(4-(2-amino-5-chloropyridin-3
 yl)phenoxy)pyrimidin-5-yl)-3-(2-(4-methyl-1H-pyrazol-1-yl)-5
  (trifluoromethyl)phenyl)urea
 TLC : Rf 0.55         (Ethyl Acetate : Hexane = 2 : 1);
 'H-NMR     (DMSO-d  6  )     : 5 2.15   (s,  3H),   5.85    (s, 2H),   7.26   (d, 2H),
 7.42    (d,    1H),    7.49-7.52       (m,  3H),  7.69     (d,  1H),  7.78   (s,  1H),
 7.95    (d, 1H),       8.18      (d, 1H),   8.57   (d,   1H),   8.70   (d,  2H),  9.83
  (s, 1H),     9.97    (s, 1 H).
Example 8-13:          1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-(5-methyl-1H-1,2,3-triazol-l
yl)-5-(trifluoromethyl)phenyl)urea
TLC : Rf 0.63          (Ethyl Acetate);
'H-NMR      (DMSO-d  6 )     : 5 2.19    (s,  3H),   5.84    (d, 2H),   7.26   (d, 2H),
 7.42   (d,     2H),    7.50      (d, 2H),   7.61   (d,   1H),   7.84   (s,  1H),  7.94
  (d,  1H),     8.29      (s,    1H),  8.64   (s,  1H),    8.66    (s, 2H),   9.45   (s,
 1H).
Example 8-14: 1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-methyl-5
  (trifluoromethyl)phenyl)urea
TLC : Rf 0.30          (Ethyl Acetate : Hexane = 2 : 1);
'H-NMR      (DMSO-d  6 )     : 5 2.32    (s,  3H),   5.85    (s, 2H),   7.28   (d, 2H),

 7.31    (d,    1H),       7.39-7.44          (m,     2H),    7.51       (d,    2H),     7.95      (d, 1H),
 8.27   (s,    1H),      8.38       (s,   1H),      8.75    (s,    2H),      9.34    (s,     1H).
 Example 8-15:           1-(2-(4-(2-amino-5-chloropyridin-3
 yl)phenoxy)pyrimidin-5-yl)-3-(2-(3-(1-hydroxyethyl)-1H
pyrazol-1-yl)-5-(trifluoromethyl)phenyl)urea
TLC   : Rf     0.19      (Hexane : Ethyl Acetate = 1 : 2);
1H-NMR      (DMSO-d    6  )    :  5    1.44     (d,    3H),     4.92      (quint.,        1H),    5.23   (d,
 1H),   5.85      (s,     2H),        6.58    (d,     1H),    7.26       (d,    2H),     7.42      (d, 1H),
 7.47-7.54        (m,     3H),       7.72     (d,     1H),    7.95       (d,    1H),      8.28-8.31      (m,
 1H),  8.50      (d, 1H),         8.69      (s, 2H),        9.69    (s, 1H),         9.85      (s, 1H).
Example 8-16: 1-(2-(lH-1,2,4-triazol-1-yl)-5
 (trifluoromethyl)phenyl)-3-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)urea
TLC   : Rf 0.46          (Ethyl Acetate);
1
  H-NMR     (DMSO-d   6  )     : 5 5.85         (s,    2H),     7.26      (d,   2H),      7.42     (d, 1H),
7.50    (d,    2H),       7.59        (d,   1H),      7.77     (d,   1H),       7.95      (d,   1H),   8.42
 (s, 1H),       8.56        (s,    1H),      8.68      (s,   2H),     8.79       (s,     1H),     9.09   (s,
1H),   9.66      (s, 1H).
Example 8-17: 1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(4-methyl-3
 (trifluoromethyl)phenyl)urea
TLC : Rf 0.80            (Ethyl Acetate);
1H-NMR     (DMSO-d    6  )    :  5 2.36        (d,    3H),    5.85      (s,    2H),    7.26      (dd,  2H),
7.34    (d,    1H),      7.42        (d,   1H),      7.51    (dd,    2H),       7.57      (d,   1H),   7.89
 (d,  1H),     7.96        (d,    1H),      8.72       (s,   2H),     8.92       (s,     1H),     9.18   (s,
1H).
                                                       0A

 Example 8-18:       1-(2-(4-(2-amino-5-chloropyridin-3
 yl)phenoxy)pyrimidin-5-yl)-3-(3-fluoro-5
 (trifluoromethyl)phenyl)urea
TLC : Rf 0.26 (Ethyl Acetate : Hexane = 1 : 1);
'H-NMR    (DMSO-d  6  )    : 6 5.85      (s,    2H),    7.26    (d,   1H),    7.27   (dd,   2H),
7.43   (d,   1H),     7.51     (dd,    2H),      7.53-7.65       (m,   2H),    7.70    (s,  1H),
7.95   (d, 1H),      8.73     (s, 2H),        9.11    (s, 1H),      9.52    (s, 1H).
Example 8-19:        1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(4-chloro-3
 (trifluoromethyl)phenyl)urea
TLC : Rf 0.53 (Ethyl Acetate : Hexane = 3 : 1);
IH-NMR    (DMSO-d  6 )    : 5 5.85       (s,    2H),    7.25    (dd,   2H),    7.42    (dd,  1H),
7.51   (d,   2H),    7.61      (d,   1H),      7.70    (d,   1H),    7.95     (dd,  1H),    8.06
 (s, 1H),    8.72    (s, 2H),       9.04      (s, 1H),      9.44    (s, 1H).
Example 8-20:        1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-(5-methyl-1H-pyrazol-1-yl)-5
 (trifluoromethyl)phenyl)urea
TLC : Rf 0.39        (Ethyl Acetate : Hexane = 2 : 1);
1H-NMR    (DMSO-d  6 )    : 5 2.20        (s,    3H),   5.84     (s, 2H),      6.40   (s, 1H),
7.26   (d, 2H),       7.41      (d, 1H),        7.52    (d, 2H),      7.53     (d, 1H),     7.55
 (d, 1H),     7.75      (d,   1H),    7.94       (d,   1H),    8.40     (s,   1H),    8.61    (s,
1H),  8.67     (s,  2H),     9.73     (s,     1H).
Example 8-21:       1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-(5-methyl-3-(trifluoromethyl)
1H-pyrazol-1-yl)-5-(trifluoromethyl)phenyl)urea
TLC : Rf 0.28        (Hexane : Ethyl Acetate = 1 : 2);
                                                 or

1
   H-NMR    (DMSO-d  6  )     : 5   2.19    (s,    3H),   5.85    (s, 2H),    6.88    (s,    1H),
7.26     (d,   2H),     7.38-7.43         (m,    1H),   7.46-7.63      (m,  4H),    7.92-7.97
  (m,  1H),    8.31       (s,    1H),    8.61      (s,  1H),     8.67   (s,  2H),    9.38      (s,
1H).
Example 8-22:          1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(3-chloro-5
 (trifluoromethyl)phenyl)urea
TLC    : Rf 0.80       (Ethyl Acetate);
1
  H-NMR    (DMSO-d   6 )      : 5  5.86     (s,    2H),   7.27    (d, 2H),   7.43    (s,     2H),
7.51     (d,   2H),    7.84       (s,  2H),       7.95   (d,   1H),   8.73   (s,   2H),      9.15
 (s, 1H),     9.51     (s, 1H).
Example 9
        The similar           procedures        as Example      4 -+ Example     5 ->
Example      6 -> Example          7 were carried         out with 3-bromo-5
chloropyridin-2-amine or 3-bromo-5-fluoropyridin-2-amine                                  in
place of 3-bromo-5-chloropyridin-2-amine; 2-chloro-5
nitropyridine in place of 2-chloro-5-nitropyrimidine;                               and the
compound produced in Example 3 or a corresponding carbamate
compound in place of the compound produced in Example 3 to
give the present compounds having the following physical
characteristics.
Example 9-1:        1- (2- (lH-pyrazol-1-yl)-5-(trifluoromethyl)phenyl
3-(6-(4-(2-amino-5-chloropyridin-3-yl)phenoxy)pyridin-3
yl)urea

                                              CF3
                       0O    N~
         N NH2                    N     N
                                  H     H     N
                                           NL/
            ci
 TLC : Rf 0.62            (Hexane              Ethyl Acetate = 1                : 4);
 'H-NMR       (DMSO-d   6  )   :   5    5.85       (s,    2H),     6.67     (t,    1H),  7.04   (d, 1H),
 7.15     (d,     2H),      7.39       (d,      1H),     7.45-7.51        (m,     3H),   7.72  (d, 1H),
 7.93-7.94         (m,    2H),       8.00        (dd,    1H),     8.19     (d,    1H),   8.39   (d, 1H),
 8.58    (d,     1H),     9.56      (s,      1H),      9.82    (s,   1H) .
Example 9-2:           1-(2-(1H-1,2,3-triazol-l-yl)-5
  (trifluoromethyl)phenyl-3-(6-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyridin-3-yl)urea
                                             CF3
           NH2                Nl NO N
                                 H     H     N
           CI                              N
TLC    : Rf 0.69          (Ethyl Acetate);
1
   H-NMR     (DMSO-d   6  )   :   5     5.84       (s,   2H),      7.04    (d,    1H),   7.16   (d, 2H),
7.39     (d,     1H),      7.47       (d,      2H),     7.59     (d,    1H),      7.72   (d,  1H),  7.94
  (d,  1H),      7.99      (dd,      1H),        8.10     (d,   1H),     8.15      (d,  1H),  8.59-8.61
  (m, 2H),      8.68      (s, 1H),          9.57       (s, 1H).
Example 9-3:           1- (2-(1H-pyrazol-1-yl)-5-(trifluoromethyl)phenyl
3-(6-(4-(2-amino-5-fluoropyridin-3-yl)phenoxy)pyridin-3
yl)urea
TLC : Rf 0.27             (Hexane : Ethyl Acetate = 1 : 3);
1
  H-NMR      (DMSO-d   6  )   : 5       5.55       (s,   2H),      6.67    (t,    1H),   7.04   (d, 1H),
7.16    (d,      2H),     7.34       (dd,       1H),     7.47-7.50        (m, 3H),       7.72  (d, 1H),
7.91-7.94          (m, 2H),         8.01         (dd, 1H),       8.19     (d, 1H),       8.39  (d, 1H),
                                                          Q -7

 8.59   (d,   1H),    9.55   (s,  1H),     9.82   (s, 1H).
 Example 10: 2-(pyridin-3-yl)-5-(trifluoromethyl)aniline
              CF3
       H2 N
                N
       To a solution of 2-bromo-5-(trifluoromethyl)aniline                       (10
g) and 3-pyridineboronic acid (5.63 g) in acetonitrile                        (20 mL)
were added water          (10 mL),     sodium carbonate        (14.57 g) and
bis(triphenylphosphine)palladium (II) dichloride                      (1.46 g).    In
an argon atmosphere, the reaction mixture was stirred at 100*C
for 14 hours.         The reaction mixture was cooled to room
temperature and extracted with ethyl acetate.                      The organic
layer was dried over magnesium sulfate and then concentrated
under reduced pressure.             The obtained residue was purified on
silica gel column chromatography (hexane : ethyl acetate = 1:0
-> 0:1),     washed with hexane and then dried to give the titled
compound having the following physical characteristics                        (7.62
g).
TLC : Rf 0.56 (Ethyl Acetate : Hexane = 3 : 1);
1 H-NMR    (DMSO-d  6 )  : 6 5.40      (s,   2H),   6.90   (d,  1H),  7.08   (s,  1H),
7.18    (d,   1H),    7.48   (dd,   1H),     7.85   (d,  1H),   8.57  (d,  1H),   8.60
 (d, 1H).
Example 11:        1-(6-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyridin-3-yl)-3-(2-(pyridin-3-yl)-5
 (trifluoromethyl)phenyl)urea
                                              00

       The similar            procedures           as Example      3 -+ Example    4 ->
Example       5 -> Example           6 -+ Example 7 were carried               out with 2
chloro-5-nitropyridine in place of 2-chloro-5-nitropyrimidine
and the compound produced in Example 10 in place of the
compound produced in Example 2 to give the present compound
having the following physical characteristics.
                                         CF3
          NH2        O     N      O
       N                       N      N
                               H    H
         CI                                N
TLC : Rf 0.43           (Ethyl Acetate);
1
  H-NMR     (DMSO-d   6  )   :   5   5.80      (s,    2H),   7.04    (d,  1H),  7.16   (s, 2H),
7.41    (d,     1H),      7.47      (s,    1H),      7.50    (s,   2H),  7.54-7.61     (m, 2H),
7.90    (dt,     1H),      7.91      (d,     1H),    7.99     (s,   1H),  8.11-8.15    (m, 2H),
8.43   (s, 1H),         8.64-8.71          (m, 2H),        9.20   (s, 1H).
Example 12:         1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-(pyridin-3-yl)-5
 (trifluoromethyl)phenyl)urea
       The similar            procedures           as Example      3 -+ Example    7 were
carried out with the compound produced in Example 10 in place
of the compound produced in Example 2 to give the present
compound having the following physical characteristics.
                                         CF3
         NH2         O YNN        0
       N                N      N    N
                               H    H
         CI                                N
TLC : Rf 0.60           (Ethyl Acetate : Methanol = 19                     : 1);
                                                      C)n

1
  H-NMR      (DMSO-d  6  )      5 5.84        (s,   2H),    7.25     (d,    2H),  7.41  (d, 1H),
7.48-7.58        (m,    5H),     7.89      (dd,     1H),   7.94      (d,   1H),  8.23   (s, 1H),
 8.38   (s,    1H),     8.65-8.68         (m,     4H),   9.23   (s,     1H).
Example 13
       The similar procedures                     as Example 10 ->           Example 3 -+
Example 7 were carried out with a corresponding boronic acid
compound or a boronate ester compound in place of 3
pyridineboronic acid to give the present compounds having the
following physical characteristics.
Example 13-1:          1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl) -3- (2- (l-methyl-lH-pyrazol-5-yl) -5
 (trifluoromethyl)phenyl)urea
                                       CF3
          NH2       O      N    O
       N               N      N'N
                              H    H
                                         N'CH3
          CI                          -N
TLC   : Rf 0.60         (Ethyl Acetate);
1
  H-NMR     (DMSO-d6 )       : 5 3.65        (s, 3H),      5.85      (s, 2H),    6.46   (s, 1H),
7.27    (d, 2H),        7.42      (d,    1H),      7.50-7.52        (m,   4H),   7.62  (s,  1H),
7.95    (d, 1H),        8.09      (s, 1H),         8.56    (s, 1H),       8.68   (s, 2H),   9.49
(s, 1H).
Example 13-2:          1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl) -3- (2- (1-methyl-1H-pyrazol-4-yl) -5
(trifluoromethyl)phenyl)urea
                                                     Q A

                                         CF3
           NH2       0      N     O
        N               N       N    N
                                H    H
           CI                           N-N
                                            ~CH
                                              3
 TLC   : Rf     0.40     (Ethyl Acetate            : Methanol = 9 : 1);
 1H-NMR      (DMSO-d  6  )    :  5 3.92        (s,  3H),   5.85    (s,    2H),   7.25-7.27    (m,
 2H),   7.39-7.42           (m,    2H),     7.49-7.51      (m,  3H),     7.76    (s,  1H),  7.95
  (d,  1H),     8.10       (s,    1H),     8.24-8.27      (m,   2H),     8.71    (s,  2H),  9.41
  (s,  1H).
 Example 13-3:          1-(2-(4-(2-amino-5-chloropyridin-3
 yl)phenoxy)pyrimidin-5-yl)-3-(2-(l-methyl-3-(trifluoromethyl)
 1H-pyrazol-5-yl) -5- (trifluoromethyl)phenyl) urea
 TLC : Rf 0.78           (Ethyl Acetate            : Hexane = 2        : 1);
 1
   H-NMR    (DMSO-d   6  )    :  5   3.73      (s,  3H),   5.85    (s,   2H),    6.96   (s, 1H),
 7.26    (d,    2H),     7.42       (d,    1H),    7.51   (d,   2H),     7.53    (d,  1H),  7.58
  (d,  1H),     7.95       (d,    1H),      8.28    (s,  1H),    8.53      (s,  1H),   8.68   (s,
 2H),   9.32     (s,    1H).
Example 13-4:           1-(2-(4-(2-amino-5-chloropyridin-3
yl) phenoxy) pyrimidin-5-yl) -3- (2- (1-methyl-1H-pyrazol-3-yl) -5
  (trifluoromethyl)phenyl)urea
TLC    : Rf 0.48        (Ethyl Acetate);
'H-NMR      (DMSO-d   6  )    :  5 4.03        (s,  3H),   8.57    (s,   2H),    6.92   (d, 1H),
7.28     (d,    2H),     7.39       (d,    1H),    7.43   (d,   1H),     7.52    (d,  2H),  7.94
  (dd,  3H),     8.65       (s,    1H),     8.74    (s,  2H),    9.93     (s,  1H),   10.77   (s,
 1H).
Example 14

       The similar             procedures       as Example      6 ->    Example     7 were
carried out with 3-bromo-5-fluoropyridin-2-amine in place of
3-bromo-5-chloropyridin-2-amine;                        and Example 3 or a
corresponding carbamate or isocyanate compound in place of
Example 3 to give the present compounds having the following
physical characteristics.
Example 14-1:           1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-fluoro-5
 (trifluoromethyl)phenyl)urea
                                       CF3
           N
       N NH          ON            N
                                H  H   F
         F
TLC   : Rf 0.65         (Hexane : Ethyl Acetate               =   1     9);
IH-NMR     (DMSO-d    6  )    :  5  5.56    (s,    2H),   7.28     (d,  2H),    7.35-7.54     (m,
5H),    7.93     (d,       1H),    8.51-8.53(m,          1H),   8.74     (s,   2H),    9.09   (s,
1H) ,  9.29    (s,      1H).
Example 14-2:           1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(3-(trifluoromethyl)phenyl)urea
TLC   : Rf 0.16         (Ethyl Acetate : Hexane = 1                   : 1);
1
  H-NMR    (DMSO-d    6  )    :  5 5.56     (s,    2H),   7.27     (d,  2H),    7.33    (d, 1H),
7.38    (dd, 1H),          7.51    (d, 1H),      7.53     (dd, 2H),      7.60    (d, 1H),   7.94
 (d,  1H),    7.97        (s,    1H),    8.73     (s,   2H),    8.98    (s,   1H),    9.431   (s,
1H).
Example 14-3:           1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(5-(trifluoromethyl)-2-(3
 (trifluoromethyl)-1H-pyrazol-1-yl)phenyl)urea

                                                    CF3
           NH2              yN           0
        N N            ON            N       N
                                     H       H      N
                                                 P
                 F,
                 F                           F3 C
TLC   : Rf      0.74        (Ethyl Acetate                   : Hexane = 2        : 1);
1
  H-NMR      (DMSO-d      6  )    :    5 5.56            (s,  2H),   7.12    (d,    1H),  7.27   (d, 2H),
7.37     (dd, 1H),             7.53         (d, 2H),         7.59   (dd, 1H),       7.71   (d, 1H),  7.94
 (d,   1H),      8.47          (s,      2H),          8.58    (s,  1H),    8.67      (s, 2H),   9.48   (s,
1H).
Example 14-4:              1-(2-(1H-pyrazol-1-yl)-5
 (trifluoromethyl)phenyl)-3-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)urea
TLC   : Rf 0.49             (Ethyl Acetate                   : Hexane = 2        : 1);
1H-NMR       (DMSO-d     6  )     :   5      5.56        (s,  2H),   6.68    (s,   1H),   7.27   (d, 2H),
7.38     (dd,     1H),         7.53          (d,       3H),   7.75   (d,   1H),    7.92-7.98     (m, 2H),
8.41     (s,    1H),         8.58          (s,       1H),    8.70   (s,   2H),     9.70   (s,  1H),  9.96
 (s, 1H).
Example 14-5:              1-(2-(lH-1,2,3-triazol-1-yl)-5
(trifluoromethyl)phenyl)-3-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)urea
                                                   CF3
           NH2       0            N         N
        N         N    '        '     'JNN
                                    H       H    ,
           F                                     N
TLC       Rf 0.69           (Ethyl Acetate);
1
 H-NMR      (DMSO-d6 ) :             5 5.55             (s, 2H),   7.27     (d, 2H),     7.37   (dd, 1H),
7.52     (d,    2H),        7.61           (d,       1H),    7.74   (d,   1H),     7.93   (d,  1H),  8.09

  (s, 1H),     8.57       (s,   1H),    8.67    (s,  3H),   8.71   (s,  1H),   9.65   (s,
1H).
Example 14-6:          1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-(pyridin-3-yl)-5
 (trifluoromethyl)phenyl)urea
                                     CF3
         NH2       O      N     O
       N    N          N
                       N      N   N
                              H   H
         F                             N
TLC : Rf 0.62          (Ethyl Acetate : Methanol = 19 : 1);
'H-NMR (DMSO-d6 ) : 5 5.55                (s, 2H),    7.25   (d, 2H),  7.36   (dd, 1H),
7.48-7.58       (m,    5H),     7.89     (dd,  1H),   7.93    (d, 1H),  8.24   (s,  1H),
8.38   (s, 1H),        8.64-8.68       (m, 4H),     9.23   (s, 1H).
Example 14-7:          1-(2- (4- (2-amino-5-fluoropyridin-3
yl) phenoxy) pyrimidin-5-yl) -3- (2- (4-methyl-1H-1,2, 3-triazol-1
yl)-5-(trifluoromethyl)phenyl)urea
TLC : Rf 0.33          (Ethyl Acetate : Hexane = 3 : 1);
1 H-NMR
           (DMSO-d   6 )    : 5 2.38       (s, 3H),    5.56   (s, 2H),  7.26   (d,  2H),
7.36   (dd,    1H),      7.52     (dd,   2H),   7.60    (d, 1H),  7.69   (d, 1H),   7.94
(d,   1H),    8.34       (s,    1H),   8.59    (d,   1H),   8.68   (d, 2H),   8.76    (s,
1H),   9.69    (s,    1H).
Example 14-8:         1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-(1-methyl-1H-pyrazol-4-yl)-5
(trifluoromethyl)phenyl)urea

                                             CF 3
          NH2         O       N       O
        NN                         N'    N
                                   H     H
          F                                 N-N
                                                'CH 3
TLC   : Rf 0.31           (Ethyl Acetate                  : Methanol = 9 : 1);
1
  H-NMR     (DMSO-d    6   )     :   5 3.92           (s,   3H),   5.56    (s,  2H),  7.27    (d, 2H),
7.35-7.42        (m,      2H),          7.51-7.55           (m,  3H),    7.76    (s,  1H),   7.93   (d,
 1H),   8.10      (s,      1H),         8.24       (s,    1H),    8.28    (s,   1H),  8.71   (s,  2H),
 9.42   (s, 1H).
Example 14-9:            1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl) -3- (2- (l-methyl-lH-pyrazol-5-yl) -5
 (trifluoromethyl)phenyl)urea
TLC : Rf 0.50             (Ethyl Acetate);
1
  H-NMR    (DMSO-d     6  )     :    5   3.65        (s,    3H),   5.56    (s,  2H),  6.45    (s, 1H),
7.27    (d,    2H),       7.37          (dd,      1H),      7.49-7.54     (m,   4H),  7.62    (s, 1H),
7.94    (d,    1H),        8.09         (s,    1H),       8.56    (s,   1H),    8.68  (s,  2H),   9.49
 (s, 1H).
Example 14-10: l-(2-(1H-1,2,4-triazol-l-yl)-5
 (trifluoromethyl)phenyl)-3-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)urea
TLC   : Rf 0.44          (Ethyl Acetate);
IH-NMR     (DMSO-d    6   )     : 5 5.56           (s,     2H),   7.27   (d,   2H),  7.36   (dd,  1H),
7.51    (d,    2H),       7.57          (d, 1H),          7.77    (d,   1H),   7.93   (d,  1H),   8.41
 (s,  1H),     8.56          (d,      1H),       8.68       (s,  2H),    8.78    (s, 1H),    9.09   (s,
1H),   9.66     (s,      1H).
Example 14-11: 1- (2- (4- (2-amino-5-fluoropyridin-3-

  yl)phenoxy)pyrimidin-5-yl)-3-(2-methyl-5
  (trifluoromethyl)phenyl)urea
 TLC : Rf 0.38        (Ethyl Acetate : Hexane = 2 : 1);
 'H-NMR    (DMSO-d  6  )  : 5 2.32    (s,   3H),    5.56  (s,  2H), 7.25-7.46   (m,
  5H),  7.54    (d,    2H),   7.94  (d,    1H),    8.27  (s,  1H),  8.38  (s, 1H),
 8.75   (s, 2H),      9.33 (s, 1H).
 Example 14-12:         1-(2-(4-(2-amino-5-fluoropyridin-3
 yl)phenoxy)pyrimidin-5-yl)-3-(2-chloro-5
  (trifluoromethyl)phenyl)urea
 TLC : Rf 0.71        (Hexane : Ethyl Acetate = 1 : 9);
 1H-NMR    (DMSO-d  6  )  : 5 5.56    (s,   2H),   7.28   (d, 2H),  7.36-7.41   (m,
 2H),   7.53    (d,    2H),   7.72  (d,    1H),   7.93   (d,  1H),  8.56  (s, 1H),
 8.74   (s, 2H),      8.78   (s, 1H),     9.71   (s, 1H).
Example 14-13:          1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-(4-methyl-1H-pyrazol-1-yl)-5
  (trifluoromethyl)phenyl)urea
TLC : Rf 0.50         (Ethyl Acetate : Hexane = 2 : 1);
'H-NMR    (DMSO-d   6 )   : 5 2.15    (s,   3H),   5.56   (s, 2H),  7.26  (d, 2H),
 7.36   (dd, 1H),        7.47-7.55   (m,    3H),   7.70   (d, lH),  7.78  (s, 1H),
7.93    (d, 1H),       8.18   (s, 1H),     8.57    (d, 1H),   8.70  (s, 2H),  9.83
  (s, 1H),    9.96 (s, 1H).
Example 14-14: 1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-(5-methyl-1H-1,2,3-triazol-l
yl)-5-(trifluoromethyl)phenyl)urea
TLC : Rf 0.63         (Ethyl Acetate);
'H-NMR    (DMSO-d   6 )   : 5 2.20    (s,   3H),   5.55   (s, 2H),  7.27  (d, 2H),

 7.37    (dd,   1H),      7.53    (d,   2H),      7.62      (d,   2H),   7.84    (s,  1H),  7.94
 (d,   1H),    8.30      (s,   1H),     8.65       (s,    1H),    8.67     (s,  2H),   9.46   (s,
 1H).
Example 14-15:           1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(4-methyl-3
 (trifluoromethyl)phenyl)urea
TLC : Rf 0.43         (Hexane : Ethyl Acetate = 1 : 4);
'H-NMR     (DMSO-d  6  )   : 5 2.36        (s,     3H),    5.57      (s, 2H),    7.27   (d, 2H),
7.30-7.42       (m,    2H),     7.50-7.60          (m,    3H),     7.89    (s,  1H),   7.94   (d,
1H),    8.72    (s, 2H),      8.92      (s, 1H),        9.18     (s, 1H).
Example 14-16:           1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-(3-methyl-1H-pyrazol-1-yl)-5
 (trifluoromethyl)phenyl)urea
TLC : Rf 0.45 (Ethyl Acetate : Hexane = 2 : 1);
1H-NMR     (DMSO-d     )
                    6      : 5 2.37       (s,      3H),    5.56      (s, 2H),    6.45   (s, 1H),
7.28    (d, 2H),      7.38      (dd, 1H),         7.48-7.60         (m,  1H),   7.53   (d, 2H),
7.70    (d, 1H),       7.94     (d, 1H),         8.28      (d, 1H),      8.57    (s, 1H),   8.70
 (s,  2H),    9.81    (s,    1H),     9.92     (s,     1H).
Example 14-17:          1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(3-fluoro-5
 (trifluoromethyl)phenyl)urea
TLC : Rf 0.20         (Ethyl Acetate : Hexane                   =  1 : 1);
1H-NMR     (DMSO-d6 ) : 5 5.57            (s, 2H),        7.22-7.33       (m,  3H),   7.38  (dd,
1H),    7.53    (d,    2H),     7.62     (d, 1H),         7.72      (s,  1H),   7.94   (d,  1H),
8.73    (s, 2H),     9.11      (s, 1H),       9.52      (s, 1H).
Example 14-18: 1-(2-(4-(2-amino-5-fluoropyridin-3
                                                   cY?-

yl)phenoxy)pyrimidin-5-yl)-3-(4-chloro-3
 (trifluoromethyl)phenyl)urea
TLC : Rf 0.46           (Ethyl Acetate : Hexane = 3 : 1);
'H-NMR     (DMSO-d    6 )   : 5 5.56     (s,   2H),  7.26    (d,   2H),  7.38     (dd, 1H),
7.52   (d,     2H),     7.61    (d,   1H),    7.68   (d,   1H),    7.93  (dd,    1H),  8.07
 (s, 1H),     8.72      (d, 2H),     9.05    (s, 1H),     9.44    (s, 1H).
Example 14-19: 1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(3-chloro-5
 (trifluoromethyl)phenyl)urea
TLC : Rf 0.80           (Ethyl Acetate);
'H-NMR (DMSO-d6 ) : 5 5.57              (s, 2H),     7.27    (dd, 2H),     7.36    (dd, 1H),
7.43   (s,    1H),      7.53    (dd,   2H),    7.83   (d,   2H),    7.93   (s,   1H),  8.73
 (s, 2H),     9.13 (s, 1H),          9.49    (s, 1H).
Example 14-20:            1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-(5-methyl-1H-pyrazol-1-yl)-5
 (trifluoromethyl)phenyl)urea
TLC : Rf 0.39           (Ethyl Acetate : Hexane = 2 : 1);
1H-NMR
          (DMSO-d     6 )   : 5 2.20     (s,    3H),  5.50    (s,   2H),   6.40    (s, 1H),
7.27   (d, 2H),         7.37    (dd, 1H),       7.51-7.55     (m,   4H),  7.75     (s, 1H),
7.93   (d, 1H),         8.40     (s, 1H),     8.61    (s, 1H),      8.67   (s, 2H),    9.73
 (s, 1H).
Example 15
      The     similar       procedures       as Example     4 -> Example       5 -+
Example 6 -> Example 7 were carried out with 3-bromo-5
chloropyridin-2-amine or a corresponding amine compound in
                                                no

 place of 3-bromo-5-chloropyridin-2-amine; 2-chloro-5
 nitropyrimidine or 2-chloro-5-nitropyridine in place of 2
 chloro-5-nitropyrimidine; and a corresponding carbamate or
 isocyanate compound in place of the compound produced in
 Example 3 to give the present compounds having the following
 physical characteristics.
 Example 15-1:            1-(2-(4-(2-amino-5-methylpyridin-3
 yl)phenoxy)pyrimidin-5-yl)-3-(3-(trifluoromethyl)phenyl)urea
                                          CF 3
          NH2           Y           0
            N
       N NHON   ~   -     N            Nb
                                 H     H
         CH 3
 TLC : Rf 0.22            (Ethyl Acetate : Methanol = 9 : 1);
 1H-NMR    (DMSO-d      6  )   : 5 2.16          (s, 3H),       5.47    (s, 2H),      7.21-7.27         (m,
 3H),  7.33         (d,     1H),      7.47-7.54          (m,   3H),   7.62     (d,    1H),     7.79     (s,
 1H),  7.97       (s,     1H),     8.73      (s,     2H),    8.99   (s,   1H),     9.32    (s,   1H).
Example 15-2:             1- (2- (lH-pyrazol-1-yl)-4
  (trifluoromethyl)phenyl)-3-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)urea
                      OCF
                      O   N                  3
            N     -         Ni
              IH                   H    N
         FNQ
TLC : Rf 0.54             (Ethyl Acetate : Hexane = 2 : 1);
'H-NMR     (DMSO-d      6  )   : 5 5.56          (s,   2H),     6.66    (d,  1H),     7.27     (d,    2H),
7.36   (dd, 1H),             7.52      (dd, 2H),        7.75     (d, 1H),     7.83     (s, 1H),       7.94
 (d,  2H),      8.42-8.44             (m,  2H),       8.70     (s,   2H),   9.57      (s,    1H),     9.97
 (s, 1H).

Example 15-3:          1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-chloro-4
 (trifluoromethyl)phenyl)urea
TLC : Rf 0.37          (Dichloromethane : Methanol = 9 : 1);
  H-NMR    (DMSO-d   6 )   : 5 5.56       (s,   2H),   7.29   (d,    2H),    7.38  (dd, 1H),
7.50-7.55      (m,     2H),     7.69    (dd,    1H),    7.89   (d,    1H),    7.94  (d, 1H),
8.43   (d, 1H),        8.75     (s, 2H),      8.80    (s, 1H),     9.77    (s, 1H).
Example 15-4:          1- (2- (1H-pyrazol-1-yl)-4
 (trifluoromethyl)phenyl)-3-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)urea
         N          O                    CF3
       N                     N    N
         C                   H    H    N
         CI
TLC : Rf 0.40          (Hexane : Ethyl Acetate              = 1 : 2);
IH-NMR     (DMSO-d   6 )   : 5 5.83       (s,    2H),   6.67   (t,    1H),    7.28  (d, 2H),
7.43   (d,    1H),      7.52     (d,   2H),     7.74-7.77     (m,    1H),     7.84  (s, 1H),
7.94-7.97      (m,     2H),      8.43-8.45        (m,  2H),   8.72     (s,   2H),  9.57   (s,
1H),   9.96    (s,    1H).
Example 15-5:         1- (2- (4- (2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-fluoro-4
 (trifluoromethyl)phenyl)urea
            2      O>N
                   0NH         N         CF3
        NH
                            H     H
                                     F
         CI
TLC : Rf 0.45          (Ethyl Acetate : Hexane = 2 : 1);
1H-NMR    (DMSO-d    6 )   : 5 5.84       (s,    2H),   7.27   (d,    2H),    7.43  (d, 1H),
                                                1 noC

 7.46-7.55      (m,     3H),      7.67      (d,    1H),     7.96    (d,    1H),   8.38   (t, 1H),
 8.75  (s, 2H),        9.24       (br, 2H).
 Example 15-6:         1-(2-(4-(2-amino-5-chloropyridin-3
 yl)phenoxy)pyrimidin-5-yl)-3-(2-chloro-4
 (trifluoromethyl)phenyl)urea
         NH2        0
                    O        N              CF3
       N                  )'   NI
                               H    H  CI
                                       CI
         CI
TLC : Rf 0.45 (Hexane : Ethyl Acetate = 1 : 2);
1H-NMR
          (DMSO-d    6  )    : 5 5.85         (s,    2H),    7.28    (d,    2H),  7.43   (d, 1H),
7.52   (d,   2H),      7.69       (dd,     1H),     7.89     (d,   1H),    7.96    (d, 1H),  8.42
 (d, 1H),    8.75      (s, 2H),        8.80       (s, 1H),      9.77     (s, 1H).
Example 15-7:          1- (2- (4- (2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2,4-dichlorophenyl)urea
TLC : Rf 0.59          (Ethyl Acetate : Hexane = 2 : 1);
1H-NMR
          (DMSO-d6 ) : 5 5.85                (s, 2H),      7.27     (d, 2H),     7.41  (dd, 1H),
7.42   (d,    1H),      7.50       (d,    2H),     7.63     (d,   1H),     7.95   (d, 1H),   8.14
 (d, 1H),    8.57      (s, 1H),        8.72       (s, 2H),      9.59     (s, 1H).
Example 15-8:         1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2,4-dichlorophenyl)urea
TLC : Rf 0.50          (Ethyl Acetate : Hexane = 2 : 1);
1H-NMR    (DMSO-d    6 )     : 5 5.56        (s,    2H),     7.27    (d,   2H),   7.35-7.43    (m,
2H),   7.51    (d,     2H),       7.63      (d, 1H),       7.93     (d,    1H),   8.14  (d,  1H),
8.57   (s, 1H),       8.72       (s, 2H),        9.59     (s, 1H).
Example 15-9:         1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2,4,5-trifluorophenyl)urea
                                                    1 (1

TLC   : Rf 0.40         (Ethyl Acetate);
'H-NMR     (DMSO-d   6  )   : 5 5.56      (s,   2H),    7.28   (d,    2H),    7.38  (dd,  1H),
7.53     (d,   2H),       7.62-7.66      (m,   1H),     7.94   (d,     1H),    8.08-8.15    (m,
1H),   8.73     (s, 2H),        8.93   (s, 1H),       9.21   (s, 1H).
Example 15-10:            1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2,4-difluorophenyl)urea
TLC   : Rf 0.45         (Ethyl Acetate : Hexane = 3 :                  1);
  H-NMR    (DMSO-d   6  )   :  5  5.85     (s,   2H),    7.04   (t,    1H),    7.26   (d, 2H),
7.31    (dd,    1H),       7.42    (d,  1H),    7.51     (d,  2H),     7.94-8.04     (m,  2H),
8.71-8.72       (m,    3H),     9.16   (s, 1H).
Example 15-11:            1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2,5-dichlorophenyl)urea
TLC : Rf 0.56          (Ethyl Acetate          : Hexane = 2         : 1);
1H-NMR     (DMSO-d   6  )   : 5   5.85    (s,  2H),     7.12   (dd,     1H),   7.26   (d, 2H),
7.42    (d,    1H),      7.49-7.55       (m,   3H),     7.95-7.97        (m,  1H),   8.26   (d,
1H),   8.64     (s,    1H),    8.74    (d, 2H),       9.68   (s, 1H).
Example 15-12: 1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2,5-difluorophenyl)urea
TLC : Rf 0.54          (Ethyl Acetate          : Hexane = 3 : 1);
1
  H-NMR    (DMSO-d   6  )   : 5   5.85     (s,   2H),    6.84   (m,    1H),    7.26-7.32    (m,
3H),   7.42      (d,    1H),     7.51   (dd,    2H),    7.93-8.01         (m,  2H),  8.73   (s,
2H),   8.96     (s, 1H),       9.27    (s, 1H).
Example 15-13: 1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(3-(difluoromethyl)phenyl)urea
TLC   : Rf    0.34     (Dichloromethane : Methanol =                   9 : 1);
  H-NMR    (DMSO-d   6  )   : 5   5.85     (s,   2H),    7.00   (t,    1H),    7.17   (d, 1H),
                                                1 n,)

 7.25-7.29       (m,     2H),       7.39-7.45           (m,   2H),    7.49-7.53         (m,   3H),  7.78
 (s,  1H),     7.95        (d,    1H),         8.73     (s,   2H),     8.91      (s,   1H),    9.17   (s,
1H).
Example 15-14: 1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(4-fluorophenyl)urea
TLC : Rf 0.50           (Ethyl Acetate : Hexane = 3 : 1);
1H-NMR     (DMSO-d    6  )    : 5 5.84            (s,   2H),    7.06-7.13         (m,   2H),   7.25   (d,
2H),   7.42       (d,     1H),      7.46-7.51            (m,   4H),    7.94      (d,   1H),    8.71   (d,
2H),   9.40     (br, 2H).
Example 15-15:             1- (2- (4- (2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2,5-dichlorophenyl)urea
TLC : Rf 0.50           (Ethyl Acetate : Hexane = 2 : 1);
IH-NMR    (DMSO-d     6 )     : 5 5.56           (s,   2H),    7.12    (dd,     1H),    7.28    (d, 2H),
7.37   (dd,     1H),       7.49       (d,      1H),     7.53    (d,   2H),     7.94     (d,   1H),  8.25
 (d, 1H),     8.64      (s, 1H),          8.73        (s, 2H),     9.68      (s, 1H).
Example 15-16: 1-(2-(4-(2-aminopyridin-3-yl)phenoxy)pyrimidin
5-yl)-3-(2-(pyridin-3-yl)-5-(trifluoromethyl)phenyl)urea
                                          CF 3
         NH 2         Y    N,     0
       N                       NN (    N)
                                H    H
                                          N
TLC : Rf 0.47           (Ethyl Acetate : Methanol = 19                           : 1);
1H-NMR
          (DMSO-d     6 )     : 5     5.57        (s,   2H),    6.66     (t,    1H),    7.24    (d, 2H),
7.34    (d,   1H),       7.46-7.58              (m,    6H),    7.89     (d,    1H),    7.94     (d, 1H),
8.24   (s, 1H),         8.38      (s, 1H),            8.65-8.68      (m, 3H),        9.24    (s, 1H).
Example 15-17:            1-(2-(4-(2-amino-5-chloropyridin-3
yl) phenoxy) pyrimidin-5-yl) -3- (3,4-difluorophenyl) urea
                                                        1 rVI

 TLC : Rf 0.79            (Ethyl Acetate : Hexane = 3                            : 1);
 1H-NMR      (DMSO-d    6  )        6 5.85         (s,    2H),      7.13-7.16          (m,     1H),     7.26   (d,
 2H),   7.30-7.40             (m,     1H),     7.42       (d,    1H),     7.51       (d,     2H),     7.59-7.67
  (m,  1H),       7.95       (d,     1H),      8.71       (s,    2H),      8.93       (s,     1H),     9.16    (s,
 1H).
 Example 15-18: 1-(2-(4-(2-amino-5-chloropyridin-3
 yl)phenoxy)pyrimidin-5-yl) -3- (2- (3-methyl-1H-pyrazol-1-yl)-4
  (trifluoromethyl)phenyl)urea
 TLC : Rf 0.23            (Hexane : Ethyl Acetate = 1                            : 1);
 1
   H-NMR     (DMSO-d    6 )     : 5 2.36           (s,    3H),      5.85     (s,    2H),       6.43     (d, 1H),
 7.27    (d,     2H),     7.42          (d,   1H),      7.50       (d,   2H),       7.70       (d,   1H),    7.76
  (s,  1H),      7.95       (d,      1H),      8.29       (d,    1H),      8.40       (d,     1H),     8.70   (s,
2H),    9.63       (s, 1H),          9.92     (s, 1H).
Example 15-19:              1-(2-(4-(2-amino-5-cyclopropylpyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(3-(trifluoromethyl)phenyl)urea
                                             CF3
                    '  0 YN~          0
             H2
        N   NH2                    N     N
                                   H     H
TLC : Rf 0.54             (Ethyl Acetate : Methanol = 9 : 1);
'H-NMR        (DMSO-d    6 )      : 5 0.59-0.64                 (m,     2H),       0.81-0.87           (m,   2H),
1.77-1.86          (m,    1H),        5.36       (s,    2H),     7.01       (d,     1H),      7.25      (d, 2H),
7.32     (d,     1H),     7.47-7.54              (m,    3H),     7.62       (d,     1H),      7.80      (d, 1H),
7.97    (s,     1H),     8.72        (s,    2H),       8.99    (s,     1H),      9.32     (s,    1H).
Example 15-20: 1-(2-(4-(2-amino-5-methylpyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-(pyridin-3-yl)-5
 (trifluoromethyl)phenyl)urea
                                                         1 r)A

 TLC      :   Rf    0.53       (Ethyl Acetate            : Methanol          : Aqueous           Ammonia   =    9
      1:    0.5);
   H-NMR        (DMSO-d   6  )     :  5 2.15      (s,    3H),     5.34      (s,    2H),      7.20-7.24      (m,
 3H),       7.46-7.58           (m,     5H),   7.78      (s,    1H),    7.87-7.90            (m, 1H),     8.24
  (s,    1H),     8.38      (s,      1H),    8.64-8.68         (m,   4H),       9.24    (s,     1H)
 Example 15-21:                1-(2-(4-(2-amino-5-chloropyridin-3
 yl)phenoxy)pyrimidin-5-yl)-3-(2-(pyridin-3-yl)-4
 (trifluoromethyl)phenyl)urea
TLC      : Rf 0.51          (Ethyl Acetate);
 1H-NMR        (DMSO-d   6   )    :   5   5.84   (s,    2H),      7.26     (d,     2H),      7.42     (d, 1H),
 7.51-7.56           (m,     5H),       7.76    (d,    1H),      7.90     (d,     1H),      7.95      (d, 1H),
 8.24       (s, 1H),       8.27        (d, 1H),       8.66-8.68       (m, 2H),          9.28      (s, 1H).
Example 15-22:                 1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(3-(difluoromethyl)phenyl)urea
TLC      : Rf 0.33          (Dichloromethane : Methanol =                         9 : 1);
1
  H-NMR       (DMSO-d    6   )    : 5     5.57   (s,    2H),      7.00     (t,     1H),     7.17      (d, 1H),
7.26-7.29            (m,    2H),        7.36-7.45       (m,     2H),   7.51-7.55             (m,    3H),  7.78
 (s,     1H),      7.94        (d,     1H),    8.73      (s,    2H),    8.91        (s,     1H),     9.17   (s,
1H).
Example 15-23: 1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(4-(trifluoromethyl)phenyl)urea
TLC      : Rf 0.82          (Ethyl Acetate);
'H-NMR        (DMSO-d    6  )     : 5     5.85   (s,    2H),      7.27     (d,     2H),      7.42     (d, 1H),
7.51        (d,    2H),      7.64        (d,  4H),     7.95      (d,   1H),       8.73       (s,    2H),  8.98
 (s,     1H) ,    9.37      (s,      1H)
Example 15-24:                1-(2-(4-(2-aminopyridin-3-yl)phenoxy)pyrimidin
                                                        1 (r~r

 5-yl)-3-(3-(trifluoromethyl)phenyl)urea
TLC : Rf 0.20         (Ethyl Acetate : Methanol = 19                        : 1);
 1H-NMR    (DMSO-d 6  )   : 5 5.58         (s,    2H),    6.60     (dd,    1H),   7.25-7.37     (m,
 4H),   7.47-7.63        (m,   4H),      7.94-7.97         (m,   2H),     8.73    (s,  2H),   9.00
  (s, 1H),    9.33    (s, 1H).
Example 15-25:          1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(4-(trifluoromethyl)-2-(3
 (trifluoromethyl)-1H-pyrazol-1-yl)-phenyl)urea
TLC : Rf 0.39        (Hexane : Ethyl Acetate = 1 : 1);
1H-NMR     (DMSO-d 6  )    : 5    5.85      (s,    2H),    7.11     (d,   1H),    7.26    (d, 2H),
7.42    (d,   1H),    7.50       (d,   2H),       7.81    (s,    1H),     7.85-7.88       (m, 1H),
7.95    (d,   1H),    8.36      (d,    1H),      8.47     (s,    1H),     8.53    (s,  1H),   8.67
 (s,  2H),    9.50   (s,     1H).
Example 15-26:         1-(2-(4-(2-aminopyridin-3-yl)phenoxy)pyrimidin
5-yl)-3-(2-(3,4-dimethylphenyl)-5-(trifluoromethyl)pyridin-3
yl)urea
                                     CF3
          NH2           ~     0
            N                          N
                            H    H
                                          CH3
                                     CH3
TLC : Rf 0.29        (Hexane : Ethyl Acetate                   =   1 : 4);
1H-NMR     (DMSO-d 6 )    : 5 2.31        (s,     6H),    5.57     (s,   2H),    6.66   (dd,  1H),
7.25    (d,   2H),    7.31-7.42(m,              4H),    7.48     (d,    2H),    7.95    (dd,  1H),
8.35   (s, 1H),      8.68-8.72         (m, 3H),         8.78    (s, 1H),      9.51    (s, 1H).
Example 15-27:         1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2,4-difluorophenyl)urea
                                                  1 ()r

 TLC : Rf 0.40           (Ethyl Acetate : Hexane = 2                   : 1);
 1H-NMR      (DMSO-d   6  )   :  5   5.55    (s,    2H),    7.00-7.09        (m,  1H),    7.27   (d,
 2H),   7.28-7.39           (m,    2H),   7.52      (d,   2H),   7.93      (d,   1H),    7.96-8.02
  (m, 1H),      8.70     (s, 1H),       8.71     (s, 2H),      9.15    (s, 1H).
 Example 15-28:            1-(2-(4-(2-amino-5-chloropyridin-3
 yl)phenoxy)pyrimidin-5-yl)-3-(2-fluorophenyl)urea
 TLC   : Rf 0.50         (Ethyl Acetate           : Hexane = 3         : 1);
 1
   H-NMR    (DMSO-d)          :  5  5.85     (s,    2H),    7.03-7.06        (m, 1H),     7.12   (t,
 1H),   7.20-7.24           (m, 1H),      7.28      (d,   2H),   7.42      (d,   1H),   7.50   (dd,
 2H),   7.95     (d, 1H),        8.04    (t, 1H),        8.73   (s, 2H),       9.15    (br, 2H).
Example 15-29:             1-(2-(4-(2-amino-5-chloropyridin-3
 yl)phenoxy)pyrimidin-5-yl)-3-(2,4,6-trifluorophenyl)urea
TLC    : Rf 0.60         (Hexane : Ethyl Acetate = 1                   : 9);
1
   H-NMR   (DMSO-d    6  )    : 5   5.85     (s,   2H),     7.24-7.30        (m,  4H),    7.42   (d,
 1H),   7.49      (d,    2H),      7.94    (d,    1H),     8.34   (s,     1H),    8.70    (s,  2H),
 9.22   (s, 1H).
Example 15-30: 1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-(pyridin-3-yl)-4
 (trifluoromethyl)phenyl)urea
TLC    : Rf 0.50         (Ethyl Acetate);
'H-NMR     (DMSO-d    6  )   :  5 5.56      (d,   2H),     7.27   (d,    2H),    7.36    (dd,  1H),
7.52     (d,    2H),      7.53-7.55        (m,    2H),     7.70    (d,    1H),    7.89-7.94      (m,
2H),    8.24      (s,     1H),     8.28    (d,    1H),     8.66    (s,    2H),    8.67-8.69      (m,
2H),    9.29     (s, 1H).
Example 15-31:             1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(3-chloro-4
                                                   1 n,7

  (trifluoromethyl)phenyl)urea
TLC : Rf 0.40           (Ethyl Acetate : Hexane = 2 : 1);
'H-NMR      (DMSO-d   6  )   : 5 5.85     (s,    2H),    7.27    (d,   2H),    7.42    (d, 1H),
7.46-7.55        (m,     3H),    7.74   (d,    1H),     7.89    (d,    1H),    7.95   (d,  1H),
8.72    (s, 2H),       9.09     (s, 1H),      9.55    (s, 1H).
Example 15-32: 1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(3,4-difluorophenyl)urea
TLC : Rf 0.73           (Ethyl Acetate);
1 H-NMR     (DMSO-d  6  )    : 5 5.56     (s,    2H),    7.13-7.17        (m, 1H),    7.26   (d,
2H),   7.29      (d,    1H),     7.38   (dd,     1H),    7.52    (d,   2H),    7.59-7.67     (m,
1H),   7.93     (d, 1H),        8.70   (s, 2H),       8.93   (s, 1H),       9.16   (s, 1H).
Example 15-33:            1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-fluoro-4
 (trifluoromethyl)phenyl)urea
TLC : Rf 0.45           (Ethyl Acetate : Hexane = 2 : 1);
1 H-NMR
           (DMSO-d   6  )   : 5 5.56     (s,    2H),    7.29   (d,    2H),    7.38   (dd,  1H),
7.52-7.56       (m,     3H),     7.69-7.76       (m, 1H),     7.94      (d,   1H),  8.32-8.42
 (m, 1H),     8.75      (s, 2H),     9.12     (d, 1H),      9.33     (s, 1H).
Example 15-34:            1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2,5-difluorophenyl)urea
TLC : Rf 0.80          (Ethyl Acetate);
'H-NMR (DMSO-d6 ) : 5 5.57               (s, 2H),       6.81-6.87        (m, 1H),   7.25-7.58
(m,   2H),     7.29     (d,    1H),   7.38     (dd,    1H),   7.53      (d,   2H),  7.92-8.00
(m, 2H),      8.73     (s, 2H),      8.96     (s, 1H),      9.26 (s, 1H).
Example 15-35: 1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(3-chloro-4
                                                1 ()p

   (trifluoromethyl)phenyl)urea
  TLC : Rf 0.40           (Ethyl Acetate : Hexane = 2 : 1);
  1H-NMR     (DMSO-d   6  )    : 5 5.57    (s,     2H),   7.28   (d,   2H),    7.39    (dd,  1H),
  7.53   (d,    3H),      7.75     (d,  1H),     7.94    (dd,   2H),    8.73      (s, 2H),   9.11
   (s, 1H),     9.57     (s,     1H).
 Example 15-36:             1-(2-(4-(2-amino-5-fluoropyridin-3
 yl)phenoxy)pyrimidin-5-yl)-3-(4-(trifluoromethyl)phenyl)urea
 TLC : Rf 0.80           (Ethyl Acetate);
 'H-NMR     (DMSO-d   6   )    : 5 5.58    (s,    2H),    7.27   (d,   2H),    7.38    (dd,  1H),
 7.54    (d,    2H),       7.61-7.68      (m,     4H),   7.93    (d,    1H),    8.73    (s,  2H),
 8.99   (s, 1H),        9.37      (s, 1H).
 Example 15-37:             1-(2-(4-(2-amino-5-chloropyridin-3
 yl)phenoxy)pyrimidin-5-yl)-3-(2-(5-methyl-1H-pyrazol-1-yl)-4
  (trifluoromethyl)phenyl)urea
 TLC : Rf 0.54           (Hexane : Ethyl Acetate = 1 : 4);
 1H-NMR
           (DMSO-d    6  )     : 5 2.18     (s,    3H),    5.85   (s,   2H),     6.40   (s,  1H),
 7.26    (d,    2H),      7.41     (d,  1H),      7.50    (d,  2H),    7.65      (d,  1H),   7.74
  (d,  1H),     7.82        (d,   1H),   7.95       (d,  1H),   8.31     (s,    1H),    8.47   (d,
 1H),   8.67     (s, 2H),         9.75   (s, 1H).
Example 15-38:             1-(2-(4-(2-amino-5-chloropyridin-3
 yl)phenoxy)pyrimidin-5-yl)-3-(3,5-difluorophenyl)urea
TLC : Rf 0.68            (Ethyl Acetate);
'H-NMR     (DMSO-d    6  )    : 5 5.85     (s,    2H),    6.81-6.87      (m,   1H),   7.19    (dd,
2H),    7.27      (d,    2H),      7.42   (d,     1H),   7.50    (d,   1H),     7.52    (d,  2H),
7.96    (d, 1H),        8.71      (s, 2H),      9.03    (s, 1H),     9.36    (s, 1H).
Example 15-39:             1-(2-(4-(2-amino-5-fluoropyridin-3
                                                   1 AQ

 yl)phenoxy)pyrimidin-5-yl)-3-(2,4,6-trifluorophenyl)urea
 TLC : Rf 0.59           (Hexane : Ethyl Acetate = 1 : 9);
 1 H-NMR
            (DMSO-d    6  )   : 5 5.56        (s,    2H),    7.25-7.30       (m, 4H),   7.37   (dd,
 1H),   7.52      (d,     2H),     7.93      (d,    1H),     8.35     (s,   1H),  8.70   (s,  2H),
 9.24   (s, 1H).
 Example 15-40:1-(6-(4-(2-amino-5-chloropyridin-3
 yl) phenoxy) pyridin-3-yl) -3- (2-chloro-4
  (trifluoromethyl)phenyl)urea
          NH2     NO     N    N          CF3
                             H   H   Cl
                 IC
 TLC : Rf 0.64           (Hexane : Ethyl Acetate                  =  1 : 3);
 1H-NMR
            (DMSO-d   6  )    : 5 5.84         (s,    2H),    7.08     (d,  lH),  7.16-7.20     (m,
 2H),   7.20     (d, 1H),         7.39-7.41           (m,   1H),    7.47-7.51     (m,  2H),   7.68
  (dd,  1H),    7.87        (d, 1H),       7.95       (d,   1H),    8.03    (dd,  1H),   8.24   (d,
 1H),  8.45 (d, 1H),             8.68     (s, 1H),         9.70   (s, 1H).
Example 15-41:             1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(3,5-difluorophenyl)urea
TLC : Rf 0.68            (Ethyl Acetate);
'H-NMR     (DMSO-d    6  )   : 5 5.56         (s,   2H),     6.81    (t,   1H),  7.20   (dd,  2H),
7.28    (d,    2H),      7.38      (dd,    1H),      7.53     (d,   2H),    7.94  (d, 1H),    8.72
 (s, 2H),     9.02       (s, 1H),       9.35       (s, 1H).
Example 15-42:             1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2,3,4-trifluorophenyl)urea
TLC : Rf 0.50           (Ethyl Acetate : Hexane = 2 : 1);
1 H-NMR
           (DMSO-d    6  )   : 5 5.56         (s,   2H),     7.28    (d,   3H),  7.38   (dd,  1H),
                                                     lin

 7.53   (d,    2H),      7.76-7.80       (m,    1H),    7.94    (s,  1H),    8.72    (s,  2H),
 8.91   (s,   1H),     9.20     (s,   1H).
 Example 15-43:           1-(2-(4-(2-amino-5-fluoropyridin-3
 yl)phenoxy)pyrimidin-5-yl)-3-(2,3-difluorophenyl)urea
TLC : Rf 0.49          (Ethyl Acetate);
'H-NMR      (DMSO-d6)        : 5 5.56       (s,  2H),    7.05-7.16      (m,  2H),    7.29   (d,
2H),   7.38     (dd,      1H),    7.53     (d,   2H),    7.63-7.66      (m,  1H),    7.87   (t,
1H),   7.94     (d, 1H),        8.73    (s, 1H),      8.96   (s, 1H),     9.26    (s, 1H).
Example 15-44:            1-(6-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyridin-3-yl)-3-(2-chloro-4
 (trifluoromethyl)phenyl)urea
TLC : Rf 0.52          (Hexane : Ethyl Acetate = 1 : 3);
1 H-NMR    (DMSO-d   6  )   : 5 5.55        (s,  2H),    7.08    (d, 1H),    7.18    (d, 2H),
7.34    (dd, 1H),         7.50    (d, 2H),      7.68     (d, 1H),    7.87     (s, 1H),    7.93
 (d,  1H),     8.04      (dd,    1H),    8.24     (d,   1H),   8.45    (d,   1H),    8.68   (s,
1H),   9.70     (s, 1H).
Example 15-45: 1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2,6-difluorophenyl)urea
TLC : Rf 0.75          (Ethyl Acetate);
1H-NMR
           (DMSO-d  6  )    : 5 5.55        (s,  2H),    7.12-7.28      (m,  2H),    7.27   (d,
2H),   7.36     (dd,      2H),    7.53     (d,  2H),     7.93   (d, 1H),     8.42    (s,  1H),
8.71   (s, 2H),       9.18      (s, 1H).
Example 15-46:           1-(2-(4-(2-amino-5-fluoropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2,3,5,6-tetrafluorophenyl)urea
TLC : Rf 0.50          (Ethyl Acetate : Hexane = 2 : 1);
1 H-NMR    (DMSO-d  6  )   : 5 5.56        (s,  2H),    7.28   (d,  2H),    7.38    (dd,  1H),
                                                111

 7.53   (d,     2H),     7.74-7.88           (m,     1H),   7.94   (d,    1H),   8.72   (s, 2H),
 8.89   (s, 1H),       9.33       (s,    1H).
 Example 15-47:           1-(2-(4-(2-aminopyridin-3-yl)phenoxy)pyrimidin
 5-yl) -3- (3- (tert-butyl) -1- (o-tolyl) -lH-pyrazol-5-yl) urea
                                       H3C CH 3
                                              CH3
          NH2         .   N               t
       N                N "-    1   N     N'
                               H    H          CH3
TLC : Rf 0.35           (Ethyl Acetate);
1H-NMR
            (DMSO-d  6  )    : 5    1.26       (s,    9H),   1.99   (s,   3H),   5.57   (s, 2H),
 6.34   (s,    1H),    6.66       (dd,      1H),     7.20-7.50    (m,    9H),   7.94  (dd,  1H),
8.39   (s, 1H),       8.64        (s, 2H),         9.07    (s, 1H).
Example 15-48:            1-(2-(4-(2-amino-5-chloropyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(3-(tert-butyl)-1-(o-tolyl)-1H
pyrazol-5-yl)urea
TLC : Rf 0.71          (Ethyl Acetate : Methanol = 9 : 1);
1H-NMR
           (DMSO-d   6  )    : 5 1.26          (s,    9H),   1.99   (s,   3H),   5.84   (s, 2H),
6.34    (s,    1H),     7.25       (d,      2H),     7.31-7.43     (m,   5H),    7.50   (d, 2H),
7.95   (d, 1H),       8.39       (s, 1H),          8.64    (s, 2H),    9.07    (s, 1H).
Example 15-49:           1- (2- (4- (2-aminopyridin-3-yl)phenoxy)pyrimidin
5-yl) -3- (3- (tert-butyl) -1- (2,3-dihydro-1H-inden-5-yl) -1H
pyrazol-5-yl)urea
                                      H3 0 CH3
                                             CH3
         NH2     N    >N         0
       N                  N      N      N
                              H    H
TLC :Rf 0.68           (Ethyl Acetate :Methanol                    =10     :1);
                                                     111)

1H-NMR      (DMSO-d 6  )    : 5 1.25        (s,     9H),    2.06     (quint.,        2H),   2.85-2.94
  (m, 4H),     5.56     (s,    2H),    6.33        (s,    1H),   6.62-6.69           (m,   1H),   7.19
7.27    (m,    3H),     7.30-7.37         (m,      3H),     7.47     (d,     2H),      7.92-7.96     (m,
1H),   8.56     (s,   1H),      8.66    (s,      2H),     9.18   (s,      1H).
Example 15-50:           1-(2-(4-(2-amino-5-methylpyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(3-(tert-butyl)-1-(o-tolyl)-1H
pyrazol-5-yl)urea
TLC   : Rf 0.67       (Ethyl Acetate : Methanol = 9                          : 1);
1H-NMR      (DMSO-d 6  )    :  5 1.26        (s,     9H),    1.99     (s,     3H),     2.15   (s,  3H),
5.33    (s,    2H),     6.34      (s,   1H),        7.20-7.24        (m,     3H),      7.31-7.48     (m,
6H),   7.78     (s, 1H),       8.39     (s,      1H),     8.64   (s, 2H),          9.06 (s,     1H).
Example 15-51:          1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyllphenoxy}-5-pyrimidinyl)-3-[2-(1H-pyrazol-1-yl)-5
 (trifluoromethyl)phenyl]urea
Purity      (LC-MS/ELSD) : 100%                (Retention Time             : 1.01 minutes);
MASS   (ESI, Pos.)           : 601    (M + H)+
1
  H-NMR    (DMSO-d6 )       : 5 6.49       (s, 2H),         6.67-6.69          (m,   1H),   7.26-7.30
 (m,  2H),     7.50-7.56         (m,   4H),        7.76     (d,   1H),      7.95       (d,  1H),   8.26
(d,   1H),     8.41      (d,    1H),    8.58        (d,    1H),    8.70        (s,    2H),   9.71    (s,
1H),   9.97     (s, 1H).
Example 15-52:          1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-{5-(trifluoromethyl)-2-[3
(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}urea
                                                    11 -

                                        CF3
          NH2          yN         0
        N N                    N     N
                               H     H  N
          CF3                              CF3
                                           CF3
 Purity      (LC-MS/ELSD) : 100%                 (Retention Time            1.07 minutes);
MASS    (ESI, Pos.)               669   (M + H)+;
'H-NMR      (DMSO-d  6  )        5 6.48        (s,    2H),     7.12   (d,  1H),   7.28    (d, 2H),
 7.50-7.60      (m,     4H),       7.71     (d,     1H),     8.27    (s,  1H),    8.48    (s, 2H),
8.59    (s, 1H),       8.67       (s, 2H),         9.48    (s, 1H).
Example 15-53:            1-{2-[4- (2-amino-5-chloro-3-pyridinyl)phenoxy]
5-pyrimidinyll-3- [2- (2H-1, 2, 3-triazol-2-yl) -5
 (trifluoromethyl)phenyl]urea
Purity (LC-MS/ELSD) : 100%                       (Retention Time : 1.00 minute);
MASS    (ESI, Pos.)          : 568      (M + H)+;
1 H-NMR
           (DMSO-d   6  )        5 5.86       (s,    2H),     7.25-7.30      (m,  2H),   7.43   (d,
1H),   7.49-7.53           (m,    2H),    7.59        (dd,    1H),   7.95   (d,   1H),   8.07   (d,
1H),   8.33      (s,    2H),        8.65    (d,     1H),     8.72    (s,  2H),    9.67    (s, 1H),
10.03    (s, 1H).
Example 15-54:           1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]
5-pyrimidinyl}-3- [5-chloro-2- (2H-1,2, 3-triazol-2
yl) phenyl] urea
Purity (LC-MS/ELSD) : 100%                       (Retention Time : 0.97 minutes);
MASS (ESI, Pos.)             : 534      (M + H)+;
1 H-NMR
           (DMSO-d   6 )    : 5 5.86          (s,    2H),     7.25-7.31      (m,  3H),   7.43   (d,
1H),   7.49-7.53           (m,    2H),      7.80       (d,   1H),   7.95    (d,  1H),    8.26   (s,
2H),   8.32     (d, 1H),         8.70     (s, 2H),         9.37    (s, 1H),    9.93    (s, 1H).
                                                     I IA

 Example 15-55:           1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]
  5-pyrimidinyl}-3-[4-(trifluoromethyl)-2-biphenylyl]urea
                                       CF3
          NH2       O            0
        N               N      N   N
                               H   H
          CI
 TLC : Rf 0.61          (Hexane : Ethyl Acetate = 1 : 4);
 'H-NMR    (DMSO-d    6 )    : 5    5.85    (s,    2H),   7.26   (d,  2H),   7.40-7.60     (m,
 10H),    7.95    (d,      1H),    8.09     (s,   1H),    8.04   (s,  1H),   8.66   (s,  2H),
 9.39   (s, 1H).
 Example 15-56:           1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]
 5-pyrimidinyl}-3-[2-(2-methyl-3-pyridinyl)-5
  (trifluoromethyl)phenyl]urea
TLC : Rf 0.58           (Ethyl Acetate : Methanol= 19                 : 1);
1 H-NMR
           (DMSO-d    6 )    : 5 2.25       (s,    3H),   5.85   (s,  2H),   7.23-7.31     (m,
2H),    7.35-7.56         (m,    6H),    7.60-7.68       (m,  1H),   7.88   (s, 1H),    7.94
7.98    (m,    1H),      8.52-8.56         (m,   1H),    8.58-8.62     (m, 1H),    8.65    (s,
2H),    9.29 (s, 1H).
Example 15-57:            1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]
5-pyrimidinyl}-3-[5-phenyl-2-(trifluoromethyl)-4
pyridinyl]urea
TLC : Rf 0.38           (Hexane : Ethyl Acetate = 1 : 4);
'H-NMR     (DMSO-d   6  )   : 5    5.86     (s,   2H),    7.25-7.31     (m,  2H),  7.42    (d,
1H),    7.50-7.66          (m,   7H),    7.95      (d,  1H),   8.43-8.46     (m,  2H),   8.69
  (s, 2H),    8.75      (s, 1H),       9.74     (s, 1H).
Example 15-58:           1-{2-[4-(2-amino-5-fluoro-3-pyridinyl)phenoxy]
5-pyrimidinyl}-3-[4-(trifluoromethyl)-2-biphenylyl]urea
                                                  1 1 -

                                       CF3
           NH2      O>N          O
        N              N -A).N     N
                               H   H
           F
 TLC   : Rf 0.60       (Hexane : Ethyl Acetate               =  1      4);
 1H-NMR     (DMSO-d  6  )    : 5 5.57       (s,   2H),  7.23-7.29       (m, 2H),    7.34-7.58
  (m, 10H),     7.92-7.96          (m,    1H),    8.09   (s,   1H),    8.41    (s,  1H),   8.66
  (s, 2H),     9.39    (s,     1H).
Example 15-59:            1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]
 5-pyrimidinyl}-3- [2- (4-fluoro-1H-pyrazol-1-yl) -5
 (trifluoromethyl)phenyl]urea
TLC   : Rf 0.56        (Hexane : Ethyl Acetate = 1                  : 4);
'H-NMR      (DMSO-d 6   )    : 5   5.86      (s,   2H),  7.24-7.32       (m,  2H),   7.42    (d,
1H),    7.48-7.58         (m,    3H),    7.67-7.73      (m,   1H),    7.95   (d, 1H),     8.03
8.07     (m,   1H),     8.56-8.60          (m,   2H),   8.70    (s,   2H),    9.27    (s,  1H),
9.85    (s, 1H).
Example 15-60:           1-{2-[4-(2-amino-5-fluoro-3-pyridinyl)phenoxy]
5-pyrimidinyl}-3- [2- (4-fluoro-1H-pyrazol-1-yl)-5
 (trifluoromethyl)phenyl]urea
TLC   : Rf 0.50        (Hexane : Ethyl Acetate = 1                  : 4);
1
  H-NMR    (DMSO-d  6  )    :  5 5.57       (s,  2H),   7.26-7.32       (m,  2H),   7.38    (dd,
1H),    7.51-7.59         (m,    3H),   7.66-7.73       (m,  1H),     7.94   (d,   1H),   8.03
8.07    (m,    1H),     8.55-8.60          (m,   2H),   8.70    (s,   2H),    9.27    (s,  1H),
9.85    (s, 1H).
Example 15-61:           1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]
5-pyrimidinyl}-3-[2-phenyl-5-(trifluoromethyl)-3
pyridinyl]urea

TLC   : Rf 0.43       (Hexane : Ethyl Acetate = 1 : 3);
1
  H-NMR    (DMSO-d  6 )   :   5 5.86         (s,   2H),    7.26     (d,   2H),  7.42   (d, 1H),
 7.49-7.70     (m,    7   H),     7.95      (d,    1H),    8.43    (s,    1H),  8.68   (s, 2H),
 8.73   (s, 1H),      8.76      (s, 1H),         9.47    (s, 1H).
Example 15-62:          1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxyl
5-pyrimidinyll-3-[3',4'-dimethyl-4-(trifluoromethyl)-2
biphenylyl]urea
TLC : Rf 0.72         (Hexane : Ethyl Acetate = 1                      : 3);
1
  H-NMR   (DMSO-d   6 )   : 5      2.29      (s,   6H),    5.85    (s,    2H),   7.12-7.55   (m,
10 H),    7.95     (d, 1H),         8.01      (s, 1H),      8.44    (s, 1H),     8.66  (s, 2H),
9.44   (s, 1H).
Example 15-63: 1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]
5-pyrimidinyl}-3-[2-(4-chloro-1H-pyrazol-1-yl)-5
 (trifluoromethyl)phenyl]urea
                                       CF3
         NH2         >N        0
       N N     .-     O     N)L N
                            H     H    N
                                     c   N
TLC   : Rf 0.43       (Chloroform : Methanol = 19                      : 1);
1
  H-NMR   (DMSO-d   6 )   :   5   5.86      (s,    2H),    7.24-7.30        (m, 2H),  7.42   (d,
1H),   7.47-7.57         (m,    3H),       7.70     (d,   1H),    7.95     (d,  1H),  8.07   (s,
1H),   8.57    (d,    1H),       8.63      (s,    1H),    8.70    (s,    2H),   9.11  (s,  1H),
9.81   (s, 1H).
Example 15-64: 1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]
5-pyrimidinyl}-3-[4'-methyl-4-(trifluoromethyl)-2
biphenylyl] urea
                                                   11 -7

 TLC  : Rf 0.63          (Methylene Chloride           : Ethyl Acetate      : Methanol      =
 8 : 4 : 1);
 1H-NMR    (DMSO-d    6  )   : 5 2.39   (s,   3H),     5.86  (brs,   2H),   7.26   (d,   2H),
 7.29-7.49      (m,      7H),    7.50  (d,    2H),     7.95  (d,   1H),   8.05   (s,   1H),
 8.43   (s, 1H),        8.67 (s, 2H),       9.42     (s, 1H).
 Example 15-65:            1-{2-[4-(2-amino-5-fluoro-3-pyridinyl)phenoxy]
 5-pyrimidinyl}-3-[4'-methyl-4-(trifluoromethyl)-2
 biphenylyl]urea
 TLC  : Rf    0.55       (Methylene Chloride           : Ethyl Acetate      : Methanol      =
 8 : 4 : 1);
 1H-NMR   (DMSO-d    6  )   : 5   2.39  (s,   3H),     5.56  (brs,   2H),   7.26   (d,  2H),
 7.29-7.48      (m,     7H),     7.52  (d,   2H),     7.94   (d,   1H),   8.05   (s,   1H),
 8.43  (s, 1H),         8.67    (s, 2H),    9.42     (s, 1H).
Example 15-66:            1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]
 5-pyrimidinyl}-3-[3'-methyl-4-(trifluoromethyl)-2
biphenylyl]urea
TLC   : Rf    0.58      (Methylene Chloride            : Ethyl Acetate      : Methanol
8 : 4 : 1);
'H-NMR    (DMSO-d    6  )   : 5 2.39    (s,   3H),     5.86  (brs,   2H),   7.19-7.55     (m,
11H),    7.95    (d,       1H),   8.04  (s,    1H),     8.43  (s,  1H),   8.66   (s,   2H),
 9.43 (s, 1H).
Example 15-67:            1-{2-[4-(2-amino-5-fluoro-3-pyridinyl)phenoxy]
5-pyrimidinyl}-3-[3'-methyl-4-(trifluoromethyl)-2
biphenylyl]urea
TLC   : Rf 0.53         (Methylene Chloride           : Ethyl Acetate       : Methanol      =
8 : 4 : 1);
                                               110 C

 1
   H-NMR      (DMSO-d   6 )     : 5 2.38      (s,   3H),    5.57  (brs,    2H),     7.19-7.48         (m,
 9H),     7.52      (d,    2H),      7.94    (d,    1H),    8.04   (s,   1H),    8.44     (s,     1H),
 8.66     (s, 2H),        9.43      (s, 1H).
 Example 15-68:             1-{2-[4- (2-amino-5-chloro-3-pyridinyl)phenoxy]
 5-pyrimidinyl}-3-{2-[4-(difluoromethyl)-1H-pyrazol-1-yl]-5
  (trifluoromethyl)phenyl}urea
TLC     :   Rf     0.20      (Hexane      :   Ethyl      Acetate     :  Methanol      =   6     :  4
 0.4);
1
   H-NMR      (DMSO-d   6 )     : 5 5.85       (s,   2H),    7.16   (t,   1H),   7.26     (d,     2H),
 7.41     (d,     1H),     7.48-7.57        (m,     3H),   7.74   (d,    1H),    7.94     (d, 1H),
 8.17     (s,     1H),    8.55      (d,   1H),     8.69    (s,  2H),    8.70    (s,   1H)     ,   9.19
  (s,  1H)      ,  9.85     (s,    1H).
Example 15-69:              1-{2-[4-(2-amino-5-fluoro-3-pyridinyl)phenoxy]
5-pyrimidinyl}-3-{2- [4- (difluoromethyl)-1H-pyrazol-1-yl] -5
 (trifluoromethyl)phenyl}urea
TLC     :   Rf     0.16      (Hexane      :   Ethyl      Acetate     :  Methanol      =   6     :  4
0.4);
'H-NMR       (DMSO-d    6 )     : 5   5.56     (s,   2H),    7.16  (t,    1H),   7.26     (d,     2H),
7.36      (dd,     1H),     7.49-7.57         (m,    3H),   7.74   (d,   1H),    7.92     (d, 1H),
8.18      (s,     1H),    8.55      (d, 1H),       8.69    (s,  2H),    8.70    (s,   1H)     ,   9.19
 (s, 1H)       ,   9.85     (s, 1H).
Example 15-70: 1-{2-[4- (2-amino-5-chloro-3-pyridinyl)phenoxy]
5-pyrimidinyl}-3-{5-chloro-2-[4-(difluoromethyl)-1H-pyrazol-1
yllphenyl}urea
TLC    :    Rf     0.17      (Hexane      :   Ethyl      Acetate     :  Methanol      =   6     :  4
0.4);

 'H-NMR     (DMSO-d     6  )   : 5   5.85      (s,   2H),   7.14    (t,    1H),   7.22-7.29        (m,
 3H),   7.41      (d,      1H),     7.47-7.53         (m,  3H),  7.94       (d,  1H),    8.12      (s,
 1H),   8.24     (d,       1H),    8.58     (s,    1H),   8.68   (s,     2H),   8.91    (s,    1H)
 9.78   (s, 1H).
Example 15-71:              1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]
 5-pyrimidinyl}-3-{5-chloro-2- [3- (trifluoromethyl) -lH-pyrazol
 1-yl] phenyl}urea
                                        CI
          NH2         ON,,
                      0Y          0
        N N           O
                                H   H   N
                                        \/N
                                           CF3
TLC   : Rf     0.21          (Hexane      : Ethyl       Acetate     : Methanol        =   6   :  4
0.4);
'H-NMR     (DMSO-d     6  )   : 5    5.85      (s,  2H),    7.07   (s,     1H),  7.22-7.31         (m,
3H),    7.39-7.53            (m,   4H),     7.94     (d,  1H),   8.18       (s,  1H),    8.37      (d,
2H),   8.65     (s, 2H),          9.43     (s, 1H).
Example 15-72:              1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]
5-pyrimidinyl}-3-{5-chloro-2- [3- (trifluoromethyl)-1H-pyrazol
1-yl]phenyl}urea
TLC : Rf 0.29             (Hexane : Ethyl Acetate = 2                   : 3);
  H-NMR    (DMSO-d     6  )   : 5    1.25      (t,  3H),    2.69   (q,     2H),  5.86     (s,   2H),
7.20-7.55       (m,       11H),     7.95      (d,   1H),   8.09   (s,     1H),   8.40     (s,   IH),
8.66    (s, 2H),         9.40     (s, 1H).
Example 15-73:             1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]
5-pyrimidinyl}-3-[3'-ethyl-4-(trifluoromethyl)-2
biphenylyl]urea
                                                    1 0n

 TLC : Rf 0.32          (Hexane : Ethyl Acetate = 2                 : 3);
 1H-NMR     (DMSO-d  6   )   :  5 1.22     (t,   3H),    2.68   (q,    2H),   5.85   (s, 2H),
 7.24-7.55       (n,    11H),      7.94   (d,    1H),    8.06   (s,    1H),    7.38-7.42   (m,
 1H),  8.65     (s, 2H),         9.41   (s, 1H).
Example 15-74:            1-{2-[4-(2-amino-5-fluoro-3-pyridinyl)phenoxy]
5-pyrimidinyl}-3-[3'-ethyl-4-(trifluoromethyl)-2
biphenylyllurea
TLC : Rf 0.33           (Hexane : Ethyl Acetate = 2                 : 3);
'H-NMR     (DMSO-d   6  )    : 5   1.22    (t,   3H),    2.68   (q,    2H),   5.57   (s, 2H),
7.24-7.56       (m,     11H),      7.94   (d,    1H),    8.07   (s,    1H),   8.39   (s, 1H),
8.66    (s, 2H),       9.41      (s, 1H).
Example 15-75: 1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]
5-pyrimidinyl}-3-[2-methoxy-4-(trifluoromethyl)phenyl]urea
Purity      (LC-MS/ELSD) : 100%               (Retention Time        : 0.94 minutes);
MASS    (ESI, Pos.)           : 531   (M + H)*;
1H-NMR     (DMSO-d    6 )    : 5 3.97      (s,   3H),    5.86   (s,    2H),   7.25-7.33    (m,
4H),   7.43      (d,     1H),     7.49-7.56       (m,   2H),   7.96      (d,  1H),  8.32   (d,
1H),   8.70     (s, 1H),        8.73    (s, 2H),      9.66   (s, 1H).
Example 15-76:            1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]
5-pyrimidinyl}-3-[2-(methylsulfonyl)-4
 (trifluoromethyl)phenyl]urea
Purity      (LC-MS/ELSD) : 100%               (Retention Time        : 0.90 minutes);
MASS   (ESI, Pos.)            : 579   (M + H)+;
1
  H-NMR    (DMSO-d   6  )    : 5   3.42    (s,   3H),    5.87   (s,    2H),   7.26-7.33    (m,
2H),   7.43     (d, 1H),         7.47-7.57      (m,   2H),   7.96     (dd, 1H),    8.04-8.12
 (m,  2H),     8.50      (d,    1H),    8.76    (s,   2H),    9.04     (s,   1H),  10.36   (s,
                                                 101

 1H).
 Example 15-77:          1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]
 5-pyrimidinyl}-3-[2,4-bis(trifluoromethyl)phenyl]urea
          NH 2      O     N     O         CF3
       N               N      N
                              H   H  CF3
          CI
 Purity     (LC-MS/ELSD) : 100%               (Retention Time : 0.98 minutes);
 MASS   (ESI, Pos.)          : 569    (M + H)+
 1H-NMR    (DMSO-d     )
                     6      : 5 5.86      (s,    2H),   7.26-7.34       (m, 2H),    7.42-7.44
  (m, 1H),     7.49-7.56         (m,   2H),     7.95-7.99      (m,    2H),     8.04   (d,  1H),
 8.33  (d, 1H),        8.56     (s, 1H),       8.75    (s, 2H),     9.80     (s, 1H).
Example 15-78:           1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]
 5-pyrimidinyl}-3-(5-chloro-2-methylphenyl)urea
 Purity (LC-MS/ELSD) : 100%                   (Retention Time : 0.88 minutes);
MASS   (ESI, Pos.)           : 481   (M + H)+;
'H-NMR     (DMSO-d  6  )    : 5 2.22      (s,    3H),   5.86   (s,    2H),    7.01  (dd,   1H),
 7.20   (d,    1H),     7.25-7.32        (m,    2H),    7.43    (d,    1H),    7.48-7.55     (m,
2H),   7.95-7.99          (m,   2H),     8.26      (s,  1H),  8.74       (s,   2H),   9.30   (s,
 1H).
Example 15-79:           l-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]
5-pyrimidinyl}-3-(5-chloro-2-methylphenyl)urea
TLC : Rf 0.32          (Chloroform : Methanol = 19 : 1);
1H-NMR
           (DMSO-d   6 )    : 5 5.86       (s,    2H),   7.23-7.30        (m,  2H),   7.42   (d,
 1H),  7.46-7.56          (m,   3H),     7.70      (d,  1H),  7.95       (d,   1H),   8.06   (s,
 1H),  8.56     (d,     1H),     8.62    (s,    1H),    8.69   (s,     2H),    9.11   (s,  1H),
 9.81  (s, 1H).

 Example 15-80:          1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]
  5-pyrimidinyl}-3-{5-(difluoromethyl)-2-[3-(trifluoromethyl)
  1H-pyrazol-1-yl]phenyl}urea
 TLC : Rf 0.47         (Hexane : Ethyl Acetate = 1 : 2);
 1H-NMR      (DMSO-d  6)   : 5 5.85     (s,   2H),  7.08   (d,  1H),  7.13  (t, 1H),
 7.25    (d,    2H),    7.39-7.44     (m,   2H),   7.50   (d,  2H),  7.60  (d,  1H),
 7.94    (d,    1H),    8.28    (s,  1H),   8.40-8.43     (d,  1H),  8.46  (s,  1H),
 8.66   (s,    2H),    9.42 (s, 1H).
 Example 15-81:          1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]
 5-pyrimidinyl}-3-{4-chloro-2-[3-(trifluoromethyl)-1H-pyrazol
 1-yl]phenyl}urea
 TLC : Rf 0.51         (Hexane : Ethyl Acetate = 1 : 2);
 1H-NMR     (DMSO-d  6 )   : 5 5.84    (s,    2H),  7.05   (d,  1H),  7.24  (d, 2H),
 7.40   (d,     1H),    7.52    (d,  2H),   7.53-7.61    (m,   2H),  7.94  (d,  1H),
 8.01   (d,     1H),    8.35    (s,  1H),   8.37-8.42    (m,   1H),  8.63  (s,  2H),
 9.35   (s, 1H).
Example 15-82:           1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-{2-[3-(difluoromethyl)-lH
pyrazol-1-yl]-5-(trifluoromethyl)phenyl}urea
 Purity (LC-MS/ELSD) : 100%               (Retention Time : 1.04 minutes);
MASS    (ESI, Pos.)         : 651   (M + H)+;
'H-NMR      (DMSO-d  6 )   : 5 6.48    (s,   2H),   6.93   (d,  1H),  7.14  (t, 1H),
7.26-7.33        (m,   2H),    7.49-7.60      (m,  4H),  7.73    (d, 1H),  8.27   (d,
1H),   8.45      (d,   1H),    8.54   (d,   1H),   8.69  (s,   2H),  8.95  (s,  1H),
9.66   (s, 1H).
Example 15-83: 1-(2-{4-[2-amino-5-(trifluoromethyl)-3
                                             1 1

 pyridinyl]phenoxy}-5-pyrimidinyl) -3-{5- (trifluoromethyl) -2-                          [3
  (trifluoromethyl)-1H-1, 2, 4-triazol-1-yl] phenyl}urea
 Purity     (LC-MS/ELSD) : 100%               (Retention Time : 1.02 minutes);
 MASS   (ESI, Pos.)             670    (M + H)+
 1H-NMR    (DMSO-d   6  )   : 5 6.48       (s,  2H),    7.25-7.32      (m, 2H),   7.48-7.58
  (m, 3H),     7.72      (dd,    1H),     7.82     (d,  1H),    8.27    (d,  1H),  8.49   (d,
 1H),  8.66-8.69          (m, 3H),      9.24    (s, 1H),     9.33    (s, 1H).
 Example 15-84:           1-[2-(3-acetyl-1H-pyrazol-1-yl)-5
  (trifluoromethyl)phenyl] -3- (2-{ 4- [2-amino-5- (trifluoromethyl)
 3-pyridinyl]phenoxy}-5-pyrimidinyl)urea
                                      CF3
         NH        O          N   N
                              H   H   N
         CF3                               O
                                      H3C
 Purity (LC-MS/ELSD) : 100%                  (Retention Time : 1.01 minutes);
MASS   (ESI, Pos.)          : 643      (M + H)+;
1 H-NMR    (DMSO-d   6 )    : 5 2.59       (s,    3H),    6.48   (s,  2H),   7.04-7.07    (m,
 1H),  7.24-7.32          (m,   2H),    7.48-7.62       (m,   4H),   7.75   (d, 1H),   8.25
8.29    (m,   1H),      8.40     (d,    1H),    8.63     (d,   1H),   8.68   (s,  2H),  8.75
 (s, 1H),     9.64     (s, 1H).
Example 15-85: 1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-[2-(2-methyl-3-pyridinyl)
5-(trifluoromethyl)phenyl]urea
Purity (LC-MS/ELSD) : 100%                   (Retention Time : 0.84 minutes);
MASS   (ESI, Pos.)          : 626      (M + H)*;
'H-NMR     (DMSO-d   6 )    : 5 2.25       (s,    3H),    6.48   (s,  2H),   7.23-7.57    (m,
                                                I  nI A

8H),   7.63     (dd,     1H),     7.88      (s,  1H),     8.27   (d,  1H),   8.53    (s,  1H),
8.59   (dd,    1H),     8.65     (s,     2H),   9.29    (s,  1H).
Example 15-86:          1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyllphenoxy}-5-pyrimidinyl) -3- [2- (4-fluoro-1H-pyrazol-1
yl)-5-(trifluoromethyl)phenyliurea
Purity (LC-MS/ELSD) : 100%                    (Retention Time : 1.02 minutes);
MASS   (ESI, Pos.)          : 619      (M + H)+
  H-NMR    (DMSO-d  6 )    : 5 6.49         (s, 2H),    7.26-7.33      (m,  2H),   7.48-7.58
 (m,  4H),    7.68      (d,    1H),       8.03-8.07      (m, 1H),    8.26-8.30      (m,   1H),
8.56-8.63      (m, 2H),        8.70       (s, 2H),    9.27    (s, 1H),    9.85   (s, 1H).
Example 15-87: 1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl) -3-[2- (4-chloro-1H-pyrazol-1
yl)-5-(trifluoromethyl)phenyl]urea
                                      CF3
         NH2       0NON        0
       N N             'O    N"N N
                             H   H    N
         CF3                            /
                                  CI
Purity (LC-MS/ELSD)                  100%     (Retention Time : 1.06 minutes);
MASS   (ESI, Pos.)          : 635     (M + H)+;
1H-NMR     (DMSO-d6 ) : 5 6.49              (s, 2H),    7.26-7.32      (m, 2H),    7.50-7.59
(m,   4H),    7.70      (d,    1H),       8.07-8.09      (m,   1H),  8.26-8.30      (m, 1H),
8.57    (d,   1H),     8.63-8.64           (m,  1H),    8.69    (s,  2H),    9.11   (s,   1H),
9.81   (s, 1H).
Example 15-88:          1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-[2-chloro-4
(trifluoromethyl)phenyl]urea
                                                 1 '1

  Purity       (LC-MS/ELSD) : 100%              (Retention Time            : 1.04 minutes);
 MASS    (ESI, Pos.)              569   (M + H)+;
  1H-NMR      (DMSO-d 6  )    : 5 6.49      (s,    2H),        7.27-7.34      (m, 2H),  7.50-7.60
   (m,  3H),     7.70     (dd,     1H),    7.89-7.93            (m,  1H),    8.26-8.31    (m, 1H),
  8.43   (d, 1H),       8.75      (s, 2H),       8.81        (s, 1H),     9.78   (s, 1H).
 Example 15-89:            1-(2-{4-[2-amino-5-(trifluoromethyl)-3
 pyridinyl]phenoxy}-5-pyrimidinyl)-3-[2-chloro-5
   (trifluoromethyl)phenyl]urea
 Purity       (LC-MS/ELSD) : 100%               (Retention Time            : 1.02 minutes);
MASS     (ESI, Pos.)             569    (M + H)*;
 'H-NMR      (DMSO-d  6 )     : 5   6.49    (s,    2H),        7.26-7.34     (m,   2H), 7.40  (dd,
 1H),    7.50-7.59          (m,   3H),    7.73        (d,     1H),   8.26-8.30      (m, 1H),  8.56
  (d, 1H),       8.75   (s, 2H),        8.79     (s,       1H),    9.72   (s, 1H).
Example 15-90:            1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-[2-fluoro-5
  (trifluoromethyl)phenyl]urea
 Purity       (LC-MS/ELSD) : 100%               (Retention Time : 0.98 minutes);
MASS     (ESI, Pos.)           : 553    (M + H)*;
'H-NMR       (DMSO-d  6 )    : 5 6.49       (s,    2H),        7.26-7.33     (m, 2H),   7.38-7.59
  (m,  5H),      8.26-8.30         (m,   1H),     8.52        (dd,   1H),   8.75    (s, 2H),  9.11
  (s,  1H),     9.31    (s,     1H).
Example 15-91: 1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-(2,5-dichlorophenyl)urea
Purity       (LC-MS/ELSD) : 100%                (Retention Time            : 1.01 minutes);
MASS     (ESI, Pos.)           : 535    (M + H)+;
1
   H-NMR    (DMSO-d6 ) : 5 6.49             (s, 2H),           7.12   (dd, 1H),     7.27-7.34   (m,
                                                    1  ')c

2H),    7.50-7.59         (m,   4H),   8.26-8.30        (m,  2H),     8.65   (s,  1H),  8.74
  (s, 2H),    9.68    (s,     1H).
Example 15-92:           1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-(2,4-dichlorophenyl)urea
Purity (LC-MS/ELSD) : 100%                  (Retention Time : 1.00 minute);
MASS    (ESI, Pos.)            535 (M + H)+
'H-NMR     (DMSO-d  6  )      5 6.49    (s,    2H),    7.27-7.33        (m, 2H),  7.39   (dd,
1H),   7.50-7.59          (m,   3H),   7.64     (d,   1H),   8.14      (d,  1H),  8.27-8.30
 (m, 1H),     8.59 (s, 1H),          8.73    (s, 2H),      9.60    (s, 1H).
Example 15-93:           1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-[2-methyl-5
 (trifluoromethyl)phenyl]urea
Purity      (LC-MS/ELSD) : 100%            (Retention Time : 0.98 minutes);
MASS   (ESI, Pos.)          : 549    (M + H)+;
1H-NMR     (DMSO-d  6 )    : 5 2.32      (s,    3H),    6.49   (s,    2H),   7.27-7.34    (m,
3H),   7.42     (d,   1H),      7.50-7.59       (m,   3H),   8.26-8.30       (m,  2H),  8.39
 (s, 1H),     8.75    (s, 2H),       9.34    (s, 1H).
Example 15-94:          1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]
5-pyrimidinyl}-3-[2-isopropyl-5-(trifluoromethyl)phenyl]urea
TLC : Rf 0.67         (Ethyl Acetate);
1 H-NMR
           (DMSO-d  6)     : 5 1.22      (d, 6H),       3.21   (m, 1H),      5.86   (s, 2H),
7.25-7.31       (m,   2H),     7.39-7.56        (m, 5H),     7.95     (d,   1H),  8.12-8.15
(m, 1H),      8.43    (s, 1H),       8.74    (s, 2H),      9.28    (s, 1H).
Example 15-95:          1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]
5-pyrimidinyl}-3-[2-ethyl-5-(trifluoromethyl)phenyl]urea
TLC : Rf 0.35         (Ethyl Acetate);
                                               1 ') 7

 'H-NMR      (DMSO-d   6  )    :   5 1.20          (t,    3H),    2.69    (q,    2H),   5.86   (s, 2H),
 7.25-7.31       (m,     2H),        7.33-7.46            (m,   3H),    7.48-7.56       (m,  2H),  7.95
   (d, 1H),     8.24-8.27             (m,     1H),       8.38    (m,   1H),     8.75    (s,  2H),  9.34
  (s,  1H) .
 Example 15-96: 1-{2-[4-(2-amino-5-fluoro-3-pyridinyl)phenoxy]
 5-pyrimidinyll-3-[2-(methylsulfonyl)-5
  (trifluoromethyl)phenyl]urea
                                           CF3
          NH2        O      N       O
        N                N       N     N
                                 H     H    ,0
                                         O0 'CH 3
          F
TLC    : Rf 0.44         (Chloroform : Methanol                      = 19     : 1);
1
   H-NMR    (DMSO-d    6  )   :    5    3.38      (s,     3H),    5.57    (s,    2H),  7.25-7.31     (m,
2H),    7.37     (dd,       1H),      7.48-7.56            (m,  2H),    7.61-7.67        (m, 1H),  7.93
  (d,  1H),     8.04-8.09             (m,    1H),        8.61-8.65       (m,    1H),   8.75   (s,  2H),
8.97    (s, 1H),         10.30        (s, 1H).
Example 15-97:             1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-[2-(methylsulfonyl)-4
  (trifluoromethyl)phenyl]urea
TLC    : Rf 0.31         (Chloroform : Methanol = 19                          : 1);
1
   H-NMR   (DMSO-d    6  )    :    5 3.42         (s,     3H),    6.49    (s,    2H),  7.27-7.33     (m,
2H),    7.49-7.58           (m,      3H),      8.03-8.11          (m,  2H),      8.25-8.30    (m,  1H),
8.50    (d, 1H),        8.76        (s, 2H),           9.04    (s, 1H),       10.36   (s, 1H).
Example 15-98: 1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-[2-(methylsulfonyl)-5
 (trifluoromethyl)phenyl]urea

                                         CF3
           NH2         YN          O
        N               N       N    N
                                H    H    IO
                                        OSCH3
           CF3
TLC      Rf 0.32        (Chloroform : Methanol = 19                       : 1);
1
  H-NMR     (DMSO-d   6  )    :   5   3.38     (s,    3H),    6.49    (s,     2H),     7.24-7.32     (m,
2H),   7.48-7.58           (m,      3H),    7.64      (d,   1H),   8.06        (d,  1H),    8.24-8.29
 (m,  1H),     8.61-8.64            (m,   1H),      8.75    (s,  2H),      8.97      (s,   1H),   10.30
  (s, 1H).
Example 15-99: 1-{2-[4-(2-amino-5-fluoro-3-pyridinyl)phenoxy]
5-pyrimidinyll-3- [2- (4-chloro-1H-pyrazol-1-yl)-5
 (trifluoromethyl)phenyl]urea
TLC : Rf       0.28     (Hexane : Ethyl Acetate = 1                       : 2);
1
  H-NMR     (DMSO-d  6   )   : 5 5.56         (s,    2H),    7.27   (d,     2H),     7.36    (dd,  1H),
7.51-7.57       (m,     3 H),        7.68-7.74         (m,  1 H),    7.93        (d, 1H),     8.06   (s,
1H),   8.56      (s,     1H),       8.62     (s,    1H),     8.69    (s,     2H),     9.10    (s,  1H),
9.80    (s, 1H).
Example 15-100:             1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[3-methyl-5
 (trifluoromethyl)phenyl]urea
Purity       (LC-MS/ELSD) : 100%                  (Retention Time          : 0.94 minutes);
MASS   (ESI, Pos.)             : 515     (M + H)*;
1
  H-NMR     (DMSO-d  6   )   : 5 2.36          (s,    3H),    5.86    (s,     2H),     7.15   (s,  1H),
7.26    (d,    2H),      7.40-7.45           (m,    2H),    7.50    (d,      2H),     7.76    (s,  1H),
7.95   (d, 1H),        8.73        (s, 2H),        8.98    (s, 1H),       9.23     (s, 1H).
Example 15-101: 1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2-methyl-4
                                                     Inn~C

 (trifluoromethyl)phenyl]urea
 Purity (LC-MS/ELSD) : 100%              (Retention Time : 0.93 minutes);
MASS   (ESI, Pos.)         : 515   (M + H)+;
1 H-NMR   (DMSO-d  6  )  : 5 2.32      (s,    3H),   5.86   (s,   2H), 7.27  (d, 2H),
7.45    (d,   1H),     7.47-7.54     (m,    3H),    7.56   (s,   1H),  7.95  (d, 1H),
8.14   (d, 1H),      8.40     (s, 1H),     8.75    (s, 2H),    9.39 (s, 1H).
Example 15-102: 1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxyl-5-pyrimidinyl}-3-[2,5
bis(trifluoromethyl)phenyl]urea
Purity      (LC-MS/ELSD) : 100%          (Retention Time : 0.97 minutes);
MASS   (ESI, Pos.)           569   (M + H)+;
1H-NMR    (DMSO-d     )
                   6         5 5.86    (s,    2H),   7.27   (d,   2H), 7.42  (d, 1H),
7.50    (d,   2H),    7.63     (d,  1H),     7.90-7.97     (m,   2H),  8.41  (s, 1H),
8.57   (s, 1H),      8.74     (s, 2H),     9.73    (s, 1H).
Example 15-103:         1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxyl-5-pyrimidinyl}-3-[2-methoxy-5
 (trifluoromethyl)phenyl]urea
Purity     (LC-MS/ELSD) : 100%           (Retention Time : 0.93 minutes);
MASS   (ESI, Pos.)        : 531    (M + H)+;
1H-NMR    (DMSO-d  6 )   : 5 3.96      (s,    3H),   5.86   (s,   2H), 7.17-7.37   (m,
4H),   7.42    (d,    1H),     7.50  (d,    2H),    7.95   (d,   1H),  8.48  (d, 1H),
8.66   (s, 1H),      8.72     (s, 2H),     9.60    (s, 1H).
Example 15-104: 1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxyl-5-pyrimidinyl}-3-[2-(methylsulfonyl)-5
 (trifluoromethyl)phenyl]urea

                                              CF3
          NH2         O       N         0
        N                 N          N    N
                                     H    H    ,0O
                                            0 SCH3
          CI
 Purity      (LC-MS/ELSD) : 100%                        (Retention Time            0.91 minutes);
MASS    (ESI, Pos.)                 : 579      (M + H)+
 1
   H-NMR    (DMSO-d     6  )      : 5      3.38       (s,   3H),   5.87     (s,  2H),   7.25-7.31    (m,
 2H),   7.43      (d,      1H),          7.48-7.54          (m,  2H),     7.62-7.67     (m,  1H),  7.96
  (d,  1H),     8.07         (d,        1H),     8.61-8.65        (m,    1H),    8.75   (s,  2H),  8.97
  (s, 1H),     10.31          (s,      1H).
Example 15-105:                 2-{ [(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)carbamoyl]amino}-N,N
dimethyl-4-(trifluoromethyl)benzenesulfonamide
                                              CF3
          NH2         O                 0
        N                 N          N)   N
                                     H    H O   -C
                                                 N~-CH3
          CF3                                    CH 3
TLC    : Rf 0.64          (Hexane : Ethyl Acetate                      =   1 : 4);
1
  H-NMR    (DMSO-d      6  )      :    5 2.76         (s,   6H),   6.49     (s,  2H),   7.27-7.35    (m,
2H),    7.50-7.65              (m,      4H),      7.94      (d,  1H),     8.26-8.30     (m,  1H),  8.61
 (s, 1H),      8.74       (s, 2H),            8.99        (s, 1H),    10.31     (s, 1H).
Example 15-106: 1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy] -5-pyrimidinyl}-3- [3'- hydroxymethyll) -4
 (trifluoromethyl)-2-biphenylyl]urea
Purity      (LC-MS/ELSD) : 100%                         (Retention Time         : 0.95 minutes);
MASS    (ESI, Pos.)                : 607       (M + H)+;
'H-NMR     (DMSO-d     6  )       : 5      4.59       (d,   2H),   5.28     (t,  1H),   5.86   (s, 2H),
7.22-7.33        (m,      3H),           7.36     (s,      1H),  7.37-7.53        (m,  7H),  7.93-7.98

  (m, 1H),     8.06      (s,    1H),   8.42     (s,   1H),   8.66   (s,  2H),   9.42   (s,
 1H).
 Example 15-107:           1-{2-[4-(2-amino-5-fluoro-3
 pyridinyl)phenoxy]-5-pyrimidinyl}-3-[3'-(hydroxymethyl)-4
  (trifluoromethyl)-2-biphenylyllurea
 Purity     (LC-MS/ELSD) : 99%           (Retention Time : 0.88 minutes);
MASS    (ESI, Pos.)             591  (M + H)*;
 1H-NMR    (DMSO-d     )     : 5 4.58
                    6                    (d,    2H),    5.28   (t, 1H),   5.57   (s, 2H),
 7.22-7.32      (m,   3H),       7.35-7.56       (m,   8H),  7.94   (d,  1H),   8.06   (s,
 1H),  8.42     (s, 1H),        8.66  (s, 2H),       9.42   (s, 1H).
 Example 15-108:          1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy-5-pyrimidinyl}-3-[3'-(1-hydroxyethyl)-4
  (trifluoromethyl)-2-biphenylyl]urea
 Purity (LC-MS/ELSD) : 100%                (Retention Time : 0.98 minutes);
MASS    (ESI, Pos.)          : 621   (M + H)*;
1 H-NMR    (DMSO-d  6 )     : 5 1.36     (d,    3H),    4.74-4.93    (m, 1H),   5.21   (d,
 1H),  5.86     (s,   2H),       7.22-7.36      (m,   3H),   7.38-7.56    (m,  8H),  7.95
  (d, 1H),    8.09       (s,    1H),  8.37      (s,   1H),   8.66   (s,  2H),   9.40   (s,
 1H).
Example 15-109: 1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[3'-(1-hydroxyethyl)-4
 (trifluoromethyl)-2-biphenylyl]urea
 Purity (LC-MS/ELSD) : 100%                (Retention Time : 0.91 minutes);
MASS   (ESI, Pos.)           : 605   (M + H)*;
'H-NMR     (DMSO-d  6 )     : 5 1.36     (d,    3H),    4.74-4.93    (m,  1H),  5.21   (d,
 1H),  5.57     (s,   2H),      7.22-7.57       (m,   11H),   7.94   (d,  1H),  8.09   (s,
                                              I   On

 1H),   8.37     (s,    1H),     8.66   (s,      2H),    9.40   (s,      1H).
 Example 15-110:            1-(2-{4-[2-amino-5-(trifluoromethyl)-3
 pyridinyl]phenoxy}-5-pyrimidinyl)-3-[2-(ethylsulfonyl)-5
  (trifluoromethyl)phenyl] urea
 TLC   : Rf    0.59     (Hexane : Ethyl Acetate =                   1 : 4);
   H-NMR    (DMSO-d   6  )   : 5   1.15      (t,    3H),    3.45     (q,    2H),   6.48   (s, 2H),
 7.27    (d,   2H),      7.51     (d,   2H),      7.55     (d,   1H),      7.62    (d,  1H),  8.02
  (d,  1H),     8.24-8.28         (m,   1H),      8.64     (s,   1H),      8.74    (s,  2H),  9.00
  (s, 1H),     10.32       (s, 1H).
Example 15-111:             1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[5-chloro-2
  (methylsulfonyl)phenyl]urea
TLC    : Rf    0.38     (Chloroform : Methanol = 19                      : 1);
'H-NMR      (DMSO-d   6 )    :  5 3.33       (s,    3H),    5.86     (s,    2H),   7.25-7.31    (m,
2H),    7.36     (dd,      1H),    7.43     (d,     1H),   7.48-7.55          (m,  2H),  7.85   (d,
1H),    7.96     (dd,      1H),    8.33     (d,     1H),   8.75     (s,    2H),    8.88   (s, 1H),
10.26     (s, 1H).
Example 15-112:             1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-[5-fluoro-2
 (methylsulfonyl)phenyl]urea
Purity      (LC-MS/ELSD) : 100%                (Retention Time : 0.92 minutes);
MASS    (ESI, Pos.)           : 563   (M + H)+;
1
  H-NMR    (DMSO-d   6  )    : 5   3.31      (s,    3H),    6.49     (s,    2H),   7.09-7.19    (m,
1H),    7.29     (d, 2H),        7.50-7.60         (m,   3H),   7.92       (dd, 1H),    8.11   (dd,
1H),    8.25-8.32          (m,   1H),    8.75       (s,   2H),   8.95       (s,   1H),  10.29   (s,
1H).

 Example 15-113: 2-{[(2-{4-[2-amino-5-(trifluoromethyl)-3
 pyridinyljphenoxy}-5-pyrimidinyl)carbamoyl]amino}-4-fluoro
 N,N-dimethylbenzenesulfonamide
 Purity   (LC-MS/ELSD) : 100%          (Retention Time : 0.98 minutes);
MASS   (ESI, Pos.)         592   (M + H)+;
 1H-NMR  (DMSO-d    )     5 2.70
                 6                   (s,    6H),    6.49   (s,  2H),   7.09-7.18    (m,
 1H),  7.28  (d, 2H),      7.48-7.59       (m,   3H),   7.80   (dd, 1H),    8.11   (dd,
 1H),  8.25-8.30      (m,   IH),  8.74      (s,   2H),   8.98   (s,  1H),   10.29   (s,
 1H).
Example 15-114:        1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxyl-5-pyrimidinyl}-3-[2-(methylthio)-5
  (trifluoromethyl)phenyl]urea
TLC : Rf 0.25      (Hexane : Ethyl Acetate = 1 : 2);
'H-NMR   (DMSO-d 6  )   : 5 2.53     (s,    3H),    5.56   (s,  2H),   7.26  (d,  2H),
7.35-7.43    (m,   2H),      7.49-7.56      (m,    3H),   7.92   (d,  1H),   8.18   (d,
1H),   8.44  (s, 1H),      8.73   (s, 2H),       9.64   (s, 1H).
Example 15-115: 1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-[2-(methylsulfinyl)-5
 (trifluoromethyl)phenyl]urea
TLC : Rf 0.34      (Ethyl Acetate);
1H-NMR
         (DMSO-d 6 )    : 5 2.88     (s,    3H),    6.47   (s,  2H),   7.27  (d,  2H),
7.48-7.57    (m,   3H),     7.65   (d,    1H),     7.90   (d, 1H),    8.26   (s,  2H),
8.73   (s, 2H),    9.25    (s, 1H),      9.68    (s, 1H).
Example 15-116:        1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2-(methylsulfinyl)-5
 (trifluoromethyl)phenyl]urea

 TLC   : Rf 0.32        (Ethyl Acetate);
 1
   H-NMR    (DMSO-d   6  )   : 5 2.88          (s,    3H),     5.56    (s,   2H),     7.27   (d, 2H),
 7.36    (dd,   1H),       7.52       (d,    2H),    7.65      (d,   1H),     7.88-7.94      (m, 2H),
 8.26 (s, 1H),          8.73      (s,     2H),     9.24     (s, 1H),       9.68    (s, 1H).
 Example 15-117:            1-(2-{4-[2-amino-5-(trifluoromethyl)-3
 pyridinyl]phenoxy}-5-pyrimidinyl)-3-[5-chloro-2
  (methylsulfinyl)phenyl]urea
 TLC   : Rf 0.43        (Ethyl Acetate              : Methanol = 19            : 1);
 1H-NMR     (DMSO-d  6  )    :  5    2.86      (s,   3H),      6.48    (s,   2H),     7.27   (d, 2H),
 7.35    (dd,   1H),       7.51      (d,     2H),    7.55      (d,   1H),    7.67     (d,  1H),  8.00
  (d,  1H),    8.25-8.29           (m,     1H),     8.73      (s,   2H),     9.24     (s,  1H),  9.69
  (s,  1H).
 Example 15-118:            1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[3'-(2-hydroxy-2
propanyl)-4-(trifluoromethyl)-2-biphenylyl]urea
 Purity      (LC-MS/ELSD) : 100%                 (Retention Time : 1.00 minute);
MASS    (ESI, Pos.)           : 635       (M + H)+;
 1
   H-NMR    (DMSO-d  6  )    : 5     1.45      (s,   6H),      5.07    (s,   1H),    5.85    (s, 2H),
 7.21-7.33      (m,     3H),       7.40-7.60           (m,   8H),     7.95     (d,   1H),   8.10   (s,
 1H),   8.34    (s, 1H),        8.65        (s, 2H),        9.38   (s, 1H).
Example 15-119:             1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-[3'-(2-hydroxy-2
propanyl)-4-(trifluoromethyl)-2-biphenylyl]urea
 Purity     (LC-MS/ELSD) : 100%                  (Retention Time : 1.06 minutes);
MASS    (ESI, Pos.)           : 669       (M + H)+
'H-NMR      (DMSO-d  6  )    : 5     1.45      (s,    6H),     5.07    (s,   1H),     6.48   (s, 2H),
                                                     1  11r

 7.22-7.34 (m,     3H),       7.41-7.60         (m,      8H),    8.10         (s,     1H),   8.25-8.29
 (m, 1H),    8.34     (s,    1H),   8.65      (s,     2H),     9.39      (s,      1H).
Example 15-120: 1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[5-chloro-2-(1H-pyrazol-1
yl)phenyllurea
TLC : Rf 0.43        (Hexane : Ethyl Acetate = 3 : 7);
'H-NMR    (DMSO-d  6  )    : 5 5.87     (s,     2H),       6.63-6.64           (m,    1 H),   7.23   (d,
1H),   7.24-7.28         (m,   2H),   7.40-7.55             (m,   4H),       7.91       (d,  1H),  7.96
 (d, 1H),    8.27       (d,   1H),    8.30        (d,     1H),     8.70        (s,     2H),   9.40   (s,
1H) , 9.91      (s, 1H).
Example 15-121:           1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[4-chloro-2-(1H-pyrazol-l
yl)phenyl]urea
TLC : Rf 0.52        (Hexane : Ethyl Acetate = 3 : 7);
1H-NMR
          (DMSO-d  6  )    : 5 5.86      (s,     2H),       6.61-6.65            (m,    1H),  7.26   (d,
2H),   7.41-7.47         (m,   2H),   7.52         (d,     2H),    7.64         (d,    1H),   7.91   (d,
1H),   7.96    (d,    1H),      8.14   (d,     1H),        8.36     (d,      1H),      8.69    (s, 2H),
9.37   (s, 1H) , 9.85           (s, 1H).
Example 15-122: 1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2-(1H-1,2,3-triazol-1
yl)-4-(trifluoromethyl)phenyl]urea
Purity (LC-MS/ELSD) : 100%                 (Retention Time : 0.87 minutes);
MASS   (ESI, Pos.)          : 568   (M + H)+
1H-NMR
          (DMSO-d  6 )     : 5 5.86      (s,     2H),       7.26     (d,     2H),       7.42   (d, 1H),
7.50   (d,   2H),     7.89-7.92        (m,     2H),        7.95     (d,     1H),       8.09    (s, 1H),
8.45   (d, 1H),      8.68-8.70       (m,     4H),        9.69    (brs, 1H).
                                                 1I' If-

Example 15-123: 1-{6-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-3-pyridinyl}-3-[2-fluoro-5
  (trifluoromethyl)phenyl]urea
Purity (LC-MS/ELSD) : 100%                        (Retention Time : 0.99 minutes);
MASS    (ESI, Pos.)           : 518       (M + H)*;
'H-NMR      (DMSO-dci    )      5    5.85     (s,      2H),   7.07    (d, 1H),  7.17   (d, 2H),
7.39-7.53        (m,     5H),     7.94      (d,    1H),     8.05    (dd,  1H),  8.22  (d,  1H),
8.56   (dd, 1H),           8.96     (d, 1H),        9.25 (s, 1H).
Example 15-124: 1-{6-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy] -3-pyridinyl}-3- [2- (1H-pyrazol-1-yl) -4
 (trifluoromethyl)phenyl]urea
                     0     N                 CF 3
          NH
         NH
                               H    H    N
                 CI                   (iN
          clN
Purity (LC-MS/ELSD) : 100%                        (Retention Time          1.01 minutes);
MASS   (ESI, Pos.)            : 566      (M + H)+
1 H-NMR
            (DMSO-d    6 )   : 5 5.85         (s,     2H),    6.65    (t, 1H),  7.05   (d, 1H),
7.16    (d,    2H),      7.40      (d, 1H),         7.47     (d,   2H),   7.74  (d,  1H),  7.81
 (d,  1H),     7.93-8.00           (m,     3H),     8.22     (d, 1H),     8.42-8.44   (m,  2H),
9.42   (s, 1H),         9.84     (s, 1H).
Example 15-125: 1-{6-[4-(2-amino-5-chloro-3
pyridinyl) phenoxy] -3-pyridinyl} -3- [2- (1H-1, 2, 3-triazol-1-yl)
4- (trifluoromethyl)phenyl] urea
Purity       (LC-MS/ELSD) : 100%                  (Retention Time : 0.93 minutes);
MASS   (ESI, Pos.)            : 567      (M + H)*;
1H-NMR      (DMSO-d    6 )   : 5 5.85         (s,     2H),    7.04    (d, 1H),  7.16   (d, 2H),
                                                     I   '

 7.40   (d,   1H),   7.47      (d,   2H),     7.59     (dd,  1H),    7.72      (d,  1H),  7.94
  (d, 1H),    7.99    (dd,     1H),   8.10      (d,   1H) ,  8.15     (d,    1H),   8.59-8.61
  (m, 2H),    8.69   (s,    1H),    9.57     (s, 1H).
 Example 15-126:         1-{2-[4-(2-amino-5-chloro-3
 pyridinyl)phenoxy]-5-pyrimidinyl}-3-[5-chloro-2-(3
pyridinyl)phenyl]urea
 Purity     (LC-MS/ELSD) : 98%           (Retention Time : 0.79 minutes);
MASS    (ESI, Pos.)           544   (M + H)*;
 1H-NMR    (DMSO-d   )    : 5 5.86
                   6                     (s,    2H),    7.23-7.30       (m,   4H),   7.42  (d,
 1H),  7.49-7.55        (m,   3H),    7.80-7.85         (m, 1H),     7.95     (d,   1H),  8.08
  (d, 1H),    8.14   (s, 1H),       8.56-8.65        (m, 4H),     9.21     (s, 1H).
Example 15-127: 1-{2-[4-(2-amino-3-pyridinyl)phenoxy]-5
pyrimidinyl}-3-[2-(1H-pyrazol-1-yl)-5
  (trifluoromethyl)phenyl]urea
Purity (LC-MS/ELSD) : 100%                 (Retention Time : 0.76 minutes);
MASS    (ESI, Pos.)       : 533     (M + H)+
1
  H-NMR    (DMSO-d 6 )    : 5 5.58       (s, 2H),       6.64-6.68       (m,   2H),   7.26  (d,
2H),   7.35    (dd, 1H),        7.47-7.54        (m, 3H),    7.75     (d, 1H),      7.93-7.95
 (m,  2H),    8.42   (d,     1H),    8.59     (d,    1H),   8.70    (s,     2H),   9.60-10.08
 (br, 2H).
Example 15-128:          1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-[2-(3-pyridinyl)-5
 (trifluoromethyl)phenyl]urea
Purity      (LC-MS/ELSD) : 100%            (Retention Time : 0.90 minutes);
MASS   (ESI, Pos.)        : 612     (M + H)+;
'H-NMR     (DMSO-d6 ) : 5 6.48          (s,   2H),     7.24-7.29      (m,    2H),   7.50-7.58
                                               1-30

  (m, 6H),    7.86-7.91        (m, 1H),       8.25-8.28     (m,   2H),   8.38  (d,  1H),
 8.62-8.71     (m, 4H),       9.25   (s, 1H).
 Example 15-129:         1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-[2-(1H-1,2,3-triazol-1
 yl)-5-(trifluoromethyl)phenyl]urea
 Purity     (LC-MS/ELSD) : 100%           (Retention Time : 0.93 minutes);
MASS   (ESI, Pos.)            602  (M + H)+;
 1H-NMR    (DMSO-d 6  )      5 6.48     (s,    2H),   7.28    (d,  2H),  7.50-7.56    (m,
 3H),  7.61    (dd,     1H),    7.74   (d,    1H),    8.10   (s,  1H),   8.27  (d,  1H),
 8.58  (d, 1H),      8.69-8.73 (m, 4H),             9.67  (s, 1H).
Example 15-130:          1-{6-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-3-pyridinyl}-3-{5-(trifluoromethyl)-2-[3
 (trifluoromethyl)-1H-pyrazol-1-yl]phenyl}urea
Purity     (LC-MS/ELSD) : 100%            (Retention Time : 1.08 minutes);
MASS   (ESI, Pos.)        : 634    (M + H)+;
'H-NMR    (DMSO-d  6  )   : 5 5.85      (s,    2H),   7.04    (d,  1H),  7.14-7.18    (m,
3H),   7.40    (d,   1H),     7.45-7.49        (m,   2H),  7.56    (dd,  1H),  7.69   (d,
1H),   7.94    (d,   1H),     7.98    (dd,    1H),    8.16   (d,  1H),   8.45  (s,  1H),
8.47   (d, 1H),      8.51     (d, 1H),      9.40    (s, 1H).
Example 15-131: 1-{6-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-3-pyridinyl}-3-{5-(trifluoromethyl)-2-[3
 (trifluoromethyl)-1H-pyrazol-1-yl]phenyl}urea
Purity     (LC-MS/ELSD) : 100%            (Retention Time : 1.01 minutes);
MASS   (ESI, Pos.)        : 618    (M + H)+
1H-NMR    (DMSO-d  6  )   : 5 5.55      (s,    2H),   7.04    (d,  1H),  7.14-7.18    (m,
3H),   7.41    (dd, 1H),       7.46-7.51        (m, 2H),   7.55     (dd, 1H),  7.68   (d,
                                              inn

 1H),   7.92    (d,    1H),      7.97   (dd,     1H),     8.15    (d, 1H),      8.44   (s, 1H),
 8.46-8.47     (m, 1H),         8.51   (d, 1H),        9.39   (s,    1H).
 Example 15-132: 1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[3-(1H-pyrazol-1-yl)-5
  (trifluoromethyl)phenyl]urea
 Purity (LC-MS/ELSD) : 100%                 (Retention Time : 0.93 minutes);
MASS    (ESI, Pos.)            567    (M + H)+;
1H-NMR
           (DMSO-d  6  )    : 5 5.87      (s,    2H),     6.58-6.59        (m, 1H),   7.28   (d,
2H),    7.43    (d,    1H),      7.49-7.54        (m,   2H),   7.80-7.84        (m,  3H),  8.00
 (d,  1H),    8.25       (s,    1H),   8.63      (d,    1H),    8.75      (s,  2H),   9.09   (s,
1H),   9.55    (s, 1H).
Example 15-133:            1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[3-(3-pyridinyl)-5
 (trifluoromethyl)phenyl]urea
Purity     (LC-MS/ELSD) : 100%              (Retention Time : 0.82 minutes);
MASS    (ESI, Pos.)          : 578    (M + H)+;
1H-NMR    (DMSO-d   6 )     : 5   5.87    (s,    2H),     7.28    (d,   2H),    7.43   (d, 1H),
7.50-7.55      (m,    3H),       7.66   (s,    1H),      7.95-7.96        (m,  2H),   8.01   (s,
1H),   8.09-8.13          (m,   1H),   8.62-8.64          (m,  1H),     8.75    (s,  2H),  8.90
 (d, 1H),    9.13     (s, 1H),       9.44     (s, 1H).
Example 15-134:            1-{6-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-3-pyridinyl}-3-[2-(4-methyl-1H-1,2,3
triazol-1-yl)-5-(trifluoromethyl)phenyl]urea
Purity     (LC-MS/ELSD) : 100%              (Retention Time : 0.96 minutes);
MASS    (ESI, Pos.)          : 581   (M + H)+
1 H-NMR
          (DMSO-d   6 )     : 5 2.39     (s,     3H),    5.84     (s,   2H),   7.04    (d, 1H),
                                                1  A n

 7.14-7.17      (m,   2H),    7.39    (d,   1H),      7.45-7.48         (m,   2H),  7.56   (dd,
 1H),   7.67    (d,   1H),    7.93    (d,   1H),      7.99    (dd,      1H),   8.15   (d, 1H),
 8.38   (d,   1H),    8.61-8.62      (m, 2H),        9.59   (s,     1H).
 Example 15-135: 1-{2-[4-(2-amino-5-chloro-3
 pyridinyl)phenoxy]-5-pyrimidinyl}-3-[5-chloro-2-(1H-1,2,3
 triazol-1-yl)phenyl]urea
 Purity (LC-MS/ELSD) : 98%               (Retention Time : 0.85 minutes);
 MASS   (ESI, Pos.)        : 534   (M + H)+;
 1H-NMR
           (DMSO-d   6)   : 5 5.86      (s,  2H),      7.24-7.29         (m, 2H),   7.32   (dd,
 1H),   7.42    (d,    1H),   7.48-7.53         (m,    3H),   7.95        (d,  1H),  8.06   (d,
 1H),  8.27     (d,   1H),    8.51     (s,   1H),      8.59     (d,    1H),    8.67  (s,  2H),
 9.60   (s, 1H).
Example 15-136: 1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2-(5-methyl-3-pyridinyl)
5-(trifluoromethyl)phenyl]urea
TLC : Rf 0.58         (Ethyl Acetate : Methanol = 19                     : 1);
'H-NMR     (DMSO-d  6 )   : 5 2.38      (s,    3H),     5.86     (s,   2H),    7.24-7.31    (m,
2H),   7.40-7.54        (m,  5H),    7.70-7.74          (m,  1H),      7.95    (d,  1H),  8.20
 (s,  1H),    8.40-8.47       (m,   2H),    8.51-8.55         (m,     1H),     8.66  (s,  2H),
9.28   (s, 1H).
Example 15-137:          1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2-(5-methyl-3-pyridinyl)
5-(trifluoromethyl)phenyl]urea
TLC : Rf 0.45         (Ethyl Acetate : Methanol = 19                     : 1);
1 H-NMR
           (DMSO-d  6)    : 5 2.38      (s,   3H),      5.57     (s,   2H),    7.22-7.31    (m,
2H),   7.37    (dd, 1H),       7.43-7.58        (m,   4H),    7.68-7.75         (m, 1H),  7.93
                                              1  AlI

   (d,  1H),    8.20       (s,    1H),    8.40-8.46          (m,  2H),     8.51-8.55     (m, 1H),
 8.66    (s, 2H),       9.29       (s, 1H).
 Example 15-138: 1-{2-[4-(2-amino-5-fluoro-3
 pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2-(2-methyl-3-pyridinyl)
 5-(trifluoromethyl)phenyl]urea
 TLC   : Rf 0.18        (Ethyl Acetate            : Methanol = 19            : 1);
 1
   H-NMR    (DMSO-d   6  )     : 5   2.25   (s,     3H),     5.56    (s,   2H),    7.22-7.30    (m,
 2H),    7.33-7.56          (m,    6H),   7.59-7.66          (m,  1H),    7.87     (s, 1H),  7.93
  (d,  1H),     8.53       (s,   1H),    8.56-8.61          (m,   1H),    8.65    (s, 2H),   9.28
  (s, 1H).
Example 15-139: 1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[5-phenyl-2
  (trifluoromethyl)-4-pyridinyl]urea
TLC    : Rf 0.44        (Hexane : Ethyl Acetate = 1 : 4);
1
  H-NMR     (DMSO-d  6  )     : 5 5.57     (s,    2H),      7.25-7.32       (m,  2H),  7.37   (dd,
1H),     7.50-7.65          (m,   7H),    7.94      (d,    1H),    8.42-8.47       (m, 2H),  8.69
 (s, 2H),      8.75     (s, 1H),        9.74    (s, 1H).
Example 15-140:              1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2-(6-methyl-3-pyridinyl)
5-(trifluoromethyl)phenyl]urea
TLC    : Rf 0.68        (Ethyl Acetate           : Methanol = 9           : 1);
'H-NMR      (DMSO-d  6  )     : 5 2.55      (s,     3H),     5.85   (s,    2H),   7.26   (d, 2H),
7.42-7.53        (m,    6H),      7.76    (dd,     1H),     7.95    (d,   1H),    8.20   (s, 1H),
8.42     (s, 1H),      8.50       (d, 1H),      8.67      (s, 2H),      9.28    (s, 1H).
Example 15-141:              1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-5-pyrimidinyll-3-[2-phenyl-5
                                                   I A 1)

  (trifluoromethyl)-3-pyridinyl]urea
 TLC   : Rf    0.43       (Hexane : Ethyl Acetate =                  1 : 3);
 1
   H-NMR    (DMSO-d    6   )   : 5   5.57     (s,    2H),     7.27  (d,    2H),    7.38   (dd, 1H),
 7.51-7.69        (m,      7H),     7.94    (d, 1H),          8.43   (s,    1H),    8.68   (s, 2H),
 8.73    (s, 1H),        8.76       (s, 1H),       9.47     (s, 1H).
 Example 15-142: l-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[3',4'-dimethyl-4
  (trifluoromethyl)-2-biphenylyl]urea
TLC    : Rf    0.79      (Hexane : Ethyl Acetate = 1 : 3);
1
   H-NMR    (DMSO-d    6  )    :  5   2.29     (s,     6H),    5.56   (s,   2H),    7.13-7.56    (m,
 10H),    7.93     (d,       1H),    8.01     (s,     1H),    8.45   (s,    1H),    8.67   (s, 1H),
 9.45   (s, 1H).
Example 15-143:               1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxyl-5-pyrimidinyll-3-[2-(6-methyl-3-pyridinyl)
5-(trifluoromethyl)phenyl]urea
TLC    : Rf 0.69         (Ethyl Acetate             : Methanol = 9          : 1);
'H-NMR      (DMSO-d    6  )    :  6 2.55      (s,     3H),    5.56   (s,    2H),    7.26   (d, 2H),
7.35-7.57       (m,      6H),      7.77    (dd,       1H),    7.94   (d,    1H),    8.20   (s, 1H),
8.42    (s, 1H),         8.50      (d, 1H),        8.70     (s, 2H),     9.28    (s, 1H).
Example 15-144:               1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2'-methyl-4
 (trifluoromethyl)-2-biphenylyl]urea
TLC    : Rf 0.59          (Methylene chloride                : Ethyl Acetate          : Methanol    =
8 : 4 : 1);
1H-NMR     (DMSO-d    6  )    : 5 2.04       (s,     3H),    5.86   (brs,    2H),     7.16-7.46   (m,
9H),    7.50     (d,      2H),      7.72    (s,     1H),     7.95   (d, 1H),       8.53    (s, 1H),

  8.65  (s,    2H),     9.45    (s,  1H).
  Example 15-145:          1-{2-[4-(2-amino-5-fluoro-3
  pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2'-methyl-4
  (trifluoromethyl)-2-biphenylyl]urea
  TLC : Rf 0.56          (Methylene chloride         : Ethyl Acetate : Methanol           =
  8 : 4 : 1);
 'H-NMR     (DMSO-d   6  )  : 5 2.04     (s, 3H),    5.56   (brs,   2H),   7.16-7.48    (m,
  9H),  7.52      (d,    2H),    7.72   (s,  1H),    7.93   (d,   1H),   8.53  (s,  1H),
  8.65  (s, 2H),        9.45   (s, 1H).
 Example 15-146: 1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxyl-5-pyrimidinyl}-3-[2'-ethyl-4
  (trifluoromethyl)-2-biphenylyl]urea
TLC : Rf 0.51           (Hexane : Ethyl Acetate = 1 : 2);
1 H-NMR
            (DMSO-d   6 )   : 5 0.99     (t,  3H),    2.21-2.50     (m,  2H),  5.85   (s,
2H),   7.16      (d,    1H),    7.15-7.51     (m,   10H),   7.66    (s,  1H),  7.94   (d,
1H),   8.53     (s, 1H),       8.64   (s, 2H),     9.47   (s, 1H).
Example 15-147:            1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2'-ethyl-4
  (trifluoromethyl)-2-biphenylyl]urea
TLC : Rf 0.50           (Hexane : Ethyl Acetate = 1 : 2);
'H-NMR     (DMSO-d    6 )   : 5 0.99     (t,  3H),    2.21-2.50     (m,  2H),  5.56   (s,
2H),   7.16     (d,     1H),    7.22-7.56     (m,   10H),   7.66    (s,  1H),  7.93   (d,
1H),   8.53     (s, 1H),      8.64    (s, 2H),     9.47   (s, 1H).
Example 15-148:            1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-{5-chloro-2-[4
  (difluoromethyl)-1H-pyrazol-1-yl]phenyl}urea
                                             IA A

 TLC        Rf   0.16      (Hexane          Ethyl       Acetate        :   Methanol      =    6 :   4
 0.4);
 1
   H-NMR     (DMSO-d  6  )   :  5   5.56    (s,     2H),    7.13      (t,    1H),    7.20-7.29        (m,
 3H),     7.36    (dd,     1H),    7.46-7.57         (m,    3H),     7.92      (d,  1H),     8.11     (s,
 1H),     8.23    (d,   1H),      8.58   (s,      1H),    8.67     (s,     2H),    8.90     (s,  1H)
 9.77     (s, 1H).
Example 15-149: 1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-{5-chloro-2-[3
 (trifluoromethyl)-1H-pyrazol-1-yl]phenyl}urea
TLC     :   Rf   0.20      (Hexane     :    Ethyl       Acetate       :    Methanol      =   6  :   4
0.4);
1H-NMR      (DMSO-d6 )      :   5 5.56      (s, 2H),        7.07     (s,     1H),   7.20-7.32        (m,
3H),      7.37    (dd, lH),        7.43-7.57         (m, 3H),       7.92       (d, 1H),      8.18    (s,
1H),     8.37    (s,   2H),     8.65    (s,     2H),     9.43    (s,      1H).
Example 15-150:            1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy] -5-pyrimidinyl}-3-[5-chloro-2- (4-fluoro-lH
pyrazol-1-yl)phenyllurea
TLC    : Rf 0.45        (Hexane : Ethyl Acetate =                   1 : 2);
'H-NMR (DMSO-d6 ) : 5 5.85                 (s, 2H),        7.19-7.30         (m, 3H),      7.38-7.54
 (m,   4H),     7.91-7.99         (m,  2H),       8.24     (d,   1H),       8.42    (d,    1H),   8.69
 (s, 2H),      8.94     (s, 1H),      9.76       (s, 1H).
Example 15-151:            1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy] -5-pyrimidinyl}-3- [5-chloro-2- (4-fluoro-1H
pyrazol-1-yl)phenyl]urea
TLC    : Rf 0.39        (Hexane : Ethyl Acetate = 1 : 2);
1
  H-NMR     (DMSO-d6 )      : 5 5.56      (s, 2H),         7.19-7.30         (m,   3H),    7.36    (dd,
                                                   1 Ar

 1H),    7.44      (d,       1H),     7.51    (d,      2H),     7.92     (d,   1H),     7.95   (d, 1H),
 8.24    (d,    1H),        8.42       (d, 1H),        8.68      (s,  2H),     8.94      (s, 1H),  9.75
  (s,  1H).
 Example 15-152:               1-{2-[4-(2-amino-5-fluoro-3
 pyridinyl)phenoxy]-5-pyrimidinyl}-3-[4'-ethyl-4
  (trifluoromethyl)-2-biphenylyl]urea
 TLC : Rf 0.31             (Hexane : Ethyl Acetate = 2                       : 3);
 1
   H-NMR     (DMSO-d     6  )    : 5    1.24     (t,    3H),     2.69     (q,   2H),    5.57   (s, 2H),
 7.24-7.31        (m,      2H),       7.34-7.56          (m,    9H),   7.93       (d,   1H),  8.09   (s,
 1H),   8.41     (s,     1H),        8.67   (s, 2H),          9.41   (s,     1H).
Example 15-153:                1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxyl-5-pyrimidinyl}-3-[5-fluoro-2-(3
pyridinyl)phenyl]urea
TLC    : Rf 0.51          (Ethyl Acetate              : Methanol = 9            : 1);
1
  H-NMR     (DMSO-d    6   )    :   5 5.86     (s,     2H),     7.02    (dt,     1H),    7.24-7.31   (m,
3H),    7.42     (d,      1H),       7.49-7.55         (m,    3H),   7.82      (dt,    1H),  7.88  (dd,
1H),    7.95      (d,       1H),      8.12    (s,      1H),     8.58-8.65         (m,   4H),  9.23   (s,
1H).
Example 15-154:                1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[3,4
bis(trifluoromethyl)phenyl]urea
Purity       (LC-MS/ELSD) : 100%                   (Retention Time            : 0.99 minutes);
MASS    (ESI, Pos.)               : 569    (M + H)*;
1
  H-NMR     (DMSO-d    6   )    : 5 5.87        (s,     2H),     7.25-7.31         (m,  2H),  7.43   (d,
1H),    7.49-7.55             (m,    2H),    7.86-7.98           (m,  3H),     8.20     (s,  1H),  8.74
 (s, 2H),      9.16       (s, 1H),        9.77       (s, 1H).
                                                       1  A r

 Example 15-155:             1-{2-[4-(2-amino-5-chloro-3
 pyridinyl)phenoxy]-5-pyrimidinyl}-3-[3-methyl-4
  (trifluoromethyl)phenyl]urea
 Purity       (LC-MS/ELSD) : 100%              (Retention Time           : 0.94 minutes);
MASS    (ESI, Pos.)              515    (M + H)+;
 1H-NMR      (DMSO-d  6  )      5  2.39     (s,    3H),     5.87   (s,    2H),     7.25-7.32    (m,
2H),    7.42-7.61           (m,   6H),    7.95      (d,   1H),    8.73      (s,   2H),   8.98   (s,
 1H) ,  9.28     (s,    1H).
Example 15-156: 1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[3-fluoro-4
 (trifluoromethyl)phenyl]urea
Purity       (LC-MS/ELSD) : 100%               (Retention Time          : 0.93 minutes);
MASS    (ESI, Pos.)           : 519    (M + H)+
1
  H-NMR     (DMSO-d  6  )    : 5   5.87    (s,    2H),    7.25-7.32        (m,   2H),  7.33-7.39
 (m,   1H),     7.43      (d,    1H),    7.48-7.51         (m,   2H),     7.63-7.74      (m,  2H),
7.96    (d, 1H),       8.73      (s, 2H),       9.10     (s, 1H),      9.62     (s, 1H).
Example 15-157:             1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[3-fluoro-4
 (trifluoromethyl)phenyl]urea
Purity      (LC-MS/ELSD) : 100%                (Retention Time : 0.90 minutes);
MASS    (ESI, Pos.)           : 531    (M + H)*;
1
  H-NMR     (DMSO-d  6  )    : 5   3.84     (s,    3H),     5.86   (s,    2H),    7.07-7.15     (m,
1H),    7.25-7.32          (m,   2H),    7.41-7.56          (m,  5H),     7.95    (d,  1H),   8.73
 (s, 2H),      8.98     (s, 1H),       9.38     (s, 1H).
Example 15-158:             1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2,3-difluoro-4
                                                  1 A -7

  (trifluoromethyl)phenyl]urea
 Purity (LC-MS/ELSD) : 100%                (Retention Time : 0.95 minutes);
 MASS    (ESI, Pos.)           537   (M + H)+;
 1 H-NMR
            (DMSO-d 6  )       5 5.86    (s,   2H),     7.25-7.32    (m,   2H),    7.43   (d,
 1H),   7.48-7.61         (m,   3H),   7.94-7.98        (m,  1H),  8.13-8.21       (m,  1H),
 8.75    (s, 2H),     9.36      (s, 2H).
 Example 15-159:           1-{2-[4-(2-amino-5-chloro-3
 pyridinyl)phenoxy]-5-pyrimidinyl}-3-[4-methoxy-3
  (trifluoromethyl)phenyl]urea
 Purity (LC-MS/ELSD) : 100%                (Retention Time : 0.87 minutes);
MASS    (ESI, Pos.)            531   (M + H)+;
 1 H-NMR
           (DMSO-d   6)       5 3.84     (s,   3H),     5.87   (s, 2H),    7.19-7.31      (m,
 3H),   7.43    (d,   1H),      7.49-7.54      (m,    2H),   7.60  (dd,    1H),   7.80    (d,
 1H),   7.95    (d, 1H),       8.71   (s, 2H),       8.90   (s, 1H),    9.03    (s, 1H).
Example 15-160:           1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[3-methoxy-5
 (trifluoromethyl)phenyl]urea
 Purity (LC-MS/ELSD) : 100%                (Retention Time : 0.91 minutes);
MASS    (ESI, Pos.)         : 531    (M + H)+;
'H-NMR     (DMSO-d  6 )     : 5 3.80     (s,   3H),    5.87    (s, 2H),    6.83-6.90      (m,
1H),    7.24-7.31        (m,    3H),   7.41-7.45        (m, 1H),   7.46-7.55       (m,  3H),
7.94-7.97       (m, 1H),       8.72   (s, 2H),       8.98   (s, 1H),   9.31     (s, 1H).
Example 15-161:           1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[3,4
bis(trifluoromethyl)phenyllurea
Purity      (LC-MS/ELSD) : 100%            (Retention Time : 0.92 minutes);
                                             I  A r)

 MASS    (ESI, Pos.)               553    (M + H)*;
 'H-NMR      (DMSO-d  6   )       5   5.58    (s,    2H),   7.25-7.33       (m,  2H),   7.38  (dd,
  1H),   7.51-7.58          (m,     2H),    7.85-7.99        (m,   3H),    8.19-8.23     (m,  1H),
 8.74    (s, 2H),       9.17        (s, 1H),       9.78    (s, 1H).
 Example 15-162: 1-{2-[4-(2-amino-5-fluoro-3
 pyridinyl)phenoxy]-5-pyrimidinyl}-3-[3-methyl-4
  (trifluoromethyl)phenyl]urea
 Purity      (LC-MS/ELSD) : 100%                  (Retention Time :          0.87 minutes);
 MASS    (ESI, Pos.)           : 499     (M + H)+;
 1
   H-NMR    (DMSO-d    6  )       5 2.40       (s,    3H),   5.58    (s,   2H),    7.25-7.60    (m,
 8H),    7.94-7.96          (in,    1H),    8.73       (s,  2H),    8.98     (s,  1H),   9.28   (s,
 1H).
 Example 15-163: 1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[3-fluoro-4
  (trifluoromethyl)phenyl]urea
 Purity      (LC-MS/ELSD) : 100%                 (Retention Time         : 0.86 minutes);
MASS     (ESI, Pos.)           : 503     (M + H)+;
'H-NMR      (DMSO-d  6   )    : 5     5.58   (s,    2H),    7.25-7.43       (m,  4H),  7.50-7.58
 (m,   2H),     7.63-7.75            (m,   2H),     7.94    (d,   1H),    8.73    (s,  2H),   9.10
 (s,   1H),    9.61     (s,      1H).
Example 15-164:             1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2-methoxy-4
 (trifluoromethyl)phenyl]urea
Purity       (LC-MS/ELSD) : 100%                 (Retention Time : 0.87 minutes);
MASS    (ESI, Pos.)            : 515     (M + H)*;
  H-NMR     (DMSO-d  6   )    : 5     3.97    (s,     3H),   5.57    (s,  2H),    7.25-7.57    (m,
                                                     1 AC

   7H),  7.94      (d,    1H),    8.29-8.36       (m,  1H),   8.69-8.75     (m,  3H),  9.66
    (s, 1H).
   Example 15-165: 1-{2-[4-(2-amino-5-fluoro-3
  pyridinyl)phenoxy]-5-pyrimidinyl}-3-[3-methoxy-4
   (trifluoromethyl)phenyl]urea
   Purity (LC-MS/ELSD) : 100%                (Retention Time : 0.83 minutes);
  MASS   (ESI, Pos.)          : 515    (M + H)+;
  'H-NMR      (DMSO-d  6  )  : 5 3.83      (s,   3H),    5.57   (s,  2H),   7.07-7.14    (m,
   1H),  7.25-7.32          (m,  2H),    7.35-7.57       (m,  5H),   7.93   (d, 1H),   8.72
   (s, 2H),     8.97     (s, 1H),      9.37    (s, 1H).
  Example 15-166: 1-{2-[4-(2-amino-5-fluoro-3
 pyridinyl)phenoxy]-5-pyrimidinyl}-3-[4-fluoro-3
   (trifluoromethyl)phenyl]urea
  Purity (LC-MS/ELSD) : 88%                (Retention Time : 0.83 minutes);
 MASS    (EST, Pos.)          : 503    (M + H)+;
 'H-NMR      (DMSO-d6 ) : 5 5.58          (s,   2H),    7.25-7.32     (m, 2H),   7.35-7.58
   (m,  4H),     7.65-7.75        (m,   1H),    7.92-8.00      (m,  2H),   8.72   (s,  2H),
  9.01   (s, 1H),        9.31   (s, 1H).
 Example 15-167:            1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[4-methoxy-3
   (trifluoromethyl)phenyl]urea
 Purity       (LC-MS/ELSD) : 100%            (Retention Time : 0.80 minutes);
MASS     (EST, Pos.)          : 515    (M + H)*;
'H-NMR       (DMSO-d   6 )   : 5 3.84     (s,    3H),    5.58   (s,  2H),   7.19-7.31    (m,
 3H),    7.38       (dd,     1H),     7.50-7.57       (m, 2H),      7.58-7.65     (m,  1H),
 7.78-7.83        (m,    1H),    7.93-7.96       (m,   1H),    8.72    (s, 2H),   8.90   (s,

  1H),  9.03    (s, 1H).
  Example 15-168: 1-{2-[4-(2-amino-5-fluoro-3
 pyridinyl)phenoxy]-5-pyrimidinyl}-3-[3-methoxy-5
   (trifluoromethyl)phenyl]urea
  Purity (LC-MS/ELSD) : 100%                 (Retention Time : 0.84 minutes);
 MASS    (ESI, Pos.)           515    (M + H)+;
 'H-NMR     (DMSO-d  6   )     6 3.80      (s,    3H),   5.57   (s,    2H),   6.86  (s, 1H),
 7.25-7.58       (m,    7H),     7.94    (d,    1H),    8.72  (s,     2H),   8.98   (s, 1H),
  9.31   (s, 1H).
 Example 15-169:           1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxyl-5-pyrimidinyl}-3-[2,6-difluoro-3
  (trifluoromethyl)phenyl]urea
 Purity (LC-MS/ELSD) : 100%                  (Retention Time : 0.84 minutes);
MASS     (ESI, Pos.)         : 537   (M + H)*;
'H-NMR (DMSO-d6 ) : 5 5.86                (s, 2H),      7.24-7.30       (m, 2H),   7.37-7.55
  (m,  4H),    7.71-7.82        (m,  1H),      7.95    (d, 1H),     8.67    (brs, 1H),  8.72
  (s, 2H),    9.38     (brs, 1H).
Example 15-170: 1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2,6-difluoro-3
  (trifluoromethyl)phenyl]urea
Purity (LC-MS/ELSD) : 100%                   (Retention Time : 0.77 minutes);
MASS    (ESI, Pos.)          : 521   (M + H)+;
'H-NMR     (DMSO-d   6  )   : 5 5.57      (s,   2H),    7.24-7.31       (m, 2H),   7.35-7.56
  (m,  4H),    7.71-7.82         (m,   1H),     7.92-7.96     (m,    1H),    8.66   (s, 1H),
8.72    (s, 2H),       9.37     (s, 1H).
Example 15-171:            1-{2-[4-(2-amino-5-chloro-3
                                                 1 Ril

 pyridinyl)phenoxy]-5-pyrimidinyl}-3-[3,5
bis(trifluoromethyl)phenyl]urea
 Purity     (LC-MS/ELSD) : 100%             (Retention Time : 1.00 minute);
MASS   (ESI, Pos.)          : 569    (M + H)+;
 1H-NMR    (DMSO-d  6  )      5 5.87    (s,   2H),    7.25-7.31       (m, 2H),      7.42-7.45
  (m, 1H),     7.49-7.55         (m,  2H),    7.65-7.70       (m,   1H),      7.95-7.98     (m,
 1H),  8.15 (s, 2H),           8.74   (s, 2H),      9.21    (s, 1H),       9.68    (s, 1H).
Example 15-172:           1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[3,5
bis(trifluoromethyl)phenyl]urea
Purity      (LC-MS/ELSD) : 100%            (Retention Time : 0.89 minutes);
MASS   (ESI, Pos.)             485   (M + H)+
'H-NMR     (DMSO-d  6 )      5 5.86     (s,   2H),    7.05-7.13       (m,    1H),   7.25-7.37
 (m,  3H),    7.43      (d,    1H),   7.48-7.56        (m,  2H),    7.95      (d,   1H),  8.20
 (dd, 1H),     8.74      (s, 2H),     8.97    (s, 1H),     9.28    (s, 1H).
Example 15-173:           1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[3,5
bis(trifluoromethyl)phenyl]urea
Purity      (LC-MS/ELSD) : 100%            (Retention Time : 0.96 minutes);
MASS   (ESI, Pos.)          : 501    (M + H)+;
1H-NMR
           (DMSO-d  6 )    : 5 5.86      (s,   2H),     7.20   (t,   1H),     7.25-7.31     (m,
2H),   7.43     (d,    1H),     7.49-7.56       (m,   4H),    7.95     (d,    1H),   8.72   (s,
2H),   9.09 (s, 1H),           9.33   (s, 1H).
Example 15-174:           1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-(3-chloro-5
methylphenyl)urea

 Purity      (LC-MS/ELSD) : 100%              (Retention Time : 0.91 minutes);
MASS    (ESI, Pos.)             481   (M + H)+
1
  H-NMR     (DMSO-d 6  )     : 5   3.32    (s,     3H),    5.86   (s,    2H),    6.86-6.90    (s,
 1H),   7.10-7.15          (m,   1H),   7.24-7.31          (m,  2H),    7.42-7.55       (m, 4H),
7.95    (d, 1H),      8.72       (s, 2H),      8.92     (s, 1H),      9.06    (s, 1H).
Example 15-175:             1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-(3-chloro-5
fluorophenyl)urea
Purity      (LC-MS/ELSD) : 100%              (Retention Time           : 0.90 minutes);
MASS    (ESI, Pos.)           : 485   (M + H)+
1 H-NMR    (DMSO-d  6 )        5 5.86     (s,    2H),     6.98-7.06       (m,  1H),   7.25-7.55
 (m,  7H),     7.95      (d,    1H),    8.72       (s,   2H),   9.06      (s,   1H),   9.36   (s,
1H).
Example 15-176:            1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-(5-chloro-2
methoxyphenyl)urea
Purity      (LC-MS/ELSD) : 100%              (Retention Time : 0.90 minutes);
MASS   (ESI, Pos.)            : 497   (M + H)+
1
  H-NMR    (DMSO-d   6)      : 5   3.88    (s,     3H),    5.86   (s,   2H),     6.98-7.08    (m,
2H),   7.25-7.32          (m,    2H),   7.43       (d,   1H),   7.49-7.55        (m, 2H),   7.95
 (d,  1H),     8.18     (d,     1H),    8.56       (s,   1H),   8.72      (s,   2H),   9.59   (s,
1H).
Example 15-177:            1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-(3-chloro-5
methoxyphenyl)urea
Purity     (LC-MS/ELSD) : 100%               (Retention Time           : 0.87 minutes);
                                                 I  r-)

 MASS   (ESI, Pos.)          : 497     (M + H)*;
 1H-NMR    (DMSO-d  6  )       5   3.74     (s,    3H),   5.86   (s,   2H),    6.60-6.66    (m,
 1H),   6.95-7.00        (i,      1H),   7.15-7.20        (m,  1H),    7.24-7.30      (m, 2H),
 7.43   (d,   1H),     7.45-7.55          (m,    2H),    7.95   (d,   1H),    8.71    (s, 2H),
 8.93   (s, 1H),      9.13      (s, 1H).
 Example 15-178:          1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyll-3-[5-chloro-2
 (trifluoromethyl)phenyl]urea
 Purity    (LC-MS/ELSD) : 100%                 (Retention Time       : 0.94 minutes);
MASS    (ESI, Pos.)          : 535     (M + H)+
'H-NMR    (DMSO-d  6  )    : 5 5.86        (s,   2H),    7.25-7.31      (m,  2H),   7.34-7.40
 (m,  1H),    7.43      (d,    1H),     7.49-7.55        (m,  2H),    7.72     (d,  1H),  7.95
 (d, 1H),    8.10-8.14           (m,   1H),     8.42    (brs, 1H),     8.74     (s, 2H),  9.67
 (brs, 1H).
Example 15-179:           1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-(2,3-dichlorophenyl)urea
Purity     (LC-MS/ELSD) : 100%                 (Retention Time       : 0.91 minutes);
MASS   (ESI, Pos.)           : 501     (M + H)+;
1
  H-NMR   (DMSO-d  6  )    : 5     5.86     (s,   2H),    7.25-7.55      (m,  7H),   7.96   (d,
1H),   8.08-8.15         (m,     1H),    8.66       (s,  1H),  8.74      (s,  2H),   9.65   (s,
1H).
Example 15-180:          1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-(4-chloro-2
methoxyphenyl)urea
Purity     (LC-MS/ELSD) : 100%                 (Retention Time       : 0.89 minutes);
MASS   (ESI, Pos.)          : 497      (M + H)+
                                                  I1~A

 1
   H-NMR    (DMSO-d   6  )  : 6 3.90     (s,   3H),     5.86   (s,    2H),    6.96    (dd,  1H),
 7.10    (d,   1H),       7.25-7.31     (n,    2H),     7.42    (d,    1H),    7.48-7.55      (m,
 2H),   7.95     (d,      1H),   8.09   (d,    1H),     8.45   (s,     1H),    8.71    (s,  2H),
 9.52   (s, 1H).
 Example 15-181:           1-{2-[4-(2-amino-5-chloro-3
 pyridinyl)phenoxy]-5-pyrimidinyl}-3-(4-chloro-2
methylphenyl)urea
 Purity      (LC-MS/ELSD) : 100%             (Retention Time         : 0.87 minutes);
MASS    (ESI, Pos.)          : 481   (M + H)+;
  H-NMR     (DMSO-d   6  )  : 5   2.23   (s,    3H),     5.86    (s,   2H),    7.18-7.31      (m,
 4H),   7.42     (d,     1H),   7.48-7.55        (m,    2H),   7.80     (d,   1H),     7.95   (d,
 1H),  8.22     (s, 1H),       8.72    (s, 2H),       9.21   (s, 1H).
Example 15-182:            1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-(4-chloro-2
fluorophenyl)urea
Purity      (LC-MS/ELSD) : 100%             (Retention Time          : 0.87 minutes);
MASS    (ESI, Pos.)          : 485   (M + H)*;
1
  H-NMR    (DMSO-d   6  )   : 5   5.86   (s,    2H),     7.20-7.55       (n,   7H),    7.95   (d,
1H),   8.09     (t, 1H),       8.73   (s, 2H),        8.56   (s, 1H),       9.22    (s, 1H).
Example 15-183:            1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxyl-5-pyrimidinyl}-3-[4-chloro-2
 (methylsulfonyl)phenyl]urea
Purity      (LC-MS/ELSD) : 100%             (Retention Time          : 0.85 minutes);
MASS    (ESI, Pos.)          : 545   (M + H)+
1
  H-NMR    (DMSO-d    6 )   : 6 3.36     (s,    3H),     5.86   (s,    2H),    7.25-7.32     (m,
2H),   7.43     (d,     1H),    7.49-7.56       (m,    2H),   7.75-7.84        (m,   2H),   7.96
                                               1 rEr.

  (d, 1H),     8.21         (d,     1H),     8.74      (s,   2H),   8.79   (s,   1H),  10.18   (s,
 1H).
 Example 15-184: 1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxyl-5-pyrimidinyl}-3-[4-chloro-3
  (methylsulfonyl)phenyl]urea
 Purity (LC-MS/ELSD) : 100%                         (Retention Time : 0.75 minutes);
MASS    (ESI, Pos.)                 545    (M + H)+;
'H-NMR      (DMSO-d   6   )        5 3.35        (s,   3H),    5.87   (s,  2H),    7.25-7.32   (m,
2H),   7.43      (d,     1H),        7.49-7.55         (m,   2H),   7.63   (d,   1H),  7.78  (dd,
1H),   7.95-7.96              (m,    1H),      8.27     (d,   1H),   8.73    (s,  2H),  9.00   (s,
1H),   9.56     (s, 1H).
Example 15-185: 1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[4-chloro-2
 (trifluoromethyl)phenyl]urea
Purity      (LC-MS/ELSD) : 100%                    (Retention Time : 0.93 minutes);
MASS   (ESI, Pos.)              : 535     (M + H)+;
1H-NMR    (DMSO-d     6  )     : 5 5.86         (s,   2H),    7.25-7.31     (m,  2H),  7.42-7.45
 (m,  1H),     7.49-7.55              (m,   2H),      7.71-7.79      (m,  2H),    7.95-8.01   (m,
2H),   8.38     (s, 1H),           8.74      (s, 2H),       9.57   (s, 1H).
Example 15-186: 1-{2-[4-(2-amino-5-chloro-3
pyridinyl) phenoxy] -5-pyrimidinyl}-3- [2- (2,3-dihydro-1H-inden
5-yl)-5-(trifluoromethyl)phenyl]urea
                                          CF 3
         NH 2        O      N       O
       N                N'         AN N
                                 H    H
         CI

 TLC   : Rf 0.49          (Hexane : Ethyl Acetate               =  1 : 2);
 1
   H-NMR     (DMSO-d   6  )    : 5   2.00-2.10       (m,   2H),    2.93    (t,  4H),  5.85   (s,
 2H),   7.17      (dd, 1H),         7.25-7.27     (m,     3H),    7.37-7.44      (m, 4H),  7.50
  (d,  2H),      7.95       (d,   1H),   8.04    (s,     1H),     8.45    (s,  1H),   8.67   (s,
 2H) ,  9.45      (s,    1H).
 Example 15-187:             1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2-(2,3-dihydro-1H-inden
 5-yl)-5-(trifluoromethyl)phenyl]urea
TLC    : Rf 0.44         (Hexane : Ethyl Acetate = 1 : 2);
 1
   H-NMR    (DMSO-d    6  )   :  5 2.00-2.10        (m,    2H),    2.93    (t,  4H),  5.57   (s,
 2H),   7.16      (dd,      1H),   7.25-7.28      (m,     3H),    7.35-7.44     (m, 4H),   7.52
  (d,  2H),     7.93        (d,   1H),   8.04    (s,     IH),     8.45    (s,  1H),   8.67   (s,
2H),    9.45      (s, 1H).
Example 15-188:              1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2-(2,3-dihydro-1
benzofuran-5-yl)-5-(trifluoromethyl)phenyl]urea
TLC    : Rf 0.28         (Hexane : Ethyl Acetate = 1 : 2);
'H-NMR      (DMSO-d    6  )   : 5   3.25   (t,  2H),       4.60     (t,  2H),   5.85   (s, 2H),
 6.91    (d,    1H),      7.14     (dd,  1H),   7.24-7.29           (m,  3H),   7.37-7.42    (m,
3H),    7.50       (d,    2H),     7.95   (d,  1H),       8.03     (s,  1H),   8.44   (s,  1H),
8.67    (s, 2H),         9.45     (s, 1H).
Example 15-189:              1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2-(2,3-dihydro-1
benzofuran-5-yl)-5-(trifluoromethyl)phenyl]urea
TLC    : Rf 0.24         (Hexane : Ethyl Acetate = 1 : 2);
'H-NMR      (DMSO-d    6  )   : 5   3.25   (t,  2H),       4.60     (t,  2H),   5.57   (s, 2H),
                                                1  r- -7

  6.91   (d,    1H),     7.14     (dd,   1H),       7.25-7.29       (m,  3H),   7.35-7.42     (m,
  3H),  7.53      (d,     2H),    7.94     (d,     1H),    8.03    (s,  1H),    8.45   (s,  1H),
  8.68  (s,    2H),     9.45     (s,   1H).
 Example 15-190:            1-{2-[4-(2-amino-5-fluoro-3
 pyridinyl)phenoxy]-5-pyrimidinyl}-3-{5-(difluoromethyl)-2-[3
  (trifluoromethyl)-1H-pyrazol-1-yl]phenyl}urea
 TLC : Rf 0.40          (Hexane : Ethyl Acetate = 1 : 2);
 'H-NMR     (DMSO-d   6  )   : 5    5.56     (s,    2H),    7.08    (d,  1H),   7.13    (t, 1H),
 7.26    (d,    2H),      7.32-7.45       (m,      2H),    7.51    (d,  2H),   7.60    (d,  1H),
 7.92    (d,    1H),      8.28     (s,  1H),       8.41    (s,   1H),   8.45    (s,  1H),   8.65
  (s, 2H),     9.42     (s, 1H).
Example 15-191:             1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-{4-chloro-2-[3
  (trifluoromethyl)-1H-pyrazol-1-yl]phenyl}urea
TLC : Rf 0.45 (Hexane : Ethyl Acetate = 1 : 2);
1H-NMR      (DMSO-d   6  )   : 6 5.56        (s,    2H),    7.06    (d,  1H),   7.25    (d, 2H),
7.36    (dd,     1H),      7.49-7.62        (m,     4H),   7.92     (d, 1H),    8.02    (d, 1H),
8.35    (s,    1H),     8.38-8.42       (m,      1H),    8.64   (s, 2H),     9.36   (s, 1H).
Example 15-192:             1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2,3-difluoro-4
  (trifluoromethyl)phenyl]urea
Purity (LC-MS/ELSD) : 93%                    (Retention Time : 0.89 minutes);
MASS    (ESI,     Pos.)       : 521    (M + H)+
'H-NMR      (DMSO-d   6 )    : 5 5.57       (s,    2H),    7.26-7.33      (m, 2H),    7.38  (dd,
IH),   7.51-7.62           (m,   3H),    7.94       (d,   1H),    8.13-8.22     (m,  1H),   8.75
  (s, 2H),     9.36     (s, 2H).

  Example 15-193:          1-{2-[4-(2-amino-5-chloro-3
 pyridinyl)phenoxy]-5-pyrimidinyl}-3-[3-chloro-2-fluoro-5
  (trifluoromethyl)phenyl]urea
  Purity (LC-MS/ELSD) : 100%                (Retention Time : 1.00 minute);
 MASS    (ESI, Pos.)         : 553   (M + H)+.
 Example 15-194:           1-(2-{4-[2-amino-5-(trifluoromethyl)-3
 pyridinyl]phenoxy}-5-pyrimidinyl)-3-[2-(5-methyl-3-pyridinyl)
 5-(trifluoromethyl)phenyl]urea
 Purity     (LC-MS/ELSD) : 100%             (Retention Time : 0.89 minutes);
MASS    (ESI, Pos.)          : 626   (M + H)*;
 'H-NMR    (DMSO-d   6  )   : 5 2.38      (s,  3H),  6.48   (s, 2H),  7.24-8.54   (m,
 13H),    8.66   (s,     2H),    9.29   (s,   1H).
Example 15-195:           1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-[4-(trifluoromethyl)-2
biphenylyl urea
Purity (LC-MS/ELSD) : 100%                  (Retention Time : 1.09 minutes);
MASS    (ESI, Pos.)         : 611    (M + H)*;
  H-NMR    (DMSO-d   6 )   : 5 6.48      (s,  2H),  7.25-7.31    (m, 2H), 7.40-7.59
  (m,  10H),   8.09       (s,   1H),   8.26-8.30     (m,  1H),  8.40-8.44   (m, 1H),
8.66    (s, 2H),       9.40    (s, 1H).
Example 15-196:           1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-[5-phenyl-2
  (trifluoromethyl)-4-pyridinyl]urea
Purity (LC-MS/ELSD) : 100%                  (Retention Time : 1.02 minutes);
MASS    (ESI, Pos.)         : 612    (M + H)*;
'H-NMR     (DMSO-d   6 )   : 5 6.48      (s,  2H),  7.26-7.32    (m, 2H), 7.49-7.66

  (m,  8H),     8.27-8.30       (m,   1H),    8.42-8.46        (m,   2H),   8.69    (s,  2H),
 8.75   (s,    1H),    9.74   (s,   1H).
 Example 15-197: 1-(2-{4-[2-amino-5-(trifluoromethyl)-3
 pyridinyljphenoxy}-5-pyrimidinyl)-3-[2-phenyl-5
  (trifluoromethyl)-3-pyridinyl]urea
 Purity      (LC-MS/ELSD) : 100%            (Retention Time : 1.01 minutes);
MASS    (ESI, Pos.)         : 612   (M + H)+;
 1H-NMR     (DMSO-d    )   : 6 6.48
                     6                   (s,  2H),     7.25-7.32       (m, 2H),   7.49-7.70
  (m, 8H),     8.26-8.30       (m,   1H),    8.43     (s,   1H),    8.68   (s,   2H),   8.74
 8.75   (m,    1H),    8.76-8.78      (m, 1H),       9.47   (s, 1H).
 Example 15-198: 1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-[3',4'-dimethyl-4
  (trifluoromethyl)-2-biphenylyllurea
 Purity      (LC-MS/ELSD) : 100%           (Retention Time : 1.17 minutes);
MASS    (ESI, Pos.)         : 639   (M + H)+
'H-NMR      (DMSO-d  6 )   : 5 2.29      (s,   6H),     6.48    (s,   2H),  7.12-7.58      (m,
 10H),   8.01     (s, 1H),      8.26-8.30        (m,   1H),   8.45-8.48      (m,  1H),   8.67
 (s, 2H),      9.46 (s, 1H).
Example 15-199:           1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-[2-(6-methyl-3-pyridinyl)
5-(trifluoromethyl)phenyl]urea
Purity (LC-MS/ELSD) : 98%                 (Retention Time : 0.84 minutes);
MASS    (ESI, Pos.)         : 626 (M + H)+;
1H-NMR     (DMSO-d   6 )   : 5 2.55      (s,   3H),     6.48    (s,   2H),  7.25-7.32      (m,
2H),    7.39-7.59        (m,  6H),     7.75-7.80        (m,  1H),     8.19-8.23     (m,  1H),
8.26-8.30        (m,   1H),   8.41-8.44        (m,    1H),   8.49-8.53       (m,  1H),   8.67
                                              1I  (

  (s, 2H),    9.28    (s,    1H).
 Example 15-200: 1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-[3
  (trifluoromethyl)phenyl]urea
 Purity (LC-MS/ELSD) : 100%                 (Retention Time : 0.96 minutes);
MASS    (ESI, Pos.)            535   (M + H)+
1H-NMR     (DMSO-d  6  )      5 6.49    (s,   2H),     7.26-7.36       (m,  3H),   7.48-7.66
 (m,  5H),     7.96-8.00         (m,  1H),    8.27-8.30        (m,   1H),    8.73   (s,  2H),
8.99   (s, 1H),       9.33     (s, 1H).
Example 15-201: 1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-[2-fluoro-4
 (trifluoromethyl)phenyl]urea
Purity (LC-MS/ELSD) : 100%                 (Retention Time          : 1.00 minute);
MASS   (ESI, Pos.)          : 553    (M + H)+
1H-NMR     (DMSO-d   6)    : 5 6.49     (s,   2H),     7.26-7.34       (m, 2H),    7.49-7.59
 (m,  4H),    7.72     (dd,     1H),   8.26-8.31        (m,  1H),    8.37     (t,  1H),  8.75
 (s, 2H),     9.14    (s, 1H),       9.34    (s, 1H).
Example 15-202:           1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyllphenoxy}-5-pyrimidinyl)-3-[2-fluoro-4
 (trifluoromethyl)phenyl]urea
TLC : Rf 0.28         (Ethyl Acetate);
1H-NMR
           (DMSO-d  6 )    : 5 1.20      (t,    3H),    2.68    (q,   2H),    5.57  (s,  2H),
7.25-7.46       (m,   5H),      7.51-7.58       (m,    2H),   7.94      (d,  1H),   8.25   (s,
1H),   8.38     (s, 1H),      8.75    (s, 2H),       9.34   (s, 1H).
Example 15-203:           1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2-(6-ethyl-3-pyridinyl)
                                               1 r-1

 5-(trifluoromethyl)phenyl]urea
TLC : Rf 0.34          (Methylene Chloride : Ethyl Acetate : Methanol =
 8 : 4 :1);
1 H-NMR    (DMSO-d     )   : 5 1.29     (t,   3H),
                    6                                  2.84    (q,  2H),  5.86   (brs,  2H),
7.26    (d,   2H),     7.39-7.54       (m,   6H),     7.80    (dd,   1H),  7.95   (d,  1H),
8.24    (s,   1H),     8.40    (s,   1H),     8.54      (d, 1H),     8.67  (s,  2H),   9.26
 (s, 1H).
Example 15-204: 1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2-(6-ethyl-3-pyridinyl)
5-(trifluoromethyl)phenyl]urea
TLC : Rf 0.34          (Methylene Chloride             : Ethyl Acetate : Methanol =
8 : 4 :1);
1H-NMR    (DMSO-d     )    : 5 1.29     (t,   3H),     2.84    (q,  2H),  5.58   (brs,  2H),
                    6
7.26   (d, 2H),       7.37    (dd, 1H),       7.41-7.55        (m,  5H),  7.80   (dd, iH),
7.94   (d,    1H),     8.24    (s,   1H),     8.40      (s,  1H),    8.54  (d,  1H),   8.67
 (s, 2H),     9.26 (s, 1H).
Example 15-205:           1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2-(5-ethyl-3-pyridinyl)
5-(trifluoromethyl)phenyllurea
TLC : Rf 0.33         (Methylene Chloride              : Ethyl Acetate : Methanol =
8 : 4 :1);
IH-NMR    (DMSO-d   6 )    : 5 1.23     (t,   3H),     2.70    (q,  2H),  5.86   (brs,  2H),
7.26    (d,   2H),     7.42    (d,   1H),     7.45-7.55         (m,  4H),  7.73   (s,  1H),
7.95   (dd,    1H),      8.23   (s,   1H),     8.38      (s,  1H),   8.47   (d, 1H),   8.54
 (d, 1H),    8.65     (s, 2H),      9.27    (s, 1H).
Example 15-206:           1-{2-[4-(2-amino-5-fluoro-3
                                               1 r- 1

 pyridinyl) phenoxy] -5-pyrimidinyl}-3- [2- (5-ethyl-3-pyridinyl)
 5-(trifluoromethyl)phenyllurea
 TLC : Rf 0.33           (Methylene Chloride : Ethyl Acetate : Methanol =
 8 : 4 :1);
 1H-NMR
            (DMSO-d  6  )   : 5 1.23          (t,    3H),    2.70    (q,   2H),    5.57   (brs,  2H),
 7.26   (d,    2H),     7.37       (dd,     1H),      7.47-7.56       (m,   4H),    7.73   (t,  1H),
 7.93   (d, 1H),         8.23      (s,    1H),       8.38    (s,   1H),     8.47    (d,  1H),   8.54
  (d, 1H),     8.65     (s, 2H),        9.27       (s, 1H).
Example 15-207:            l-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxyl-5-pyrimidinyl}-3-[2-isopropyl-5
  (trifluoromethyl)phenyl]urea
                                        CF3
          NH2       ONN          0
       N               Na      N   N
                               H   H
                                    H3C   CH 3
         F
TLC : Rf 0.38          (Ethyl Acetate);
1H-NMR
           (DMSO-d   6  )   : 5 1.22           (d, 6H),       3.14-3.27       (m, 1H),     5.57  (s,
2H),   7.26-7.33          (m, 2H),        7.36-7.57          (m, 5H),      7.94    (d, 1H),    8.12
8.15   (m, 1H),        8.43      (s, 1H),          8.74    (s, 2H),      9.28    (s, 1H).
Example 15-208:            1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2-(methylsulfonyl)-4
 (trifluoromethyl)phenyl]urea
TLC : Rf 0.62          (Ethyl Acetate);
1H-NMR     (DMSO-d   6  )   : 5 3.42           (s,    3H),    5.58    (s,   2H),    7.27-7.34    (m,
2H),   7.38     (dd,      1H),     7.52-7.60           (m,  2H),    7.94     (d,  1H),    8.05-8.12
 (m,  2H),     8.46-8.56          (m, 1H),          8.76    (s,  2H),     9.04    (s,   1H),   10.36
 (s, 1H).
                                                     1 CQ

 Example 15-209: 1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2-(4-cyano-1H-pyrazol-1
yl)-5-(trifluoromethyl)phenyliurea
TLC : Rf 0.20         (Hexane : Ethyl Acetate = 1 : 2);
1 H-NMR    (DMSO-d    )    : 6 5.85     (s,
                   6                         2H),     7.26    (d,  2H),   7.41   (dd,  1H),
7.50    (d,   2H),    7.58      (d, 1H),    7.73     (d,   1H),    7.94   (dd, 1H),    8.52
 (s,  1H),    8.54      (s,   1H),    8.69     (s,   2H),    8.80    (s,  1H),    9.13  (s,
1H),   9.63    (s,   1H).
Example 15-210: 1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2-(4-cyano-1H-pyrazol-1
yl)-5-(trifluoromethyl)phenyl]urea
TLC : Rf 0.16        (Hexane : Ethyl Acetate = 1 : 2);
'H-NMR    (DMSO-d  6  )    : 5 5.56     (s,  2H),     7.26   (d,   2H),   7.37   (dd,  1H),
7.52    (d,   2H),    7.58      (d,  1H),   7.73      (d,   1H),    7.92   (d,  1H),   8.52
 (s,  1H),    8.54      (s,   1H),   8.68      (s,   2H),    8.80    (s,  1H),    9.13  (s,
1H),   9.63    (s, 1H).
Example 15-211:           1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-phenylurea
Purity (LC-MS/ELSD) : 100%                (Retention Time : 0.77 minutes);
MASS   (ESI, Pos.)          : 433   (M + H)+;
1 H-NMR    (DMSO-d 6  )    : 6 5.86     (s,    2H),    6.98    (t,  1H),   7.23-7.32    (m,
4H),   7.41-7.55         (m,   5H),   7.95     (dd,   1H),    8.72    (s,  2H),   8.85  (s,
1H),   8.93    (s,  1H).
Example 15-212:           1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[5-(trifluoromethyl)-2
thienyl]urea
                                             I   r A

                          N               CF3
          NH2                   0     S\
       N N           O             N
                              H    H
          CI
 Purity      (LC-MS/ELSD) :           100%        (Retention Time        : 0.90 minutes);
MASS    (ESI, Pos.)             507      (M + H)+
 1H-NMR     (DMSO-d6 )         5 5.86         (s, 2H),      6.62-6.66 (m,       1H),  7.25-7.32
 (m,  2H),      7.38-7.45         (m,     2H),       7.49-7.55     (m,    2H),   7.95  (d,   1H),
 8.72  (s, 2H),         9.23    (s, 1H),           10.60   (s, 1H).
Example 15-213:            1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2-(4-morpholinyl)-3
pyridinyl]urea
 Purity      (LC-MS/ELSD) : 100%                 (Retention Time         : 0.71 minutes);
MASS   (ESI, Pos.)              519      (M + H)+
1
  H-NMR     (DMSO-d 6 )        5 2.96-3.03             (m,  4H),   3.80-3.86      (m, 4H),   5.86
 (s, 2H),      7.08     (dd, 1H),         7.25-7.32         (m,  2H),     7.43  (d, 1H),    7.48
7.55    (m,    2H),     7.95-8.02          (m,      2H),   8.14   (s,    1H),   8.28  (dd,   1H),
8.74   (s, 2H),        9.71     (s, 1H).
Example 15-214:            1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-(2,3-dihydro-1-benzofuran
7-yl)urea
Purity       (LC-MS/ELSD) : 100%                 (Retention Time         : 0.80 minutes);
MASS   (ESI, Pos.)           : 475       (M + H)*;
'H-NMR      (DMSO-d    6)   : 5    3.22       (t,     2H),   4.60    (t,   2H),  5.86   (s,  2H),
 6.76   (t,    1H),      6.89     (d,     1H),       7.24-7.30     (m,    2H),   7.42   (d,  1H),
7.49-7.55        (m,    2H),     7.77       (d,      1H),   7.95-7.98       (m,  1H),  8.35    (s,
1H),   8.71      (s, 2H),       9.24      (s, 1H).

 Example 15-215:           1-{2-[4-(2-amino-5-chloro-3
 pyridinyl)phenoxy]-5-pyrimidinyl}-3-(2,3-dihydro-1-benzofuran
 5-yl)urea
 Purity (LC-MS/ELSD) : 100%                       (Retention Time : 0.75 minutes);
MASS    (ESI, Pos.)              475     (M + H)+
1 H-NMR
           (DMSO-d   6  )       5 3.14          (t,   2H),   4.47   (t,  2H),  5.86  (s, 2H),
 6.67   (d,   1H),      7.06      (dd,       1H),     7.24-7.29     (m,  2H),  7.34-7.38   (m,
 1H),   7.42-7.44         (m,     1H),       7.48-7.55       (m,  2H),   7.95-7.98   (m, 1H),
8.65-8.97      (m, 4H).
Example 15-216: 2-[({2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxyl-5-pyrimidinyl}carbamoyl)aminol-N,N
dimethyl-4-(trifluoromethyl)benzenesulfonamide
                                        CF3
         NH2       O       OY
       N               Na     N    N
                              H    H         CH
                                       -SC,   CH3
         F                                  CH3
TLC : Rf 0.57          (Hexane : Ethyl Acetate = 1 : 4);
1 H-NMR
          (DMSO-d    6  )   : 5 2.76            (s,   6H),   5.57   (s,  2H),  7.26-7.32   (m,
2H),   7.38    (dd, 1H),           7.51-7.64           (m, 3H),    7.92-7.98   (m, 2H),  8.61
 (s, 1H),    8.74      (s, 2H),         8.99        (s, 1H),   10.31    (s, 1H).
Example 15-217:            1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxyl-5-pyrimidinyl}-3-[2
 (methylsulfonyl)phenyl]urea
Purity (LC-MS/ELSD) : 99%                       (Retention Time : 0.76 minutes);
MASS   (ESI, Pos.)           : 511       (M + H)+;
1 H-NMR
          (DMSO-d    6)     : 5     3.28        (s,   3H),   5.87   (s,  2H),  7.26-7.34   (m,
3H),   7.42-7.45          (m,    1H),        7.49-7.55       (m,  2H),   7.66-7.73   (m, 1H),

 7.85    (dd,    1H),     7.95-7.98      (m, 1H),       8.15    (d,    1H),  8.75    (s, 2H),
 8.77   (s,    1H),     10.13    (s,  1H).
 Example 15-218: 1-{2-[4-(2-amino-5-fluoro-3
 pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2
  (methylsulfonyl)phenyl]urea
 Purity (LC-MS/ELSD) : 100%                 (Retention Time : 0.69 minutes);
MASS    (ESI, Pos.)            495   (M + H)+
 1 H-NMR
            (DMSO-d   6 )   : 5 3.28      (s,    3H),   5.57    (s,    2H),  7.25-7.34     (n,
 3H),   7.38     (dd, 1H),       7.51-7.57        (i, 2H),    7.69      (td, 1H),   7.85   (dd,
 1H),   7.94     (d,    1H),    8.15    (d,    1H),    8.75    (s,    2H),   8.77   (s,  1H),
 10.13    (s, 1H).
Example 15-219:            1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-[2
 (methylsulfonyl)phenyl]urea
Purity      (LC-MS/ELSD) : 100%             (Retention Time : 0.85 minutes);
MASS    (ESI, Pos.)          : 545 (M + H)+;
'H-NMR     (DMSO-d   6  )   : 5 3.28     (s,    3H),    6.49    (s,    2H),  7.26-7.33     (m,
3H),    7.50-7.59         (n, 3H),    7.69     (td, 1H),      7.85      (dd, 1H),   8.15   (d,
1H),   8.26-8.30          (m, 1H),    8.75-8.81        (m, 3H),     10.13    (s, 1H).
Example 15-220:            1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-(5-chloro-2
methylphenyl)urea
Purity (LC-MS/ELSD) : 100%                  (Retention Time : 0.82 minutes);
MASS    (ESI, Pos.)          : 465   (M + H)+
1H-NMR
           (DMSO-d    6)    : 5 2.22    (s,    3H),    5.57   (s,    2H),   7.00   (dd,  1H),
7.20    (d,    1H),     7.28    (d,  2H),     7.38     (dd,  1H),     7.52   (d,  2H),   7.93
                                               1  CZ-7

  (d, 1H),    7.97       (d,   1H),    8.26     (s,   1H),  8.74    (s,  2H),   9.30    (s,
 1H).
 Example 15-221:          1-(2-{4-[2-amino-5-(trifluoromethyl)-3
 pyridinyl]phenoxy}-5-pyrimidinyl)-3-[3'-(hydroxymethyl)-4
  (trifluoromethyl)-2-biphenylyllurea
 Purity     (LC-MS/ELSD) : 99%            (Retention Time : 1.01 minutes);
MASS   (ESI, Pos.)           : 641   (M + H)+;
 1H-NMR    (DMSO-d6 ) : 5 4.58            (d, 2H),     5.28   (t, 1H),    6.48   (s, 2H),
 7.22-7.58     (m,    11H),      8.06    (s, 1H),      8.27   (s, 1H),   8.42    (s, 1H),
 8.66  (s, 2H),       9.42     (s, 1H).
Example 15-222:           1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyllphenoxy}-5-pyrimidinyl)-3-{5-chloro-2-[3
 (trifluoromethyl)-1H-pyrazol-1-yllphenyl}urea
 Purity (LC-MS/ELSD) : 100%                 (Retention Time : 1.06 minutes);
MASS   (ESI, Pos.)          : 635    (M + H)*;
'H-NMR     (DMSO-d  6  )   : 5 6.48      (s,   2H),    7.08   (d,  1H),   7.22-7.35     (m,
 3H),  7.43-7.59         (m,   4H),   8.18     (d, 1H),    8.23-8.29    (m,   1H),   8.36
8.42   (m, 2H),       8.66     (s, 2H),      9.44    (s, 1H).
Example 15-223:           2-{[(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)carbamoyl]amino}-N-methyl-4
 (trifluoromethyl)benzenesulfonamide
TLC : Rf 0.36         (Hexane : Ethyl Acetate = 1 : 4);
1H-NMR     (DMSO-d  6 )    : 5 3.27-3.38         (m,  3H),  6.49    (s, 2H),   7.27-7.34
 (m,  2H),    7.49-7.63         (m,   4H),     7.93-7.99     (m,  1H),    8.02-8.13     (m,
1H),   8.28     (s,    1H),     8.56    (s,   1H),    8.75   (s,  2H),   8.90    (s,  1H),
10.23   (s, 1H).

Example 15-224: 2-[({2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}carbamoyl)amino]-N,N
dimethyl-4-(trifluoromethyl)benzenesulfonamide
Purity (LC-MS/ELSD) : 100%                (Retention Time : 0.98 minutes);
MASS    (ESI, Pos.)            608  (M + H)*;
1 H-NMR
           (DMSO-d  6  )    : 5 2.76    (s,    6H),    5.87   (s,  2H),  7.28   (d, 2H),
7.43    (d,    1H),    7.52     (d,  2H),     7.60     (d,  1H),   7.92-7.98    (m, 2H),
8.61    (s, 1H),      8.75     (s, 2H),     8.99    (s, 1H),     10.31  (s, 1H).
Example 15-225: 1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyljphenoxy}-5-pyrimidinyl)-3-[5-methyl-2
 (methylsulfonyl)phenyl]urea
Purity      (LC-MS/ELSD) : 100%           (Retention Time : 0.92 minutes);
MASS   (ESI, Pos.)          : 559 (M + H)*;
1 H-NMR
           (DMSO-d  6 )    : 5 2.37    (s,     3H),    3.24   (s,  3H),  6.49   (s, 2H),
7.12    (d,    1H),    7.28     (d,  2H),    7.52     (d,   2H),   7.55  (d,  1H),  7.73
 (d,  1H),     7.99     (s,   1H),   8.26-8.29        (m,   1H),   8.72  (s,  1H),  8.75
 (s, 2H),     10.12      (s, 1H).
Example 15-226:           1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-[5-chloro-2
(methylsulfonyl)phenyl]urea
Purity (LC-MS/ELSD) : 100%                (Retention Time : 0.97 minutes);
MASS   (ESI, Pos.)          : 579   (M + H)+.
Example 15-227:           1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[5-fluoro-2
(methylsulfonyl)phenyl]urea
Purity (LC-MS/ELSD) : 100%                (Retention Time : 0.85 minutes);
                                              1 C (

 MASS   (ESI, Pos.)            529   (M + H)+
 1H-NMR    (DMSO-d  6  )      5 3.15      (d,    3H),     5.87   (s,    2H),  7.10-7.19    (m,
 1H),  7.28     (d,   2H),      7.43   (d,     1H),     7.52   (d,    2H),   7.92  (dd,  1H),
 7.96   (d, 1H),      8.11      (dd, 1H),       8.75     (s, 2H),     8.95   (s, 1H),   10.29
  (s, 1H).
 Example 15-228:          1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-[2-(methylthio)-5
 (trifluoromethyl)phenyl]urea
 TLC : Rf 0.30        (Hexane : Ethyl Acetate = 1                    : 2);
 1H-NMR    (DMSO-d  6 )    :  5 2.53      (s,    3H),     6.47   (s,   2H),   7.27  (d,  2H),
 7.40   (dd,   1H),      7.48-7.57       (m,    4H),      8.18   (s,   1H),   8.24-8.28    (m,
 1H),  8.44    (s, 1H),       8.73    (s, 2H),         9.64   (s, 1H).
Example 15-229:           1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxyl-5-pyrimidinyl}-3-[4-fluoro-3
 (trifluoromethyl)phenyl]urea
 Purity (LC-MS/ELSD) : 100%                 (Retention Time           : 0.94 minutes);
MASS   (ESI, Pos.)          : 519    (M + H)+;
1
  H-NMR    (DMSO-d6 )      : 5 5.86      (s,     2H),     7.27   (d,    2H),  7.40-7.57    (m,
 4H),  7.64-7.72         (m,   1H),   7.94-7.99          (m,  2H),    8.73   (s, 2 H),   9.03
 (s, 1H),     9.33    (s, 1H).
Example 15-230:           1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-[3'-(1-hydroxyethyl)-4
 (trifluoromethyl)-2-biphenylyl]urea
 Purity (LC-MS/ELSD) : 100%                 (Retention Time           : 1.05 minutes);
MASS   (ESI, Pos.)          : 655    (M + H)*;
'H-NMR     (DMSO-d  6 )    : 5    1.36     (d,     3H),    4.79    (quint,    1H),  5.20   (d,
                                                  i 7n

 1H),  6.48      (s,    2H),      7.27    (d,     2H),      7.27-7.35        (m,   1H),   7.39-7.58
  (m, 8H),     8.09       (s,    1H),    8.27        (d,    1H)),  8.37       (s,   1H),    8.66   (s,
2H),   9.40     (s,    1H).
Example 15-231:             1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-[5-chloro-2
  (methylthio)phenyllurea
TLC : Rf 0.55          (Ethyl Acetate);
'H-NMR     (DMSO-d   6  )    : 5    2.42     (s,     3H),     6.48   (s,    2H),     7.08-7.14     (m,
1H),   7.27      (d,    2H),      7.43     (d,     1H),      7.51   (d,    2H),     7.55    (d,  1H),
8.06    (d,   1H),       8.25-8.28        (m,     1H),      8.48    (s,    1H),     8.73    (s, 2H),
9.76   (s, 1H).
Example 15-232:            1-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[5-chloro-2
 (methylthio)phenyl]urea
TLC : Rf 0.42          (Ethyl Acetate);
1 H-NMR    (DMSO-d   6 )    : 5 2.42        (s,    3H),     5.57    (s,   2H),     7.10    (dd,  1H),
7.27    (d,   2H),     7.37       (dd,   1H),       7.43      (d,  1H),    7.52      (d,  2H),   7.93
 (d,  1H),    8.06        (d,   1H),     8.48        (s,    1H),   8.73       (s,   2H),    9.76   (s,
1H).
Example 15-233: l-{2-[4-(2-amino-5-fluoro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[5-chloro-2
 (methylsulfinyl)phenyl]urea
TLC : Rf 0.61          (Ethyl Acetate : Methanol = 9 : 1);
1H-NMR     (DMSO-d   6  )    : 5 2.85        (s,     3H),     6.48   (s,    2H),     7.27    (d, 2H),
7.32-7.41       (m,    2H),      7.53     (d,     2H),      7.67    (d,    1H),     7.93    (d,  1H),
8.00   (d, 1H),        8.73     (s, 2H),         9.23      (s, 1H),     9.69      (s, 1H).
                                                    1 '7 1

Example 15-234: 1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxyl-5-pyrimidinyl)-3-[2-(1-methyl-1H-pyrazol-5
yl)-5-(trifluoromethyl)phenyl]urea
 Purity (LC-MS/ELSD) : 100%                  (Retention Time : 1.02 minutes);
MASS    (ESI, Pos.)             615   (M + H)+
1 H-NMR     (DMSO-d  6  )      5 3.65      (s,     3H),        6.48     (s,  2H),  7.27   (d, 2H),
7.46-7.61        (m,    6H),     7.62    (d,     1H),         8.10    (s,    1H), 8.27    (d, 1H),
8.56    (s, 1H),       8.68     (s, 2H),       9.50        (s, 1H).
Example 15-235:            2-[({2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}carbamoyl)amino]-N-ethyl-N
methyl-4-(trifluoromethyl)benzenesulfonamide
TLC : Rf 0.65          (Ethyl Acetate);
1H-NMR     (DMSO-d   6  )   : 5 1.04      (t,      3H),        2.80     (s,  3H),  3.20   (q, 2H),
5.85    (s,     2H),     7.26-7.32       (m,     2H),         7.43     (d,   1H),  7.50-7.55    (m,
2H),   7.57-7.62          (m,   1H),    7.94-8.01              (m,   2H),    8.54-8.58    (m, 1H),
8.75    (s, 2H),      8.92      (s, 1H),      10.30         (s, 1H).
Example 15-236:            1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-(tetrahydro-2H-pyran-4
yl)urea
Purity      (LC-MS/ELSD) : 100%              (Retention Time : 0.65 minutes);
MASS    (ESI, Pos.)          : 441    (M + H)+
IH-NMR       (DMSO-d 6 )      : 5    1.32-1.50             (m,     2H),     1.71-1.83    (m,  2H),
3.32-3.42        (m,   2H),      3.60-3.89          (m,     3H),      5.85    (s, 2H),   6.48   (d,
1H),   7.22-7.28          (m,   2H),    7.42       (d,      1H),     7.47-7.54     (m,  2H),  7.95
 (d,  1H),     8.54    (s,    1H),   8.65      (s,       2H).
Example 15-237: rel-1-{2-[4-(2-amino-5-chloro-3
                                                  1  '7 ')

pyridinyl)phenoxy]-5-pyrimidinyl}-3-[                         (1R,2S,5R) -2-isopropyl-5
methylcyclohexyl]urea
                                     CH3
         NH2   ~     YN       0
      N NH               N-N)KN
                            H   H
                                 H3C   CH3
         ci
Purity     (LC-MS/ELSD) : 100%               (Retention Time              1.01 minutes);
MASS   (ESI, Pos.)         : 495 (M + H)+;
1H-NMR      (DMSO-d 6 )        5    0.70-1.15         (m,     12H),    1.32-2.04     (m,  6H),
3.31-3.50       (m, 1H),       5.85      (s,   2H),      6.21      (d,  1H),   7.21-7.28    (m,
2H),   7.42      (d,   1H),     7.47-7.54         (m,    2H),     7.95    (d,  1H),  8.48   (s,
1H),  8.65-8.69         (m, 2H).
Example 15-238:          1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-(2-hydroxycyclohexyl)urea
Purity (LC-MS/ELSD) : 100%                   (Retention Time : 0.67 minutes);
MASS   (ESI, Pos.)         : 455      (M + H)+;
1H-NMR      (DMSO-d6 )          6    1.00-1.35         (m,     4H),    1.45-1.70     (m,  2H),
1.78-1.97       (m,   2H),     3.15-3.38          (m,    2H),     4.68    (d,  1H),  5.85   (s,
2H),  6.28      (d,   1H),     7.22-7.28         (m,    2H),     7.41    (d,  1H),  7.47-7.54
 (m, 2H),     7.94-7.98       (m, 1H),        8.62-8.69         (m, 3H).
Example 15-239:          1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-(2-hydroxycyclohexyl)urea
Purity    (LC-MS/ELSD) : 100%                (Retention Time : 0.65 minutes);
MASS  (ESI, Pos.)          : 455      (M + H)+.
Example 15-240:          2-[({2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinylicarbamoyl)amino]-N,N-diethyl
4-(trifluoromethyl)benzenesulfonamide
                                                - -70

TLC : Rf 0.45             (Chloroform : Methanol = 19 : 1);
  H-NMR     (DMSO-d     6  )    :  5 1.03    (s,     6H),     3.30   (q,   4H),     5.87   (s, 2H),
 7.25-7.31       (m,      2H),      7.43   (d,    1H),      7.49-7.56      (m,    2H),   7.58   (dd,
 1H),   7.96      (d,      1H),      8.00   (d, 1H),         8.49   (d,   1H),     8.75    (s, 2H),
 8.84   (s,    1H),      10.30       (s, 1H).
Example 15-241:                1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxyl-5-pyrimidinyl}-3-[5-chloro-2-(4-cyano-1H
pyrazol-1-yl)phenyl]urea
TLC : Rf 0.40             (Hexane : Ethyl Acetate = 1                   : 2);
1
  H-NMR     (DMSO-d     6  )    : 5   5.85   (s,    2H),      7.23-7.32      (m,   3H),   7.42   (d,
1H),    7.47-7.54             (m,   3H),   7.95      (d, 1H),       8.24    (d,    1H),   8.48   (s,
1H),   8.56     (s, 1H),           8.68   (s, 2H),         9.04   (s, 1H),      9.56    (s, 1H).
Example 15-242:               2-[({2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}carbamoyl)amino]-N
methylbenzenesulfonamide
Purity      (LC-MS/ELSD) : 100%                 (Retention Time          : 0.80 minutes);
MASS    (ESI, Pos.)              : 526   (M + H)*;
1
  H-NMR    (DMSO-d    6   )    : 5 2.46     (s,    3H),      6.04   (brs,    2H),     7.19-7.33    (m,
3H),   7.47-7.65             (m,    4H),   7.72-7.80          (m,  2H),   7.98      (d,  1H),  8.12
 (d, 1H),     8.71-8.79             (m, 3H),     10.06      (s, 1H).
Example 15-243:               2-[({2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}carbamoyl)amino]-N-propyl-4
 (trifluoromethyl)benzenesulfonamide
Purity      (LC-MS/ELSD) : 100%                 (Retention Time          : 1.01 minutes);
MASS   (ESI, Pos.)               : 622   (M + H)*;
'H-NMR (DMSO-d6 ) : 5 0.77                  (t, 3H),         1.32-1.47      (m, 2H),     2.77-2.88
                                                   1  '7 A

 (m,  2H),     6.15      (brs,     2H),    7.27-7.35          (m, 2H),  7.50-7.62     (m, 4H),
7.96-8.04        (m,     2H) ,    8.17-8.25         (m,     1H),   8.54  (s,   1H),  8.76   (s,
2H),   8.89     (s,     1H),     10.22     (s,   1H).
Example 15-244:             2-[({2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}carbamoyl)amino]-N,N
dimethylbenzenesulfonamide
Purity       (LC-MS/ELSD) : 100%               (Retention Time : 0.85 minutes);
MASS   (ESI, Pos.)               540    (M + H)*;
'H-NMR      (DMSO-d   6  )    : 5 2.69       (s,   6H),      5.86   (s, 2H),   7.25-7.32    (m,
3H),   7.43      (d,    1H),      7.49-7.56        (m,     2H),   7.62-7.78     (m, 2H),  7.96
 (d,  1H),     8.14       (d,   1H),     8.74     (s,     2H),    8.80  (s,   1H),  10.14   (s,
1H).
Example 15-245: 2-[({2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}carbamoyl)amino]-N-(2
hydroxypropyl)-N-methyl-4-(trifluoromethyl)benzenesulfonamide
Purity (LC-MS/ELSD) : 100%                     (Retention Time : 0.97 minutes);
MASS   (ESI,     Pos.)        : 652     (M + H)+.
Example 15-246: 2-{[(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)carbamoyl]amino}-N-ethyl-N
methyl-4-(trifluoromethyl)benzenesulfonamide
Purity (LC-MS/ELSD) : 100%                     (Retention Time : 1.07 minutes);
MASS   (ESI, Pos.)            : 656     (M + H)+;
  H-NMR    (DMSO-d    6 )    : 5 1.04        (s,   3H),      2.80   (s, 3H),   3.20   (q, 2H),
6.49    (s,    2H),      7.25-7.32         (m,   2H),       7.50-7.64    (m,   4H),  7.97   (d,
1H),   8.26-8.29           (m,    1H),    8.55      (d,     1H),   8.75   (s,  2H),  8.93   (s,
1H),   10.31      (s,     1H).
                                                  1  -7 r

 Example 15-247: 2-{[(2-{4-[2-amino-5-(trifluoromethyl)-3
 pyridinyllphenoxy}-5-pyrimidinyl)carbamoyl]amino}-N,N-diethyl
 4-(trifluoromethyl)benzenesulfonamide
 Purity (LC-MS/ELSD) : 100%               (Retention Time : 1.09 minutes);
MASS    (ESI, Pos.)           670   (M + H)+;
  H-NMR    (DMSO-d  6 )      5 1.03     (s,   6H),  3.27-3.35   (m,  4H),  6.48  (s,
 2H),  7.25-7.32        (m,   2H),   7.50-7.61     (m, 4H),   8.00  (d, 1H),   8.27
 8.30   (m,   1H),    8.47-8.49        (m,  1H),   8.75   (s, 2H),  8.85   (s,  1H),
 10.30   (s, 1H).
Example 15-248:          1-(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyl]phenoxy}-5-pyrimidinyl)-3-[2-(1-azetidinylsulfonyl)
 5-(trifluoromethyl)phenyl]urea
Purity      (LC-MS/ELSD) : 100%           (Retention Time : 1.05 minutes);
MASS   (ESI, Pos.)         : 654    (M + H)+;
'H-NMR     (DMSO-d 6 )    : 5 2.02-2.15        (m, 2H),  3.77-3.82    (m, 4H),  6.49
 (s,  2H),    7.25-7.32        (m,   2H),   7.49-7.66    (m,  4H),  7.99   (d, 1H),
8.26-8.29       (m,   1H),     8.68   (d,   1H),   8.75   (s, 2H),  8.94   (s,  1H),
10.35    (s, 1H).
Example 15-249: 2-{[(2-{4-[2-amino-5-(trifluoromethyl)-3
pyridinyljphenoxy}-5-pyrimidinyl)carbamoyl]amino}-N-(2
hydroxypropyl)-N-methyl-4-(trifluoromethyl)benzenesulfonamide
LC-MS/ELSD : Retention Time : 1.02 minutes;
MASS   (ESI, Pos.)         : 686    (M + H)+.
Example 15-250: 1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2-(3-hydroxy-3
methylbutyl)-5-(trifluoromethyl)phenyl]urea
                                             1 -7C

Purity      (LC-MS/ELSD) : 100%            (Retention Time          : 0.95 minutes);
MASS    (ESI, Pos.)            587   (M + H)*;
'H-NMR (DMSO-d6 )             5 1.17     (s, 6H),       1.61-1.70      (m, 2H),    2.63-2.75
 (m,  2H),    4.37      (s,    1H),    5.86    (s,    2H),    7.27    (d,  2H),    7.32-7.44
 (m,  3H),    7.51      (d,    2H),    7.95     (d,    1H),    8.09    (s,  1H),    8.39   (s,
1H),   8.74    (s, 2H),        9.28    (s, 1H).
Example 15-251:           1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2-(3-hydroxy-3-methyl-1
butyn-1-yl) -5- (trifluoromethyl)phenyl]urea
Purity      (LC-MS/ELSD) :          100%   (Retention Time : 1.01 minutes);
MASS   (ESI, Pos.)             583   (M + H)+;
1
  H-NMR    (DMSO-d 6  )       5 1.54     (s,    6H),     5.60   (s,   1H),  5.86     (s, 2H),
7.28    (d, 2H),     7.35       (dd,   1H),    7.43      (d,  1H),   7.52    (d,   2H),  7.58
 (d,  1H),    7.96      (d,    1H),    8.32     (s,    1H),   8.35     (d,  1H),    8.74   (s,
2H),   9.84    (s, 1H).
Example 16
       The similar          procedures       as Example       6 -+   Example     7 were
carried out with 4-amino-5-bromopyrimidine in place of 3
bromo-5-chloropyridin-2-amine, and a corresponding carbamate
or isocyanate compound in place of the compound produced in
Example 3 to give the present compounds having the following
physical characteristics.
Example 16-1:        1-(2-(4-(4-aminopyrimidin-5
yl)phenoxy)pyrimidin-5-yl)-3-(2-chloro-5
(trifluoromethyl)phenyl)urea
                                               1 -7-7

                                         CF3
        N  ~~             N ~NN      N
                                H    H
           N
 TLC : Rf 0.58           (Ethyl Acetate                Methanol        =   19   : 1);
 1H-NMR     (DMSO-d    6  )  : 5     6.66     (s,    2H),       7.29    (d,    2H),   7.40   (d, 1H),
 7.48    (d, 2H),         7.75      (d, 1H),        8.03        (s, 1H),      8.36    (s, 1H),   8.57
 (s,  1H),     8.75-8.79 (m,            3H),      9.72      (s,   1H).
Example 16-2:            1-(2-(4-(4-aminopyrimidin-5
yl)phenoxy)pyrimidin-5-yl)-3-(2-fluoro-5
 (trifluoromethyl)phenyl)urea
TLC   : Rf 0.51          (Ethyl Acetate            : Methanol =            19   : 1);
'H.-NMR     (DMSO-d    6  )  : 5     6.67     (s,    2H),       7.28    (d,    2H),   7.43-7.54    (m,
4H),    8.03     (s,      1H),     8.36      (s,    1H),      8.52     (d,    1H),   8.75   (s,  2H),
9.10    (s, 1H),         9.30     (s, 1H).
Example 16-3: 1-(2-(4-(4-aminopyrimidin-5
yl)phenoxy)pyrimidin-5-yl)-3-(2-(pyridin-3-yl)-5
 (trifluoromethyl)phenyl)urea
                                       CF3
          NH2        O.N~
                     0 ON        0
       N                       N    N
                               H    H
          N
TLC   : Rf     0.45       (Ethyl Acetate             : Methanol          : Aqueous Ammonia            9
: 1:   0.5);
'H-NMR (DMSO-d6 )           : 5      6.66     (s,    2H),       7.26    (d, 2H),      7.45-7.58    (m,
5H),   7.89     (d,      1H),      8.03     (s,    1H),       8.24     (s,    lH),   8.35   (s,  1H),
8.38    (s, lH),        8.60-8.68         (m, 4H),         9.24    (s, 1H).
Example 16-4: 1-(2-(4-(4-aminopyrimidin-5
                                                    1 -7 0

 yl) phenoxy) pyrimidin-5-yl) -3-                 (3- (trifluoromethyl) phenyl) urea
 TLC : Rf 0.51            (Ethyl Acetate           : Methanol         : Aqueous Ammonia =           9
  : 1: 0.5);
 'H-NMR    (DMSO-d   6  )   : 5 6.67       (s,    2H),      7.27-7.34        (m, 3H),   7.47-7.54
  (m, 3H),     7.62       (d,   1H),     7.97      (s,     1H),   8.03       (s,  1H),   8.36   (s,
 1H),   8.75    (s,    2H),     8.99    (s,     1H),     9.32   (s,     1H).
Example 16-5:          1-(2-(4-(4-aminopyrimidin-5
yl)phenoxy)pyrimidin-5-yl)-3-(2-phenyl-5
  (trifluoromethyl)pyridin-3-yl) urea
                                      CF3
         NH 2
               N   ~                    N
                              H   H
TLC : Rf 0.25          (Ethyl Acetate);
1 H-NMR    (DMSO-d   6  )   : 5    6.65     (s,    2H),     7.26     (d,   2H),   7.45-7.67     (m,
7H),    8.02     (s,    1H),     8.35     (s,    1H),      8.55     (s,   1H),    8.67   (s,  2H),
8.72    (s, 1H),      8.74      (s, 1H),        9.60     (s, 1H).
Example 16-6: 1-(2-(4-(4-aminopyrimidin-5
yl) phenoxy) pyrimidin-5-yl) -3- (2- (3,4-dimethylphenyl) -5
 (trifluoromethyl)pyridin-3-yl) urea
TLC : Rf 0.68          (Ethyl Acetate : Methanol = 9 : 1);
1H-NMR
           (DMSO-ds)        : 5 2.31        (s,    6H),     6.65     (s,   2H),   7.25-7.48     (m,
7H),   8.02     (s,    1H),     8.35-8.40          (m,    2H),   8.60-8.65        (m,  3H),   8.77
 (s, 1H),     9.55     (s, 1H).
Example 16-7:         1-(2-(4-(4-aminopyrimidin-5
yl)phenoxy)pyrimidin-5-yl) -3- (3- (tert-butyl)-1- (2,3-dihydro
1H-inden-5-yl) -lH-pyrazol-5-yl) urea
                                                  '1 70(

                                      H3C  CH 3
                                             CH3
          NH2       O:t         0     I~
        N             N       N    N    N
                              H    H
          N
TLC : Rf 0.49          (Ethyl Acetate                    Methanol    =    10       1);
  H-NMR     (DMSO-d 6  )    : 5    1.25       (s,     9H),    2.05   (quint.,        2H),   2.85-2.95
 (m,  4H),     6.33     (s,    1H),      6.65        (s,    2H),   7.18-7.30         (m,   3H),   7.30
7.36    (m,    2H),     7.46      (d,     2H),       8.02     (s,   1H),     8.35      (s,  1H),   8.56
 (s, 1H),      8.66   (s, 2H),          9.19        (s, 1H).
Example 16-8:         1-(2-(4-(4-aminopyrimidin-5
yl)phenoxy)pyrimidin-5-yl) -3- (3- (tert-butyl) -1- (o-tolyl) -1H
pyrazol-5-yl)urea
TLC : Rf 0.48         (Ethyl Acetate                 : Methanol = 9          : 1);
1
  H-NMR     (DMSO-d 6  )    :  5 1.25          (s,     9H),    1.99   (s,     3H),    6.34    (s,  1H),
6.66    (s,    2H),     7.25      (d,     2H),       7.31-7.48       (m,     6H),     8.02    (s,  1H),
8.35 (s, 1H),         8.40      (s, 1H),           8.64     (s, 2H),      9.07     (s, 1H).
Example 17:        3-bromo-5-chloropyrazolo[1,5-a]pyrimidine
       A solution of 5-chloropyrazolo[1,5-a]pyrimidine (9 g) in
THF   (147    mL)   was stirred            at      5*C.     The reaction mixture was
added with N-bromosuccinimide                          (11 g)     and stirred at room
temperature for 1 hour.                    The reaction mixture was added with a
sodium hydrogen sulfite aqueous solution and stirred for 5
minutes followed by distillation of THF under reduced
pressure.        The obtained residue was added with a saturated
sodium carbonate aqueous solution and extracted with ethyl
acetate.       The obtained organic layer was washed twice with a
                                                      ion

 saturated sodium carbonate aqueous solution, once with water
and once with a saturated sodium chloride aqueous solution.
The obtained organic layer was dried over sodium sulfate and
filtered followed by distillation of the solvent to give the
titled compound having the following physical characteristics
 (13.6 g).
TLC : Rf 0.40       (Hexane : Ethyl Acetate = 4 : 1);
'H-NMR  (DMSO-d  6  ) : 5 6.85  (d,  1H), 8.12 (s, 1H), 8.54  (d, 1H).
Example 18:    3-bromo-5-(pyrrolidin-1-yl)pyrazolo[1,5
a]pyrimidine
             N'N
         N N     Br
      To a solution of the compound produced in Example 17         (2.5
g) in dimethylsulfoxide (hereinafter abbreviated as DMSO)          (20
mL) were added triethylamine (2.25 mL) and pyrrolidine          (1.3
mL) and the mixture was stirred at room temperature for 1
hour.   The reaction mixture was poured to a sodium hydrogen
carbonate aqueous solution and extracted with ethyl acetate.
The obtained organic layer was washed with water and a
saturated sodium chloride aqueous solution and dried over
anhydrous sodium sulfate.         The obtained organic layer was
filtered followed by distillation of the solvent.          The obtained
residue was added with tert-butyl methyl ether and filtered to
give the titled compound having the following physical
characteristics       (2.49 g).
TLC : Rf 0.30       (Hexane : Ethyl Acetate = 2 : 1);
                                      101

 1
   H-NMR     (DMSO-d     6  )   : 5 1.95-2.12           (br s,    4H),   3.35-3.85    (br s, 4H),
 6.14    (d,     1H),      7.80       (s,    1H),  8.18     (d,  1H).
 Example 19: 2-(4-(5-(pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin
 3-yl)phenoxy)pyrimidin-5-amine
         N
             N         O          NH2
               N
                 D
        The similar procedure as Example 6 was carried out with
the compound produced in Example 18                             in place of 3-bromo-5
chloropyridin-2-amine to give the titled compound having the
following physical characteristics.
TLC    : Rf      0.52        (Dichloromethane             :  Ethyl Acetate       : Methanol  = 8
 : 4 : 1);
1
  H-NMR     (DMSO-d     6  )   : 5      1.94-2.08       (br s,    4H),  3.40-3.74     (br s, 4H),
5.05-5.35         (br s,         2H),      6.41   (d,    1H),   7.04   (d,  2H),   7.96  (s, 2H),
8.05    (d, 2H),          8.33       (s, 1H),      8.61     (d, 1H).
Example 20:           1-(2-(lH-pyrazol-1-yl) -5- (trifluoromethyl)phenyl)
3-(2-(4-(5-(pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3
yl)phenoxy)pyrimidin-5-yl)urea
                                            CF3
                                  H    H
            NI                              N
          NN          O      N
            N       N                      N
                                          NJ
                D
        The similar procedure as Example 7 was carried out with
the compound produced in Example 19                             in place of the compound
                                                      1 Q0

 produced in Example 6 to give the present compound having the
 following physical characteristics.
 TLC : Rf 0.50 (Ethyl Acetate);
 1 H-NMR
            (DMSO-d   6 )    : 5 1.94-2.08         (br s,   4H),   3.40-3.72      (br s,  4H),
 6.42    (d,    1H),    6.67     (dd,     1H),  7.15    (d,  2H),   7.51     (dd,  1H),  7.74
  (d,  1H),      7.95     (d,    1H),     8.10   (d,   2H),   8.36     (s,   1H),   8.40   (d,
 1H),   8.58      (d,   1H),     8.62     (d,  1H),   8.67   (s,   2H),    9.68   (br s,  1H),
 9.92    (br s, 1H).
Example 21
        The similar procedure as Example 7 was carried out with
the compound produced in Example 19 or a corresponding amine
compound in place of the compound produced in Example 19, and
the compound produced in Example 3 or a corresponding
carbamate or isocyanate compound in place of the compound
produced in Example 3 to give the present compounds having the
following physical characteristics.
Example 21-1: 1-(2-(4-(5-(azetidin-1-yl)pyrazolo[1,5
a]pyrimidin-3-yl)phenoxy)pyrimidin-5-yl)-3-(2-(pyridin-3-yl)
5-(trifluoromethyl)phenyl)urea
                                      CF3
                      0     Nk
        NNI                    H  H
                  o
              N
TLC : Rf 0.22           (Chloroform : Methanol = 19 : 1);
1H-NMR     (DMSO-d 6 )      : 5 2.32-2.42         (m,  2H),   4.12-4.18       (m,  4H),  6.23
 (d,   1H),     7.10-7.16         (m,    2H),   7.46-7.58      (m,   3H),    7.86-7.90    (m,

 1H),  8.03-8.09            (m, 2H),      8.22      (s,    1H),    8.35-8.39      (m, 2H),    8.60
 8.68  (m,    5H),      9.21     (s,  1H).
Example 21-2: 1-(2-(4-(5-(azetidin-1-yl)pyrazolo[1,5
a]pyrimidin-3-yl)phenoxy)pyrimidin-5-yl) -3- (2- (1-methyl-1H
pyrazol-5-yl)-5-(trifluoromethyl)phenyl)urea
                                      CF 3
                    O      N       N
            N          N ""N     ,N
                               H   H
         N                               N-C3
                                       N
                    N
TLC : Rf 0.33           (Ethyl Acetate);
'H-NMR     (DMSO-d    6  )   : 5 2.37        (t,     2H),     3.65    (s,   3H),   4.15   (t,  4H),
6.23    (d,   1H),       6.44     (d,    1H),      7.14      (d,   2H),     7.48   (d,  2H),   7.61
 (d,  1H),     8.04-8.10          (m,   3H),       8.36      (s,   1H),     8.55   (s,  1H),   8.62
 (d, 1H),     8.64      (s, 2H),      9.46       (s, 1H).
Example 21-3:           1-(2-(4-(5-(azetidin-1-yl)pyrazolo[1,5
a]pyrimidin-3-yl)phenoxy)pyrimidin-5-yl) -3- (2- (3-methyl-lH
pyrazol-1-yl)-5-(trifluoromethyl)phenyl)urea
TLC : Rf 0.66           (Ethyl Acetate);
1H-NMR     (DMSO-d    6 )    : 5 2.35-2.44             (m,   5H),    4.15     (t,  4H),  6.24    (d,
1H),   6.44     (d,     1H),     7.14      (d,    2H),      7.48    (dd,    1H),   7.69   (d,  1H),
8.06   (d,    2H),       8.26     (d,   1H),       8.36      (s,   1H),     8.56   (d, 1H),    8.62
 (d, 1H),     8.67      (s, 2H),      9.78       (s, 1H),        9.87     (s, 1H).
Example 21-4: l-(2-(1H-pyrazol-1-yl)-5
 (trifluoromethyl)phenyl)-3-(2-(4-(5-(azetidin-1
yl) pyrazolo [1,5-a] pyrimidin-3-yl) phenoxy) pyrimidin-5-yl) urea
TLC : Rf 0.47           (Ethyl Acetate);

 1
   H-NMR       (DMSO-d   6   )    :    5 2.37       (t,       2H),    4.15      (t,    4H),  6.24   (d, 1H),
 6.68     (d,      1H),     7.14        (d,   2H),        7.51       (dd,    1H),      7.74   (d, 1H),  7.95
  (d,   1H),        8.07       (d,     2H),      8.36        (s,   1H),      8.40      (d,  1H),   8.58-8.67
  (m,  4H),        9.68     (s,      1H),    9.92        (s,     1H).
 Example 21-5:             1-(2-(4-(5-(azetidin-1-yl)pyrazolo[1,5
a]pyrimidin-3-yl)phenoxy)pyrimidin-5-yl)-3-(3
  (trifluoromethyl)phenyl)urea
                                            CF 3
                          N
                                        N
         N\  /I                     H   H
            N
                 N
TLC    : Rf 0.19           (Chloroform                  Methanol         =   19     : 1);
  H-NMR       (DMSO-d 6 )        : 5     2.33-2.43             (m,   2H),     4.06-4.12       (m, 4H),  6.25
 (d,   1H),        7.13-7.20            (m,    2H),        7.33      (d,    1H),      7.52   (t,  1H),  7.62
 (d,   IH),        7.98       (s,      1H),     8.05-8.12            (m,    2H),      8.39   (s,  1H),  8.65
 (d,  1H),        8.71     (s, 2H),         8.96        (s, 1H),         9.31       (s, 1H).
Example 21-6: 1-(2-(pyridin-3-yl)-5-(trifluoromethyl)phenyl)
3-(2-(4-(5-(pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3
yl)phenoxy)pyrimidin-5-yl)urea
TLC   : Rf 0.34            (Ethyl Acetate);
1 H-NMR       (DMSO-d 6 )        : 5     1.94-2.05             (m,   4H),     3.51-3.67       (m, 4H),  6.43
 (d,  1H),         7.14     (d,       2H),    7.47-7.58             (m,    3H),      7.89   (dd,  1H),  8.10
 (d,  2H),         8.23      (s,      1H),     8.38         (d,    2H),     8.61-8.68        (m,  5H),  9.22
 (s, 1H).
Example 21-7:            1-(2-(4-(5-(pyrrolidin-1-yl)pyrazolo[1,5
a]pyrimidin-3-yl)phenoxy)pyrimidin-5-yl)-3-(3
                                                            1 Or

   (trifluoromethyl)phenyl)urea
 TLC : Rf 0.68              (Ethyl Acetate);
 'H-NMR      (DMSO-d 6 )         : 5 1.95-2.04         (m,    4H),   3.52-3.65    (m, 4H),  6.44
  (d,  1H),       7.24        (d,    2H),     7.46    (d,    1H),    7.57   (t, 2H),   7.72   (d,
 1H),   7.93        (s,     1H),      8.16     (d,  2H),      8.36    (s,  1H), 8.64    (d, 1H),
 8.76    (s, 2H),          10.23      (s, 1H).
Example 21-8: 1-(2-phenyl-5-(trifluoromethyl)pyridin-3-yl)-3
  (2-(4-(5-(pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3
yl)phenoxy)pyrimidin-5-yl)urea
TLC : Rf 0.76              (Ethyl Acetate);
1H-NMR      (DMSO-d 6 )         : 5 1.92-2.05          (m,   4H),    3.52-3.65    (m, 4H),  6.43
  (d,  1H),      7.15        (d,    2H),     7.56    (d,    3H),    7.65-7.68    (m,  2H),  8.11
  (d,  2H),      8.39        (s,    1H),      8.41    (s,    1H),    8.62   (d, 1H),   8.65   (s,
2H),    8.72       (s, 1H),         8.76     (s, 1H),      9.44    (s, 1H).
Example 21-9:              1-(2-(4-(5-methoxypyrazolo[1,5-a]pyrimidin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-(pyridin-3-yl)-5
  (trifluoromethyl)phenyl)urea
                                          CF3
              X      O     N~"NJ
        N              O
            N
                      NN
                O-CH3
TLC : Rf 0.45              (Ethyl Acetate);
'H-NMR .(DMSO-d          6 )    : 5 4.03        (s,  3H),      6.61    (d, 1H), 7.21    (d, 2H),
7.46-7.58          (m,     3H),      7.89     (dt,  IH),      8.10    (d,  2H), 8.23    (s, 1H),
8.39     (s,     1H),       8.58      (s,   1H),    8.64-8.68        (m,   4H), 8.93   (d,  1H),
9.23    (s, 1H).
                                                    1 O/

 Example 21-10: 1-(2-(1H-pyrazol-1-yl)-5
   (trifluoromethyl)phenyl)-3-(2-(4-(5-methoxypyrazolo[1,5
 alpyrimidin-3-yl)phenoxy)pyrimidin-5-yl)urea
 TLC : Rf 0.45             (Chloroform : Methanol = 19                     : 1);
 1
   H-NMR     (DMSO-d     6  )   :   5 4.04        (s,   3H),    6.62    (d,   1H),  6.68   (t, 1H),
 7.20-7.26        (m,      2H),       7.53     (dd,    1H),     7.76   (d,    1H),  7.96   (d, 1H),
 8.09-8.14         (m,     2H),       8.42      (d,   1H),     8.58-8.61       (m, 2H),   8.70   (s,
 2H),   8.94      (d, 1H),           9.71     (s, 1H),       9.96 (s, 1H).
 Example 21-11:              1-(2-(4-(5-methoxypyrazolo[1,5-ajpyrimidin-3
 yl)phenoxy)pyrimidin-5-yl)-3-(3-(trifluoromethyl)phenyl)urea
 TLC : Rf 0.45             (Hexane : Ethyl Acetate = 1                     : 2);
 1
   H-NMR     (DMSO-d    6  )    : 5     4.04     (s,    3H),    6.62    (d,   1H),  7.21-7.27    (m,
 2H),   7.33       (d,      1H),       7.52     (t,    1H),    7.63    (d,   1H),   7.96-8.00    (m,
 1H),   8.10-8.15             (m,     2H),     8.59      (s,   1H),   8.72     (s, 2H),   8.94   (d,
 1H),   8.99      (s, 1H),           9.32     (s, 1H).
Example 21-12: 1-(2-(4-(5-((2-hydroxy-2
methylpropyl)amino)pyrazolo[1,5-a]pyrimidin-3
yl)phenoxy)pyrimidin-5-yl)-3-(3-(trifluoromethyl)phenyl)urea
                                           CF3
                         N          0
               N\                 H    H
          NI
               N
                H N-) OH
                       CH3
                 HC OH
TLC    : Rf 0.41           (Chloroform : Methanol                  = 9 : 1);
'H-NMR      (DMSO-d     6  )   :    5   1.19     (s,    6H),    3.43   (d,   2H),  4.62    (s, 1H),
6.48     (d,     1H),       7.14-7.20          (m,    2H),     7.33   (d,    1H),  7.48-7.56    (m,
2H),    7.63      (d,      1H),       7.96-8.00         (m,   1H),   8.06-8.12      (m,  2H),  8.31
                                                       1 O'7

   (s,  1H),      8.47       (d,    1H),       8.71     (s,    2H),    8.97     (s,  1H),   9.32    (s,
  1H) .
  Example 21-13: 1-(2-(4-(pyrazolo[1,5-a]pyrimidin-3
  yl)phenoxy)pyrimidin-5-yl)-3-(2-(pyridin-3-yl)-5
  (trifluoromethyl)phenyl)urea
                                           CF3
                NH                    H
          N
           JN
 TLC : Rf 0.22            (Ethyl Acetate);
 'H-NMR       (DMSO-d   6  )     : 5 7.11        (dd,    1H),     7.24    (d,  2H),   7.47-7.58     (m,
 3H),    7.86-7.91             (m,   1H),       8.16     (d,   2H),     8.22    (s,  1H),   8.39   (s,
 1H),    8.60-8.68            (m,   5H),       8.76     (s,   1H),     9.16    (dd,  1H),   9.23   (s,
 1H).
 Example 21-14:              1-(2-(4-(pyrazolo[1,5-a]pyrimidin-3
 yl)phenoxy)pyrimidin-5-yl)-3-(3-(trifluoromethyl)phenyl)urea
 TLC : Rf 0.65            (Ethyl Acetate);
 1 H-NMR     (DMSO-d    6 )     : 5 7.11         (dd,    1H),     7.25   (d,   2H),   7.32   (d, 1H),
 7.51    (t,     1H),      7.61       (d,    1H),     7.97      (s,   1H),    8.17   (d,   2H),  8.66
  (dd, 1H),        8.71       (s,   2H),       8.76     (s,   1H),    8.98     (s,  1H),   9.16   (dd,
 1H),    9.32      (s, 1H).
 Example 21-15: 1-(2-(1H-pyrazol-1-yl)-5
  (trifluoromethyl)phenyl)-3-(2-(4-(pyrazolo[1,5-ajpyrimidin-3
 yl)phenoxy)pyrimidin-5-yl)urea
TLC : Rf 0.74             (Ethyl Acetate);
'H-NMR       (DMSO-d    6 )     : 5 6.67         (t,  1H),     7,11     (dd,   1H),   7.25   (d, 2H),
 7.52    (dd,      1H),      7.74      (d,     1H),   7.95       (d,  1H),    8.17    (d,  2H),  8.40
                                                       100

  (d,   1H),     8.58      (d, 1H),      8.64-8.70        (m,  3H),     8.75    (s,  1H),   9.15
  (dd,   1H),     9.67     (s,   1H),   9.94     (s,   1H).
 Example 21-16: 1-(2-(lH-1,2,3-triazol-1-yl)-5
  (trifluoromethyl)phenyl)-3-(2-(4-(pyrazolo[1,5-a]pyrimidin-3
 yl)phenoxy)pyrimidin-5-yl)urea
 TLC : Rf 0.60          (Ethyl Acetate);
 1 H-NMR     (DMSO-d     )
                      6       : 5 7.10     (dd,    1H),    7.24    (d,   2H),   7.61    (d, 1H),
 7.73     (d, 1H),        8.09     (s,  1H),     8.16     (d,  2H),     8.57    (s,  1H),   8.66
  (s,  2H),      8.67-8.70         (m,  2H),     8.75     (s,  2H),     9.15   (s,   1H),   9.63
  (s, 1H).
 Example 21-17:            1-(2-fluoro-5-(trifluoromethyl)phenyl)-3-(2-(4
  (pyrazolo[1,5-alpyrimidin-3-yl)phenoxy)pyrimidin-5-yl)urea
 TLC : Rf 0.65          (Ethyl Acetate);
 1H-NMR
            (DMSO-d   6 )     : 5 7.11     (dd,    1H),    7.26    (d,   2H),   7.37-7.44     (m,
 1H),    7.46     (t,   1H),     8.17    (d,  2H),      8.51   (dd,    1H),   8.65    (dd,  1H),
 8.72    (s,    2H),    8.75      (s,  1H),     9.08     (s,  1H),     9.15   (dd,   1H),   9.28
  (s, 1H).
Example 21-18:            1-(2-chloro-5-(trifluoromethyl)phenyl)-3-(2-(4
 (pyrazolo[1,5-a]pyrimidin-3-yl)phenoxy)pyrimidin-5-yl)urea
TLC : Rf 0.69           (Ethyl Acetate);
'H-NMR      (DMSO-d   6 )    : 5 7.10      (dd,    1H),    7.26    (d,   2H),   7.40   (dd,  1H),
7.72     (d,    1H),    8.17      (d,  2H),     8.56     (d,  1H),     8.66   (dd,   1H),   8.73
 (s,   2H),     8.75      (s,   1H),    8.77     (s,    1H),   9.15     (dd,   1H),    9.69   (s,
1H).
Example 21-19:            1-(2-methyl-5-(trifluoromethyl)phenyl)-3-(2-(4
 (pyrazolo[1,5-alpyrimidin-3-yl)phenoxy)pyrimidin-5-yl)urea
                                                 100

 TLC  : Rf 0.72        (Ethyl Acetate);
 1H-NMR    (DMSO-d  6   )   : 5 2.32       (s,    3H),      7.11     (dd,    1H),    7.26     (d,  2H),
 7.29    (d,   1H),     7.42      (d,   1H),      8.17       (d,   2H),     8.27    (s,   1H),     8.37
  (s, 1H),     8.66     (dd,     1H),    8.73       (s,    2H),     8.76     (s,  1H),    9.16      (dd,
 1H),  9.31     (s, 1H).
 Example 21-20: 1-(3-fluoro-5-(trifluoromethyl)phenyl)-3-(2-(4
 (pyrazolo[1,5-a]pyrimidin-3-yl)phenoxy)pyrimidin-5-yl)urea
 TLC : Rf 0.76         (Ethyl Acetate);
 1H-NMR     (DMSO-d  6  )    :  5    7.11      (dd,      1H),     7.20-7.30       (m,    3H),     7.54
 7.72   (m,   2 H),       8.18     (d,  2H),      8.65-8.76          (m,   4 H),     9.09     (s,  1H),
 9.16-9.20      (m, 1H),        9.51    (s, 1H).
 Example 21-21:          1-(4-methyl-3-(trifluoromethyl)phenyl)-3-(2-(4
 (pyrazolo[1,5-a]pyrimidin-3-yl)phenoxy)pyrimidin-5-yl)urea
TLC   : Rf    0.76     (Ethyl Acetate);
'H-NMR     (DMSO-d  6  )    : 5 2.36       (s,    3H),      7.10     (dd,    1H),    7.25     (d,  2H),
 7.33   (d,   1H),     7.52      (dd,    1H),      7.88       (d,   1H),    8.17     (d,  2H),     8.65
 (dd,  1H),     8.70       (s,   2H),     8.75       (s,    1H),     8.91     (s,   1H),    9.15     (d,
 1H),  9.17     (d, 1H).
Example 21-22: 1-(2-phenyl-5-(trifluoromethyl)pyridin-3-yl)-3
 (2-(4-(pyrazolo[1,5-a]pyrimidin-3-yl)phenoxy)pyrimidin-5
yl)urea
TLC   : Rf 0.77        (Ethyl Acetate);
'H-NMR     (DMSO-d  6  )    : 5 7.11       (dd,      1H),      7.25    (d,   2H),    7.52-7.62       (m,
3H),   7.62-769         (m,    2H),     8.17      (d,     2H),     8.41     (s,   1H),     8.62-8.80
 (m, 6H),     9.16     (dd, 1H),        9.45     (d, 1H).
Example 21-23:           1-(3-(difluoromethyl)phenyl)-3-(2-(4
                                                   1 C(Cn

  (pyrazolo[1,5-a]pyrimidin-3-yl)phenoxy)pyrimidin-5-yl)urea
 TLC : Rf 0.73          (Ethyl Acetate);
 1H-NMR     (DMSO-d      )
                      6     : 5 7.00        (t,   1H),    7.11      (dd,    1H),    7.18   (di, 1H),
 7.26    (d,   2H),      7.42    (t,      1H),    7.52     (d,    1H),    7.77     (s,   1H),   8.17
  (d, 2H),     8.66       (dd,  1H),       8.71-8.76        (m,   3H),     8.89     (s,  1H),   9.17
  (d, 2H).
Example 21-24: 1-(3,5-difluorophenyl)-3-(2-(4-(pyrazolo[1,5
a]pyrimidin-3-yl)phenoxy)pyrimidin-5-yl)urea
TLC : Rf 0.74           (Ethyl Acetate);
1 H-NMR                        5     6.80
            (DMSO-d6 )                         (dt,   1H),      7.11     (dd,    1H),    7.19    (dd,
2H),   7.26      (d,    2H),   8.17        (d,   2H),   8.66       (dd,    1H),    8.70    (s,  2H),
8.75    (s, 1H),        9.00   (s, 1H),         9.16 (dd, 1H),           9.30    (s, 1H).
Example 21-25:            1-(2-(1H-pyrazol-1-yl)-4
 (trifluoromethyl)phenyl)-3-(2-(4-(5-(azetidin-1
yl)pyrazolo[1,5-a]pyrimidin-3-yl)phenoxy)pyrimidin-5-yl)urea
                   / TOy
                       N               CF3
                                     N
        N
TLC : Rf 0.63 (Ethyl Acetate);
'H-NMR     (DMSO-d    6 )   : 5 2.45-2.42           (m,    2H),     4.15     (t,   4H),   6.24    (d,
1H),   6.65      (t,    1H),   7.15        (d,   2H),   7.74       (dd,    1H),    7.82    (d,  1H),
7.93    (d,    1H),     8.60    (d,     2H),     8.36    (s,     1H),    8.43     (dd,   2H),   8.63
 (d, 1H),     8.67      (s, 2H),       9.54     (s, 1H),       9.26    (s, 1H).
Example 21-26:            1-(2-(4-(5-(azetidin-1-yl)pyrazolo[1,5
a]pyrimidin-3-yl)phenoxy)pyrimidin-5-yl)-3-(2-chloro-4
 (trifluoromethyl)phenyl)urea

TLC    : Rf       0.44      (Hexane : Ethyl Acetate = 1                      : 2);
   H-NMR       (DMSO-d    6  )    : 5   2.36-2.42       (m,   2H),      4.15       (t,  4H),    6.24    (d,
 1H),     7.16       (d,    2H),      7.68    (dd,    1H),    7.87       (s,    1H),    8.07     (d,  2H),
8.37       (s,    1H),       8.42      (d,   1H),    8.63     (d,    1H),       8.72     (s,   2H),   8.78
  (s,  1H),      9.73       (s,     1H).
Example 21-27:                1-(2-(4-(5-(azetidin-1-yl)pyrazolo[1,5
ajpyrimidin-3-yl)phenoxy)pyrimidin-5-yl)-3-phenylurea
TLC : Rf 0.20               (Chloroform : Methanol =                  19    :   1);
'H-NMR       (DMSO-d 6 )         : 5 2.33-2.43         (m,   2H),      4.11-4.19          (m,  4H),   6.25
 (d,   1H),        6.95-7.02           (m,   1H),    7.13-7.19          (m,     2H),    7.25-7.34       (m,
2H),      7.42-7.47            (m,   2H),     8.06-8.10        (m,    2H),      8.38     (s,   1H),   8.64
 (d, 1H),        8.70 (s, 2H),             8.82    (s, 1H),        8.91      (s, 1H).
Example 21-28:                1-(2-chloro-4-(trifluoromethyl)phenyl)-3-(2-(4
 (5-(pyrrolidin-1-yl)pyrazolo[l,5-a]pyrimidin-3
yl)phenoxy)pyrimidin-5-yl)urea
TLC     :    Rf    0.62        (Dichloromethane            :   Ethyl       Acetate        :   Methanol     =
8 : 4 : 1);
1
  H-NMR      (DMSO-d     6  )   :   5 1.92-2.06        (br s,       4H),      3.40-3.70       (br s,   4H),
6.43      (d,     1H),      7.17      (d,   2H),    7.69     (dd,     1H),      7.88     (d,   1H),   8.12
 (d,   2H),       8.37        (s,    1H),    8.43     (d,    1H),      8.63       (d,   1H),    8.72    (s,
2H),     8.79       (s, 1H),         9.75    (s, 1H).
Example 21-29:                1-(2-chloro-4-(trifluoromethyl)phenyl)-3-(2-(4
 (pyrazolo[1,5-a]pyrimidin-3-yl)phenoxy)pyrimidin-5-yl)urea
TLC : Rf 0.80               (Ethyl Acetate);
1
  H-NMR      (DMSO-d      6 )   : 5 7.10       (dd,    1H),     7.26      (d,    2H),    7.68    (dd,  1H),
7.87      (s,     1H),      8.17      (d,   2H),    8.42     (d, 1H),          8.66    (dd,    1H),   8.73
                                                      -inn~

  (s, 2H),     8.75      (s,    1H),    8.78      (s,   1H),    9.16    (d,   1H),   9.74   (s,
 IH).
 Example 21-30:          1-{2-[4-(5-methoxypyrazolo[1,5-a]pyrimidin-3
 yl)phenoxy]-5-pyrimidinyl}-3-[2-(1-methyl-lH-pyrazol-5-yl)-5
  (trifluoromethyl)phenyl] urea
 Purity     (LC-MS/ELSD) : 100%              (Retention Time : 1.01 minutes);
MASS    (ESI, Pos.)             602   (M + H)+;
 1H-NMR    (DMSO-d     )
                    6          5 3.65      (s,    3H),    4.03   (s,   3H),   6.45   (d,  1H),
 6.61   (d,    1H),    7.22       (d,  2H),      7.46-7.52      (m,   2H),    7.62   (d,  1H),
 8.09-8.12      (m,   3H),       8.56    (s,     1H),    8.59   (s,   1H),    8.66   (s,  2H),
 8.93  (d, 1H),       9.48      (s,   1H).
 Example 21-31:         1-{2-[4-(5-methoxypyrazolo[1,5-a]pyrimidin-3
yl)phenoxyl-5-pyrimidinyl}-3-[2-(3-methyl-1H-pyrazol-1-yl)-5
  (trifluoromethyl)phenyl]urea
'H-NMR     (DMSO-d  6 )     : 5 2.37      (s,     3H),    4.03   (s,   3H),   6.45   (d,  1H),
 6.61   (d,   1H),    7.20-7.25         (m,     2H),    7.48   (dd,   1H),    7.69   (d,  1H),
 8.09-8.13      (m,   2H),       8.28    (d,     1H),    8.57   (d,   1H),    8.58   (s,  1H),
 8.68  (s, 2H),      8.93       (d, 1H),       9.80    (s, 1H),     9.90    (s, 1H).
Example 21-32:          1-{2-[4-(5-methoxypyrazolo[1,5-a]pyrimidin-3
yl)phenoxy]-5-pyrimidinyl}-3-[2-(4-methyl-1H-pyrazol-1-yl)-5
  (trifluoromethyl)phenyl]urea
Purity (LC-MS/ELSD) : 100%                   (Retention Time : 1.08 minutes);
MASS   (ESI, Pos.)           : 602    (M + H)*;
'H-NMR     (DMSO-d  6 )     : 5 2.14      (s,     3H),    4.03   (s,   3H),   6.61   (d,  1H),
7.22    (d,   2H),    7.49       (dd,   1H),      7.70    (d,  1H),   7.78     (s, 1H),   8.11
 (d,  2H),    8.18      (s,    1H),    8.57-8.58         (m,  2H),    8.69    (s,  2H),   8.93

  (d, 1H),    9.83     (s,   1H),    9.95    (s,     1H)
 Example 21-33:          1-{2-[4-(5-methoxypyrazolo[1,5-a]pyrimidin-3
 yl)phenoxyl-5-pyrimidinyl}-3-[2-(3-pyridinyl)-4
  (trifluoromethyl)phenyl]urea
 Purity     (LC-MS/ELSD) : 100%            (Retention Time : 0.92 minutes);
MASS    (ESI, Pos.)           599    (M + H)*;
 1H-NMR    (DMSO-d  6  )   : 5 4.03      (s,    3H),       6.61    (d,   1H),   7.19-7.24    (m,
 2H),    7.53-7.57         (m, 2H),       7.75         (dd,    1H),     7.88-7.92     (m,  1H),
 8.08-8.12      (m,   2H),     8.24-8.29        (m,      2H),    8.58    (s,   1H),  8.64-8.68
  (m, 4H),    8.93    (d, 1H),       9.28    (brs, 1H).
Example 21-34:           1-[2-chloro-5-(trifluoromethyl)phenyl]-3-{2-[4
  (5-methoxypyrazolo[1,5-a]pyrimidin-3-yl)phenoxy]-5
pyrimidinyl}urea
 Purity (LC-MS/ELSD) : 100%                (Retention Time : 1.05 minutes);
MASS    (ESI, Pos.)        : 556     (M + H)*;
1H-NMR     (DMSO-d  6  )   : 5 4.03      (s,    3H),      6.61     (d,   1H),   7.24   (d, 2H),
7.40    (dd,   1H),      7.73    (d,   1H),     8.11       (d,   2H),    8.57-8.59     (d, 2H),
8.73   (s, 2H),       8.78    (s, 1H),       8.94       (d, 1H),      9.70    (s, 1H).
Example 21-35:          1-{2-[4-(5-methoxypyrazolo[1,5-alpyrimidin-3
yl)phenoxyl-5-pyrimidinyl}-3-[2-methyl-5
 (trifluoromethyl)phenyl]urea
Purity      (LC-MS/ELSD) : 100%            (Retention Time : 1.00 minute);
MASS   (ESI, Pos.)         : 536     (M + H)+;
'H-NMR     (DMSO-d  6  )   : 5 2.32      (s,    3H),      4.03     (s,   3H),   6.61   (d, 1H),
7.24    (d,   2H),     7.30     (d,   1H),     7.41       (d,   1H),     8.09-8.13     (m, 2H),
8.28    (s,   1H),     8.37    (s,    1H),    8.59        (s,   1H),    8.73    (s,  2H),  8.94
                                                | f\ A

  (d, 1H),       9.32     (s, 1H).
 Example 21-36:              1-(2,4-dichlorophenyl)-3-{2-[4-(5
 methoxypyrazolo[1,5-a]pyrimidin-3-yl)phenoxy]-5
 pyrimidinyl}urea
 Purity      (LC-MS/ELSD) : 100%                   (Retention Time : 1.03 minutes);
MASS    (ESI, Pos.)                 522     (M + H)+;
 1H-NMR     (DMSO-d     6  )     : 5   4.03      (s,    3H),    6.61   (d,   1H),    7.23  (d, 2H),
 7.39   (dd,      1H),         7.63    (d,     1H),     8.10-8.16      (m,  3H),    8.57   (s, 1H),
 8.59  (s, 1H),           8.71       (s, 2H),        8.93     (d, 1H),    9.58    (s, 1H).
 Example 21-37:             1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
alpyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2-(3-pyridinyl)-5
 (trifluoromethyl)phenyl]urea
                                           CF3
            N/N        O N~ "-     NN
       N\                       *H    H
         N
              N
                N-CH 3
            H3 C
TLC : Rf 0.32             (Chloroform : Methanol                  =  19 : 1);
'H-NMR     (DMSO-d      6 )     : 5 3.19         (s,    6H),    6.62   (d,   1H),    7.12-7.17   (m,
2H),   7.46-7.57               (m,   3H),      7.86-7.90        (m,  1H),    8.06-8.11     (m, 2H),
8.22    (s,      1H),      8.37-8.38            (m,   2H),     8.61-8.68      (m,   5H),  9.21   (s,
 1H).
Example 21-38:              1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
ajpyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2-(1H-pyrazol-1
yl) -5- (trifluoromethyl)phenyl]urea
                                                       I -Inr

                                        CF3
                N   O
                                 0
                               H    H
             N                            N
              N-CH3
           H3C
TLC : Rf 0.30            (Chloroform              Methanol = 19                1);
  H-NMR   (DMSO-d     6  )   :   5 3.19       (s,     6H),    6.63       (d,   1H),   6.67-6.68   (m,
1H),   7.14-7.17            (m,   2H),      7.52      (dd,    1H),      7.75     (d,  1H), 7.95   (d,
1H),    8.08-8.11           (m,    2H),     8.39       (s,   1H),     8.41      (d, 1H),   8.59   (d,
1H),   8.64     (d,     1H),     8.68      (s, 2H),        9.69     (s, 1H),       9.93 (s, 1H).
Example 21-39:             1-[2-fluoro-5-(trifluoromethyl)phenyl]-3-{2-[4
 (5-methoxypyrazolo[1,5-a]pyrimidin-3-yl)phenoxy]-5
pyrimidinyl}urea
Purity     (LC-MS/ELSD) : 100%                  (Retention Time              : 1.01 minutes);
MASS    (ESI, Pos.)           : 540      (M + H)+;
1
  H-NMR   (DMSO-d     6  )   : 5     4.03     (s,     3H),    6.61      (d,    1H),   7.21-7.26  (m,
2H),   7.39-7.53           (m, 2H),       8.09-8.14          (m, 2H),         8.53   (dd, 1H),  8.59
 (s, 1H),     8.73      (s, 2H),        8.93      (d, 1H),       9.02-9.36 (br s, 2H).
Example 21-40:             1-[5-chloro-2-(3-pyridinyl)phenyl]-3-{2-[4-(5
methoxypyrazolo[1,5-a]pyrimidin-3-yl)phenoxy]-5
pyrimidinyl}urea
Purity    (LC-MS/ELSD) : 100%                   (Retention Time              : 0.87 minutes);
MASS   (ESI, Pos.)            : 565      (M + H)+;
1
  H-NMR   (DMSO-d6 )         : 5 4.03         (s,    3H),     6.60      (d, 1H),      7.20-7.30  (m,
4H),    7.53      (dd,       1H),       7.81-7.85          (m,     1H),       8.08-8.12    (m,  4H),
8.55-8.64       (m, 5H),         8.93     (d,     1H),     9.18     (s,    1H).
Example 21-41:            1-{2-[4-(5-methoxypyrazolo[1,5-a]pyrimidin-3
                                                    I  Cn

yl)phenoxy] -5-pyrimidinyl}-3-{5- (trifluoromethyl) -2-                          [3
 (trifluoromethyl)-lH-pyrazol-1-yl]phenyl}urea
Purity     (LC-MS/ELSD) :             100%      (Retention Time        : 1.09 minutes);
MASS   (ESI, Pos.)              656     (M + H)+;
1
  H-NMR   (DMSO-d     6 )       5 4.03        (s,    3H),   6.61   (d,  1H),  7.12   (d,  1H),
7.20-7.24       (m, 2H),         7.58       (dd, 1H),       7.10   (d,  1H),  8.09-8.13     (m,
2H),   8.47-8.48           (m, 2H),         8.58      (s, 2H),   8.65    (s, 2H),   8.93    (d,
1H),   9.46    (s, 1H).
Example 21-42:            1-{2-[4-(5-ethoxypyrazolo[1,5-a]pyrimidin-3
yl)phenoxy]-5-pyrimidinyl}-3-[2-(3-pyridinyl)-5
 (trifluoromethyl)phenyl] urea
                                       CF 3
       Nj   N       O         H    H
          N
                 CH 3
Purity     (LC-MS/ELSD) : 100%                  (Retention Time        : 0.98 minutes);
MASS   (ESI, Pos.)           : 613      (M + H)*;
 H-NMR    (DMSO-d     6 )   : 5     1.40     (t,     3H),   4.49   (q,  2H),  6.58   (d,  1H),
7.18-7.22      (m, 2H),          7.47-7.58          (m, 3H),    7.87-7.91    (m, 1H),    8.05
8.10   (m,    2H),      8.23      (s,    1H),      8.39    (s, 1H),    8.57  (s,  1H),   8.64
8.68   (m, 4H),        8.92      (d, 1H),         9.23    (s, 1H).
Example 21-43:           1-{2-[4-(5-cyclobutylpyrazolo[1,5-a]pyrimidin
3-yl)phenoxy]-5-pyrimidinyl}-3-[2-(3-pyridinyl)-5
(trifluoromethyl)phenyl]urea
Purity    (LC-MS/ELSD) : 99%                 (Retention Time          : 1.03 minutes);
MASS   (ESI, Pos.)           : 623      (M + H)+

 'H-NMR       (DMSO-d 6 )           5    1.85-2.12         (m,    2H),      2.33-2.42     (m,   4H),
3.73-3.84          (m,     1H),     6.97     (d,     1H),    7.24    (d,     2H),  7.47-7.58      (m,
 3H),    7.87-7.91           (m,   1H),    8.18-8.23         (m,   3H),     8.39  (s,   1H),   8.64
8.68      (m, 5H),       9.01      (d,   1H),      9.23    (s,   1H) .
Example 21-44:              1-{2-[4-(5-methoxypyrazolo[1,5-a]pyrimidin-3
yl) phenoxyl -5-pyrimidinyl}-3- [2- (2H-1, 2, 3-triazol-2-yl) -5
  (trifluoromethyl)phenyl]urea
Purity        (LC-MS/ELSD) : 100%                (Retention Time           : 1.09 minutes);
MASS     (ESI, Pos.)            : 589     (M + H)+;
1
  H-NMR      (DMSO-d   6  )    : 5    4.03     (s,    3H),     6.62    (d,   1H),  7.23    (d,  2H),
7.58      (dd,    1H),      8.05-8.13         (m,     3H),    8.33    (s,    2H),  8.59    (s,  1H),
8.65      (d,    1H),    8.70       (s,   2H),      8.93    (d,    1H),    9.66   (s,   1H),   10.00
  (s, 1H).
Example 21-45:              1-[5-chloro-2-(2H-1,2,3-triazol-2-yl)phenyl]-3
{2-[4-(5-methoxypyrazolo[1,5-a]pyrimidin-3-yl)phenoxy]-5
pyrimidinyl}urea
Purity        (LC-MS/ELSD) : 99%               (Retention Time            : 1.08 minutes);
MASS     (ESI, Pos.)            : 555    (M + H)*;
1
  H-NMR      (DMSO-d   6  )    : 5 4.03        (s,    3H),     6.61    (d,   1H),  7.20-7.25      (m,
2H),    7.29      (dd,      1H),      7.80    (d,     1H),     8.09-8.13      (m,  2H),   8.26    (s,
2H),     8.33      (d,    1H),      8.58    (s,     1H),     8.69    (s,    2H),   8.93    (d,  1H),
9.36     (s,    1H),     9.91     (s,    1H) .
Example 21-46:              1-(2-{4-[5-(1-azetidinyl)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[4
 (trifluoromethyl)-2-biphenylyl]urea
TLC : Rf 0.24            (Chloroform           : Methanol        = 19     : 1);

 1
   H-NMR      (DMSO-d   6  )    : 5 2.31-2.44            (m,     2H),     4.10-4.19            (m,  4H),  6.24
  (d,   1H),      7.10-7.18          (m,   2H),       7.39-7.59            (d,       7H),     8.03-8.12     (m,
 3H),      8.37       (s,     1H),      8.41      (s,       1H),       8.60-8.66             (m,   3H),   9.37
  (s,1H).
Example 21-47:              1-(2-{4-[5-(1-azetidinyl)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2-(6-methyl-3
pyridinyl)-5-(trifluoromethyl)phenyl]urea
TLC    : Rf 0.33          (Chloroform : Methanol = 19                            : 1);
1
  H-NMR      (DMSO-d    6 )     : 52.32-2.43           (m,    2H),     2.55       (s,   3H),    4.10-4.19    (m,
4H),     6.24     (d,   1H),      7.11-7.18       (m,      2H),     7.40-7.51          (m,    3H),   7.76  (dd,
1H),     8.03-8.10         (m,    2H),   8.18      (s,      1H),      8.37      (s,    1H),     8.41-8.43    (m,
1H),    8.51     (d,1H),       8,61-8.69      (m, 3H),          9.25     (s, 1H).
Example 21-48:              1-(2-{4-[5-(dimethylamino) pyrazolo[1,5
a]pyrimidin-3-yllphenoxy}-5-pyrimidinyl)-3-[2-(6-methyl-3
pyridinyl)-5-(trifluoromethyl)phenyl]urea
TLC    : Rf 0.30          (Methylene chloride                    : Ethyl acetate                : Methanol     =
8 : 4      : 1);
1
  H-NMR      (DMSO-d    6 )     :  5 2.55     (s,      3H),       3.19      (s,      6H),     6.63    (d, 1H),
7.15     (d,     2H),     7.38-7.52         (m,     3H),       7.76       (dd,       1H),     8.10    (d, 2H),
8.18      (s,    1H),      8.38      (s,  1H),       8.42         (s,    1H),       8.50      (d,  1H),   8.64
 (s, 2H),       8.64      (d, 1H),       9.25      (s, 1H).
Example 21-49:              1-(2-{4-[5-(1-azetidinyl)pyrazolo[1,5
a]pyrimidin-3-yllphenoxy}-5-pyrimidinyl)-3-[4'-methyl-4
 (trifluoromethyl)-2-biphenylyl]urea
TLC    : Rf 0.32          (Chloroform : Methanol = 19                           : 1);
1H-NMR      (DMSO-d     6 )    : 6 2.30-2.45             (m,     5H),     4.10-4.19            (m,  4H),  6.24

 (d,  1H),      7.11-7.18            (m,    2H),   7.30-7.47     (m,  6H),    8.01-8.10    (m,
 3H),  8.37       (s,      1H),     8.42-8.45       (m,  1H),   8.62-8.66     (m,  3H),  9.39
 (s,  1H).
Example 21-50:               1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2-phenyl-5
 (trifluoromethyl)-3-pyridinyllurea
Purity      (LC-MS/ELSD) : 100%                  (Retention Time : 1.01 minutes);
MASS   (ESI, Pos.)              : 612     (M + H)*;
'H-NMR     (DMSO-d      6  )   : 5 3.19        (s,  6H),   6.63   (d, 1H),    7.12-7.19    (m,
2H),   7.51-7.68              (m,  5H),      8.05-8.13     (m,  2H),  8.36-8.47      (m, 2H),
8.62-8.67        (m,      3H),     8.71-8.73        (m, 1H),    8.75-8.78     (m,. 1H),  9.45
 (s, 1H).
Example 21-51:              1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2-(1-methyl-1H
pyrazol-5-yl)-5-(trifluoromethyl)phenyl]urea
                                         CF3
                 N    O      N     O
         N     ~        N        N
                                 H
                                     N
                                     H
         N                                 N'CH3
                                        -N
              N-CH3
           H3C
Purity (LC-MS/ELSD) : 100%                       (Retention Time : 0.98 minutes);
MASS   (ESI, Pos.)              : 615     (M + H)+;
1H-NMR
           (DMSO-d     6  )    : 5    3.19     (s,  6H),   3.65   (s, 3H),    6.45   (d, 1H),
6.63    (d,    1H),        7.13-7.19          (m,  2H),   7.44-7.54     (m,  2H),   7.62   (d,
1H),   8.06-8.14             (m,   3H),      8.38   (s,  1H),   8.56   (s,  1H),   8.63-8.68
 (m, 3H),     9.47       (s, 1H).
Example 21-52:              1-(2-{4-[5-(dimethylamino)pyrazolo[1,5-

 a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2-(3-methyl-1H
 pyrazol-1-yl)-5-(trifluoromethyl)phenyl]urea
 Purity     (LC-MS/ELSD) : 100%             (Retention Time        : 1.04 minutes);
MASS    (ESI, Pos.)        : 615     (M + H)+;
 'H-NMR    (DMSO-d  6  )      5 2.37     (s,    3H),    3.19   (s,   6H),  6.45   (d, 1H),
 6.63   (d,   1H),    7.14-7.21        (m,    2H),    7.48   (dd,   1H),   7.69  (d,  1H),
 8.07-8.14      (m,   2H),      8.28    (d,    1H),    8.39   (s,   1H),   8.57  (d,  1H),
 8.63-8.70     (i, 3H),        9.80   (s, 1H),       9.89   (s, 1H).
Example 21-53:          1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
alpyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-{5
  (trifluoromethyl)-2-[3-(trifluoromethyl)-1H-pyrazol-1
yllphenyl}urea
Purity      (LC-MS/ELSD) : 100%             (Retention Time : 1.07 minutes);
MASS    (ESI, Pos.)            669  (M + H)+
1H-NMR     (DMSO-d    )       5 3.19
                    6                     (s,   6H),    6.63   (d,   1H),  7.10-7.20    (m,
3H),   7.58    (dd,      1H),    7.70    (d,    1H),    8.07-8.14     (n,  2H),  8.38   (s,
1H),   8.45-8.50         (m,   2H),   8.57      (s,   1H),   8.63-8.67     (m,  3H),  9.45
  (s, 1H).
Example 21-54:          1-[2-(4-chloro-1H-pyrazol-1-yl)-5
  (trifluoromethyl)phenyl]-3-(2-{4-[5
  (dimethylamino)pyrazolo[1,5-a]pyrimidin-3-yl]phenoxy}-5
pyrimidinyl)urea
Purity      (LC-MS/ELSD) : 100%             (Retention Time : 1.06 minutes);
MASS    (ESI, Pos.)           635   (M + H)+;
'H-NMR     (DMSO-d  6 )       5 3.19      (s,   6H),    6.63   (d,   1H),  7.14-7.20    (m,
2H),   7.53    (dd,      1H),    7.70    (d,    1H),    8.06-8.14      (m, 3H),  8.39   (s,

 1H),  8.56-8.71         (m,   5H),  9.09    (s,   1H),  9.78     (s,    1H).
 Example 21-55:          1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
 a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-{5
  (trifluoromethyl)-2-[3-(trifluoromethyl)-1H-1,2,4-triazol-1
 yl]phenyl}urea
 Purity     (LC-MS/ELSD) : 100%            (Retention Time        : 1.02 minutes);
MASS    (ESI, Pos.)         : 670   (M + H)+
 1H-NMR    (DMSO-d     )      5 3.19
                    6                    (s,  6H),    6.63    (d,   1H),     7.13-7.20    (m,
 2H),  7.60-7.65          (m, 1H),    7.81    (d,   1H),    8.05-8.14        (m,  2H),  8.38
  (s, 1H),    8.50      (d,    1H),   8.57-8.68      (m,   4H),    9.21      (s,  1H),  9.33
  (s, 1H).
Example 21-56:          1-[5-chloro-2-(2H-1,2,3-triazol-2-yl)phenyl]-3
  (2-{4-[5-(dimethylamino)pyrazolo[1,5-a]pyrimidin-3
yl]phenoxy}-5-pyrimidinyl)urea
 Purity (LC-MS/ELSD) : 100%                (Retention Time : 1.02 minutes);
MASS    (ESI, Pos.)         : 568   (M + H)+;
'H-NMR     (DMSO-d  6 )    : 5 3.19     (s,   6H),    6.63    (d,   1H),     7.13-7.21    (m,
2H),   7.29     (dd,     1H),    7.80   (d,   1H),    8.07-8.14       (m,   2H),   8.26   (s,
2H),   8.32     (d,    1H),     8.38   (s,   1H),    8.64    (d,   1H),     8.68    (s, 2H),
 9.36 (s, 1H),       9.90      (s, 1H).
Example 21-57: 1-[5-chloro-2-(3-pyridinyl)phenyl]-3-(2-{4-[5
 (dimethylamino)pyrazolo[1,5-a]pyrimidin-3-yljphenoxy}-5
pyrimidinyl)urea
Purity      (LC-MS/ELSD) : 100%            (Retention Time : 0.83 minutes);
MASS   (ESI, Pos.)          : 578   (M + H)*;
1H-NMR     (DMSO-d  6 )    : 5 3.19     (s,   6H),    6.62    (d,   1H),     7.15   (d, 2H),

 7.21-7.30      (m, 2H),    7.49-7.55       (m,   1H),    7.80-7.85      (m,    1H),   8.06
 8.12   (m,   4H),   8.38   (s,  1H),     8.56-8.66       (m,   5H),   9.17    (s,   1H)
Example 21-58:         1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2-(lH-pyrazol-l
yl)-4-(trifluoromethyl)phenyl]urea
Purity      (LC-MS/ELSD) : 100%         (Retention Time : 1.02 minutes);
MASS    (ESI, Pos.)       : 601  (M + H)+
'H-NMR     (DMSO-d 6 )   : 5 3.19     (s,    6H),     6.60-6.68      (m,  2H),     7.16    (d,
2H),   7.74     (dd, 1H),    7.80-7.85        (m,   1H),    7.92-7.95      (m,   1H),    8.10
 (d,  2H),     8.37-8.46     (m,  3H),     8.61-8.69         (m,  3H),    9.55     (s,   1H),
9.94    (s, 1H).
Example 21-59:         1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
a]pyrimidin-3-yllphenoxy}-5-pyrimidinyl)-3-[2-fluoro-4
 (trifluoromethyl)phenyl]urea
Purity (LC-MS/ELSD) : 100%              (Retention Time : 1.00 minute);
MASS    (ESI, Pos.)      : 553   (M + H)+;
1H-NMR
           (DMSO-d 6 )   : 5 3.16     (s,    6H),     6.62    (d, 1H),    7.17     (d,   2H),
7.54    (d,   1H),    7.70   (d,  1H),      8.06-8.16        (m,  2H),    8.32-8.42        (m,
2H),   8.64     (d, 1H),    8.72  (s, 2H),        9.17    (s, 1H),     9.40    (s, 1H).
Example 21-60:         1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
a]pyrimidin-3-yllphenoxy}-5-pyrimidinyl)-3-[3
 (trifluoromethyl)phenyl]urea
Purity (LC-MS/ELSD) : 100%              (Retention Time : 0.97 minutes);
MASS (ESI, Pos.)         : 535   (M + H)+
1 H-NMR    (DMSO-d   )
                   6     : 5 3.19     (s,    6H),     6.63    (d,  1H),   7.17     (d,   2H),
7.32    (d,   1H),   7.51    (t,  1H),     7.62      (d,   1H),   7.97    (s,    1H),    8.10

  (d, 2H),     8.39      (s,    1H),    8.64   (d,  1H),    8.70  (s, 2H),   8.96   (s,
 1H),  9.31     (s, 1H).
 Example 21-61: 1-[2-chloro-5-(trifluoromethyl)phenyl]-3-(2-{4
  [5-(dimethylamino)pyrazolo[1,5-a]pyrimidin-3-yl]phenoxy}-5
 pyrimidinyl)urea
 Purity     (LC-MS/ELSD) : 100%             (Retention Time : 1.03 minutes);
MASS   (ESI, Pos.)              569 (M + H)+
 1H-NMR    (DMSO-d     )       5 3.19     (s,
                    6                          6H),   6.63   (d, 1H),  7.17   (d, 2H),
 7.39   (d,   1H),     7.72       (d,  1H),   8.11   (d,   2H),  8.39  (s,  1H),  8.57
  (d, 1H),    8.65       (d,    1H),    8.72   (s,  2H),    8.78  (s, 1H),   9.69   (s,
 1H).
Example 21-62:          1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2-methyl-5
  (trifluoromethyl)phenyl]urea
TLC : Rf 0.18         (Hexane : Ethyl acetate = 1 : 4);
'H-NMR     (DMSO-d  6 )     : 5 2.32      (s,  3H),   3.19   (s, 6H),  6.62   (d, 1H),
7.16    (d, 2H),       7.29      (d, 1H),     7.41   (d, 1H),    8.10  (d, 2H),   8.27
 (s,  1H),    8.37      (d,     2H),   8.64    (d,  1H),    8.71  (s, 2H),   9.30   (s,
1H).
Example 21-63:          1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2-fluoro-5
 (trifluoromethyl)phenyl]urea
Purity      (LC-MS/ELSD) : 100%             (Retention Time : 0.99 minutes);
MASS   (ESI, Pos.)           : 553    (M + H)+;
1H-NMR     (DMSO-d  6 )    : 5 3.19       (s,  6H),   6.62   (d, 1H),  7.16   (d, 2H),
7.36-7.43       (m,   1H),       7.45-7.54     (m,  1H),    8.10  (d, 2H),   8.38   (s,

 1H),   8.49-8.56            (m,      1H),       8.64    (d,   1H),   8.71     (s,   2H),   9.08   (s,
 1H),  9.27      (s,    1H).
Example 21-64: 1-(2,4-dichlorophenyl)-3-(2-{4-[5
 (dimethylamino)pyrazolo[1,5-a]pyrimidin-3-yl]phenoxy}-5
pyrimidinyl)urea
Purity      (LC-MS/ELSD)                  100%       (Retention Time : 1.01 minutes);
MASS   (ESI, Pos.)                   535 (M + H)+
1H-NMR     (DMSO-d    6  )      : 5 3.19           (s,  6H),    6.62    (d,   1H),    7.16   (d, 2H),
7.38    (dd,     1H),        7.62       (d,     1H),    8.09    (d,  2H),    8.13     (d,  1H),  8.38
 (s,  1H),     8.56         (s,      1H),       8.64    (d,   1H),    8.70     (s,   2H),   9.56   (s,
1H).
Example 21-65:              1-{2-[4-(5-methylpyrazolo[1,5-a]pyrimidin-3
yl)phenoxy]-5-pyrimidinyl}-3-[2-(3-pyridinyl)-5
 (trifluoromethyl)phenyl]urea
                                            CF3
                    S  N '-      N0'N N   '
       N                         H     H
         N
             N
              CH3
TLC : Rf 0.43           (Methylene chloride : Methanol = 9 : 1);
1H-NMR     (DMSO-d    6 )      : 5 2.60            (s,  3H),    6.99    (d,   1H),    7.23   (d, 2H),
7.45-7.59        (m,    3H),          7.89       (d,   1H),    8.14    (d,   2H),    8.23    (s, 1H),
8.39   (s, 1H),         8.61-8.72              (m, 5H),      9.00   (d, 1H),       9.23   (s, 1H).
Example 21-66:             1-(2-{4-[5-(ethylamino)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2-(3-pyridinyl)-5
 (trifluoromethyl)phenyl]urea
TLC : Rf 0.31           (Chloroform : Methanol = 19                        : 1);

 1H-NMR     (DMSO-d6 )                5 1.22        (t,  3H),    3.38-3.47           (m,    2H),  6.26   (d,
 1H),   7.11-7.18              (m,      2H),     7.46-7.65       (m,    4H),      7.86-7.92        (m, 1H),
 8.04-8.11         (m,      2H),        8.23      (s,   1H),    8.31      (s,     1H),      8.37-8.41    (m,
1H),   8.46       (d,     1H),         8.61-8.69        (m,   4H),    9.22      (s,     1H).
Example 21-67: 1-(2-{4-[5-(ethylamino)pyrazolo[1,5
a]pyrimidin-3-yljphenoxy}-5-pyrimidinyl)-3-[3'-methyl-4
 (trifluoromethyl)-2-biphenylyl]urea
                                             CF3
       N,   /                       H    H
         N             O
              N
               N'                   /CH              3
               H    CH3
TLC   : Rf 0.36            (Chloroform : Methanol                   =   19 : 1);
1
  H-NMR    (DMSO-d       6 )      :   5   1.22     (t,   3H),    2.38      (s,    3H),      3.36-3.48    (m,
2H),   6.26        (d,     1H),         7.11-7.46        (m,   8H),     7.60       (t,    1H),   8.00-8.11
 (m,  3H),      8.30         (s,      1H),     8.42-8.48        (m,    2H),      8.63       (s,  2H),  9.39
 (s, 1H).
Example 21-68:               1-(2-{4-[5-(1-azetidinyl)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2
 (methylsulfonyl)-5-(trifluoromethyl)phenyl]urea
TLC : Rf 0.43              (Chloroform : Methanol =                     19     : 1);
  H-NMR    (DMSO-d      6  )     : 5 2.32-2.44            (m, 2H),       3.38       (s,   3H),   4.10-4.20
 (m,  4H),      6.24         (d,      1H),     7.13-7.20        (m,    2H),      7.61-7.66        (m,  1H),
8.04-8.11         (m,      3H),         8.38     (s,    1H),    8.61-8.67           (m,    2H),   8.73   (s,
2H),   8.96       (s, 1H),            10.27      (s, 1H).
Example 21-69:               1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2-

  (methylsulfonyl)-5-(trifluoromethyl)phenyl]urea
 TLC : Rf 0.48            (Ethyl acetate);
 'H-NMR     (DMSO-d    6   )   : 5 3.19       (s, 6H),     3.38    (s,   3H),     6.63   (d,  1H),
  7.15-7.22       (m,     2H),     7.61-7.69         (m, 1H),   8.05-8.15         (m,  3H),   8.39
  (s,  1H),     8.63-8.68           (m,   2H),     8.73   (s,  2H),    8.96     (s,   1H),   10.27
  (s, 1H).
 Example 21-70: 1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
 alpyrimidin-3-yllphenoxy}-5-pyrimidinyl)-3-[4
  (trifluoromethyl)-2-biphenylyl]urea
                                        CF 3
                      01- N   -NK0~
         N
              N
               N-CH3
            H3C
 Purity (LC-MS/ELSD) : 100%                     (Retention Time : 1.09 minutes);
MASS    (ESI, Pos.)             : 611    (M + H)*;
1 H-NMR     (DMSO-d    6  )    : 5 3.19       (s,    6H),  6.62   (d,   1H),     7.15    (d,  2H),
 7.40-7.58        (m,     7H),      8.06-8.12        (m,  3H),   8.38     (s,    1H),   8.41    (s,
 1H),   8.61-8.66            (m, 3H),      9.36 (s, 1H).
Example 21-71:              1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[4'-methyl-4
  (trifluoromethyl)-2-biphenylyl] urea
 Purity (LC-MS/ELSD) : 100%                     (Retention Time : 1.13 minutes);
MASS    (ESI, Pos.)             : 625    (M + H)+
'H-NMR     (DMSO-d     6  )       5 2.39      (s,    3H),  3.19   (s, 6H),       6.62    (d,  1H),
7.15    (d,     2H),      7.28-7.47          (m,   6H),   8.03   (s,    1H),     8.09    (d,  2H),
 8.38   (s, 1H),        8.43       (s, 1H),       8.61-8.66    (m, 3H),       9.39    (s, 1H).

 Example 21-72:             1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
 a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[4'-ethyl-4
  (trifluoromethyl)-2-biphenylyl]urea
 Purity (LC-MS/ELSD) : 100%                        (Retention Time : 1.16 minutes);
 MASS   (ESI, Pos.)                 639    (M + H)+;
 1 H-NMR    (DMSO-d     6 )        5 1.24       (t,    3H),   2.68   (q, 2H),  3.19  (s, 6H),
 6.62    (d,    1H),       7.14       (d,   2H),      7.35-7.49     (m,  6H),  8.03-8.12   (m,
 3H),   8.38      (s,      1H),      8.41      (s,    1H),    8.61-8.66    (m, 3H), 9.38   (s,
 1H).
 Example 21-73:             1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
 a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[3'-methyl-4
 (trifluoromethyl)-2-biphenylyl]urea
                                          CF3
                      0
                   N        N,,    0
        N                        H   H
          N
              N
               N-CH 3                         CH3
            H3C
 Purity (LC-MS/ELSD) : 100%                        (Retention Time : 1.13 minutes);
MASS    (ESI, Pos.)             : 625      (M + H)+
'H-NMR      (DMSO-d     6 )     : 5 2.38        (s,    3H),   3.19   (s,  6H), 6.62  (d, 1H),
 7.14    (d,    2H),       7.19-7.32          (m,    3H),    7.36-7.47     (m, 3H), 8.02   (s,
 1H),   8.09      (s,     1H),       8.11     (s,     1H),   8.38   (s,  1H),  8.44  (s, 1H),
 8.64   (s, 2H),         8.66       (s, 1H),        9.40    (s, 1H).
Example 21-74:             1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[3'-ethyl-4
 (trifluoromethyl)-2-biphenylyl]urea
Purity      (LC-MS/ELSD) : 100%                    (Retention Time : 1.17 minutes);
                                                       1)AO

MASS    (ESI, Pos.)                      639     (M + H)+;
  H-NMR     (DMSO-d        6  )    : 5       1.22    (t,    3H),   2.68   (q,   2H),  3.19  (s, 6H),
 6.62    (d,     1H),          7.15         (d,    2H),     7.22-7.36    (m,   3H),  7.40-7.49    (m,
3H),    8.05        (s,       1H),         8.10     (d,    2H),   8.38   (s,   1H),  8.40  (s,  1H),
8.63    (s, 2H),             8.66         (d, 1H),        9.38   (s, 1H).
Example 21-75:                 1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
alpyrimidin-3-yllphenoxy}-5-pyrimidinyl)-3-[2'-methyl-4
 (trifluoromethyl)-2-biphenylyl]urea
                                                CF3
                        0                0N
              /     -N             N  "'
        N                            H     H
           NN             O      N                  CH 3
                N-CH 3
             H3C
Purity       (LC-MS/ELSD) : 100%                         (Retention Time : 1.14 minutes);
MASS    (ESI, Pos.)                 : 625        (M + H)*;
1
  H-NMR     (DMSO-d       6  )     : 5 2.04          (s,    3H),   3.19   (s,   6H),  6.62 (d,  1H),
7.10-7.22          (m,       3H),         7.26-7.46          (m,  5H),  7.70     (s, 1H),  8.09   (d,
2H),    8.38       (s,        1H),        8.53      (s,    1H),   8.62   (s,   2H),  8.65  (s,  1H),
9.42    (s, 1H).
Example 21-76:                 1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[3',4'-dimethyl-4
 (trifluoromethyl)-2-biphenylyliurea
Purity      (LC-MS/ELSD) : 100%                          (Retention Time      : 1.17 minutes);
MASS    (ESI, Pos.)                : 639         (M + H)+;
1
  H-NMR     (DMSO-d        6)      : 5 2.29          (s,    6H),   3.19   (s,   6H),  6.62 (d,  1H),
7.12-7.19          (m,       3H),         7.19-7.22          (m,  1H),  7.30     (d, 1H),  7.36   (d,
1H),   7.42        (dd,         1H),        8.00     (s,    1H),   8.09  (d,   2H),  8.38  (s,  1H),

  8.44-8.48     (i,   1H),      8.62-8.67     (m, 3H),      9.42    (s,    1H).
 Example 21-77:          1-(2-{4-[5-(methylamino)pyrazolo[1,5
 ajpyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2
   (methylsulfonyl)-4-(trifluoromethyl)phenyl]urea
 Purity (LC-MS/ELSD) : 100%                 (Retention Time : 0.93 minutes);
MASS    (ESI, Pos.)             599   (M + H)*;
 'H-NMR     (DMSO-d6 )         5 2.93     (d,   3H),    3.41    (s,   3H),     6.27   (d, 1H),
 7.17    (d,   2H),    7.56-7.67         (m,  1H),    8.03-8.17         (m,   4H),   8.32   (s,
 1H),   8.43-8.55         (m,    2H),   8.73    (s,  2H),     9.03    (s,    1H),   10.33   (s,
 1H).
Example 21-78: 1-(2-{4-[5-(methylamino)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2'-methyl-4
  (trifluoromethyl)-2-biphenylyl]urea
TLC : Rf 0.38         (Chloroform : Methanol = 19                  : 1);
1H-NMR      (DMSO-d 6 )      : 5 2.04     (s,  3H),     2.92    (d,   3H),     6.28   (d, 1H),
7.11-7.45       (m,   8H),       7.56-7.73     (n,   2H),     8.06-8.13        (m,  2H),  8.31
  (s,  1H),    8.46     (d,     1H),   8.51-8.54       (m,   1H),    8.62      (s,  2H),  9.42
  (s, 1H).
Example 21-79:          1-(2-{4-[5-(methylamino)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2-(3-pyridinyl)-5
  (trifluoromethyl)phenyl]urea
TLC : Rf 0.30         (Chloroform : Methanol = 19                  : 1);
1H-NMR
            (DMSO-d 6 )      : 5 2.92     (d,  3H),     6.27    (d,   1H),     7.11-7.18   (m,
2H),    7.46-7.65        (i,    4H),   7.89   (dt,    1H),    8.06-8.14         (n, 2H),  8.23
 (s,   1H),    8.31    (s,     1H),    8.39    (s,   1H),    8.46     (d,    1H),   8.61-8.69
  (m, 4H),    9.22    (s, 1H).
                                                ni

 Example 21-80:           1-(2-{4-[5-(methylamino)pyrazolo[1,5
 a]pyrimidin-3-yljphenoxy}-5-pyrimidinyl)-3-[4
  (trifluoromethyl)-2-biphenylyl]urea
 TLC : Rf 0.42          (Chloroform : Methanol = 19                   : 1);
 1 H-NMR
             (DMSO-d 6  )   : 5 2.92      (d,    3H),     6.26    (d,    1H),    7.11-7.17     (m,
 2H),   7.38-7.64          (m, 8H),     8.04-8.12        (m, 3H),      8.31     (s, 1H),    8.39
 8.42   (m, 1H),       8.46     (d, 1H),      8.63    (s,    2H),    9.35 (s, 1H).
 Example 21-81:           1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
 a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2
 (methylsulfinyl)-5-(trifluoromethyl)phenyl]urea
TLC : Rf 0.14          (Ethyl acetate);
'H-NMR      (DMSO-d  6  )   : 5 2.89      (s,    3H),     3.19    (s,    6H),    6.62   (d,  1H),
 7.15    (d,    2H),    7.64      (d,  1H),    7.90      (d,   1H),     8.09     (d,  2H),   8.26
 (s,   1H),     8.38      (s, 1H),      8.63     (d,    1H),    8.70      (s,   2H),   9.22    (s,
1H),    9.65     (s,   1H).
Example 21-82:           1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
a]pyrimidin-3-yllphenoxy}-5-pyrimidinyl)-3-[3'-(1
hydroxyethyl)-4-(trifluoromethyl)-2-biphenylyl]urea
Purity (LC-MS/ELSD) : 99%                 (Retention Time : 1.07 minutes);
MASS    (ESI, Pos.)            655    (M + H)+;
1H-NMR
            (DMSO-d  6 )    : 5    1.36   (d,    3H),     3.19    (s,    6H),    4.74-4.83     (m,
1H),    5.20-5.23         (m, 1H),      6.62     (d,   1H),     7.15     (d,   2H),   7.27-7.36
 (m, 1H),       7.38-7.56        (m,   5H),    8.04-8.26         (m,    3H),    8.37   (s,   1H),
8.38    (s, 1H),      8.63     (s, 2H),      8.66     (s, 1H),       9.36     (s, 1H).
Example 21-83:           1-{2-[4-(5-methoxypyrazolo[1,5-a]pyrimidin-3
yl)phenoxy]-5-pyrimidinyl}-3-[2-(1H-pyrazol-1-yl)-4
                                                ,-1 1

  (trifluoromethyl)phenyl]urea
 Purity     (LC-MS/ELSD) : 100%           (Retention Time : 1.05 minutes);
 MASS   (ESI, Pos.)           588   (M + H)+
 'H-NMR    (DMSO-d  6  )     5   4.03   (s,  3H),  6.61    (d,   1H),   6.65-6.66    (m,
 1H),  7.20-7.25         (m,  2H),   7.73-7.83    (m,  2H),    7.93   (d, 1H),    8.00
 8.13   (m,   2H),     8.41-8.44      (m,   2H),  8.58    (s,   1H),   8.69   (s,  2H),
 8.93   (d, 1H),      9.56 (brs, 1H),        9.95  (brs, 1H).
Example 21-84:          1-[3-(difluoromethyl)phenyl]-3-{2-[4-(5
methoxypyrazolo[1,5-a]pyrimidin-3-yl)phenoxy]-5
pyrimidinyl}urea
Purity     (LC-MS/ELSD) : 100%            (Retention Time : 0.92 minutes);
MASS    (ESI, Pos.)           504   (M + H)+;
IH-NMR    (DMSO-d   6 )    : 5 4.03     (s,  3H),  6.61    (d,   1H),   7.00-7.24    (m,
4H),   7.42     (t,    1H),    7.52   (d,   1H),  7.78    (s,   1H),   8.10-8.13     (m,
2H),   8.59     (s,    IH),    8.71   (s,   2H),  8.90-8.95       (m,  2H),   9.16   (s,
1H).
Example 21-85:          1-(2,5-dichlorophenyl)-3-{2-[4-(5
methoxypyrazolo[1,5-a]pyrimidin-3-yl)phenoxy]-5
pyrimidinyl}urea
Purity     (LC-MS/ELSD) : 100%            (Retention Time : 1.04 minutes);
MASS   (ESI, Pos.)         : 522    (M + H)+
1H-NMR    (DMSO-d   6)    : 5 4.03     (s,  3H),  6.61   (d,   1H),   7.12   (dd,  1H),
7.21-7.26      (m,    2H),     7.51   (d,   1H),  8.09-8.14       (m, 2H),    8.26   (s,
1H),   8.59    (s,    1H),     8.63   (s,   1H),  8.72   (s,   2H),    8.93   (d,  1H),
9.66   (s, 1H).
Example 21-86:         1-(2,5-difluorophenyl)-3-{2-[4-(5-

methoxypyrazolo[1,5-a]pyrimidin-3-yl)phenoxy]-5
pyrimidinyl}urea
 Purity      (LC-MS/ELSD) : 100%            (Retention Time : 0.94 minutes);
MASS    (ESI, Pos.)            490   (M + H)*;
1 H-NMR     (DMSO-d     )      5 4.03     (s,  3H),   6.61
                     6                                       (d, 1H),     6.81-6.89     (m,
1H),   7.21-7.34          (m,   3H),   7.93-8.00      (m,  1H),   8.10-8.14       (m, 2H),
8.59   (s, 1H),        8.72     (s, 2H),     8.92-8.96    (m, 2H),     9.25    (s, 1H).
Example 21-87: 1-[2-chloro-4-(trifluoromethyl)phenyl]-3-{2-[4
 (5-methoxypyrazolo[1,5-a]pyrimidin-3-yl)phenoxy]-5
pyrimidinyl}urea
Purity      (LC-MS/ELSD) : 100%             (Retention Time : 1.06 minutes);
MASS   (ESI, Pos.)          : 556    (M + H)*;
1 H-NMR    (DMSO-d     )       5 4.03    (s,
                     6                         3H),   6.61   (d,  1H),    7.22-7.26     (m,
2H),   7.69     (dd,      1H),    7.89   (d,   1H),   8.00-8.14    (m,    2H),   8.43   (d,
1H),   8.59      (s,    1H),     8.73   (s,   2H),   8.79   (s,  1H),    8.93     (d, 1H),
9.76   (s, 1H).
Example 21-88: 1-{2-[4-(5-methoxypyrazolo[1,5-a]pyrimidin-3
yl)phenoxy]-5-pyrimidinyl}-3-[2-(4-methyl-1H-1,2,3-triazol-1
yl)-5-(trifluoromethyl)phenyl]urea
Purity (LC-MS/ELSD) : 100%                  (Retention Time : 1.00 minute);
MASS   (ESI, Pos.)          : 603    (M + H)*;
1H-NMR     (DMSO-d   6 )   : 5    2.38   (s,   3H),   4.03   (s,  3H),    6.62    (d, 1H),
7.20-7.24       (m,    2H),     7.58-7.71      (m,  2H),   8.08-8.13      (m,   2H),  8.33
 (s,  1H),     8.51-8.60         (m,  2H),    8.67   (s, 2H),    8.75     (s,   1H),  8.93
 (d, IH),     9.68     (s, 1H).
Example 21-89:           1-[5-chloro-2-(lH-pyrazol-1-yl)phenyl]-3-{2-[4-

 (5-methoxypyrazolo[1,5-a]pyrimidin-3-yl)phenoxy]-5
pyrimidinyl}urea
Purity      (LC-MS/ELSD) : 100%            (Retention Time : 1.05 minutes);
MASS    (ESI, Pos.)         : 554    (M + H)*;
'H-NMR (DMSO-d6 )            5 4.03     (s, 3H),       6.59-6.62    (m, 2H),    7.19-7.24
 (m,  3H),    7.51      (d, 1H),      7.89    (d,    1H),    8.08-8.12     (m,  2H),  8.26
 (d,  1H),    8.27      (d,    1H),   8.58     (s,    1H),    8.67  (s,   2H),   8.92   (d,
1H),   9.36    (s, 1H),       9.87    (s, 1H).
Example 21-90:          1-(2-{4-[5-(3-oxetanyloxy)pyrazolo[1,5
ajpyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2-(3-pyridinyl)-5
 (trifluoromethyl)phenyl]urea
Purity (LC-MS/ELSD) : 94%                (Retention Time : 0.89 minutes);
MASS   (ESI, Pos.)            641    (M + H)+
1 H-NMR    (DMSO-d  6 )      5 4.67-4.71         (m, 2H),     4.99  (t,  2H),   5.71-5.79
 (m,  1H),    6.69      (d,   1H),    7.21-7.26        (m,   2H),  7.47-7.58     (m,  3H),
7.83-7.91      (m,    1H),      8.00-8.04      (m,    2H),    8.24   (s,  1H),   8.39   (s,
1H),   8.60     (s, 1H),        8.64-8.69       (m,   4H),    9.00   (d,  1H),   9.24   (s,
1H).
Example 21-91:          1-[5-chloro-2-(1H-1,2,3-triazol-1-yl)phenyl]-3
{2-[4-(5-methoxypyrazolo[1,5-a]pyrimidin-3-yl)phenoxy]-5
pyrimidinyl}urea
Purity (LC-MS/ELSD) : 100%                 (Retention Time : 0.95 minutes);
MASS   (ESI, Pos.)          : 555    (M + H)+
1H-NMR     (DMSO-d  6 )    : 5   4.03    (s,  3H),      6.61   (d, 1H),    7.22   (d, 2H),
7.31    (dd,   1H),      7.51    (d,   1H),   8.06-8.12        (m, 3H),    8.27   (d, 1H),
8.49    (s,   1H),    8.59      (s, 1H),     8.65      (s,  2H),   8.70    (s, 1H),   8.93
                                              n~ I A

   (d, 1H),     9.58    (s, 1H).
  Example 21-92:          1-(2-{4-[5-(1-azetidinyl)pyrazolo[1,5
  a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-{5
   (trifluoromethyl)-2-[3-(trifluoromethyl)-1H-pyrazol-1
  ylIphenyl}urea
  Purity (LC-MS/ELSD) : 99%               (Retention Time : 1.10 minutes);
 MASS (ESI, Pos.)                681  (M + H)+;
  'H-NMR     (DMSO-d   6)     : 5 2.32-2.42        (m, 2H),    4.15   (t,    4H),    6.23   (d,
  1H),   7.12-7.17         (m, 3H),    7.58     (dd, 1H),     7.70   (d, 1H),       8.04-8.09
   (m, 2H),     8.37      (s,   1H),   8.48     (s,   2H),   8.57    (s, 1H),       8.62-8.65
   (m, 3H),     9.45    (s, 1H).
 Example 21-93:           1-(2-{4-[5-(1-azetidinyl)pyrazolo[1,5
 alpyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2-(4-methyl-1H
pyrazol-1-yl)-5-(trifluoromethyl)phenyl]urea
 Purity (LC-MS/ELSD) : 98%                (Retention Time : 1.10 minutes);
MASS     (ESI, Pos.)          : 627   (M + H)*;
 'H-NMR     (DMSO-d   6 )    : 5   2.15   (s,   3H),    2.32-2.42     (m,    2H),    4.15   (t,
 4H),   6.24      (d,   1H),     7.15   (d,   2H),    7.49   (dd,   1H),     7.70    (d,  1H),
 7.78    (s,    1H),     8.05-8.09       (m,   2H),    8.18   (s,   1H),    8.37     (s,  1H),
 8.58    (d, 1H),      8.62-8.68       (m, 3H),      9.82   (s, 1H),      9.94    (s, 1H).
Example 21-94:            1-(2-{4-[5-(1-azetidinyl)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2-(3-pyridinyl)-4
   (trifluoromethyl)phenyl]urea
Purity       (LC-MS/ELSD) : 97%           (Retention Time : 0.93 minutes);
MASS     (ESI, Pos.)          : 624   (M + H)+
'H-NMR     (DMSO-d    6 )    : 6 2.32-2.42        (m, 2H),     4.15   (t,    4H),    6.24   (d,

 1H),   7.11-7.16           (m,    2H),    7.53-7.58           (m,     2H),      7.76   (dd,   1H),
 7.88-7.92      (m,      1H),    8.06    (d,   2H),       8.23     (s,    1H),     8.28   (d,  1H),
 8.37   (s, 1H),       8.62-8.68        (m, 5H),       9.27     (s, 1H).
 Example 21-95:           1-(2-{4-[5-(1-azetidinyl)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl) -3- [5-chloro-2- (lH
pyrazol-1-yl)phenyl]urea
Purity (LC-MS/ELSD) : 100%                   (Retention Time : 1.03 minutes);
MASS    (ESI, Pos.)             579   (M + H)+;
'H-NMR     (DMSO-d    6)    : 5 2.32-2.42            (m,   2H),    4.15      (t,   4H),  6.24    (d,
1H),   6.62     (t,     1H),     7.13-7.17        (m,    2H),    7.22      (dd,    1H),  7.51    (d,
1H),   7.89      (d,     1H),    8.04-8.09         (m,    2H),    8.26      (d,    1H),  8.28    (d,
1H),   8.37      (s,     1H),    8.62-8.66         (m,    3H),    9.37      (s,    1H),  9.87    (s,
1H).
Example 21-96:            1-(2-{4-[5-(1-azetidinyl)pyrazolo[1,5
alpyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[5-chloro-2-(3
pyridinyl)phenyl]urea
Purity (LC-MS/ELSD) : 100%                   (Retention Time : 0.86 minutes);
MASS   (ESI, Pos.)           : 590    (M + H)*;
1H-NMR
           (DMSO-d   6  )   : 5   2.32-2.42          (m,   2H),    4.15      (t,   4H),  6.24    (d,
1H),  7.11-7.16           (m,   2H),   7.23    (dd, 1H),         7.28      (d, 1H),     7.53    (dd,
1H),  7.80-7.85           (m,   1H),    8.04-8.12         (m,   4H),     8.37     (s, 1H),    8.59
8.65   (m,    5H),     9.17     (s, 1H).
Example 21-97:           1-(2-{4-[5-(1-azetidinyl)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2-(2H-1,2,3
triazol-2-yl)-5-(trifluoromethyl)phenyl]urea
Purity (LC-MS/ELSD) : 100%                  (Retention Time : 1.08 minutes);
                                               ,-   1I

 MASS    (ESI, Pos.)              614   (M + H)+
 1
   H-NMR     (DMSO-d  6  )       5   2.32-2.42      (m,    2H),    4.15    (t,   4H),  6.24  (d,
 1H),   7.13-7.18          (m, 2H),      7.58    (dd, 1H),        8.05-8.09       (m, 3H),  8.32
  (s,  2H),     8.38      (s,     1H),   8.62-8.66        (m,    2H),   8.69     (s,  2H),  9.66
  (s,  1H),     9.99    (s,     1H).
 Example 21-98:           1-(2-{4-[5-(l-azetidinyl)pyrazolo[1,5
 a]pyrimidin-3-yllphenoxy}-5-pyrimidinyl)-3-[5-chloro-2-(lH
 1,2,3-triazol-1-yl)phenyl]urea
 Purity      (LC-MS/ELSD) : 96%             (Retention Time           : 0.94 minutes);
MASS    (ESI, Pos.)            : 580    (M + H)+;
 1
   H-NMR    (DMSO-d  6  )     : 5 2.32-2.42        (m,    2H),     4.15   (t,    4H),  6.24  (d,
 1H),   7.12-7.17          (m, 2H),      7.31   (dd, 1H),         7.51   (d, 1H),     8.05-8.08
  (m,  3H),     8.27      (d,    1H),    8.37    (s,    1H),     8.48   (s,    1H),   8.59-8.65
  (m, 4H),     9.57     (s, 1H).
Example 21-99: 1-(2-{4-[5-(l-azetidinyl)pyrazolo[1,5
alpyrimidin-3-yllphenoxy}-5-pyrimidinyl)-3-[5-chloro-2-(2H
1,2,3-triazol-2-yl)phenyl]urea
Purity       (LC-MS/ELSD) : 100%             (Retention Time : 1.06 minutes);
MASS    (ESI, Pos.)           : 580     (M + H)+
'H-NMR      (DMSO-d  6  )    : 5     2.32-2.42     (m,    2H),     4.15   (t,    4H),  6.24  (d,
1H),    7.13-7.18          (m, 2H),      7.29   (dd, 1H),         7.80   (d, 1H),     8.05-8.09
 (m,   2H),     8.26      (s,    2H),    8.33    (d,     1H),     8.37   (s,    1H),   8.64  (d,
1H),    8.68     (s, 2H),        9.36    (s, 1H),      9.90     (s, 1H).
Example 21-100:             1-(2-{4-[5-(1-azetidinyl)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2-chloro-5
 (trifluoromethyl)phenyl]urea

 Purity       (LC-MS/ELSD) : 100%                (Retention Time : 1.03 minutes);
MASS     (ESI, Pos.)               581    (M + H)+
 1
   H-NMR     (DMSO-d  6   )    : 5    2.32-2.42       (m,   2H),    4.15   (t,  4H),  6.24   (d,
 1H),   7.14-7.19            (m,    2H),   7.40    (dd, 1H),       7.72   (d, 1H),   8.05-8.09
  (m,  2H),      8.38       (s, 1H),        8.57    (d,   1H),     8.64   (d,  1H),   8.72   (s,
2H),    8.78      (s, 1H),         9.69    (s, 1H).
Example 21-101:               1-(2-{4-[5-(1-azetidinyl)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2-fluoro-5
 (trifluoromethyl)phenyl]urea
Purity       (LC-MS/ELSD) : 100%                (Retention Time         : 1.00 minute);
MASS    (ESI, Pos.)             : 565     (M + H)*;
'H-NMR      (DMSO-d  6   )     : 5    2.32-2.42       (m,   2H),    4.15   (t,  4H),  6.24   (d,
1H),    7.13-7.18            (m,    2H),    7.38-7.53       (m,   2H),   8.04-8.09     (m, 2H),
8.37     (s,    1H),    8.52         (dd,   1H),   8.63     (d,   1H),   8.71   (s,  2H),  9.08
 (s, 1H),      9.27     (s, 1H).
Example 21-102:               1-(2-{4-[5-(1-azetidinyl)pyrazolo[1,5
alpyrimidin-3-yllphenoxy}-5-pyrimidinyl)-3-[2-methyl-5
 (trifluoromethyl)phenyl]urea
Purity       (LC-MS/ELSD) : 99%               (Retention Time : 1.03 minutes);
MASS    (ESI, Pos.)            : 561      (M + H)+;
1
  H-NMR     (DMSO-d  6  )         5   2.32-2.42       (m,   5H),    4.15   (t, 4H),   6.24   (d,
1H),    7.14-7.18           (m,    2H),    7.29    (dd, 1H),       7.41   (d, 1H),   8.05-8.09
 (m,   2H),     8.27      (s,      1H),    8.37-8.38       (m,   2H),    8.64   (d,  1H),  8.72
 (s,  2H),     9.31     (s,      1H).
Example 21-103:               1-(2-{4-[5-(1-azetidinyl)pyrazolo[1,5
a]pyrimidin-3-yllphenoxy}-5-pyrimidinyl)-3-(2,5
                                                   I)1 0

 dichlorophenyl)urea
 Purity (LC-MS/ELSD) : 97%             (Retention Time : 1.06 minutes);
MASS    (ESI, Pos.)          547  (M + H)+
 1H-NMR    (DMSO-d   6)   : 5 2.32-2.42        (m,   2H),    4.15    (t,    4H),  6.24   (d,
 1H),  7.10-7.18        (m,  3H),    7.50   (d,    1H),    8.05-8.09        (m,  2H),  8.26
  (d, 1H),   8.38     (s, 1H),    8.63-8.71 (m, 4H),            9.66     (s, 1H).
Example 21-104:          1-(2-{4-[5-(1-azetidinyl)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-(2,4
dichlorophenyl)urea
Purity     (LC-MS/ELSD) : 100%          (Retention Time : 1.02 minutes);
MASS   (ESI, Pos.)          547   (M + H)+
'H-NMR    (DMSO-d6)       : 5 2.32-2.42        (m,   2H),    4.15    (t,    4H),  6.24   (d,
1H),   7.13-7.17        (m, 2H),    7.38   (dd, 1H),        7.63    (d, 1H),     8.04-8.09
 (m, 2H),     8.14     (d, 1H),    8.37   (s, 1H),        8.56    (brs, 1H),      8.66   (d,
1H),   8.70    (s, 2H),     9.57    (brs, 1H).
Example 21-105:          1-(2-{4-[5-(1-azetidinyl)pyrazolo[1,5
a]pyrimidin-3-yllphenoxy}-5-pyrimidinyl)-3-(2,5
difluorophenyl)urea
Purity     (LC-MS/ELSD) : 100%          (Retention Time : 0.93 minutes);
MASS   (ESI, Pos.)        : 515   (M + H)+;
1H-NMR    (DMSO-d  6  )   : 5 2.32-2.42        (m,   2H),    4.15    (t,   4H),   6.24   (d,
1H),   6.81-6.88        (m,  1H),   7.13-7.18        (m,   2H),    7.25-7.34      (m,  1H),
7.94-8.00      (m, 1H),      8.05-8.09      (m,     2H),    8.38    (s,    1H),   8.64   (d,
1H),   8.70    (s, 2H),     8.95    (s, 1H),      9.25    (s, 1H).
Example 21-106:          1-(2-{4-[5-(1-azetidinyl)pyrazolo[1,5
a]pyrimidin-3-yllphenoxy}-5-pyrimidinyl)-3-[3
                                           n-,  C
                                                n

   (difluoromethyl)phenyl]urea
   Purity (LC-MS/ELSD) : 99%            (Retention Time           : 0.90 minutes);
  MASS   (ESI, Pos.)          529   (M + H)*;
  'H-NMR    (DMSO-d 6  )  : 5 2.32-2.42          (m,   2H),   4.15    (t,  4H),  6.24    (d,
   1H),  6.81-7.19       (m,   4H),   7.41      (t,   1H),   7.51    (d,  1H),   7.77    (s,
  1H),   8.05-8.09       (n,   2H),   8.38      (s,   1H),   8.64    (d,  1H),   8.70    (s,
  2H),   8.89   (s, 1H),      9.16 (s, 1H).
  Example 21-107:        1-{6-[4-(5-methoxypyrazolo[1,5-a]pyrimidin-3
  yl)phenoxy-3-pyridinyl}-3-[2-(3-pyridinyl)-5
   (trifluoromethyl)phenyl]urea
  Purity (LC-MS/ELSD) : 100%              (Retention Time : 0.96 minutes);
 MASS    (ESI, Pos.)       : 598    (M + H)*;
 'H-NMR    (DMSO-d  6 )      5 4.02     (s,    3H),    6.60   (d,   1H),   6.99   (d,  1H),
 7.10-7.15      (m,   2H),    7.45-7.58        (m,   3H),   7.87-7.91      (m,  1H),   7.97
   (dd, 1H),    8.07-8.09       (n, 4H),      8.42    (s, 1H),     8.56   (s, 1H),    8.64
 8.69    (m, 2H),    8.92     (d, 1H),      9.16    (s, 1H).
 Example 21-108:         1-{6-[4-(5-methoxypyrazolo[1,5-a]pyrimidin-3
 yl)phenoxy]-3-pyridinyl}-3-[2-(1H-pyrazol-1-yl)-5
   (trifluoromethyl)phenyl]urea
 Purity (LC-MS/ELSD) : 100%               (Retention Time : 1.08 minutes);
MASS     (ESI, Pos.)       : 587    (M + H)*;
'H-NMR     (DMSO-d  6 )   : 5 4.02     (s,     3H),    6.60   (d,   1H),   6.66-6.68    (m,
 1H),    7.01   (d, 1H),      7.11-7.16        (m, 2H),     7.49    (dd, 1H),    7.73   (d,
 1H),    7.94   (d, 1H),      7.99    (dd, 1H),        8.06-8.11     (m, 2H),    8.16   (d,
 1H),    8.40   (d,   1H),     8.56   (s, 1H),        8.60   (s, 1H),     8.92   (d, 1H),
 9.54    (s, 1H),    9.80     (s, 1H).

 Example 21-109:           1-{6-[4-(5-methoxypyrazolo[1,5-alpyrimidin-3
 yl)phenoxyl-3-pyridinyl}-3-{5-(trifluoromethyl)-2-[3
  (trifluoromethyl)-lH-pyrazol-1-yl]phenyl}urea
 Purity (LC-MS/ELSD) : 100%                 (Retention Time : 1.13 minutes);
 MASS    (ESI, Pos.)           655   (M + H)*;
 1 H-NMR    (DMSO-d  6  )   : 5 4.02      (s,    3H),    6.60    (d,   1H),    7.01    (d,  1H),
 7.12-7.15       (m,   3H),    7.55    (dd, 1H),        7.68    (d, 1H),      7.96   (dd, 1H),
 8.07-8.13       (m,   3H),     8.43    (s,     1H),    8.47    (d, 1H),       8.52    (d,  1H),
 8.56   (s, 1H),       8.92    (d, 1H),       9.38    (s, 1H).
Example 21-110:           1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2-(4-methyl-1H
pyrazol-1-yl)-5-(trifluoromethyl)phenyl]urea
 Purity (LC-MS/ELSD) : 100%                 (Retention Time : 1.06 minutes);
MASS    (ESI, Pos.)         : 615    (M + H)+.
Example 21-111:           1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
ajpyrimidin-3-yllphenoxy}-5-pyrimidinyl)-3-[2-(3-pyridinyl)-4
 (trifluoromethyl)phenyl]urea
Purity       (LC-MS/ELSD) : 100%            (Retention Time : 0.89 minutes);
MASS    (ESI, Pos.)         : 612    (M + H)*;
'H-NMR      (DMSO-d  6 )    : 5 3.19     (s,     6H),    6.63    (d,   1H),    7.12-7.19      (m,
2H),    7.52-7.60         (m,   2H),    7.75      (dd,     1H),    7.90     (dt,   1H),    8.07
8.13    (m,    2H),    8.22     (s,  1H),      8.28    (d,   1H),    8.38     (s,  1H),    8.62
8.70    (m,    5H),   9.26     (s, 1H).
Example 21-112:           1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2
 (methylsulfonyl)-4-(trifluoromethyl)phenyl]urea

TLC : Rf 0.50           (Ethyl acetate);
'H-NMR      (DMSO-d   6  )    :  5 3.32   (s,   6H),     3.41    (s,    3H),   6.63    (d,  1H),
7.15-7.22        (m,    2H),      8.04-8.15     (m,   4H),     8.39      (s,  1H),   8.48-8.55
 (m,  1H),     8.65       (d,    1H),  8.73    (s,   2H),     9.03      (s,  1H),   10.33     (s,
1H).
Example 21-113:             1-(2-{4-[5-(1-azetidinyl)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2
 (methylsulfonyl)-4-(trifluoromethyl)phenyl]urea
TLC : Rf 0.37           (Chloroform : Methanol = 19                  : 1);
1H-NMR     (DMSO-d   6  )    : 5 2.31-2.42       (m,   2H),    3.41      (s,  3H),  4.12-4.18
 (m,  4H),     6.24       (d,    1H),   7.10-7.19       (m,   2H),     8.01-8.11      (m,   4H),
8.37    (s,    1H),     8.49      (d,  1H),   8.63     (d,   1H),      8.73    (s,  2H),    9.02
 (s, 1H),     10.32        (s, 1H).
Example 21-114:             1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2-(5-methyl-3
pyridinyl)-5-(trifluoromethyl)phenyl]urea
Purity      (LC-MS/ELSD) : 100%             (Retention Time           : 0.89 minutes);
MASS   (ESI, Pos.)             : 626  (M + H)+
  H-NMR    (DMSO-d   6  )    : 5   2.38   (s,  3H),     3.19    (s,    6H),    6.63    (d,  1H),
7.13-7.19       (m, 2H),         7.44-7.53    (m, 2H),      7.69-7.73         (m, 1H),     8.07
8.13    (m,    2H),     8.18      (s,  1H),   8.38      (s,   1H),     8.42-8.45      (m,   2H),
8.51-8.54       (m, 1H),         8.63-8.67    (m, 3H),      9.25      (s, 1H).
Example 21-115:             1-(2-{4-[5-(1-azetidinyl)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2-(5-methyl-3
pyridinyl)-5-(trifluoromethyl)phenyl]urea
Purity     (LC-MS/ELSD) : 99%             (Retention Time : 0.90 minutes);

MASS    (ESI, Pos.)             : 638    (M + H)+
1H-NMR
            (DMSO-d 6 )          6 2.32-2.47          (m,  5H),   4.12-4.19        (m,   4H),  6.24
 (d,  1H),      7.12-7.18            (m,  2H),      7.43-7.53      (m,   2H),     7.70-7.73      (m,
1H),    8.04-8.10           (m,    2H),    8.18      (s,  1H),    8.37    (s,    1H),    8.42-8.46
 (m, 2H),      8.51-8.54          (m, 1H),        8.63-8.66     (m, 3H),       9.26    (s, 1H).
Example 21-116:              1-(2-{4-[5-(1-azetidinyl)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[3',4'-dimethyl-4
 (trifluoromethyl)-2-biphenylyl]urea
Purity      (LC-MS/ELSD) : 99%                (Retention Time          : 1.19 minutes);
MASS    (ESI, Pos.)            : 651     (M + H)*;
1
  H-NMR    (DMSO-d   6  )     : 5 2.30       (s,    6H),   2.33-2.44      (m,    2H),    4.11-4.19
 (m,  4H),     6.24       (d,     1H),    7.12-7.18         (m,  3H),    7.20-7.22        (m,  1H),
7.28-7.46        (m,    3H),       8.00     (s,    1H),    8.04-8.10       (m,    2H),    8.37   (s,
1H),   8.45-8.48          (m, IH),        8.62-8.66       (m, 3H),      9.42    (s, 1H).
Example 21-117:             1-(2-{4-[5-(1-azetidinyl)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxyl-5-pyrimidinyl)-3-[3'-methyl-4
(trifluoromethyl)-2-biphenylyl]urea
Purity      (LC-MS/ELSD) : 100%                  (Retention Time        : 1.15 minutes);
MASS   (ESI, Pos.)             : 637     (M + H)*;
1H-NMR     (DMSO-d 6 )       : 5 2.32-2.43            (m,  5H),   4.11-4.20        (m,   4H),  6.24
(d,   1H),     7.12-7.18            (m,   2H),     7.20-7.32       (m,   3H),     7.37-7.48      (m,
3H),   8.00-8.11           (m, 3H),       8.37      (s, 1H),    8.43-8.46        (m,   1H),   8.63
8.66   (m, 3H),        9.41       (s, 1H).
Example 21-118:             1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2
(methylsulfonyl)phenyl]urea

 Purity      (LC-MS/ELSD) : 100%                 (Retention Time      : 0.86 minutes);
MASS    (ESI, Pos.)               545   (M + H)*;
 'H-NMR     (DMSO-d   6  )       5   3.19    (s,    6H),   3.28   (s,   3H),    6.63   (d, 1H),
 7.14-7.20       (m, 2H),         7.27    (td, 1H),       7.65-7.71      (m, 1H),    7.85   (dd,
 1H),   8.09-8.18          (m,     3H),   8.39      (s,  1H),   8.65     (d,  1H),   8.72-8.78
  (m, 3H),     10.09       (s, 1H).
Example 21-119: 1-(2-{4-[5-(methylamino)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2
  (methylsulfonyl)-5-(trifluoromethyl)phenyllurea
Purity       (LC-MS/ELSD) : 100%                (Retention Time       : 0.92 minutes);
MASS    (ESI, Pos.)            : 599    (M + H)+
1
  H-NMR     (DMSO-d  6  )        5 2.93      (d,    3H),   3.38   (s,   3H),    6.27   (d, 1H),
7.17     (d,    2H),     7.56-7.68         (m,     2H),   8.03-8.18       (m,  3H),   8.32   (s,
1H),   8.47      (d,     1H),      8.63    (s,     1H),   8.73   (s,   2H),    8.96    (s, 1H),
10.28     (s, 1H).
Example 21-120:             1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2-(ethylsulfonyl)
5-(trifluoromethyl)phenyl]urea
TLC   : Rf 0.24         (Hexane : Ethyl Acetate = 1 : 4);
1
  H-NMR    (DMSO-d   6  )     : 5    1.14    (t,    3H),   3.18   (s,   6H),    3.45   (q, 2H),
6.61    (d,    1H),     7.16       (d,  2H),      7.62   (dd,   1H),   8.01     (d,  1H),  8.10
 (d,  2H),     8.38       (s,    1H),    8.61-8.67        (m,  2H),    8.72     (s,  2H),  8.99
 (s,  1H),     10.28      (s,    1H).
Example 21-121:             1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[2-(methylthio)-5
 (trifluoromethyl)phenyl]urea

 TLC : Rf 0.28               (Ethyl Acetate);
 1H-NMR      (DMSO-d      6   )    :  5   2.53       (s,  3H),   3.19     (s,   6H),    6.62   (d, 1H),
 7.16    (d,     2H),        7.40        (dd,    1H),     7.54    (d,  1H),    8.10      (d, 2H),  8.19
  (d,  1H),       8.38          (s,    1H),      8.42      (s,  1H),    8.63     (d,   1H),   8.70   (s,
 2H),   9.62       (s,      1H) .
 Example 21-122:                 1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
 a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[5-fluoro-2
  (methylsulfonyl)phenyl]urea
 Purity      (LC-MS/ELSD) : 100%                       (Retention Time        : 0.93 minutes);
MASS    (ESI, Pos.)                    599     (M + H)+;
 1
   H-NMR    (DMSO-d      6   )        5 3.20        (s,   6H),   3.30    (s,   3H),     6.63   (d, 1H),
 7.09-7.21         (m,      3H),        7.91      (dd,    1H),   8.08-8.17        (m,   3H),  8.39   (s,
 1H),   8.65       (d, 1H),            8.72      (s, 2H),      8.93   (s, 1H),       10.26   (s, 1H).
Example 21-123:                  2-{[(2-{4-[5-(dimethylamino)pyrazolo[1,5
a]pyrimidin-3-yllphenoxy}-5-pyrimidinyl) carbamoyl]amino}-N,N
dimethyl-4-(trifluoromethyl)benzenesulfonamide
                                             CF3
               N       O       N
          N                                  S, CH3
                N-CH3
            H3C
Purity       (LC-MS/ELSD) : 100%                       (Retention Time : 1.04 minutes);
MASS    (ESI, Pos.)                 : 642     (M + H)+;
'H-NMR      (DMSO-d      6  )     : 5     2.75      (s,   6H),   3.19    (s,   6H),     6.63   (d, 1H),
7.17    (d,      2H),       7.59        (dd,     1H),    7.94    (d,   1H),    8.11     (d,  2H),  8.39
 (s,   1H),       8.61         (d,     1H),      8.65     (d,   1H),   8.72      (s,   2H),   8.98   (s,
1H),    10.28       (s, 1H).

 Example 21-124: 2-{[(2-{4-[5-(1-azetidinyl)pyrazolo[1,5
 a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)carbamoyl]amino}-N,N
 dimethyl-4-(trifluoromethyl)benzenesulfonamide
 Purity      (LC-MS/ELSD) : 100%           (Retention Time : 1.06 minutes);
MASS    (ESI, Pos.)            654   (M + H)+;
 1H-NMR
            (DMSO-d  6  )     5 2.31-2.44        (m,   2H),   2.75   (s,  6H),   4.15    (t,
 4H),   6.24     (d,   1H),    7.16    (d,   2H),    7.60    (dd,  1H),   7.95    (d,  1H),
 8.08    (d,    2H),    8.38     (s,  1H),    8.61    (d,   1H),   8.64   (d,   1H),   8.72
  (s, 2H),     8.98    (s, 1H),      10.28    (s, 1H).
Example 21-125:           2-{[(2-{4-[5-(dimethylamino)pyrazolo[1,5
a]pyrimidin-3-yllphenoxy}-5-pyrimidinyl)carbamoyl]amino}-4
fluoro-N,N-dimethylbenzenesulfonamide
Purity       (LC-MS/ELSD) : 100%           (Retention Time : 0.98 minutes);
MASS    (ESI, Pos.)         : 592    (M + H)+.
Example 21-126:           1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[3'
 (hydroxymethyl)-4-(trifluoromethyl)-2-biphenylyl]urea
Purity      (LC-MS/ELSD) : 100%            (Retention Time : 1.04 minutes);
MASS   (ESI, Pos.)          : 641    (M +,H)+
1H-NMR
           (DMSO-d   6 )   : 6 3.19      (s,   6H),    4.58   (d,  2H),   5.28    (t,  1H),
6.63    (d,    1H),    7.15     (d,  2H),    7.31    (d, 1H),     7.36   (s,   1H),   7.37
7.56    (m,    4H),    8.04      (s,  1H),    8.10    (d,   2H),   8.38   (s,   1H),   8.42
 (s, lH),      8.62-8.68       (m, 3H),     9.39    (s, 1H).
Example 21-127:           1-(2-{4-[5-(1-azetidinyl)pyrazolo[1,5
a]pyrimidin-3-yl]phenoxy}-5-pyrimidinyl)-3-[3'
 (hydroxymethyl)-4-(trifluoromethyl)-2-biphenylyl]urea

 Purity      (LC-MS/ELSD) :          100%    (Retention Time         : 1.05 minutes);
 MASS    (ESI, Pos.)           653    (M + H)+;
 1
   H-NMR    (DMSO-d  6  )      5   2.37    (quint,     2H),    4.15     (t,  4H),  4.58   (d,
 2H),   5.30     (t,     1H),    6.24    (s,   1H),     7.14    (d,   2H),   7.24-7.56    (m,
 6H),   8.02-8.09         (m,   3H),    8.37    (s,   1H),    8.42     (s,  1H),  8.60-8.63
  (m, 3H),     9.38    (s, 1H).
 Example 21-128:           1-(2-{4-[5-(1-azetidinyl)pyrazolo[1,5
 a]pyrimidin-3-yl]phenoxyl-5-pyrimidinyl)-3-[3'-(hydroxyethyl)
 4-(trifluoromethyl)-2-biphenylyl]urea
 Purity     (LC-MS/ELSD) : 100%              (Retention Time         : 1.08 minutes);
MASS    (ESI, Pos.)            667    (M + H)*;
 1
   H-NMR    (DMSO-d  6  )      5   1.36    (d,   3H),     2.37    (quint,    2H),  4.15   (t,
 4H),   4.75-4.82          (m,   1H),   5.21     (d,   IH),    6.24     (d,  1H),  7.14   (d,
2H),    7.29-7.34         (m,   1H),    7.38-7.53        (m,  5H),    8.02-8.10    (m,  3H),
 8.37   (s, 2H),       8.62-8.64       (m, 3H),      9.37    (s, 1H).
Example 21-129:            1-(2-{4-[5-(dimethylamino)pyrazolo[1,5
a]pyrimidin-3-yllphenoxy}-5-pyrimidinyl)-3-[3'-(2-hydroxy-2
propanyl)-4-(trifluoromethyl)-2-biphenylyl]urea
Purity      (LC-MS/ELSD) :          100%     (Retention Time         : 1.06 minutes);
MASS    (ESI, Pos.)          : 669    (M + H)+.
Example 21-130:            1-[3'-(hydroxymethyl)-4-(trifluoromethyl)-2
biphenylyl]-3-{2-[4-(5-methylpyrazolo[1,5-a]pyrimidin-3
yl)phenoxy]-5-pyrimidinyl}urea
Purity      (LC-MS/ELSD) : 100%              (Retention Time         : 1.02 minutes);
MASS    (ESI, Pos.)            612    (M + H)+;
'H-NMR     (DMSO-d   6 )    : 5   2.60    (s,   3H),    4.58     (d,  2H),   5.28   (t, 1H),

 6.98    (d,    1H),      7.23       (d,   2H),    7.30        (d,  1H),    7.34-7.56    (m, 5H),
 8.05    (s,   1H),       8.14      (d,   2H),     8.42       (d,   1H),    8.65  (s,  2H),  8.66
  (s, 1H) ,    9.00      (d,     1H) ,   9.40    (s,     1H).
Example 21-131:              1-[3'-(1-hydroxyethyl)-4-(trifluoromethyl)-2
biphenylyll-3-{2-[4-(5-methylpyrazolo[1,5-a]pyrimidin-3
yl)phenoxy]-5-pyrimidinyl}urea
Purity       (LC-MS/ELSD) : 100%                (Retention Time :            1.04 minutes);
MASS    (ESI,     Pos.)         : 626    (M + H)+;
'H-NMR     (DMSO-d    6  )     : 5    1.36   (d,     3H),      2.60    (s,  3H),  4.74-4.83    (m,
1H),    5.21      (d,     1H),      6.98    (d,    1H),       7.23    (d,   2H),  7.27-7.35    (m,
1H),   7.39-7.52            (m,    5H),    8.07      (s,    1H),     8.10-8.17     (m, 2H),  8.37
 (s,  1H),     8.64        (s,     2H),    8.66      (s,    1H),     9.00    (d, 1H),   9.38   (s,
1H).
Example 21-132:              1-[3'-(2-hydroxy-2-propanyl)-4
 (trifluoromethyl)-2-biphenylyl]-3-{2-[4-(5-methylpyrazolo[1,5
a]pyrimidin-3-yl)phenoxy]-5-pyrimidinyl}urea
Purity      (LC-MS/ELSD) : 100%                 (Retention Time            : 1.06 minutes);
MASS   (ESI, Pos.)              : 640    (M + H)+
1
  H-NMR    (DMSO-d     6 )     : 5    1.45   (s,     6H),     2.60     (s,  3H),  5.07   (s, 1H),
6.98    (d,    1H),      7.23       (d,   2H),     7.24-7.31          (m,   1H),  7.41-7.59   (m,
5H),   8.08       (s,    1H),       8.11-8.18         (m,   2H),     8.34    (s,  1H),  8.64   (s,
2H),   8.66      (s, 1H),         9.00    (d, 1H),        9.37     (s, 1H).
Example 21-133:              1-{2-[4-(5-methylpyrazolo[1,5-a]pyrimidin-3
yl)phenoxy]-5-pyrimidinyl}-3-{5-(trifluoromethyl)-2-[3
 (trifluoromethyl)-1H-pyrazol-1-yl]phenyl}urea
Purity      (LC-MS/ELSD) : 100%                 (Retention Time            : 1.09 minutes);

MASS    (ESI, Pos.)             640   (M + H)+;
1
  H-NMR     (DMSO-d 6  )       5  2.60    (s,  3H),   6.98    (d,  1H),  7.12   (d,  1H),
7.23    (d,    2H),    7.58      (dd,   1H),   7.70   (d,   1H),   8.14  (d,  2H),   8.47
 (s,  2H),     8.57      (s,   1H),    8.63-8.67     (m,   3H),    9.00  (d,  1H),   9.46
 (s,  1H).
Example 21-134:           1-[2-(methylsulfonyl)-5
 (trifluoromethyl)phenyl]-3-(2-{4-[5-(3
oxetanyloxy)pyrazolo[1,5-a]pyrimidin-3-yl]phenoxy}-5
pyrimidinyl)urea
Purity      (LC-MS/ELSD) :          100%    (Retention Time       : 0.97 minutes);
MASS   (ESI, Pos.)           : 642    (M + H)+;
1H-NMR     (DMSO-d  6 )    : 5 3.38      (s,  3H),   4.63-4.76      (m, 2H),   4.96-5.04
 (m, 2H),     5.76    (quint, 1H),          6.70   (d, 1H),     7.26  (d, 2H),   7.64   (d,
1H),   7.99-8.11         (m,   3H),    8.59-8.64     (m,  2H),    8.75  (s, 2H),    8.93
9.03   (m,    2H),    10.29      (s, 1H).
Example 22
       The similar procedure as Example 7 was carried out with a
corresponding amine compound produced with 6
chloroimidazo[1,2-b]pyridazine in place of Example 19 produced
with 5-chloropyrazolo[1,5-a]pyrimidine, and the compound
produced in Example 3 or a corresponding carbamate or
isocyanate compound in place of the compound produced in
Example 3 to give the present compounds having the following
physical characteristics.
Example 22-1:        1-(2-(lH-pyrazol-1-yl)-5
(trifluoromethyl)phenyl)-3-(2-(4-(6-(azetidin-l-

 yl)imidazo[1,2-b]pyridazin-3-yl)phenoxy)pyrimidin-5-yl)urea
                                        CF3
                     0 YN~        0
            NN              N   ' N>N
       N                          H
                     NjN
TLC : Rf 0.50           (Ethyl Acetate              Methanol           9     1);
1 H-NMR
           (DMSO-d     6)    : 5 2.32-2.42         (m,    2H),    4.08     (t,  4H),    6.64-6.68
  (m, 2H),     7.27       (d,     2H),    7.51    (d,    1H),    7.74      (d,   1H),    7.88   (d,
 1H),  7.95      (s,     2H),       8.21    (d,  2H),     8.40     (d,   1H),    8.58    (s,  1H),
8.69   (s, 2H),         9.69 (s, 1H),           9.95    (s,   1H).
Example 22-2: 1-(2-(4-(6-(azetidin-1-yl)imidazo[1,2
b]pyridazin-3-yl)phenoxy)pyrimidin-5-yl)-3-(2-(pyridin-3-yl)
5-(trifluoromethyl)phenyl)urea
TLC : Rf 0.52           (Ethyl Acetate : Methanol = 9 : 1);
1H-NMR
           (DMSO-d 6) : 5 2.32-2.42                 (m,    2H),    4.08     (t, 4H),     6.66   (d,
1H),   7.24-7.27           (m,    2H),    7.47-7.58         (m,  3H),     7.87-7.95      (m,  3H),
8.20-8.23       (m,     3H),       8.38     (s,  1H),     8.65-8.68        (m,   4H),    9.24   (s,
1H).
Example 22-3: 1-(2-(4-(6-(azetidin-1-yl)imidazo[1,2
b]pyridazin-3-yl)phenoxy)pyrimidin-5-yl)-3-(3
 (trifluoromethyl)phenyl)urea
TLC   : Rf 0.28         (Chloroform : Methanol = 19 : 1);
1H-NMR
           (DMSO-d6 ) : 5 2.33-2.43                (m,    2H),   4.06-4.12         (m, 4H),   6.67
 (d,  1H),     7.25-7.36            (m,  3H),    7.52     (t,   1H),     7.62     (d,  1H),   7.90
 (d,  1H),     7.96-7.99            (m,  2H),    8.19-8.26        (m,    2H),    8.73    (s,  2H),
8.99 (s, 1H),          9.31      (s, 1H).

 Example 22-4:           1-(2-(4-(6-(azetidin-1-yl)imidazo[1,2
b]pyridazin-3-yl)phenoxy)pyrimidin-5-yl)-3-(2-phenyl-5
  (trifluoromethyl)pyridin-3-yl)urea
TLC : Rf 0.34            (Chloroform : Methanol = 19 : 1);
 'H-NMR    (DMSO-d     6 )  : 5 2.33-2.43         (m,   2H),  4.06-4.11     (m, 4H),  6.68
  (d, 1H),     7.25-7.29           (m,   2H),   7.53-7.61      (m,  3H),  7.64-7.69     (m,
2H),    7.90     (d,      1H),     7.97     (s, 1H),    8.20-8.25    (m,  2H),   8.43   (s,
 1H),   8.69    (s,      2H),     8.72-8.75      (m,   1H),   8.76-8.79    (m,  1H),  9.47
  (s, 1H).
Example 22-5:           1-(2-(pyridin-3-yl)-5-(trifluoromethyl)phenyl)
3-(2-(4-(6-(pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3
yl)phenoxy)pyrimidin-5-yl)urea
                                       CF3
                    OYN
                                 O
                    f, N /     N   N
                               H   H
             N
                                           N
TLC : Rf 0.59            (Ethyl Acetate : Methanol             =  9 : 1);
1H-NMR     (DMSO-d6 ) : 5 1.96-2.01               (m,   4H),  3.47-3.52     (m, 4H),  6.87
 (d,  1H),     7.25-7.28           (m,   2H),   7.50-7.58      (m,  3H),  7.85-7.94    (m,
3H),   8.23-8.28           (m,   3H),      8.39  (s,   1H),   8.65-8.68    (m,  4H),  9.24
 (s, 1H).
Example 22-6:          1-(2-(4-(6-(pyrrolidin-1-yl)imidazo[1,2
b]pyridazin-3-yl)phenoxy)pyrimidin-5-yl)-3-(3
 (trifluoromethyl)phenyl)urea
TLC   : Rf 0.40         (Ethyl Acetate);
'H-NMR (DMSO-d6 ) : 5 1.96-2.02                    (m,   4H),   3.47-3.54(m, 4H),     6.88

  (d, 1H),       7.26-7.36          (m,   3H),    7.53  (t,  1H),    7.61  (dd,  1H),  7.87
  (d, 1H),        7.95-7.99         (m,   2H),    8.28   (d,  2H),    8.73  (s,  2H),  8.98
  (s, 1H),       9.31     (s,    1H).
 Example 22-7:           1-(2-phenyl-5-(trifluoromethyl)pyridin-3-yl)-3
 (2-(4-(6-(pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3
yl)phenoxy)pyrimidin-5-yl)urea
TLC : Rf 0.50             (Ethyl Acetate : Methanol = 9 : 1);
1 H-NMR    (DMSO-d     6  )   : 5 1.96-2.03         (m, 4H),    3.46-3.55    (m, 4H),  6.87
 (d,  1H),       7.27       (d,   2H),     7.52-7.69     (m,  5H),    7.86  (d,  1H),  7.94
 (s,  1H),       8.26       (d,   2H),     8.40-8.44     (m,   1H),   8.67-8.78   (m,  4H),
9.45   (s, 1H).
Example 22-8:            1-(2-(4-(6-methoxyimidazo[1,2-b]pyridazin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-(pyridin-3-yl)-5
 (trifluoromethyl)phenyl)urea
                                        CF3
                  N       NO
              N     \H               H
           \NN
               0
            H3 C
TLC : Rf 0.27            (Ethyl Acetate           : Methanol = 9 : 1);
1H-NMR     (DMSO-d     6  )   : 5 4.01        (s,  3H),   6.95   (d,  1H),  7.29-7.32    (m,
2H),   7.47-7.58             (m,   3H),     7.87-7.91     (m, 1H),    8.07-8.10   (m,  2H),
8.20-8.24          (m,    3H),     8.39      (s,  1H),  8.65-8.69      (m, 4H),   9.25   (s,
1H).
Example 22-9:            1- (2- (lH-pyrazol-1-yl) -5
 (trifluoromethyl)phenyl)-3-(2-(4-(6-methoxyimidazo[1,2
b]pyridazin-3-yl)phenoxy)pyrimidin-5-yl)urea

 TLC  : Rf 0.68          (Ethyl Acetate                : Methanol = 9 : 1);
 'H-NMR    (DMSO-d     6  )    :   5 4.02        (s,     3H),    6.68     (t,    1H),    6.95    (d,  1H),
 7.31-7.34      (m,      2H),        7.52      (dd,     1H),     7.75    (d,     1H),    7.96    (d, 1H),
 8.07-8.10      (m,       2H),       8.21-8.24           (m,   2H),     8.41      (d,    1H),   7.58    (d,
 1H),  8.71    (s, 2H),             9.70      (s, 1H),        9.97    (s, 1H).
 Example 22-10:            1-(2-(4-(6-methoxyimidazo[1,2-b]pyridazin-3
 yl)phenoxy)pyrimidin-5-yl)-3-(3-(trifluoromethyl)phenyl)urea
TLC   : Rf 0.59          (Ethyl Acetate                : Methanol = 9            : 1);
1
  H-NMR   (DMSO-d     6  )    :    5 4.02        (s,     3H),    6.95     (d,    1H),    7.31-7.34      (m,
 3H),   7.51    (t,       1H),       7.62       (d,     1H),    7.98     (s,     1H),    8.07-8.10      (m,
2H),    8.21-8.24            (m,     2H),      8.74       (s,   2H),    8.99      (s,    1H),   9.31    (s,
 1H).
Example 22-11:             1-(2-(4-(6-(2-hydroxypropan-2-yl)imidazo[1,2
bjpyridazin-3-yl)phenoxy)pyrimidin-5-yl)-3-(3
  (trifluoromethyl)phenyl)urea
                                          CF3
                    0      N~
                    N            N    N6
          NN                     H    H
            N
               CH,
          H3C OH
TLC   : Rf 0.20          (Chloroform : Methanol                     =  19     : 1);
1
  H-NMR   (DMSO-d     6  )    :    5   1.59      (s,     6H),    5.61     (s, 1H),       7.31-7.38      (m,
3H),   7.50-7.64            (m,     3H),    7.97-8.00           (m,   1H),      8.17    (d,   1H),   8.22
8.28   (m, 3H),         8.75        (s, 2H),         9.00     (s, 1H),        9.32    (s, 1H).
Example 22-12: 1-(2-(4-(6-(1-hydroxyethyl)imidazo[1,2
b]pyridazin-3-yl)phenoxy)pyrimidin-5-yl)-3-(3
 (trifluoromethyl)phenyl)urea

 TLC : Rf 0.19             (Chloroform : Methanol = 19 : 1);
 1
   H-NMR    (DMSO-d    6   )     :   5 1.49        (d,   3H),      4.85-4.93         (m,    1H),    5.74   (d,
 1H),   7.31-7.37               (m,   3H),      7.41     (d,    1H),     7.52      (t,    1H),    7.60-7.65
  (m,  1H),      7.97-8.00             (m,     1H),     8.18-8.25         (m,     4H),     8.75     (s,  2H),
 9.00    (s, 1H),        9.32         (s, 1H).
 Example 22-13:              1-(2-(4-(6-((2-hydroxy-2
methylpropyl) amino) imidazo[1,2-b]pyridazin-3
yl)phenoxy)pyrimidin-5-yl)-3-(3-(trifluoromethyl)phenyl)urea
                                            CF3
        NH    ~~N                 N    H
                                         b~
              N
               N
               HCH       3
                 H3C OH
TLC : Rf 0.35             (Ethyl Acetate               : Methanol         =    9 : 1);
1
  H-NMR    (DMSO-d     6   )     : 5     1.19     (s,    6H),     3.27     (d,    2H),     4.57     (s,  1H),
6.87-6.90         (m,     2H),        7.26-7.34          (m,    3H),     7.51       (t,    1H),    7.62    (d,
1H),    7.73       (d,     1H),        7.85      (s,    1H),     7.97      (s,    1H),     8.20-8.25       (m,
2H),    8.73      (s, 2H),           8.98      (s, 1H),       9.31     (s, 1H).
Example 22-14:              1-(2-(4-(imidazo[1,2-b]pyridazin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-(pyridin-3-yl)-5
 (trifluoromethyl)phenyl)urea
                                            CF3
                  NN         N,
            N      -    N     ,-   N  ~N
                                   H   H
              NN
TLC : Rf 0.50            (Ethyl Acetate                : Methanol         =    19   : 1);
1
  H-NMR     (DMSO-d     6   )      :   5    7.26-7.34          (m,    3H),       7.47-7.58         (m,   3H),
7.87-7.93          (m,       1H),        8.15-8.28          (m,     5H),      8.38       (s,    1H),    8.63-

 8.70(m, 5H),        9.24        (s, 1H).
 Example 22-15:            1-(2-(1H-1,2,3-triazol-1-yl)-5
  (trifluoromethyl)phenyl)-3-(2-(4-(imidazo[1,2-b]pyridazin-3
 yl)phenoxy)pyrimidin-5-yl)urea
 TLC : Rf 0.45          (Ethyl Acetate);
 1 H-NMR    (DMSO-d      )    : 5
                      6              7.27-7.38    (m,   4H),    7.59-7.65      (m, 1H),    7.74
 (d,   1H),    8.10       (s,    1H),    8.16-8.28     (m,    4H),   8.58    (s,   1H),   8.63
 8.73   (m, 4H),       9.66       (s,   1H).
 Example 22-16: 1-(2-(1H-pyrazol-1-yl)-5
 (trifluoromethyl)phenyl)-3-(2-(4-(imidazo[1,2-blpyridazin-3
 yl)phenoxy)pyrimidin-5-yl)urea
 TLC : Rf 0.38          (Hexane : Ethyl Acetate = 1 : 2);
'H-NMR       (DMSO-d 6 )       :   5    6.67-6.72     (m,     1H),   7.26-7.40       (m,   3H),
 7.50-7.57       (m,    1H),       7.75   (d,  1H),    7.95-8.00       (m,   1H),   8.16-8.30
 (m,   4H),     8.40-8.45           (m,  1H),   8.59     (s,   1H),   8.64-8.68       (m,  1H),
 8.70   (s, 2H),       9.70 (s, 1H),          9.96    (s, 1H).
Example 22-17:            1-(2-chloro-5-(trifluoromethyl)phenyl)-3-(2-(4
 (imidazo[1,2-b]pyridazin-3-yl)phenoxy)pyrimidin-5-yl)urea
TLC : Rf 0.27          (Ethyl Acetate);
1 H-NMR     (DMSO-d  6  )     : 5 7.28-7.43       (m,   4H),    7.74    (d,  1H),   8.16-8.27
 (m,   4H),    8.56      (dd,     1H),    8.64   (dd,    1H),    8.75    (s,  2H),   8.78    (s,
1H),    9.72     (s, 1H).
Example 22-18:            1-(2-fluoro-5-(trifluoromethyl)phenyl)-3-(2-(4
 (imidazo[1,2-b]pyridazin-3-yl)phenoxy)pyrimidin-5-yl)urea
TLC : Rf 0.30          (Ethyl Acetate);
'H-NMR      (DMSO-d   6)      : 5 7.27-7.54       (m,   5H),    8.16-8.27      (m,  4H),   8.53

  (dd, 1H),    8.63      (dd,   1H),   8.75    (s,   2H),   9.08   (s,  1H),   9.31  (s,
 1H).
 Example 22-19:        1-(2-(4-(imidazo[1,2-b]pyridazin-3
 yl)phenoxy)pyrimidin-5-yl)-3-(2-methyl-5
  (trifluoromethyl)phenyl)urea
 TLC : Rf 0.43       (Ethyl Acetate);
 1H-NMR   (DMSO-d    )    : 5 2.32     (s,
                   6                        3H),    7.27-7.41     (m,  6H),   8.17-8.26
  (m, 6H),   8.64    (dd, 1H),       8.75 (s, 2H).
 Example 22-20:        1-(2-(4-(imidazo[1,2-b]pyridazin-3
 yl)phenoxy)pyrimidin-5-yl)-3-(3-(trifluoromethyl)phenyl)urea
TLC : Rf 0.47        (Ethyl Acetate);
 1H-NMR
          (DMSO-d  6 )    : 5   7.27-7.36      (m,   4H),  7.51    (t,  1H),   7.62  (d,
 1H),  7.97    (s,    1H),     8.17-8.26      (m,   4H),   8.64    (d, 1H),    8.74  (s,
2H),   8.99   (s, 1H),        9.31   (s, 1H).
Example 22-21:         1-(3-fluoro-5-(trifluoromethyl)phenyl)-3-(2-(4
 (imidazo[1,2-b]pyridazin-3-yl)phenoxy)pyrimidin-5-yl)urea
TLC : Rf 0.22        (Ethyl Acetate);
'H-NMR    (DMSO-d  6 )    : 5 7.22-7.37        (m,   4H),  7.62    (d,  1H),   7.70  (s,
1H),   8.15-8.27        (m,   4H),   8.26    (d,   1H),   8.63   (dd,   1H),   8.73  (s,
2H),   9.12   (s, 1H),        9.52   (s, 1H).
Example 22-22:        1-(2-(4-(6-(azetidin-1-yl)imidazo[1,2
b]pyridazin-3-yl)phenoxy)pyrimidin-5-yl)-3-(2-chloro-4
 (trifluoromethyl)phenyl)urea
TLC : Rf 0.57         (Ethyl Acetate         : Methanol      = 9   : 1  ;   CHROMATOREX
NH TLC PLATE);
1H-NMR
          (DMSO-d  6 )    : 5 2.32-2.42        (m,   2H),  4.08    (t,  4H),   6.67  (d,

 1H),  7.27-7.30          (m,  2H),    7.69   (dd,    1H),   7.88-7.91     (m,  2H),   7.97
 (s,  1H),     8.21-8.24         (m,  2H),    8.44    (d,   1H),   8.75    (s,  2H),   8.82
 (br s,    1H),   9.76       (brs,   1H) .
Example 22-23:           1-(2-chloro-4-(trifluoromethyl)phenyl)-3-(2-(4
 (6-methoxyimidazo[1,2-b]pyridazin-3-yl)phenoxy)pyrimidin-5
yl)urea
TLC : Rf 0.53 (Ethyl Acetate : Methanol = 9 : 1);
1H-NMR     (DMSO-d   6 )    : 5 4.02      (s,  3H),    6.95   (d,  1H),    7.32-7.35    (m,
2H),   7.69     (dd,     1H),    7.89    (d,  1H),    8.07-8.10     (m,  2H),   8.21-8.24
 (m,  2H),     8.43      (d,   1H),    8.76    (s,   2H),    8.80    (s,  1H),   9.78    (s,
1H).
Example 22-24:           1-(2-chloro-4-(trifluoromethyl)phenyl)-3-(2-(4
 (imidazo[1,2-b]pyridazin-3-yl)phenoxy)pyrimidin-5-yl)urea
TLC : Rf 0.33          (Ethyl Acetate);
IH-NMR    (DMSO-d   6  )   : 5 7.31      (dd,   1H),   7.36    (d,  2H),   7.68   (dd,  1H),
7.88-7.92       (m,    1H),     8.17-8.28      (m,   4H),   8.43   (d,   1H),   8.64   (dd,
1H),   8.75     (s, 2H),       8.79   (s, 1H),      9.78   (s, 1H).
Example 22-25:           1-(2-(4-(imidazo[1,2-b]pyridazin-3
yl) phenoxy) pyrimidin-5-yl) -3- (4- (trifluoromethyl)phenyl) urea
TLC : Rf 0.20          (Hexane : Ethyl Acetate = 1 : 3);
1 H-NMR
          (DMSO-d   6  )   : 5 7.28      (dd,   1H),   7.35    (d,  2H),   7.61-7.69    (m,
4H),   8.16-8.28          (m,   4H),    8.64    (d,   1H),   8.74    (s,  2H),   8.99    (s,
1H),   9.37     (s, 1H).
Example 22-26:           1-(2-(4-(6-(azetidin-1-yl)imidazo[1,2
b]pyridazin-3-yl)phenoxy)pyrimidin-5-yl)-3-(3,5
difluorophenyl)urea

TLC   : Rf 0.25          (Ethyl Acetate);
 1H-NMR   (DMSO-d        )   : 5 6.76-6.85           (m, 1H),      7.19     (dd,
                       6                                                             2H),   7.27-7.35    (m,
 3H),  8.17-8.27         (m,    4H),    8.64     (dd,     1H),    8.72     (s,    2H),    9.15   (s, 1H),
 9.46  (s, 1H).
Example 22-27:             1-(6-(4-(imidazo[1,2-b] pyridazin-3
yl)phenoxy)pyridin-3-yl)-3-(3-(trifluoromethyl)phenyl)urea
                                        CF3
                    0      N
                                N    Nb
                               H     H
TLC : Rf 0.51            (Ethyl Acetate);
1
  H-NMR    (DMSO-d    6  )   : 5     7.07     (d,    1H),      7.22-7.31          (m,    4H),  7.50   (t,
1H),   7.59     (d,     1H),      7.97-8.00         (m,    1H),     8.03       (dd,    1H),   8.14-8.25
 (m, 5H),     8.63       (dd, 1H),        8.90     (s, 1H),        9.14      (s, 1H).
Example 22-28:             1-{2-[4-(6-methoxyimidazo[1,2-b]pyridazin-3
yl) phenoxy -5-pyrimidinyl}-3- [2- (1-methyl-1H-pyrazol-5-yl) -5
 (trifluoromethyl)phenyl] urea
Purity      (LC-MS/ELSD) : 96%                (Retention Time : 0.87 minutes);
MASS   (ESI, Pos.)            : 602      (M + H)+
1
  H-NMR   (DMSO-d    6   )   : 5 3.65        (s,     3H),      4.01    (s,      3H),     6.45   (d,  1H),
6.95    (d,   1H),        7.30-7.33         (m,    2H),      7.46-7.52           (m,    2H),   7.62   (d,
1H),   8.07-8.23            (m,   5H),      8.56      (s,    1H),     8.69       (s,    2H),   9.50   (s,
1H).
Example 22-29:             1-{2-[4-(6-methoxyimidazo[1,2-b]pyridazin-3
yl)phenoxy] -5-pyrimidinyl}-3- [2- (3-methyl-1H-pyrazol-1-yl)-5
 (trifluoromethyl)phenyl]urea
Purity      (LC-MS/ELSD) : 99%                (Retention Time : 0.94 minutes);

MASS     (ESI, Pos.)           : 602       (M + H)+;
 1
   H-NMR    (DMSO-d   6  )   :    5 2.37     (s,    3H),   4.02   (s,     3H),     6.45     (d,    IH),    6.95
  (d,  1H),    7.30-7.35         (m,   2H),     7.49     (dd,   1H),     7.70     (d,     1H),    8.07-8.11
  (m, 2H),    8.23-8.25         (m,   2H),    8.28     (d,  1H),     8.57     (d,    1H),    8.71     (s,   2H),
 9.81   (s,   1H),   9.93       (s,   1H).
Example 22-30:             1-{2-[4-(6-methoxyimidazo[1,2-b]pyridazin-3
yl) phenoxyl -5-pyrimidinyl}-3- [2- (4-methyl-lH-pyrazol-1-yl)-5
  (trifluoromethyl)phenyl]urea
Purity       (LC-MS/ELSD) : 96%                 (Retention Time :              0.95 minutes);
MASS     (ESI, Pos.)           : 602      (M + H)*;
'H-NMR      (DMSO-d   6  )   : 5 2.14          (s,    3H),    4.02      (s,     3H),      6.95     (d,    1H),
7.32     (d, 2H),       7.49        (dd, 1H),        7.70     (d, 1H),       7.79      (s, iH),         8.07
8.11     (m,    2H),     8.19-8.24           (m,     3H),    8.57      (d,     1H),     8.71      (s,     2H),
9.84     (s, 1H),       9.98        (s, 1H).
Example 22-31: 1-{2-[4-(6-methoxyimidazo[1,2-b]pyridazin-3
yl)phenoxy] -5-pyrimidinyl}-3- [2- (3-pyridinyl) -4
 (trifluoromethyl)phenyl]urea
Purity       (LC-MS/ELSD) : 100%                 (Retention Time            : 0.78 minutes);
MASS     (ESI, Pos.)           : 599      (M + H)+;
'H-NMR      (DMSO-d   6 )    : 5 4.01          (s,    3H),    6.95      (d,     1H),     7.31     (d,     2H),
7.54-7.57        (m, 2H),          7.76     (dd, 1H),        7.88-7.92           (m, 1H),        8.07-8.10
 (m, 2H),      8.20-8.29            (m, 4H),       8.65-8.69       (m, 4H),          9.30      (s, 1H).
Example 22-32:            1-{2-[4-(6-methoxyimidazo[1,2-b]pyridazin-3
yl)phenoxy]-5-pyrimidinyl}-3-[2-methyl-5
 (trifluoromethyl)phenyl]urea
Purity       (LC-MS/ELSD) : 100% (Retention Time                            : 0.87 minutes);

MASS    (ESI,      Pos.)             536        (M + H)+;
 1H-NMR    (DMSO-d     6   )        5 2.32           (s,    3H),   4.02    (s,   3H),    6.95   (d,   1H),
 7.29-7.34        (m,     3H),          7.42       (d,    1H),    8.08-8.11       (m,  2H),   8.20-8.25
  (m, 2H),      8.28         (s,     1H),         8.38      (s,   1H),   8.75      (s,  2H),   9.34     (s,
 1H).
Example 22-33: 1-{2-[4-(6-methoxyimidazo[1,2-b]pyridazin-3
yl)phenoxy]-5-pyrimidinyl}-3-{5-(trifluoromethyl)-2-[3
  (trifluoromethyl)-lH-pyrazol-1-yl]phenyl}urea
Purity      (LC-MS/ELSD) :                   100%       (Retention Time :          0.97 minutes);
MASS    (ESI, Pos.)               : 656         (M + H)+
'H-NMR     (DMSO-d     6  )      : 5      4.01       (s,    3H),   6.93    (d,    1H),   7.12   (s,   1H),
7.31    (d,    2H),        7.58          (d,     1H),      7.70    (d, 1H),      8.07-8.10      (m,   2H),
8.21    (d,    2H),       8.47          (s,      2H),     8.59     (s,  1H),     8.67    (s,  2H),    9.49
 (s, 1H).
Example 22-34:              1-{2-[4-(6-ethoxyimidazo[1,2-b]pyridazin-3
yl)phenoxy]-5-pyrimidinyl}-3-[2-(3-pyridinyl)-5
 (trifluoromethyl)phenyl]urea
                                              CF3
             N           N          NN,       .
             NH                          H
            N O
                   CH3
Purity     (LC-MS/ELSD) : 99%                        (Retention Time           : 0.86 minutes);
MASS   (ESI, Pos.)               : 613          (M + H)*;
1
  H-NMR    (DMSO-d     6  )         5     1.41       (t,    3H),   4.40    (q,   2H),    6.92    (d,  1H),
7.28-7.32        (m,     2H),        7.47-7.58             (m,   3H),  7.87-7.91        (m,  1H),    8.05
8.09    (m,    2H),        8.16-8.20               (m,    2H),    8.24    (s,    1H),    8.38   (s,   1H),

 8.64-8.68       (m, 4H),       9.24    (s, 1H).
 Example 22-35:           1-(2-{4-[6-(3-oxetanyloxy)imidazo[1,2
b]pyridazin-3-yllphenoxy}-5-pyrimidinyl)-3-[2-(3-pyridinyl)-5
 (trifluoromethyl)phenyl]urea
 Purity    (LC-MS/ELSD) : 99%              (Retention Time : 0.79 minutes);
MASS    (ESI, Pos.)             641   (M + H)+;
1 H-NMR   (DMSO-d    6  )      5 4.70     (dd,    2H),    4.95       (t,   2H),   5.62-5.71    (m,
 1H),  7.02      (d, 1H),       7.32-7.36       (m, 2H),        7.36-7.59        (m, 3H),   7.87
7.91    (m, 1H),         8.06-8.10       (m,   3H),     8.15       (d,    1H),   8.25   (s,  1H),
8.39   (s, 1H),        8.65-8.69        (m, 4H),      9.26 (s, 1H).
Example 22-36:           1-{2-[4-(6-methylimidazo[1,2-b]pyridazin-3
yl)phenoxy-5-pyrimidinyl}-3-[2-(3-pyridinyl)-5
 (trifluoromethyl)phenyl]urea
Purity (LC-MS/ELSD) : 100%                  (Retention Time : 0.76 minutes);
MASS   (ESI, Pos.)           : 583    (M + H)*;
1H-NMR
          (DMSO-d    6 )    : 5 2.59      (s,   3H),      7.19      (d,    1H),   7.29-7.34    (m,
2H),   7.47-7.58          (m, 3H),      7.87-7.91        (m, 1H),        8.09    (d, 1H),   8.16
8.24   (m, 4H),       8.39      (s, 1H),      8.64-8.69       (m, 4H),         9.25  (s, 1H).
Example 22-37:           1-[2-fluoro-5-(trifluoromethyl)phenyl]-3-(2-{4
 [6-(3-oxetanyloxy)imidazo[1,2-b]pyridazin-3-yl]phenoxy}-5
pyrimidinyl)urea
                                      F
              :.   1            N:  oN          t      o
       N   ,N    N           H    H  F
                                                                1)
            N
             0-0
TLC : Rf 0.31          (Chloroform :Methanol                =19         :1);

 'H-NMR     (DMSO-d   6 )   : 5 4.70     (dd,     2H),   4.96    (dd,    2H),     5.63-5.71     (m,
  1H),  7.03      (d,   1H),    7.34-7.55        (m,   4H),   8.06-8.13         (m,  3H),   8.15
  (d,  1H),    8.53       (dd,  1H),    8.76      (s,   2H),   9.13     (s,    1H),   9.32    (s,
 1H).
 Example 22-38: 1-[3'-(2-hydroxy-2-propanyl)-4
  (trifluoromethyl)-2-biphenylyl]-3-(2-{4-[6-(3
 oxetanyloxy)imidazo[1,2-b]pyridazin-3-yllphenoxy}-5
pyrimidinyl)urea
 Purity      (LC-MS/ELSD) : 100%             (Retention Time         : 0.94 minutes);
MASS    (ESI, Pos.)            698   (M + H)+
'H-NMR     (DMSO-d    6 )   : 5 1.45     (s,   6H),     4.70   (dd,    2H),    4.95     (dd, 2H),
 5.07    (s,    1H),      5.61-5.72      (m,    1H),     7.02    (d,    1H),     7.29(d,    1H),
 7.35(d,      2H),     7.41-7.60       (m,    5H),     8.03-8.19       (m,    5H),    8.34    (s,
 1H),   8.67     (s, 2H),      9.39 (s, 1H).
Example 22-39:            1-{2-[4-(6-methoxyimidazo[1,2-b]pyridazin-3
yl)phenoxyl-5-pyrimidinyl}-3-[2-(1H-pyrazol-1-yl)-4
  (trifluoromethyl)phenyl]urea
Purity      (LC-MS/ELSD) : 98%            (Retention Time          : 0.91 minutes);
MASS    (ESI, Pos.)          : 588   (M + H)+
1
  H-NMR     (DMSO-d   6 )   : 5 4.01      (s,   3H),     6.65-6.66       (m, 1H),     6.95    (d,
 1H),   7.32      (d,   2H),    7.75    (d,    1H),     7.83   (s,    1H),     7.94    (d,  1H),
8.07-8.11        (m,    2H),    8.22    (d,    2H),     8.41-8.44       (m,   2H),    8.71    (s,
2H),    9.57     (s, 1H),      9.98   (s, 1H).
Example 22-40:            1-[3-(difluoromethyl)phenyl]-3-{2-[4-(6
methoxyimidazo[1,2-b]pyridazin-3-yl)phenoxyl-5
pyrimidinyl}urea

Purity     (LC-MS/ELSD) : 100%          (Retention Time       : 0.77 minutes);
MASS   (ESI, Pos.)         : 504  (M + H)*;
'H-NMR    (DMSO-d 6 )       5 4.02   (s,   3H),   6.82-7.19      (n, 3H),  7.31-7.35
 (m, 2H),    7.42     (t,    1H),  7.52    (d,   1H),   7.78    (s,  1H),  8.08-8.11
 (m, 2H),    8.20-8.25        (m,  2H),   8.74    (s,  2H),    8.92    (s, 1H),  9.17
 (s, 1H).
Example 22-41:        1-[2-chloro-5-(trifluoromethyl)phenyl]-3-{2-[4
 (6-methoxyimidazo[1,2-b]pyridazin-3-yl)phenoxy]-5
pyrimidinyl}urea
Purity (LC-MS/ELSD) : 100%              (Retention Time : 0.91 minutes);
MASS   (ESI, Pos.)        : 556   (M + H)+;
1H-NMR    (DMSO-d   )     : 5 4.02    (s,   3H),   6.95   (d,   1H),   7.31-7.36   (n,
                  6
2H),  7.40    (dd, 1H),       7.73   (d, 1H),     8.08-8.11     (m,  2H),  8.21-8.25
 (m, 2H),    8.57     (d,    1H),   8.76    (s,  2H),   8.79     (s,  1H),  9.72   (s,
1H).
Example 22-42: 1-[2-fluoro-5-(trifluoromethyl)phenyl]-3-{2-[4
 (6-methoxyimidazo[1,2-b]pyridazin-3-yl)phenoxy]-5
pyrimidinyl}urea
Purity (LC-MS/ELSD) : 100%              (Retention Time : 0.87 minutes);
MASS   (ESI, Pos.)        : 540   (M + H)+
1H-NMR
          (DMSO-d 6 )     : 5 4.02    (s,   3H),   6.95   (d,   1H),   7.31-7.36   (m,
2H),   7.38-7.54       (m,   2H),   8.08-8.11      (n,  2H),   8.20-8.25     (n, 2H),
8.53   (dd, 1H),      8.75    (s, 2H),    9.10    (d, 1H),    9.31   (s, 1H).
Example 22-43: 1-(2,5-dichlorophenyl)-3-{2-[4-(6
methoxyimidazo[1,2-b]pyridazin-3-yl)phenoxy]-5
pyrimidinyllurea

 Purity    (LC-MS/ELSD) : 100%            (Retention Time          : 0.89 minutes);
MASS    (ESI,   Pos.)         522   (M + H)+
 1H-NMR   (DMSO-d    )       5 4.02    (s,    3H),    6.95   (d,    1H),    7.11    (dd,  1H),
                   6
 7.31-7.35     (m,   2H),      7.50   (d,    1H),    8.07-8.10       (m,    2H),    8.20-8.26
  (m, 3H),   8.64    (s, 1H),       8.74    (s, 2H),      9.68    (s, 1H).
Example 22-44:         1-(2,4-dichlorophenyl)-3-{2-[4-(6
methoxyimidazo[1,2-b]pyridazin-3-yl)phenoxy]-5
pyrimidinyl}urea
Purity     (LC-MS/ELSD) : 100%            (Retention Time : 0.89 minutes);
MASS    (ESI, Pos.)       : 522     (M + H)+;
'H-NMR    (DMSO-d  6 )       5 4.02     (s,    3H),    6.95    (d,   1H),     7.31-7.35     (m,
2H),   7.39    (dd,     1H),    7.64    (d,    1H),    8.07-8.11      (m,    2H),    8.14   (d,
1H),   8.20-8.25        (m,    2H),   8.58      (s,   1H),   8.74     (s,    2H),    9.60   (s,
1H).
Example 22-45: 1-(2,5-difluorophenyl)-3-{2-[4-(6
methoxyimidazo[1,2-b]pyridazin-3-yl)phenoxy]-5
pyrimidinyl}urea
Purity (LC-MS/ELSD) : 100%                (Retention Time : 0.79 minutes);
MASS   (ESI, Pos.)        : 490     (M + H)*;
1H-NMR    (DMSO-d  6 )   : 5 4.02       (s,    3H),    6.81-6.90       (m, 1H),      6.95   (d,
1H),   7.26-7.35        (m,    3H),   7.94-8.00        (m, 1H),      8.08-8.12       (m,  2H),
8.20-8.25     (m, 2H),        8.74   (s, 2H),       8.97   (s, 1H),       9.28    (s, 1H).
Example 22-46:         1-{2-[4-(6-methoxyimidazo[1,2-b]pyridazin-3
yl)phenoxy]-5-pyrimidinyl}-3-[2-(4-methyl-1H-1,2,3-triazol-1
yl) -5- (trifluoromethyl)phenyl]urea
Purity (LC-MS/ELSD) : 99%                (Retention Time : 0.86 minutes);

 MASS    (ESI, Pos.)              603   (M + H)+;
 1
   H-NMR     (DMSO-d    6)       5 2.38      (s,   3H),    4.01     (s,    3H),  6.95  (d,  1H),
 7.30-7.34        (m,    2H),     7.59     (dd,    1H),    7.70     (d,    1H),  8.07-8.10    (m,
 2H),    8.20-8.24           (m,   2H),    8.39     (s,   1H),     8.60     (s,  1H),  8.69   (s,
 2H),   8.76     (s, 1H),        9.70     (s, 1H).
 Example 22-47: 1-[5-chloro-2-(1H-pyrazol-1-yl)phenyl]-3-{2-[4
  (6-methoxyimidazo[1,2-b]pyridazin-3-yl)phenoxy]-5
pyrimidinyl}urea
 Purity      (LC-MS/ELSD) : 100%               (Retention Time : 0.88 minutes);
MASS    (ESI, Pos.)            : 554    (M + H)*;
'H-NMR      (DMSO-d   6  )    : 5 4.01       (s,   3H),    6.61-6.63         (m, 1H),  6.94   (d,
 1H),   7.22      (dd,      1H),    7.30-7.34        (m,   2H),    7.51     (d,  1H),  7.89   (d,
1H),    8.07-8.10           (m,   2H),    8.19-8.24        (m,    2H),    8.26   (d, 1H),   8.27
 (d,   1H),    8.69     (s, 2H),        9.37     (s, 1H),     9.89      (s, 1H).
Example 22-48:             1-[5-chloro-2-(3-pyridinyl)phenyl]-3-{2-[4-(6
methoxyimidazo[1,2-b]pyridazin-3-yl)phenoxy]-5
pyrimidinyl}urea
Purity       (LC-MS/ELSD) : 77%              (Retention Time            : 0.75 minutes);
MASS    (ESI, Pos.)            : 565    (M + H)*;
1
  H-NMR     (DMSO-d   6  )    : 5 4.02      (s,    3H),    6.95     (d,    1H),  7.22-7.34    (m,
4H),     7.54      (dd,       1H),     7.80-7.85         (m,    1H),     8.07-8.23    (m,   6H),
8.59-8.66        (m, 4H),        9.20    (brs, 1H).
Example 22-49:             1-{6-[4-(6-methoxyimidazo[1,2-b]pyridazin-3
yl)phenoxy]-3-pyridinyl}-3-[2-(3-pyridinyl)-5
 (trifluoromethyl)phenyl]urea
Purity      (LC-MS/ELSD) : 98%               (Retention Time            : 0.83 minutes);

 MASS   (ESI, Pos.)            598    (M + H)*;
 1
   H-NMR    (DMSO-d   6  )     5 4.00      (s,    3H),     6.94     (d,    1H),   7.05    (d, 1H),
 7.18-7.23       (m,    2H),    7.45-7.59         (m,    3H),     7.87-7.91        (m,  1H),  8.00
  (dd,  1H),    8.06-8.21         (m,   6H),      8.42     (s,    1H),    8.64-8.69       (m, 2H),
 9.18   (s, 1H).
 Example 22-50:           1-{6-[4-(6-methoxyimidazo[1,2-b]pyridazin-3
 yl)phenoxy]-3-pyridinyl}-3-[2-(1H-pyrazol-1-yl)-5
  (trifluoromethyl)phenyl]urea
 Purity     (LC-MS/ELSD) : 100%              (Retention Time : 0.95 minutes);
MASS    (ESI, Pos.)          : 587    (M + H)+
 1H-NMR    (DMSO-d   6  )   : 5  4.01     (s,     3H),    6.67-6.68          (m,  1H),   6.94   (d,
 1H),  7.07      (d,    1H),    7.19-7.24         (m,   2H),     7.50      (dd,   1H),   7.73   (d,
 1H),  7.95      (d,    1H),    8.00-8.10         (m,   3H),     8.18-8.21        (m,   3H),  8.40
 (d, 1H),     8.59      (s, 1H),      9.56     (s, 1H),        9.83     (s, 1H).
Example 22-51:            1-{6-[4-(6-methoxyimidazo[1,2-b]pyridazin-3
yl)phenoxy]-3-pyridinyl}-3-{5-(trifluoromethyl)-2-[3
 (trifluoromethyl)-lH-pyrazol-1-yl]phenyl}urea
Purity      (LC-MS/ELSD) : 100%              (Retention Time             : 1.01 minutes);
MASS    (ESI, Pos.)          : 655    (M + H)+;
'H-NMR     (DMSO-d   6  )   : 5  4.01     (s,     3H),    6.94      (d,   1H),    7.07    (d, 1H),
7.13    (d,    1H),     7.19-7.24       (m,    2H),     7.55      (dd,    1H),    7.69    (d, 1H),
7.99     (dd,     1H),      8.01-8.21         (m,     5H),      8.45-8.52        (m,   3H),   9.40
 (s,1H).
Example 22-52:           1-(2-{4-[6-(3-oxetanyloxy)imidazo[1,2
b]pyridazin-3-yl]phenoxy}-5-pyrimidinyl)-3-[3
 (trifluoromethyl)phenyl]urea

 Purity     (LC-MS/ELSD) : 100%              (Retention Time      : 0.84 minutes);
MASS    (ESI, Pos.)          : 564    (M + H)+
 1H-NMR      (DMSO-d 6 )         5   4.68-4.72       (m,   2H),    4.93-4.98    (m,  2H),
 5.63-5.72       (m,    1H),    7.02     (d,   1H),    7.31-7.40      (m, 3H),  7.51   (t,
 1H),   7.61     (d,    1H),    7.96-8.00       (m,   1H),   8.07-8.17     (m, 4H),  8.74
  (s, 2H),     9.00    (s, 1H),      9.32     (s, 1H).
Example 22-53: 1-[2-chloro-5-(trifluoromethyl)phenyl]-3-(2-{4
 [6- (3-oxetanyloxy)imidazo [1,2-b] pyridazin-3-yl] phenoxy}-5
pyrimidinyl)urea
Purity      (LC-MS/ELSD) : 100%              (Retention Time      : 0.90 minutes);
MASS    (ESI, Pos.)            598    (M + H)+;
1 H-NMR     (DMSO-d 6 )          5   4.68-4.73       (m,   2H),    4.93-4.99    (m,  2H),
5.63-5.72        (m,   1H),     7.03     (d,   1H),    7.35-7.43      (m, 3H),  7.73   (d,
1H),   8.07-8.17          (m,   4H),    8.57     (d,  1H),   8.76     (s, 2H),  8.80   (s,
1H),   9.73     (s, 1H).
Example 22-54:           1-[2-methyl-5-(trifluoromethyl)phenyl]-3-(2-{4
 [6-(3-oxetanyloxy)imidazo[1,2-b]pyridazin-3-yl]phenoxy}-5
pyrimidinyl) urea
Purity      (LC-MS/ELSD) : 100%              (Retention Time      : 0.86 minutes);
MASS   (ESI, Pos.)          : 578     (M + H)+;
1 H-NMR    (DMSO-d   6 )   : 5 2.32       (s,  3H),    4.67-4.74     (m, 2H),  4.93-4.99
 (m,  2H),     5.63-5.71        (m,    1H),    7.03    (d,  1H),    7.27-7.45    (m, 4H),
8.07-8.18       (m,    4H),     8.27-8.30       (m,   1H),   8.39     (s, 1H),  8.76   (s,
2H),   9.35     (s, 1H).
Example 22-55: 1-(2,4-dichlorophenyl)-3-(2-{4-[6-(3
oxetanyloxy)imidazo[1,2-b]pyridazin-3-yl]phenoxy}-5-

 pyrimidinyl)urea
  Purity    (LC-MS/ELSD) : 100%                   (Retention Time : 0.87 minutes);
 MASS   (ESI, Pos.)                564     (M + H)+
 'H-NMR      (DMSO-d 6 )              5   4.67-4.74         (m,    2H),    4.92-5.00         (m,   2H),
 5.63-5.72        (m,     1H),      7.03      (d,   1H),     7.34-7.43        (m,    3H),   7.64    (dd,
 1H),   8.06-8.19             (m,    5H),     8.59     (s,    1H),   8.75      (s,    2H),   9.61     (s,
 1H).
Example 22-56:              1-(5-chloro-2-methylphenyl)-3-(2-{4-[6-(3
oxetanyloxy)imidazo[1,2-b]pyridazin-3-yl]phenoxy}-5
pyrimidinyl)urea
Purity      (LC-MS/ELSD) : 100%                   (Retention Time : 0.84 minutes);
MASS    (ESI, Pos.)             : 544      (M + H)+
1H-NMR     (DMSO-d     6  )       5 2.22       (s,   3H),    4.70    (dd,     2H),     4.96   (dd,   2H),
5.63-5.72         (m,     1H),       6.98-7.05         (m,   2H),    7.20      (d,    1H),   7.36     (d,
2H),    7.98       (d,     1H),      8.05-8.19         (m,   4H),    8.27      (s,    1H),   8.75     (s,
2H) ,  9.31      (s,     1H).
Example 22-57:              1-(2,5-difluorophenyl)-3-(2-{4-[6-(3
oxetanyloxy)imidazo[1,2-b]pyridazin-3-yllphenoxy}-5
pyrimidinyl)urea
Purity (LC-MS/ELSD) : 99%                       (Retention Time : 0.81 minutes);
MASS    (ESI, Pos.)             : 532     (M + H)*;
1H-NMR
           (DMSO-d     6 )     : 5 4.70        (dd,    2H),    4.96     (dd,    2H),    5.62-5.72       (m,
1H),   6.81-6.92             (m,    1H),     7.03     (d,   1H),    7.23-7.32          (m,  1H),   7.38
 (d,  2H),      7.93-8.01            (m,    1H),     8.04-8.19       (m,     4H),     8.75    (s,  2H),
8.98   (s,     1H) ,     9.29      (s,    1H).
Example 22-58:             1-[5-methyl-2-(methylsulfonyl)phenyl]-3-(2-{4-

  [6-(3-oxetanyloxy)imidazo[1,2-b]pyridazin-3-yl]phenoxy}-5
 pyrimidinyl)urea
 Purity (LC-MS/ELSD) : 100%                  (Retention Time : 0.77 minutes);
 MASS   (ESI, Pos.)             588   (M + H)+;
 1 H-NMR
            (DMSO-d  6  )      5 2.37    (s,    3H),  3.24   (s,  3H),   4.71   (dd,  2H),
 4.96    (dd,   2H),      5.62-5.72      (m,    1H),   7.03   (d,  1H),   7.12   (d, 1H),
 7.37    (d,   2H),      7.73     (d,  1H),     7.99   (s,  1H),   8.05-8.20     (m,  4H),
 8.73   (s, 1H),       8.77     (s, 2H),      10.13 (s, 1H).
 Example 22-59:          1-[5-chloro-2-(methylsulfonyl)phenyl]-3-(2-{4
 [6-(3-oxetanyloxy)imidazo[1,2-bpyridazin-3-yl]phenoxy}-5
pyrimidinyl) urea
 Purity (LC-MS/ELSD) : 100%                 (Retention Time : 0.83 minutes);
MASS    (ESI, Pos.)             608   (M + H)+
'H-NMR     (DMSO-d   6 )       5 3.32    (s,    3H),  4.70   (dd,  2H),    4.95  (dd,  2H),
5.63-5.71       (m,    1H),      7.03   (d,    1H),   7.23-7.31     (m,  3H),   7.85    (d,
1H),    8.03-8.19          (m,   4H),   8.33     (d, 1H),    8.77   (s,  2H),   8.88    (s,
1H),   10.14     (s,     1H).
Example 22-60:           1-[5-fluoro-2-(methylsulfonyl)phenyl]-3-(2-{4
 [6-(3-oxetanyloxy)imidazo[1,2-b]pyridazin-3-yl]phenoxy}-5
pyrimidinyl)urea
Purity      (LC-MS/ELSD) : 99%            (Retention Time : 0.79 minutes);
MASS    (ESI, Pos.)          : 592    (M + H)+;
1 H-NMR
           (DMSO-d   6)     : 5 3.32     (s,   3H),   4.71   (dd,  2H),    4.96  (dd,  2H),
5.62-5.72       (m,    1H),      7.03   (d,    1H),   7.20-7.30     (m,  1H),   7.37    (d,
2H),   7.92     (dd,      1H),    8.03-8.20       (m, 5H),   8.76    (s,  2H),   8.95   (s,
1H),   10.30     (s,     1H).

 Example 22-61:         1-[2-(methylsulfonyl)-5
 (trifluoromethyl)phenyl]-3-(2-{4-[6-(3
 oxetanyloxy)imidazo[1,2-b]pyridazin-3-yl]phenoxy}-5
pyrimidinyl)urea
 Purity (LC-MS/ELSD) : 98%              (Retention Time : 0.87 minutes);
MASS    (ESI, Pos.)        : 642   (M + H)*;
1 H-NMR   (DMSO-d  6  )   : 5 3.39    (s,   3H),   4.70   (dd,   2H),  4.95   (dd,  2H),
5.62-5.73      (m,    1H),    7.03   (d,    1H),   7.37   (d,   2H),  7.64   (d,   1H),
8.03-8.20      (m,    5H),    8.63   (s,    1H),   8.77   (s,   2H),  8.98   (s,   1H),
10.32    (s, 1H).
Example 22-62:         1-[2-(methylsulfonyl)phenyl]-3-(2-{4-[6-(3
oxetanyloxy)imidazo[1,2-b]pyridazin-3-yl]phenoxy}-5
pyrimidinyl)urea
Purity (LC-MS/ELSD) : 93%              (Retention Time : 0.73 minutes);
MASS   (ESI, Pos.)         : 574   (M + H)+;
1 H-NMR   (DMSO-d  6 )   : 5 3.28     (s,   3H),   4.70  (dd,    2H),  4.96   (dd,  2H),
5.62-5.73      (m,   1H),     7.03   (d,    1H),   7.25-7.33      (m, 1H),   7.37    (d,
2H),   7.62-7.72        (m,  1H),   7.85     (dd, 1H),   8.04-8.20     (m,  5H),   8.77
 (s, 3H),    10.14      (s, 1H).
Example 22-63: 2-[({2-[4-(6-ethoxyimidazo[1,2-b]pyridazin-3
yl)phenoxy]-5-pyrimidinyl}carbamoyl)amino]-N,N-dimethyl-4
 (trifluoromethyl)benzenesulfonamide
Purity     (LC-MS/ELSD) : 100%           (Retention Time : 0.99 minutes);
MASS   (ESI, Pos.)        : 643    (M + H)+
1H-NMR
          (DMSO-d  6 )    : 5 1.41     (t,   3H),   2.76   (s,   6H),  4.42   (q,  2H),
6.92   (d, 1H),      7.33    (d, 2H),      7.60   (dd, 1H),    7.94   (d, 1H),    8.05-

 8.10    (m,   2H),     8.20      (d,   2H),    8.61   (s,   1H),   8.75    (s,  2H),    8.99
  (s, 1H),     10.31     (s, 1H).
 Example 22-64:          l-{2-[4-(6-ethoxyimidazo[1,2-bpyridazin-3
 yl)phenoxy]-5-pyrimidinyl}-3-[2-(methylsulfonyl)-5
 (trifluoromethyl)phenyl]urea
 Purity (LC-MS/ELSD) : 100%                  (Retention Time : 0.94 minutes);
 MASS (ESI, Pos.)              614    (M + H)+
  H-NMR     (DMSO-d 6  )    : 5 1.41       (t,   3H),   3.38   (s,   3H),  4.42     (q,  2H),
 6.93    (d,   1H),     7.33     (d,    2H),    7.64   (d,   1H),   8.03-8.26      (m,   3H),
 8.20   (d,    2H),   8.63      (s,    1H),    8.76   (s,  2H),    8.97   (s,   1H),    10.31
 (s, 1H).
 Example 22-65:          1-[5-chloro-2-(methylsulfonyl)phenyl]-3-{2-[4
 (6-ethoxyimidazo[1,2-b]pyridazin-3-yl)phenoxy]-5
pyrimidinyllurea
 Purity (LC-MS/ELSD) : 100%                  (Retention Time : 0.91 minutes);
MASS    (ESI, Pos.)          : 580    (M + H)+
'H-NMR      (DMSO-d 6 )    : 5 1.43        (t,   3H),  3.32    (s,  3H),   4.45    (q,   2H),
7.26    (d,    1H),    7.35-7.41         (m,   3H),   7.85    (d,   1H),   8.18    (d,   2H),
8.27    (d,    1H),    8.33      (d,   1H),    8.40    (s,  1H),    8.77   (s,   2H),    8.89
 (s,  1H),    10.33      (s,   1H).
Example 22-66:          1-[3'-(hydroxymethyl)-4-(trifluoromethyl)-2
biphenylyl]-3-(2-{4-[6-(3-oxetanyloxy)imidazo[1,2-b]pyridazin
3-yl]phenoxy}-5-pyrimidinyl)urea
Purity (LC-MS/ELSD) : 99%                  (Retention Time : 1.07 minutes);
MASS    (ESI, Pos.)          : 670    (M + H)+;
1H-NMR     (DMSO-d  6 )    : 5 4.58       (d,  2H),   4.70    (dd,   2H),  4.95     (dd,  2H),

 5.29   (t,   1H),     5.67     (quint,      1H),   7.03   (d, 1H),  7.27-7.56    (m,
8H),   8.04-8.15         (m,   4H),   8.15     (d,  1H),   8.42  (d, 1H),  8.68   (s,
2H) ,  9. 43 .(s,    1H) .
Example 22-67: 1-[3'-(1-hydroxyethyl)-4-(trifluoromethyl)-2
biphenylyl] -3- (2-{ 4- [6- (3-oxetanyloxy)imidazo [1,2-b] pyridazin
3-yl]phenoxy}-5-pyrimidinyl)urea
Purity (LC-MS/ELSD) : 99%               (Retention Time : 0.94 minutes);
MASS   (ESI, Pos.)         : 684    (M + H)+;
1 H-NMR
          (DMSO-d  6 )    : 5 1.36     (d,    3H),  4.70   (dd, 2H),  4.76-4.83   (m,
1H),   4.95    (dd,     2H),    5.21    (d,    1H),   5.67   (quint, 1H),  7.02   (d,
1H),   7.27-7.56        (m,   8H),    8.03-8.13      (m,  4H),  8.15  (d, 1H),  8.37
 (s, 1H),    8.67    (s,    2H),    9.41    (s, 1H).
Example 23
       The similar procedure as Example 7 was carried out with a
corresponding amine compound produced with a corresponding
bicyclic heterocycle compound in place of Example 19 produced
with 5-chloropyrazolo[1,5-a]pyrimidine, and the compound
produced in Example 3 or a corresponding carbamate or
isocyanate compound in place of the compound produced in
Example 3 to give the present compounds having the following
physical characteristics.
Example 23-1:       1-(2-(4-(6-methoxyimidazo[1,2-a]pyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(3-(trifluoromethyl)phenyl)urea

                                          CF3
                        ONN        0
                       N
             N                   H    H
               0 -CH 3
 TLC   : Rf 0.52           (Ethyl acetate                Methanol    =    9     1);
 1
   H-NMR    (DMSO-d       6)   : 5 3.81        (s,    3H),    7.10   (dd,     1H),     7.30-7.37    (m,
 3H),   7.52       (t,     1H),      7.54-7.65         (m,   2H),   7.71     (s,    1H),    7.73-7.77
  (m,  2H),      7.98-8.03           (m,    2H),     8.75     (s,  2H),     9.00      (s,  1H),   9.32
  (s, 1H).
 Example 23-2:             1-(2-(4-(6-(2-hydroxypropan-2-yl)imidazo[1,2
 a]pyridin-3-yl)phenoxy)pyrimidin-5-yl)-3-(3
 (trifluoromethyl)phenyl)urea
 TLC   : Rf 0.26           (Chloroform : Methanol = 19                    : 1);
 1H-NMR     (DMSO-d     6  )   : 5     1. 48    (s,    6H) , 5. 30    (s,    1H) ,    7. 30-7. 43  (m,
 4H),   7.49-7.74            (m,    6H)),    7.95-7.99         (m,  1H),     8.50-8.53       (m,  1H),
 8.75   (s, 2H),          9.00      (s, 1H),        9.32    (s, 1H).
Example 23-3:             1- (2- (lH-pyrazol-1-yl) -5
 (trifluoromethyl)phenyl)-3-(2-(4-(imidazo[1,2-a]pyridin-3
yl)phenoxy)pyrimidin-5-yl)urea
TLC    : Rf 0.59           (Ethyl acetate            : Methanol = 9 : 1);
'H-NMR      (DMSO-d      6 )   :  5    6.67    (t,     1H),    6.96   (t,    1H),     7.27-7.37    (m,
3H),    7.51       (d,     1H),      7.64-7.77          (m,  5H),    7.95      (s,   1H),    8.41  (d,
1H),    8.55-8.58            (m,    2H),      8.71      (s,  2H),    9.70      (s,   1H),    9.97  (s,
1H).
Example 23-4: 1-(2-(4-(imidazo[1,2-a]pyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-(pyridin-3-yl)-5-

  (trifluoromethyl)phenyl)urea
 TLC : Rf 0.27          (Ethyl acetate);
 1H-NMR      (DMSO-d6 )          5     6.95-7.00          (m,     1H),     7.27-7.36     (m,  3H),
 7.48-7.60       (m,    3H),    7.64-7.72           (m,    3H),     7.77     (s,  1H),  7.88   (dt,
 1H),  8.24       (s,    1H),    8.39      (s,     1H),      8.56     (d,    1H),  8.65-8.69    (m,
 4H),  9.25      (s,   1H).
Example 23-5:          1-(2-(4-(imidazo[1,2-a]pyridin-3
yl)phenoxy)pyrimidin-5-yl) -3- (3- (trifluoromethyl)phenyl)urea
TLC : Rf 0.46 (Ethyl acetate);
1 H-NMR    (DMSO-d 6 )     : 5    6.95-7.05          (m,    1H),     7.28-7.38      (m, 4H),  7.52
 (t,  1H),      7.60-7.74       (m,      4H),     7.78       (s,   1H),     7.98   (s,  1H),  8.57
 (d, 1H),      8.74    (s, 2H),        9.02     (s, 1H),         9.34     (s, 1H).
Example 23-6:          1-(2-(4-(imidazo[1,2-a]pyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-phenyl-5
 (trifluoromethyl)pyridin-3-yl)urea
TLC : Rf 0.29          (Ethyl acetate);
'H-NMR      (DMSO-d 6 )      :   5     6.95-7.01          (m,     1H),     7.27-7.37     (m,  3H),
7.54-7.78        (m,    9H),    8.43      (s,     1H),      8.56     (d,    1H),   8.70   (s, 2H),
8.73   (s,     1H),    8.76    (d,     1H),     9.48     (s,     1H).
Example 23-7: 1-(2-(4-(1H-pyrrolo[2,3-b]pyridin-5
yl)phenoxy)pyrimidin-5-yl)-3-(2-(pyridin-3-yl)-5
 (trifluoromethyl)phenyl)urea
                                           CF3
                      . OY N
                                     o
           N              N ""N    ',N
                                 H     H
       HN
          ----                                N
TLC : Rf 0.23          (Ethyl acetate);

 1
   H-NMR     (DMSO-d      6)      :   5 6.49          (d,  1H),    7.26    (d,  2H),   7.47-7.58    (m,
 4H),    7.73       (d,     2H),         7.90       (d,   1H),    8.19-8.25      (m,  2H),  8.39    (s,
 1H),    8.49-8.51             (m,      1H),       8.65-8.68       (m,   4H),   9.24   (s, 1H),  11.7
  (s,  1H) .
 Example 23-8: 1-(2-(4-(1H-pyrrolo[2,3-b]pyridin-5
yl)phenoxy)pyrimidin-5-yl)-3-(3-(trifluoromethyl)phenyl)urea
TLC    : Rf     0.60       (Ethyl acetate);
'H-NMR        (DMSO-d6)             :    5     6.49-6.50        (m,    1H),    7.26-7.36    (m,  3H),
7.46-7.54          (m,     2H),         7.62       (d,    1H),    7.74    (d,  2H),   7.97   (s, 1H),
8.21     (s,     1H),       8.50-8.53              (m,    1H),    8.73    (s,  2H),   8.98   (s, 1H),
9.31    (s, 1H),          11.7         (s, 1H).
Example 23-9:             1-(2-(4-(6-amino-1H-pyrrolo[2,3-b]pyridin-5
yl)phenoxy)pyrimidin-5-yl)-3-(2-(pyridin-3-yl)-5
 (trifluoromethyl)phenyl)urea
                                                     CF3
               NH2           O         N    O
                   NN                       ),N
                                          H     H
        HN
                     --                                 N
TLC    : Rf 0.35          (Ethyl acetate);
1
  H-NMR     (DMSO-d     6  )     : 5      5.19       (s,   2H),    6.20-6.24      (m, 1H),  6.99   (t,
1H),    7.23       (d,    2H),         7.46-7.58           (m,   6H),    7.88-7.92    (m,  1H),  8.23
 (s,   1H),     8.38         (s,      1H),        8.63-8.68       (m,   4H),   9.23   (s,  1H),  10.9
 (s, 1H).
Example 23-10:              1-(2-(4-(imidazo[1,2-a]pyrazin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-(pyridin-3-yl)-5
 (trifluoromethyl)phenyl)urea

                                                CF3
               N
                       XH                   H
               N
                                                 SN
 TLC   : Rf 0.34          (Dichloromethane : Methanol                    9       1);
 1H-NMR      (DMSO-d    6  )    :   5   7.38     (d,  2H),   7.46-7.59       (m,    3H),  7.78  (d,
 2H),    7.85-7.91            (m,     1H),     7.92    (d,  1H),   8.06     (s,    1H),   8.24  (s,
 1H),    8.38      (s,     1H),       8.58-8.69        (m,  5H),   9.13     (d,    1H),   9.25  (s,
 1H).
Example 23-11:              1-(2-(4-(pyrazolo[1,5-a]pyridin-3
yl)phenoxy)pyrimidin-5-yl)-3-(2-(pyridin-3-yl)-5
 (trifluoromethyl)phenyl)urea
                                           CF3
                    . O     N       O
             N           N        N    N
        N    /                    H   H
          N
TLC   : Rf 0.29           (Ethyl acetate);
1
  H-NMR     (DMSO-d     6 )    : 5 6.94         (t,  1H),   7.74-7.35      (m,    3H),   7.46-7.58
 (m,  3H),       7.71       (d,     2H),      7.89    (d,  1H),    7.96    (d,     1H),   8.23  (s,
1H),    8.36-8.38           (m,     2H),     8.64-8.74     (m,   5H),   9.22     (s, 1H).
Example 23-12:              1-(2-(4-(lH-pyrazolo[3,4-b]pyridin-5
yl)phenoxy)pyrimidin-5-yl)-3-(2-(pyridin-3-yl)-5
 (trifluoromethyl)phenyl)urea
                                                CF3
                               ON
                                N        O
            NN                         N   N
                                       H   H
        HN
TLC : Rf 0.23             (Ethyl acetate);

1
  H-NMR    (DMSO-d  6  )       5   7.29   (d, 2H),    7.47-7.58     (m,  3H),   7.79   (d,
2H),    7.87-7.93         (m,    1H),   8.18-8.21     (m,   1H),  8.24   (s,   1H),  8.38
 (s,  1H),    8.47       (d,   1H),    8.64-8.68     (m,   4H),   8.83   (d,   1H),  9.23
 (s,  1H),   13.7     (s,     1H).
Pharmacological Experiment Examples:
Pharmacological Experiment Example 1: Measurement of TrkA
kinase-inhibiting activity using human TrkA-expressing cells
       TrkA kinase-inhibiting activity in cell systems was
measured using CHO-Ki cells exressing human TrkA and NFAT-bla
                M
 (CellSenser        TrkA-NFAT-bla          CHO-Ki   cells,     Invitrogen).
       On the day before the assay,                 CellSenserM      TrkA-NFAT-bla
CHO-K1 cells were suspended in an assay medium                         (Opti-MEMi
Reduced Serum Medium               (Invitrogen) containing 0.5% dialysed
fetal bovine serum              (Invitrogen),      0.1 mM nonessential amino
acids    (Invitrogen),           1 mM sodium pyruvate          (Invitrogen) and
antibiotics       (100 U/mL penicillin and 100 pg/mL streptomycin
                                                                          4
(Invitrogen)))         and plated at a density of 2.4 x 10                   cells/40
ptL/well in a 96-well clear bottom plate                     (Corning, Catalogue
No.:   3882).      In some wells were added only the assay medium at
40 ptL/well     (Cell-free).           On the day of the assay,          10 mM of the
present compound             (DMSO solution) was distributed in a 96-well
plate    (Costar, Catalogue No.:              3363) and serially diluted with
DMSO with the geometrical ratio of 3.                      The serial dilutions
were diluted with the assay medium to 100-fold to prepare a
solution of the present compound with a 10-fold concentration

 (DMSO concentration:         1%).      To the plate where cells were plated
was added the present          compound at        5 piL/well and the plate         was
incubated       in  a C02 incubator with 5% C02,               95% Air at    37*C for
30 minutes.        For a control and a blank,               the assay medium
containing 1%        DMSO was added at 5 pL/well in place of the
solution of the present compound.                  Subsequently the assay
medium containing NGF           (Mouse 2.5s, Natural, Invitrogen) was
added to the plate at 5 pL/well               (final concentration of NGF:
50  ng/ml)      and the plate       was incubated        in   a C02 incubator with
5% C02,      95% Air at   370C for 5 hours.           For the blank group,         the
assay medium was added in place of NGF at 5 pL/well.                          A
reporter assay detection reagent                (10 pL/well) was added to the
plate which was        then incubated in the dark at room temperature
for 120 minutes.         The reporter assay detection reagent was
prepared from LiveBLAzerTM-FRET              B/G Loading Kit           (Invitrogen)
On the Analyst GT         (Molecular Devices Japan, K.K.)                 the wells
were irradiated with excitation light at 405 nm and the
fluorescence intensities at 460 nm and 530 nm were measured.
The time resolved fluorescence resonance energy transfer                          (TR
FRET) ratio of each well was calculated according to the
following Equation 1:
[Eq.  1]
      TR-FRET ratio =         (A 4 6 0x - A46oF)/(A  53 ox  -   A530F)
      wherein:
      A 4 6 ox:  the fluorescence intensity at 460 nm of the present

compound, control or blank;
      A46oF:     the fluorescence intensity at 460 nm of the Cell
free;
      A 53ox:    the fluorescence intensity at 530 nm of the present
compound, control or blank;           and
      A530F:     the fluorescence intensity at 530 nm of the Cell
free.
      The TR-FRET inhibition rate            (%) of the present compound
was calculated according to the following Equation 2:
 [Eq. 21
      Inhibition       rate   (%) =  {l-(Ax-AB)/(Ac-AB)}  X 100
      wherein Ax:       the TR-FRET ratio     when the present      compound
is added;
      AB:   the TR-FRET of the blank;          and
      Ac:   the TR-FRET of the control.
      The IC 5 0 value by the present         compound  was calculated     from
the inhibition curve based on the inhibition rate of the
present compound at respective concentrations.
      As a result, it was          found that the present compounds had
IC50 values      of 0.5     M or lower and had TrkA-inhibiting
activity.       IC5o values of some of the present compounds are
shown in the following Table 1 or 2.
      Table 1
                      TrkA-inhibiting activity
     Example
                                (IC50; gM)

    7   0.001
   8-1  0.001
   8-2  0.002
   8-4  0.001
   9-1  0.003
   9-2  0.001
   11   0.001
  13-1  0.002
  14-5  0.001
  14-6  0.001
  15-4 0.001
  15-5  0.003
  15-6  0.002
 15-52 0.004
 15-55 0.004
 15-58 0.002
 15-63 0.002
 15-71 0.002
 15-77 0.002
 15-87 0.001
 15-96 0.0004
 15-98 0.0008
15-104 0.0005
15-105 0.004

      Table 2
                TrkA-inhibiting activity
     Example
                       (IC50;   tM)
       21-1               0.001
       21-2               0.001
       21-9               0.001
      21-13               0.001
      21-37               0.001
      21-51               0.001
      21-65              0.0007
      21-67               0.004
      21-70               0.002
      21-73               0.003
      21-75               0.004
       22-8               0.001
       22-9               0.001
      22-34               0.001
       23-3               0.001
       23-7               0.002
      23-10               0.001
      23-11               0.001
      23-12               0.001
Pharmacological Experiment Example 2:  Enzyme-inhibiting
activity test of kinases  other than Trk (selectivity

experiment)
      A test substance (the present compound) was dissolved in
dimethylsulfoxide to adjust a 100-fold concentration of the
test concentration, 3 RM.    The solution was further diluted to
25-fold with an assay buffer    (20 mM HEPES, 0.01% Triton X-100,
2 mM DTT, pH 7.5) to obtain a test substance solution.        In a
similar manner a positive control substance solution was
prepared with a positive control substance.
     A 4-times concentration solution     (5 RL) of the test
substance adjusted with the assay buffer, 5      L of a 4-times
concentration solution of substrate/ATP/metal      (Mg) and 10   L
of a 2-times concentration solution of kinase were mixed in a
well of a polypropylene 384-well plate and allowed to react at
room temperature for 1 hour.    The reaction was terminated by
adding 60   L of a Termination Buffer (QuickScout Screening
Assist MSA; Carna Biosciences).     The substrate peptide and the
phosphorylated peptide in the reaction solution were separated
and quantified.   The kinase reaction was assessed from the
product ratio   (P/(P+S)) calculated from the height     (S) of the
peak of the substrate peptide and the height      (P) of the peak
of the phosphorylated peptide.     Other kinases used in the
kinase selectivity experiments were, for example, b-Raf and
KDR.  The following Table 3 indicates substrates, substrate
concentrations, ATP concentrations and positive control
substances used in respective kinase enzyme inhibition

activity tests.
      Table 3
 Kinase       Substrate                 ATP  (pJM)   Positive control
             Name           (nM)
 b-Raf       MAP2K1         1           1000         ZM336372
 KDR          CSKtide       1000        75           Staurosporine
      The inhibition rate was calculated from the average
signal intensity of the test wells containing respective test
substances provided that the average signal intensity of
control wells each containing all reaction components was 0%
inhibition and the average signal intensity of background
wells   (without addition of the enzyme) was 100% inhibition.       As
a result, the present compounds at a concentration of 3         M had
the inhibition rates of kinases as shown in the following
Table 4.
      Table 4
                            Inhibition rate  (%)
    Example
                      b-Raf                      KDR
        7               40                         0
       8-1              6.5                        0
       8-2              21                         0
      13-1              33                       7.5
      14-5              13                         0
      14-6              45                       1.7

  15-4              0                    0
  15-6             37                    0
 15-52             20                    0
 15-55             30                    0
 15-58             30                    0
 15-63             43                    0
 15-71             40                    0
 15-77             32                    0
 15-87             34                    0
 15-96             22                    2
15-98             23                     8
15-104             53                   18
15-105            26                     0
 21-1              36                  1.5
 21-2              30                    1
21-37              50                   16
21-51              49                    9
21-65              58                   19
21-67              19                    0
21-70              19                    0
21-73             21                     0
21-75              41                    0
22-34             56                    19
  From this result, it is demonstrated that the present

 compounds show low inhibition of kinases other than TrkA,
e.g.,  b-Raf and KDR, while exhibit strong inhibition of TrkA.
 In other words, the present compounds have TrkA inhibition as
strong as IC 5 0 of 0.5   M or less   according to the result   from
Pharmacological Example 1, while the present compounds inhibit
kinases other than TrkA only at 0% to about 58%        even at the
concentration of 3      M according to the result from
Pharmacological Example 2.      Thus it is demonstrated that the
present compounds have high selectivity towards TrkA
inhibition and have excellent kinase selectivity.
      Pharmacological Experiment Example 3:       Inhibition of rat
NGF-induced vascular hyper permeability
      TrkA-inhibiting activity of the present compound was
evaluted in vivo.     The present compound dissolved in a medium
was orally administered     (adminstered volume:    5 mL/kg) to male
CD(SD)IGS rats    (7- to 9-week old, Charles River laboratories
Japan, Inc.)   shaved on the back.      A medium was orally
administered    (adminstered volume:     5 mL/kg) to the control and
normal groups.    After 6,   12 or 14 hours of administration, 3
ptg/mL of a NGF   (Mouse 2.5s, Natural, Invitrogen) solution
prepared in 0.1%    BSA  (Sigma-Aldrich)-containing saline was
intracutaneously administered       (dose; 50 ptL/site) at 3 sites on
the back of animals under halothane anesthesia.         For the normal
group, 0.1% BSA-containing saline was intracutaneously
administered    (dose; 50 ptL/site) at 3 sites on the back.

 Immediately after intracutaneous administration, 1% Evans Blue
 (Tokyo Chemical Industriy Co.,     Ltd.) was administered
intravenously from tail     (adminstered volume:      3 mL/kg).  After
10 minutes of administration, the animals were sacrificed by
bleeding due to incision of the abdominal aorta.           The sites of
intracutaneous administration on the back          (3 sites) were
excised and the   skin samples were respectively transferred to
the wells in a 48-well plate      (Asahi Glass Co.,     Ltd.).
Formamide   (0.8 mL/well) was added to the plate and the plate
was sealed and incubated overnight at      60 0 C.   The formamide
extraction solution    (200  tL) was transferred to a 96-well
plate and the absorbance     (wavelength: 620 nm) of Evans Blue
extracted in formamide was measured on an absorbance
microplate reader    (SpectraMAX 190, Molecular Devices Japan,
K.K.).   Standard samples of Evans Blue dissolved in formamide
 (0, 0.78, 1.56, 3.13, 6.25, 12.5, 25 and 50 pg/mL) were
measured at the   same time for the absorance        (wavelength: 620
nm) to generate a calibration curve.       Based on the calibration
curve and the absorbances of samples, the concentrations of
Evans Blue in the sample was calculated.         The concentrations of
Evans Blue for three skin samples collected from one aminal
were averaged to obtain the vale for the animal.           The rate of
inhibition for rat NGF-induced vascular hyper permeability of
the present compound was calculated according to the following
Equation:

 [Eq.  31
       Inhibition rate   (%) =  {1 -   (Ax - AN) / (Ac - AN) } X 100
       wherein Ax:  the concentration      of Evans Blue of the test
compound    (an average value of 3 samples       from one animal);
       AN: the concentration of Evans Blue of the normal group
 (an average value of 3 samples from one animal);
       Ac: the concentration of Evans Blue of the control group
(an average value of 3 samples from one animal).
       As a result, the present compound        (3 mg/kg;   6 hours after
administration) had the rate of inhibition for rat NGF-induced
vascular hyper permeability of about         70%, and it was found
that the present compounds strongly inhibited vascular hyper
permeability even after a long period of time.
       For example, some of the present compounds          (1 mg/kg; 14
or 12 hours after administration) had inhibition rate of rat
NGF-induced vascular hyper permeability as shown in the
following Tables 5 and 6.
       Table 5
                     Inhibition rate of vascular hyper
   Example                     permeability      (%)
                       (time after administration       (h))
        7                          97%   (14 h)
      8-1                          94%   (14 h)
      8-2                         100%    (14 h)
      8-4                          96%   (14 h)

     9-1                       86% (14   h)
     9-2                      100% (14 h)
     11                       100% (14 h)
    13-1                      100%   (14 h)
    14-5                       93%  (14 h)
    14-6                       78%  (12 h)
    15-4                      100% (14 h)
    15-5                       92%  (14 h)
    15-6                       95%  (14 h)
   15-52                       96%  (14 h)
   15-55                       94%  (14 h)
   15-58                      100%   (14 h)
   15-63                       99%  (14 h)
   15-71                      100%   (14 h)
   15-77                      100%   (14 h)
   15-87                       86%  (14 h)
  15-96                        90%  (14 h)
  15-98                        80% (14 h)
  15-104                      100%   (14 h)
  15-105                      100%   (14 h)
     Table 6
           Inhibition rate of vascular hyper permeability
Example                            (%)
                   (time after administration (h))

    21-1                        87% (14  h)
    21-2                       100%  (14 h)
    21-9                       100%  (14 h)
   21-13                       100%  (12 h)
   21-37                        98% (14 h)
   21-51                        95% (14 h)
   21-65                        92% (14 h)
   21-67                        90% (14 h)
   21-70                       100%  (14 h)
   21-73                        92% (14 h)
   21-75                       100%  (14 h)
    22-8                       100%  (14 h)
    22-9                       100%  (14 h)
   22-34                        91% (14 h)
Pharmacological Experiment Example 4: Analgesic effect on
sodium monoiodoacetate-induced model rats
      Using model rats induced with sodium monoiodoacetate
(hereinafter abbreviated as MIA)    (Sigma-Aldrich Japan), the
present compounds were evaluated for the analgesic effect
thereof.
       (1) Generation of MIA-induced model rats
      Under isoflurane anaesthesia, rats were shaved on around
knees of right hind limbs and 25 ptL solution of 120 mg/mL MIA
was administered into the right hind limb knee joint using a

syringe    (BD Lo-Dose, Beckton Dickinson Japan) with a 29 G
needle.    To a normal control group, 25 pL of saline was
administered.
       (2) Group organisation and grouping
      The groups included were a normal control group, a
disease control group, a test substance group and a tramadol
or morphine group.     Other than the normal control group, rats
were grouped so that the right hind limb weight load ratio
 (the measurement of the ratio is described hereinbelow) of
model rats 14 days after induction with MIA generated
according to the method as described in the above          (1) was
equivalent between all groups.
       (3) Administration of test substances, tramadol or
morphine
      The present compounds which are the test substances were
respectively dissolved in Wellsolve      (Celeste Corporation) to
prepare the solutions with concentrations of         0.1, 0.3 and 1
mg/mL.    The prepared   0.1, 0.3 or 1 mg/mL solution     was diluted
5-fold with distilled water to prepare 0.02, 0.06 or 0.2 mg/mL
solution    (final concentration of Wellsolve:     20%).    The positive
control drug, tramadol, was dissolved in saline to prepare a
solution of 2 mg/mL.      Alternatively the positive control drug,
morphine, was dissolved in saline to prepare a solution of 0.6
mg/mL.    From day 14 to day 23 after induction with MIA, a test
substance solution     (0.1, 0.3 or 1 mg/kg) was orally
administered to the test substance group twice a day over 10

days.   On day 24 after induction with MIA, the test substance
solution was further orally administered 3 hours before the
measurement of the right hind limb weight load ratio and
saline was subcutaneously administered 1 hour before the
measurement.    The tramadol group or the morphine group orally
received 20% Wellsolve twice a day over 10 days from day 14 to
day 23 after induction with MIA.    On day 24 after induction
with MIA, 20% Wellsolve was further orally administered 3
hours before the measurement of the right hind limb weight
load ratio and a tramadol solution    (10 mg/kg) or a morphine
solution (3 mg/kg) was subcutaneously administered 1 hour
before the measurement.    The normal control group and the
disease control group received 20% Wellsolve twice a day over
10 days from day 14 to day 23 after induction with MIA.     On day
24 after induction with MIA, 20% Wellsolve was further orally
administered 3 hours before the measurement of the right hind
limb weight load ratio and saline was subcutaneously
administered 1 hour before the measurement.
      (4) Measurement of right hind limb weight load ratio
      The weight load on right and left hind limbs was measured
with the Linton Incapacitance Tester     (MJS Technology INC., UK).
Namely, a rat was transferred into a cage of the Linton
Incapacitance Tester and adjusted so that right and left hind
limbs were respectively on each of a pair of gravimetric
sensors.   After confirming that the rat was balanced on left
and right and forward and back, the weight load of left and

right hind limbs was respectively measured for 3 seconds.      The
measurement was repeated 3 times per rat.     In order to obtain
stable results, rats were conditioned in the cage for 20
minutes or longer per day over 5 or more days between the day
of induction with MIA and day 14 after induction.     Further,
rats were also conditioned in the cage immediately before the
measurement for about 10 minutes.    The weight load of right and
left hind limbs was measured before grouping on day 14 after
induction with MIA and day 24 after induction for the normal
control group, the disease control group, the test substance
group   (3 hours after administration), the tramadol group (1
hour after administration) and the morphine group (1 hour
after  administration) .  Based on the averages of right and left
hind limb weight loads, the right hind limb weight load ratio
with respect to the weight load of both hind limbs was
calculated according to the following Equation 4.     The
measurement was carried out in a blind manner.     The percent
improvement for the present compounds which are the test
substances was calculated based on the right hind limb weight
load ratio of each group at day 24 after induction with MIA
according to the following Equation 5, thereby evaluating
analgesic effect of the test substances    (present compounds).
[Eq.  4]
      Right hind limb weight load ratio B (%) = {AR/ (AR + AL)   X
100}
      wherein:

         AR:   weight load of right hind limb      (average of three
measurements per rat);          and
         AL: weight load of left hind limb        (average of three
measurements per rat).
 [Eq. 5]
         Percent improvement of test substance         (%) =  {l -  (BT
Bc) /(BN     -  Bc) } X 100
        wherein:
         Bc:   average of the normal control group;
         BN:   average of the disease control group;       and
        BT:    average of the test    substance group.
        As a result,       the present compounds had percent
improvement that was equivalent to or higher than that of
tramadol and morphine which are commonly used as analgesic
agents.        Accordingly, it was found that the present compounds
had analgesic effect that was equivalent or superior to
tramadol and morphine.
        Examples of the analgesic effect         (percent improvement) of
some of the present compounds on MIA-induced model rats are
shown in the following Table 7           (the results obtained with the
positive control drug of tramadol) and Table 8              (the results
obtained with the positive control drug of morphine).
        Table 7
               Example                  Percent improvement     (%)
                    7                               61

             8-1                   60
            14-5                   47
            15-6                   51
            21-9                   64
           21-13                   66
 Positive control drug  Percent improvement  (%)
         Tramadol                  43
    Table 8
        Example        Percent improvement  (%)
          14-6                    53
          15-52                   60
          15-55                   62
          15-63                   53
         15-77                    55
         15-87                    57
         15-98                    57
         15-104                   54
         21-37                    67
         21-51                    68
         21-70                    61
         21-73                    62
Positive control drug  Percent improvement (%)
       Morphine                   54

      [Formulation Examples]
Formulation Example 1
     The following components were mixed and compressed to
tablets according to a conventional method to give 10,000
tablets containing 10 mg of the active ingredient per tablet.
     1-(2-(4-(2-amino-5-chloropyridin-3-yl)phenoxy)pyrimidin
5-yl)-3-(2-(4-methyl-1H-1,2,3-triazol-1-yl)-5
(trifluoromethyl)phenyl)urea                        100 g
     Calcium carboxymethylcellulose  (disintegrating agent)
                                                    20 g
     Magnesium stearate  (lubricant)                10 g
     Microcrystalline cellulose                     870 g
Formulation Example 2
     The following components were mixed according to a
conventional method, filtered through a dust filter,
distributed to ampoules at 5 ml and thermally sterilized in an
autoclave to obtain 10,000 ampoules containing 20 mg of the
active ingredient per ampoule.
     1-(2-(4-(2-amino-5-chloropyridin-3-yl)phenoxy)pyrimidin
5-yl)-3-(2-(4-methyl-1H-1,2,3-triazol-1-yl)-5
(trifluoromethyl)phenyl)urea                        200 g
     Mannitol                                       20 g
     Distilled water                                50 L
                    INDUSTRIAL APPLICABILITY
     The present compound has Trk-inhibiting activity and thus

is useful for prophylaxis and/or therapy of diseases to which
Trk is involved, for example, pain, pruritus, lower urinary
tract dysfunction, asthma, allergic rhinitis, inflammatory
bowel disease and Chagas disease.

                                   277
CLAIMS
1. 1-{ 2- [4- (2-amino-5-chloro-3-pyridinyl) phenoxy] -5-pyrimidinyl}
3-[2-(methylsulfonyl)-5-(trifluoromethyl)phenyl]urea.
2. A salt of 1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]-5
pyrimidinyl}-3-[2-(methylsulfonyl)-5
 (trifluoromethyl)phenyl]urea.
3. A pharmaceutical composition comprising 1-{2-[4-(2-amino-5
chloro-3-pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2
 (methylsulfonyl)-5-(trifluoromethyl)phenyl]urea or a salt
thereof, as an active ingredient.
4. A prophylactic and/or therapeutic agent for Trk-related
disease comprising 1-{2-[4-(2-amino-5-chloro-3
pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2-(methylsulfonyl)-5
 (trifluoromethyl)phenyl]urea or a salt thereof, as an active
ingredient.
5. The agent according to claim 4, wherein Trk-related disease
is cancer.
6. The agent according to claim 5, wherein cancer is cancer
expressing Trk.
7. The agent according to claim 6, wherein the cancer is
neuroblastoma, prostate cancer or pancreatic cancer.
8. A method for preventing or treating a TRK-related disease in
a subject, the method comprising administering 1-{2-[4-(2-amino
5-chloro-3-pyridinyl)phenoxy]-5-pyrimidinyl}-3-[2
 (methylsulfonyl)-5-(trifluoromethyl)phenyl]urea or a salt
thereof to the subject.

                                       278
9. The method according to claim 8, wherein Trk-related disease
is cancer.
10.  The method according to       claim 9, wherein cancer is cancer
expressing Trk.
11.  The method according to       claim 10, wherein the cancer is
neuroblastoma, prostate cancer or pancreatic cancer.
12.  Use of: 1-{2-[4-(2-amino-5-chloro-3-pyridinyl)phenoxy]-5
pyrimidinyl}-3-[2-(methylsulfonyl)-5
 (trifluoromethyl)phenyl]urea or a salt thereof, in the
preparation of a medicament        for preventing      or treating a TRK
related disease.
13.  The use according to claim 12,         wherein Trk-related disease
is cancer.
14.  The use according to claim 13, wherein cancer is cancer
expressing Trk.
15.  The use according to claim 14,         wherein the cancer is
neuroblastoma, prostate cancer or pancreatic cancer.
                          Ono Pharmaceutical Co., Ltd.
              Patent Attorneys for the Applicant/Nominated Person
                           SPRUSON & FERGUSON

